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Abstract
Proton beam therapy shows dosimetric advantages in terms of sparing healthy tissue compared
to conventional photon radiotherapy. Those patients who are supposed to experience the great-
est reduction in side effects should preferably be treated with proton beam therapy. One option
for this patient selection is the model-based approach. Its feasibility in patients with intracranial
tumours is investigated in this thesis. First, normal tissue complication probability models for
early and late side effects were developed and validated in external cohorts based on data of pa-
tients treated with proton beam therapy. Acute erythema as well as acute and late alopecia were
associated with high-dose parameters of the skin. Late mild hearing loss was related to the mean
dose of the ipsilateral cochlea. Second, neurocognitive function as a relevant side effect for brain
tumour patients was investigated in detail using subjective and objective measures. It remained
largely stable during recurrence-free follow-up until two years after proton beam therapy. Finally,
potential toxicity differences were evaluated based on an individual proton and photon treatment
plan comparison as well as on models predicting various side effects. Although proton beam
therapy was able to achieve a high relative reduction of dose exposure in contralateral organs at
risk, the associated reduction of side effect probabilities was less pronounced. Using a model-
based selection procedure, the majority of the examined patients would have been eligible for
proton beam therapy, mainly due to the predictions of a model on neurocognitive function.
Kurzzusammenfassung
Die Protonentherapie zeigt dosimetrische Vorteile gegenüber konventioneller Photonentherapie
in der Schonung gesunden Gewebes. Patienten, welche eine hohe Reduktion von Nebenwirkun-
gen erwarten können, sollten bevorzugt mit einer Protonentherapie behandelt werden. Die Pa-
tientenauswahl kann durch den modellbasierten Ansatz geschehen, dessen Realisierbarkeit bei
Patienten mit intrakraniellen Tumoren in dieser Arbeit untersucht wird. Dazu wurden, basierend
auf Daten von mit Protonentherapie behandelten Patienten, zuerst Modelle zur Vorhersage von
Nebenwirkungswahrscheinlichkeiten von Früh- und Spätfolgen entwickelt und an externen Kohor-
ten validiert. Akute Erytheme sowie akute und späte Alopezie waren mit Hochdosisparametern
der Haut assoziiert. Späte leichte Hörminderung zeigte einen Zusammenhang mit der mittleren
Dosis der ipsilateralen Cochlea. Des Weiteren wurde die neurokognitive Funktion als relevante
Nebenwirkung bei Hirntumorpatienten eingehend mit subjektiven und objektiven Methoden un-
tersucht. Sie blieb innerhalb der rezidivfreien Zeit bis zu zwei Jahre nach Protonentherapie weit-
gehend stabil. Abschließend wurden anhand eines individuellen Vergleichs von Protonen- und
Photonentherapieplänen sowie verschiedener Modelle potentielle Toxizitätsunterschiede evalu-
iert. Obwohl die Protonentherapie eine hohe relative Reduktion der Dosisbelastung in kontralate-
ralen Risikoorganen erzielte, war die begleitende Reduktion der Nebenwirkungswahrscheinlich-
keit weniger deutlich ausgeprägt. Bei Verwendung eines modellbasierten Verfahrens wäre die
Mehrheit der untersuchten Patienten für eine Protonentherapie ausgewählt worden, vor allem
aufgrund der Vorhersagen eines Modells zur neurokognitiven Funktion.
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1 Introduction
In the 1950s, the first cancer patients have been treated with proton beam therapy (PBT) (Smith,
2006). A superiority to conventional photon radiotherapy (XRT) is mainly expected due to the
physical properties of protons. As charged particles, they interact differently with matter than
photons and therefore stop after a certain range in tissue. Consequently, the healthy tissue be-
hind the tumour is less exposed and high dose conformity can be achieved. These dosimetric
advantages may be beneficial in two different ways. First, dose could be escalated in radioresis-
tant tumours, increasing tumour control while keeping potential side effects at a level comparable
to non-escalated XRT regimes. Second, radiation-induced side effects and the risk of secondary
tumour induction could be generally reduced due to the lower exposure of healthy tissue. The
clinical implementation of PBT was mainly based on the dosimetric superiority of protons shown
in comparative in silico planning studies (Goitein and Cox, 2008; Suit et al., 2008). Although the
dosimetric advantages of PBT over XRT are often apparent, the respective dose reduction does
not always lead to a substantial reduction in side effects (Durante et al., 2017). Thus, the ques-
tion is raised whether it is indeed appropriate to justify the use of PBT solely based on planning
studies and the ALARA principle (as low as reasonably achievable), as previously done when
introducing new radiotherapy (RT) techniques such as intensity-modulated radiotherapy (IMRT)
(Jacobs et al., 2017). This question is accompanied by concerns about the considerably higher
technical, personnel and therefore financial effort required to operate a PBT facility compared to
conventional XRT (Lievens and Pijls-Johannesma, 2013; Bekelman and Hahn, 2014).
Despite high capital costs, which constitute an important limiting factor for the installation of a
PBT facility (Lievens and den Bogaert, 2005), the number of PBT centres has increased rapidly
in recent decades, especially since the 2000s (figure 1.1). Although many patients have already
been treated with PBT, the published clinical evidence for its superiority over XRT is still limited
(Grau, 2013). One reason for this lack of evidence could be that university-based facilities tend
to focus on research in physics but less on patient care, while hospital-based facilities operate
more on a commercial basis and have less academic focus (Grau, 2013). Commonly, a proof
for the clinical superiority of PBT in terms of prospective randomised controlled trials (RCTs) is
demanded (Zips and Baumann, 2013). However, it is controversial whether RCTs are suited to
reveal potential differences between PBT and XRT (Glimelius and Montelius, 2007; Macbeth and
Williams, 2008). In contrast to RCTs comparing systemic therapies, there are more degrees of
freedom when comparing PBT with a conventional irradiation technique. There exists no stan-
dard application of RT, neither XRT (Fairchild et al., 2014; Das et al., 2017) nor PBT (Taylor et al.,
2016). The heterogeneity between centres in terms of treatment planning systems, quality as-
surance routines, training skills, image guidance, treatment adaptation, immobilisation strategies
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Figure 1.1: Number of proton beam therapy treatment rooms in clinical operation, data as of September
2019 (Particle Therapy Co-Operative Group, 2019).
etc. may be so pronounced that it can be difficult to transfer results from RCTs into clinical routine
(Widder et al., 2016; Langendijk et al., 2018).
When comparing PBT and XRT in terms of reduced side effects, some additional obstacles
may occur. Late radiation-induced side effects as relevant endpoints of such clinical trials may
manifest many years following RT. Thus, results from large long-term RCTs may be obsolete as
RT (and PBT in particular) is still a rapidly evolving technology (Langendijk et al., 2013). Usually,
all eligible patients are enrolled in an RCT, regardless of their presumed extent of side effect
reduction under PBTs. This requires the inclusion of a large number of patients to observe any
significant difference between both treatment modalities. The number of included patients may
be reduced by a proper preselection of eligible patients. Due to this preselection process, the
estimated difference in complication probability between both treatment groups is enhanced, so
that an adequate balance between risks and benefits for patients in both groups (equipoise)
is supposed to be lacking (Bentzen, 2008). Consequently, RCTs may be considered unethical
(Goitein and Cox, 2008; Suit et al., 2008).
As an alternative possibility for PBT patient selection, the model-based approach has been
suggested and introduced into clinical practice in the Netherlands (Langendijk et al., 2013). In
this approach, patients with non-standard indications are selected for PBT who could benefit
most in terms of reduced side effects, see figure 1.2. In a first step, valid normal tissue compli-
cation probability (NTCP) models predicting certain radiation-induced side effects are developed
and selected since they provide the basis for the whole approach. During the next step, two
treatment plans, one using PBT and the other using state-of-the-art XRT, are created for each
patient. Using the selected NTCP models and the two treatment plans, the complication risk of
the relevant side effect can be estimated for each modality. The difference ∆NTCP determines
the clinical benefit that can potentially be achieved if the patient is treated with protons instead of
photons. If this estimate exceeds a predefined threshold, e.g. 10 percentage points, the patient is
treated with PBT, otherwise with XRT. Besides patient selection, evaluation is an integral part of
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Figure 1.2: Schematic overview of the model-based patient selection for proton beam therapy. NTCP,
normal tissue complication probability. Adapted from Langendijk et al. (2013).
the model-based approach. Only by systematically selecting suitable patients for PBT, the PBT
cohort can be enriched to generate evidence for PBT more efficiently (Widder et al., 2016).
This approach has mainly been implemented for patients with head and neck cancer, as a
variety of validated NTCP models for several side effects have been developed for this tumour
entity, such as xerostomia, sticky saliva or tube feeding (Beetz et al., 2012a; Beetz et al., 2012b;
Beetz et al., 2012c; Wopken et al., 2014). For other tumour entities, fewer validated NTCP
models for radiation-induced side effects are available. The prediction of NTCP models may vary
depending on the patient population (Peeters et al., 2006) or the applied RT techniques (Beetz
et al., 2012b; Christianen et al., 2012; Troeller et al., 2015; Pedersen et al., 2020). Almost all
models have been developed using XRT data, although it is not entirely certain whether all of
these models can also be applied to PBT.
Cranial RT may be associated with mild to severe side effects such as alopecia, hearing im-
pairment, neurocognitive and endocrine dysfunctions, cranial nerve failure or brain necrosis (Shih
et al., 2009; Landier, 2016). These side effects can affect patients’ quality of life (QoL) adversely.
Patients with benign tumours or low-grade gliomas (LGGs) often have prolonged survival and
young age at diagnosis (Buckner et al., 2016). These long-term survivors may be affected by late
side effects. Patients with high-grade gliomas (HGGs) have a short life expectancy (Stupp et al.,
2009) and thus, an important goal of treatment is the preservation of QoL as long as possible
by reducing early side effects. Comparative dosimetric studies in brain tumour patients showed
dosimetric advantages of PBT over XRT also in these entities (Harrabi et al., 2016; Adeberg et
al., 2018). A significant dose reduction, especially in organs at risk (OARs) associated with neu-
rocognitive function and QoL, promises potential for reducing late side effects. So far, treatment
decisions for patients with brain tumours have been based mainly on dosimetric comparisons.
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Alternatively, the selection of these patients for PBT patients may be realised using the model-
based approach. For XRT, NTCP models for different endpoints have been developed, such as
neurocognitive function, radiation-induced brain necrosis, tinnitus, and ocular toxicity (Burman et
al., 1991; Bender, 2012; Gondi et al., 2012; Batth et al., 2013; Lee et al., 2015). However, studies
based on data from PBT or combined PBT and XRT are rare (De Marzi et al., 2015; Palma et al.,
2020).
This thesis investigates whether the model-based approach can be applied to patients with
intracranial tumours. In a multi-centre approach, data from a total of 305 patients treated with
cranial PBT at one of three different PBT facilities were evaluated. NTCP models for common
early and late physician-rated side effects were developed and validated. The preservation of
neurocognitive function is of paramount importance for brain tumour patients and was addition-
ally investigated in more detail using subjective patient-reported as well as objective measures.
Finally, the potential of dose and NTCP reduction in comparison to XRT was estimated based on
an in silico treatment plan comparison.
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2.1 Treatment strategies for tumours in the brain and skull base
The most common types of adult intracranial tumours and their management are discussed in this
section with focus on RT, particularly PBT. All primary brain tumours originate from cells within
the central nervous system (CNS) and account for 2 % of all cancer types. About two-thirds of
primary brain tumours are non-malignant, see figure 2.1. The World Health Organization (WHO)
classified tumours of the central nervous system into different grades based on histology and
molecular parameters (Louis et al., 2016). Low-grade meningiomas are the most common non-
malignant brain tumours with a 5-year overall survival of 87 %. Almost half (47 %) of all malignant
brain tumours are glioblastomas. They are considered extremely difficult to treat as their 5-year
overall survival is only 5.5 % (Ostrom et al., 2017).
Besides clinical and genetic parameters, differential diagnosis is primarily based on multimodal
magnetic resonance imaging (MRI) including imaging with contrast agent, diffusion-weighted or
diffusion tensor imaging, magnetic resonance (MR) perfusion and spectroscopy. Diagnostic im-
ages contribute to a better definition of the tumour or surgical cavity, surrounding oedema and
healthy tissues. Subsequently, MR images are used in the phase of delineation of treatment
volumes and OARs for RT treatment planning.
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Malignant tumours (32%)
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Figure 2.1: Yearly incidence rates of primary brain tumours. Adapted from Ostrom et al. (2017). WHO
grades are given in Roman numerals.
5
2 Theoretical background
2.1.1 Gliomas
Gliomas arise from glial or precursor cells and comprise glioblastomas, astrocytomas, and oligo-
dendrogliomas. Primary treatment of most gliomas is surgery aiming at maximum resection
safety, as the extent of resection determines survival and functional status in LGG (van den Bent
et al., 2017b) and HGG (Chaichana et al., 2014; Noorbakhsh et al., 2014). Postoperative treat-
ment depends on tumour classification and risk stratification of the patient. It includes either RT
or chemotherapy (CTx) or a combination of both. Unresectable tumours are generally treated
with chemoradiotherapy (CRT).
Diffuse low-grade gliomas (WHO grade II) The 5-year survival rate of patients with diffuse
oligodendrogliomas grade II and diffuse astrocytomas grade II are 81 % and 50 %, respectively
(Lapointe et al., 2018). For low-risk patients, the European Organisation for Research and Treat-
ment of Cancer (EORTC) 22845 trial recommends a postoperative watch-and-wait with regular
MRI follow-up (van den Bent et al., 2005; Weller et al., 2017). For isocitrate dehydrogenase
(IDH)-mutant high-risk patients, standard of care is adjuvant RT with doses of 50 – 54 Gy fol-
lowed by chemotherapy with procarbazine-lomustine-vincristine (PCV) or temozolomide (TMZ)
(Karim et al., 1996; Shaw et al., 2002; Buckner et al., 2016; Weller et al., 2017).
Diffuse high-grade gliomas (WHO grade III) The 5-year survival rate of patients with anaplas-
tic oligodendrogliomas grade III and anaplastic astrocytomas grade III are 57 % and 30 %, respec-
tively (Lapointe et al., 2018). Patients with high-grade gliomas are treated with postoperative
combination treatment including radiation with doses of 60 Gy and adjuvant chemotherapy with
PCV. For specific patient groups, the combination of RT and adjuvant chemotherapy with TMZ
improves overall survival (van den Bent et al., 2017a).
Glioblastomas (WHO grade IV) Glioblastomas are the most aggressive brain tumours. On
average, only 5.5 % of glioblastoma patients are still alive 5 years after diagnosis (Ostrom et al.,
2017). Standard of care of patients with glioblastomas and Karnofsky performance status ≥ 60 is
adjuvant CRT including RT with doses of 60 Gy and concomitant and adjuvant TMZ (Stupp et al.,
2005). For elderly patients (age ≥ 70 years), a hypofractionated RT regimen with a total dose of
40.05 Gy in 15 daily fractions with or without concomitant and adjuvant TMZ reduces treatment
time (Perry et al., 2017).
2.1.2 Meningiomas
Meningiomas are commonly slow-growing and well-circumscribed tumours that originate from
the meninges (Whittle et al., 2004). Most meningiomas are benign (90 %, WHO grade I), but they
also occur in atypical (5 – 7 %, WHO grade II) and anaplastic (1 – 3 %, WHO grade III) forms
(Whittle et al., 2004). Meningiomas can reach considerable sizes and displace the brain of the
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contralateral hemisphere. Treatment varies depending on the WHO grade, site and size of the
lesion, symptoms and age of the patient (Wilson, 1994; Black et al., 2001). Primary treatment of
operable patients is surgical resection (Whittle et al., 2004). Curative RT is indicated in case of
inoperability or if surgery is refused by the patient. Incompletely resected or inoperable atypical
or anaplastic meningiomas are indications for RT with doses up to 60 Gy (Hug et al., 2000).
Symptomatic patients or progressive meningiomas grade I may benefit from normo-fractionated
RT with doses of 50 – 54 Gy (Rogers et al., 2015). Stereotactic radiosurgery or fractionated
stereotactic RT is a primary treatment option for small meningiomas grade I (Rogers et al., 2015).
As RT can achieve a similar outcome in terms of local tumour control as surgery, RT may be
considered as primary treatment option for small tumours (Pollock et al., 2003).
2.1.3 Pituitary adenomas
Pituitary adenomas are classified according to their size on MRI (Raverot et al., 2014). About
one-third of pituitary adenomas are clinically nonfunctioning adenomas. Functioning adenomas
secrete excess hormones, such as prolactin (prolactinoma), growth hormone or adrenocorti-
cotropic hormone (Molitch, 2017). The initial treatment for most pituitary adenomas except for
prolactinomas is transsphenoidal surgical resection of the tumour. The first treatment option for
prolactinomas are dopamine agonists (Casanueva et al., 2006). In the cases of inoperability,
tumour recurrence or progression after surgery or in patients with functioning pituitary adenomas
with increased hormone levels after medical therapy and radical resection, RT is indicated (Loef-
fler and Shih, 2011). Single fraction stereotactic radiosurgery with doses of 14 – 18 Gy is suitable
for microadenomas or small macroadenomas that are not in the immediate vicinity of the optic
nerves or chiasm. Pituitary adenomas are irradiated with normo-fractionated doses between 45.0
– 54.0 Gy (Loeffler and Shih, 2011).
2.1.4 Tumours of the skull base
This term is used to describe both lesions of the skull base that can invade the cranial cavity,
neck or face and lesions of the brain, face and neck that are adjacent to the skull base (Mazzoni
and Krengli, 2016; Kunimatsu and Kunimatsu, 2017). Since the skull base consists of a multitude
of different tissues such as meninges, bone, cartilage, soft tissue, nerves and nerve sheaths,
benign and malignant skull base tumours have extremely heterogeneous histologies. Surgery
and RT are the most relevant treatment options for skull base tumours. As these tumours are
often located in the proximity of vital structures such as the brain stem, optic pathways, inner
and middle ear, cranial nerves and major vessels, complete resection is limited in many cases.
Post-operative RT is applied either as stereotactic RT for small and simple-shaped lesions or with
highly conformal RT techniques for larger lesion and complex shapes (Fossati et al., 2016).
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2.1.5 Role of proton beam therapy
No RCTs are available confirming any clinical benefit of PBT over XRT in CNS tumours (Combs,
2017). Use of PBT in brain tumours is mainly justified with a potential reduction of side effects,
i.e. neurocognitive sequelae or secondary malignancies (Combs, 2017). Tumours located in the
immediate vicinity of OARs, such as brain stem, chiasm or optic nerves, may benefit from PBT.
Due to the sharp dose gradient close to the tumour, high doses can be applied to the tumour
while sparing OARs. In patients with LGG treated with PBT, stable neurocognitive function and
QoL was observed (Sherman et al., 2016). A multicentre study on patients with LGG reported
acute side effects of grade 1 and 2 following PBT: 81 % alopecia, 78 % dermatitis, 47 % fatigue
and 40 % headache. No acute side effects grade ≥3 were observed (Wilkinson et al., 2016).
Moreover, PBT offers the option of dose escalation that may lead to increased tumour control
for HGGs (Fitzek et al., 2001), atypical meningiomas (McDonald et al., 2015) and for chordoma
and chondrosarcoma of the skull base (Palm et al., 2019). Since radioresistant chordomas and
chondrosarcomas have to be treated to high radiation doses (> 70 Gy) but are adjacent to critical
organs, they were among the first entities to be irradiated with protons (Mazzoni and Krengli,
2016). Due to the more favourable outcome of PBT (5-year locoregional control of 46 – 81 %)
compared to XRT (15 – 65 %), PBT is considered the gold standard for chordomas (Fossati et al.,
2016; Combs, 2017).
In case of re-irradiation of tumour recurrences, the applied total dose to the tumour may have
to be reduced as the normal tissue may have been damaged during the primary course of RT.
To reduce the dose exposure of the pre-irradiated normal tissue during re-irradiation, PBT could
be a treatment option (Glimelius et al., 2009).
Because available evidence is still limited, especially concerning to long-term side effects, there
are a few ongoing trials comparing proton and photon RT of different techniques. These in-
clude preference-based non-randomised studies (NCT02824731, 2016) and RCTs for grade II/III
glioma (NCT03180502, 2017) and glioblastoma (NCT01854554, 2013; NCT02179086, 2014).
2.2 Radiotherapy with photons and protons
The effect of RT treatment is based on energy transfer to tumour cells to prevent further tumour
growth and subsequently eliminate the malignant cells. The mean absorbed energy per unit
mass is defined as energy dose D. Both photons and charged particles are used to deposit dose
in the tumour. Because of fundamental differences in their physical properties, the resulting dose
distributions vary mainly in their depth-dose distributions. This section summarises the basic
biological effects of radiation as well as physical principles of RT with charged and uncharged
particles and their impact on treatment planning for both radiation types used in this thesis: pho-
tons and protons.
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2.2.1 Biological effect of radiation
The critical target of radiation-induced tumour cell death is deoxyribonucleic acid (DNA) (Wouters
and Begg, 2009). DNA damage may inhibit cell proliferation and thus tumour growth and metas-
tatic spread. Radiation can directly ionise molecules within the DNA but more often the DNA is
indirectly affected. Radiation may create chemical radicals, e.g. by ionising cellular water, that
in turn damages the molecular structure. The most effective damages to DNA are complex
or clustered double-strand breaks as the probability of repair is low. Particles with high linear
energy transfer (LET) will more likely cause complex double-strand breaks due to multiple in-
teractions with the same structure alongside a single particle trajectory. For low-LET radiation,
double-strand breaks are more likely induced by single sublethal damages of several indepen-
dent particle trajectories. Accumulation of multiple sublethal damages can finally cause lethal
damage (Krieger, 2012).
Tumour cells are less efficient in repair of DNA damage compared to late-responding normal
tissue cells with slow cell division. Thus, the total dose is generally applied in fractions to allow
healthy cells to recover during the time between daily fractions. Standard fractionation for curative
treatment is 1.8 – 2.0 Gy per fraction, five fractions a week (Baumann and Grégoire, 2009). The
biological effect of different fractionation schemes can be calculated with the linear-quadratic
model, that characterises the survival fraction S/S0 of an original cell population S0 irradiated with
dose D by
S/S0(D) = e−(αD+βD
2), (2.1)
where α and β are tissue-specific parameters describing the mechanisms of cell damage (Joiner,
2009). The ratio α/β characterises the steepness and bend of the survival curve. The α/β ratio
is a widely used parameter to characterise the radiosensitivity and repair capacity of tumour and
normal tissues: the greater α/β the lower its repair capacity. Since the α/β ratio for tumours
is considerably higher than for late responding normal tissues, healthy tissue can be spared
from lethal damage. The biological effect of different fractionation schemes is determined by
converting the total dose into a biologically equivalent dose delivered in 2 Gy fractions. This
equivalent dose EQD2 is calculated by
EQD2 = D ·
α/β + d
α/β + 2 Gy
(2.2)
where d is the dose per fraction in Gy and D is the total dose of the alternative fractionation
scheme (Joiner and Bentzen, 2009).
To compare the biological effects of different types of radiation, the radiobiological effectiveness
(RBE) was introduced. RBE is the ratio of the absorbed dose of a reference radiation type Dref
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and the absorbed dose of the investigated radiation type Dtest, which is required for the same
biological effect under otherwise identical experimental conditions (Krieger, 2012)
RBE =
Dref
Dtest
⃓⃓⃓⃓
⃓
same biological effect
. (2.3)
Photon radiation is often set as a reference. RBE does not only depend on the radiation
type and the specific biological effect, but also on LET and dose. For proton beams in clinical
applications, RBE is considered constant at 1.1. However, with increasing LET along the proton
path, RBE increased up to 1.7 at the distal dose fall-off in preclinical studies (Paganetti, 2014).
Although these RBE variations are reported (Paganetti and van Luijk, 2013; Lühr et al., 2018;
Willers et al., 2018), to date, a constant RBE has been accepted and used in clinical practice
(Paganetti et al., 2002). Hence, in PBT, the physical dose with its unit Gy is weighted by the RBE
factor 1.1 and the unit of this biological dose is renamed to Gy(RBE).
2.2.2 Basic physical principles of radiotherapy
Energy transfer and deposition in exposed tissues is caused by interactions of radiation with
matter. These interactions differ depending on whether the radiation particles are charged or
not. Charged particles such as protons ionise directly, i.e. the radiation field interacts directly with
biomolecules. Uncharged particles, however, ionise indirectly, i.e. effects on biomolecules are
caused by radiation-induced free water radicals (Krieger, 2012).
Photon radiotherapy An electron linear accelerator is used to produce high-energy photon
beams with nominal beam energies between 4 MeV and 18 MeV. In historical analogy to diag-
nostic X-ray tubes, nominal beam energies are usually expressed in terms of acceleration volt-
ages in the unit MV. To produce high-energy photons, electrons are accelerated in a waveguide
and deflected onto a tungsten target. There, the kinetic energy of the electrons is converted into
photon energy (bremsstrahlung). Photons in the given energy range interact with matter mainly
by incoherent scattering. In such a process, a photon collides with a shell electron of an atom
in the tissue, thereby transferring a part of the photon energy onto the scattered electron. The
collision causes the electron to recoil and a new low-energy photon to be emitted into a different
direction. This recoil electron may ionise many other atoms in the surrounding matter. Further
interactions of photons with matter are coherent scattering, photoelectric effect, pair and triplet
production and photodisintegration (Krieger, 2012). However, the probabilities for such interac-
tions are very low for therapeutic photon energies and the atomic composition of human tissue.
As photons pass through matter, the photon fluence is continuously attenuated according to the
Beer-Lambert law. Thus, a photon beam has no finite range. These properties are reflected in
the depth dose curve, see figure 2.2. In the built-up region, the dose increases to the dose maxi-
mum at a depth of a few centimetres depending on the initial photon energy and then decreases
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exponentially (Krieger, 2012). Due to these physical properties, it is impossible to deliver high
doses to deep-seated tumours while simultaneously sparing normal tissues with one single beam
direction. Thus, the clinical dose is applied by multiple beams from different directions, whereby
the dose contributions of every single beam superimpose in the target.
Proton beam therapy Protons for clinical applications are accelerated to therapeutical energies
up to 250 MeV using circular accelerators such as cyclotrons (Krieger, 2012). In contrast to
photons, charged particles usually lose their kinetic energy in many individual steps as they pass
through matter and are slowed down continuously until they stop at a finite range depending on
their initial energy. Energy losses are mainly caused by multiple interactions with the electron
shells (ionisation and excitation) and by generating bremsstrahlung in the electric field of the
atomic nuclei. For therapeutic proton energies and for the atomic composition of human tissue,
stopping of protons is dominated by interactions with electrons.
The loss of energy per unit path length is defined as the stopping power of a material. Most of
the initial proton energy is transferred at the end of its trajectory. This region of high dose is called
Bragg peak (Krieger, 2012). Its location is determined by the initial proton energy, see figure 2.2.
If beams with different initial proton energies and intensities are superimposed, the high dose
region can be extended to cover an entire tumour volume from a single beam direction. This
area is called spread-out Bragg peak (SOBP). As protons stop entirely after travelling a certain
distance, the normal tissue behind the Bragg peak can be almost completely spared from dose.
Thus, tumour coverage and sparing of healthy tissue can be achieved with few beams.
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Figure 2.2: Depth dose curves of photon and proton beams in water. A monoenergetic proton beam and a
spread-out Bragg peak (superimposition of monoenergetic proton beams of different energies) are shown.
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2.2.3 Field formation in radiotherapy
The techniques of radiation therapy have been continuously developed to achieve a more confor-
mal dose distribution to spare healthy tissue. This process was mainly driven by the introduction
of three-dimensional image modalities and multi-leaf collimators as well as the development of
inverse planning techniques.
Photon radiotherapy XRT started with single conformal fields in simple anterior-posterior beam
configurations. With the introduction of computed tomography (CT) and sufficient dose compu-
tation capacities, three-dimensional conformal radiotherapy (3D-CRT) was developed. In this
technique, single fields with a homogeneous beam profile are applied from several determined
beam directions. This homogeneous beam profile is created by a flattening filter inserted in the
beam directly behind the tungsten target. Each field is laterally collimated to the target volume
using a multi-leaf collimator.
Nowadays, 3D-CRT is more and more replaced by inverse planning techniques with inhomo-
geneous fluence profiles. In these techniques, a single field is divided into multiple segments.
For each field segment, the dose rate as well as the dose output is modulated. The segment is
shaped using a multi-leaf collimator. The radiation technique is called IMRT if several fixed beam
directions are used or volumetric modulated arc therapy (VMAT) if the radiation is delivered while
the modulated beam rotates around the patient, see figure 2.3. Inverse techniques are seen as
state-of-the-art XRT as they offer high conformity while sparing normal tissues.
Figure 2.3: Radiotherapy techniques. A Proton beam therapy in double scattering (top) and pencil-beam
scanning technique (bottom). B In photon volumetric modulated arc therapy (VMAT), radiation is delivered
while the modulated beam rotates around the patient. Adapted from Jakobi (2015).
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Proton beam therapy Two different PBT delivery methods were applied in this work: passive
double scattering (DS) and active pencil-beam scanning (PBS), see figure 2.3. In DS, an SOBP
is generated by a set of range modulator wheels or ridge filters that produce a spectrum of proton
energies. The SOBP covers the target volume in beam direction. Since the beam generated in
the cyclotron is very narrow, it is broadened by two scattering materials to cover the target laterally
with a uniform dose profile. A field-specific collimator (aperture) conforms the dose laterally to
the target volume and a milled range compensator aligns the dose to the distal edge of the target.
With this technique, the dose cannot be adjusted to the proximal edge of the target.
In PBS techniques, narrow monoenergetic proton beams are deflected by sweeper magnets.
Each monoenergetic beam scans the target volume along a two-dimensional grid in a determined
energy layer. To cover the entire target volume, successive energy layers are scanned in beam
direction. The penetration depth of the Bragg peak is adjusted by varying the beam energy using
an energy degrader. Since the proton minimum energy is fixed due to technical constraints,
targets directly below the body surface cannot be covered. For superficial tumours, a uniform
material is inserted into the beam to reduce its energy. According to its function, this material
(e.g. plastic) is called range shifter (Shen et al., 2015).
2.2.4 Target definition and delineation of organs at risk
Imaging modalities CT scans are performed in preparation of RT treatment planning. They
contain information on tissue electron density. The anatomy is visualised by grey values in
Hounsfield units (HU). The HU scale represents the photon attenuation coefficient of tissue in
relation to that of water. The tumour as well as several OARs are delineated based on the
planning CT scan. For optimal soft tissue differentiation, information drawn from MRI scans are
considered. Commonly used sequences for the delineation of brain tumours are T1-weighted,
T2-weighted and fluid-attenuated inversion recovery (FLAIR) with and without contrast agent
(gadolinium). A functional imaging technique that visualises metabolic processes depending on
the applied biologically active tracer molecule is positron emission tomography (PET). For brain
tumour patients, the amino acid PET tracer 11C-methionine is frequently used in some centres
(Glaudemans et al., 2013).
Target definition The delineation of the target volume based on several diagnostic modali-
ties is an essential step in the RT planning process. All macroscopic tumour volumes (primary
tumour, metastatic regional nodes or distant metastases) are delineated in the gross tumour vol-
ume (GTV). In addition to the macroscopic tumour volume, the clinical target volume (CTV) also
includes volumes in which proliferating tumour cells (microscopic tumour) are suspected (ICRU,
2010).
In general, the CTV underlies intra- and interfractional spatial displacements due to e.g. organ
movement, daily patient setup variations, dose calculation approximations and uncertainties in
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beam delivery. To ensure that the prescribed dose is still delivered to the CTV, the International
Commission on Radiation Units and Measurements (ICRU) introduced the planning target volume
(PTV) concept for XRT (ICRU, 1999). The PTV is created by applying safety margins to the CTV.
Margin sizes vary depending on tumour location with respect to moving organs, applied radiation
technique, image-guided radiotherapy (IGRT) regimes and patient immobilisation devices.
For PBT, however, there is a further uncertainty in beam direction. This is due to the PBT dose
calculation algorithm which uses the proton stopping power of the traversed materials. For this
sake, photon derived HU values are converted into relative stopping power values in the planning
CT scan. This is achieved by conversion schemes having uncertainties (Paganetti, 2012). The
uncertainty is different in lateral direction to that in beam direction and depends on the location
of the tumour. Thus, the PTV concept of XRT cannot easily be employed. Instead, non-uniform
margins are applied. Treatment planning with DS technique assumes an uncertainty in the proton
beam range of a specific percentage plus an additional absolute margin (Paganetti, 2012). For
PBS, these uncertainties are included in robust optimisation and evaluation (Liu et al., 2012).
Delineation of organs at risk Delineation of OARs is essential for optimisation and assess-
ment of a treatment plan. For patients with brain tumours, the following OARs should be con-
sidered: brain stem, chiasm, optic nerves, lacrimal glands, eye lenses, cochleae or inner ears,
brain excluding the target volume, and depending on the tumour location spinal cord and salivary
glands (Wright et al., 2019). For treatment planning and assessment as well as consistency in
multi-centre clinical trials, OARs should be contoured according to standardised guidelines on CT
and MR images. For the sake of NTCP modelling or retrospective studies, it may be necessary
to delineate further OARs.
2.2.5 Treatment plan assessment
In general, an RT treatment plan of an individual patient is assessed with regard to a balance of
risks and benefits based on clinical experience: Benefits in terms of sufficient tumour coverage
and risks in terms of acceptable doses to normal tissues. For treatments with curative intent, un-
derdosage of the tumour may be more serious than normal tissue complications as local tumour
recurrences are difficult to manage (Marks et al., 2010). The dose distribution is visualised with
isodoses to evaluate target coverage and dose conformity as well as to detect undesired dose
maxima, see figure 2.4.
The commonly used tool to evaluate dosimetric parameters of target volumes and OARs is the
dose-volume histogram (DVH). Figure 2.5 shows an exemplary DVH of an OAR for two different
treatment plans, one VMAT and one PBS plan. The ICRU proposed a standardised assessment
of treatment plans (ICRU, 1999; ICRU, 2007; ICRU, 2010). Common criteria are the volume of
a structure receiving x Gy (VxGy ) and the dose in x% of the volume of a structure (Dx%). To
achieve sufficient tumour coverage and avoid high doses exceeding the prescribed dose, mean,
14
2.2 Radiotherapy with photons and protons
Figure 2.4: Dose distributions for a patient with oligodendroglioma grade III. The clinical and planning
target volumes are delineated in red and brown, respectively. A Proton treatment plan created with double-
scattering technique. B Photon treatment plan created with VMAT technique.
minimum and maximum dose values in the target should be close to the prescribed dose. There-
fore, the near-minimum and near-maximum parameters D98% and D2% of the target volumes
are usually evaluated. Additionally, the parts of the target volumes receiving 95 % or 107 % of the
prescribed dose (V95% and V107%) are assessed. To evaluate how well the dose distribution
conforms to the size and shape of the target volume, conformity indices are calculated. A widely
used conformity index CI was developed by Paddick (2000):
CI =
TV 2isodose
TV · Visodose
, (2.4)
where TVisodose represents the part of the absolute target volume (CTV or PTV) receiving the
considered dose (V95% or V98% of the target volume). TV describes the absolute target volume
and Visodose the absolute volume of the external structure (body) exposed to the considered dose.
CI = 1 indicates 100 % conformity, while CI = 0 means total failure.
The homogeneity index HI characterises the uniformity of the dose distribution in the target:
the lower the score, the higher the uniformity of the plan. It is defined by the ICRU (2010) as
HI =
D2% − D98%
D50%
, (2.5)
where D2%, D98% and D50% refer to the investigated target volume (CTV or PTV). To evaluate
the risk of radiotoxic normal tissue doses, DVH parameters are compared to clinical population-
based constraints for different OARs. Such constraints have been summarised in organ-specific
publications by Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) (Marks
et al., 2010). Although a number of NTCP models for certain complications have been developed,
the calculation of numerical complication probability for individual patients is rarely done in clinical
routine (Bentzen et al., 2010).
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Figure 2.5: (A) Cumulative and (B) the corresponding differential DVH of the ipsilateral frontal lobe for a
patient with astrocytoma treated to 60 Gy(RBE). Proton treatment was planned using a DS technique and
the comparable photon treatment was planned using a VMAT technique.
2.3 Patient outcome
As many types of cancer are life-threatening, tumour control has a high priority in cancer treat-
ment. However, radical treatment is often limited as surrounding healthy organs will lose their
functions. Already in the early years of RT, Holthusen (1936) described the probability of achiev-
ing tumour control and developing normal tissue damage following RT as a function of radiation
dose, see figure 2.6. The difference between doses required for tumour control and tissue toler-
ance doses is referred to as the therapeutic window (Joiner et al., 2009). Efforts have been made
to widen the therapeutic window by increasing tumour control and decreasing the risk of side
effects by introducing new technologies or biological modulation (Combs, 2017). The different
measures of tumour control, as well as normal tissue complications, are explained in this section.
2.3.1 Scoring of side effects
Radiation dose does not only affect the tumour but also damages normal tissue. Over time,
many centres developed own scales for reporting the severity of side effects. Thus, it was nearly
impossible to compare the outcome of clinical studies conducted at different centres in terms of
normal tissue toxicity (Pavy et al., 1995). Therefore, a standardisation of the scoring procedure
was (and still is) an important task, especially when conducting prospective multi-centre trials.
To achieve uniform reporting of side effects different scoring systems defining a multitude of
possible injuries have been developed and are regularly updated, especially by the Radiation
Therapy Oncology Group (RTOG) and EORTC.
Proliferating tissues, such as epithelial tissues, are the first to respond to radiation dose leading
to normal tissue reactions during or shortly after RT. Side effects that occur up to 90 days after
treatment are referred to as early (acute) side effects. They usually heal completely, but may
also turn into consequential late effects in case of very severe acute toxicities. Non-proliferating
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Figure 2.6: Schematic dose-response curves for tumour control and severe normal tissue complication.
Adapted from Karger (2018).
tissues may react months or years after RT leading to late (chronic) side effects. These injuries
are often permanent or even increase in their severity leading to serious organ dysfunction. Es-
pecially for patients with a long life expectancy, chronic side effects play an important role. Con-
sequently, they are often chosen as study endpoints in clinical trials. In 1995, the late effects of
normal tissues – subjective, objective, management and analytic (LENT-SOMA) scale has been
developed to standardise the reporting of late side effects (Pavy et al., 1995; Rubin et al., 1995).
Generally, the scoring systems are used by physicians to assess the dysfunction of more or less
single organs.
In this work, the widely used scoring system Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0 by the US National Cancer Institute (2009) was employed. This scale covers
a range of five grades of severity: mild (1), moderate (2), severe (3), life-threatening (4) and death
(5). A revised version 5.0 has been published by the National Cancer Institute (2017).
Side effects following cranial irradiation Early side effects following cranial irradiation include
rather unspecific reactions such as fatigue, somnolence, headache, nausea or vomiting and less
frequent vertigo and seizures (Lawrence et al., 2010). Fatigue may be associated with irradiation
of the brain stem (Ferris et al., 2018) and the cerebellum (Gulliford et al., 2012b) and simultane-
ous CTx, even though the mechanism of fatigue remains very often unknown. These symptoms
are transient and can be treated with pharmaceutical drugs. Skin reactions such as alopecia
(complete or partial hair loss) and erythema are also common (Salvo et al., 2010). Late side ef-
fects comprise radiation-induced brain necrosis (Burman et al., 1991; Shih et al., 2009; Lawrence
et al., 2010), cranial neuropathies (Meeks et al., 2000; Shih et al., 2009) and neurocognitive dys-
function including memory and concentration impairment (Lawrence et al., 2010). Organ-specific
toxicities such as otitis, tinnitus and hearing loss (Burman et al., 1991; Jereczek-Fossa et al.,
2003; De Marzi et al., 2015; Lee et al., 2015), cataract (Kleiman, 2012), dry eye syndrome (Par-
sons et al., 1994), endocrine dysfunction (Constine et al., 1993; Pai et al., 2001; De Marzi et al.,
2015) and visual impairment (Burman et al., 1991; Martel et al., 1997; Brizel et al., 1999), highly
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depend on the tumour location. Table 2.1 summarises side effects and potentially associated
OARs.
2.3.2 Patient-reported outcome measures – Quality of life
Physician-rated assessment of side effects aims to report essential organ dysfunctions objec-
tively. The individual patient may, however, measure a successful treatment result based on
further criteria, such as the ability to work, sleep and conduct daily activities, social participa-
tion or even outward appearance. Therefore, patient-reported outcome (PRO) measures that go
beyond pure organ functions are becoming increasingly important in clinical studies, as they pro-
vide a more comprehensive picture of the success of the treatment in terms of patients’ quality of
life. There are also efforts to combine the physician-rated symptoms using the CTCAE with the
patients’ point of view in so-called PRO-CTCAE™ (Basch et al., 2014).
A multitude of quality of life questionnaires (QLQs) have been developed for various diseases
and even different types of cancer or tumour location, for example, the Functional Assessment
of Cancer Therapy (FACT) (Cella et al., 1993), Rotterdam Symptom Checklist (de Haes et al.,
1990) or Symptom Distress Scale (McCorkle and Young, 1978). The Quality of Life Group of the
EORTC has developed an integrated instrument for assessing QoL for cancer patients partici-
pating in clinical trials. The quality of life core questionnaire (QLQ-C30) addresses issues that
patients with all types of cancer may experience. The supplementary modules focus on spe-
cific symptoms and functions for different tumour entities. The EORTC QLQs including symptom
and functional scales have been thoroughly tested and validated and are available in different
languages (Bottomley et al., 2005). The EORTC questionnaires employed in this thesis are pre-
sented in the following.
Core questionnaire QLQ-C30 This questionnaire comprises 30 questions that are combined
into five functional scales, nine symptom scales and global health status. The functional scales
address physical, role, social, emotional and neurocognitive function. The symptoms are fatigue,
Table 2.1: Side effects following cranial radiotherapy and potentially associated organs at risk.
Side effect Associated organs at risk
Alopecia Hair follicle within the skin
Cataract Eye lenses
Cranial nerve failure Associated cranial nerve
Dry eye syndrome Lacrimal glands
Erythema Skin
Fatigue Brain stem, cerebellum
Hearing impairment Cochlea, inner ear
Hypopituitarism Pituitary
Memory impairment Hippocampus, potentially further brain areas
Nausea Brain stem or brain tissue
Radiation-induced brain necrosis Brain stem of brain tissue
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nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea and finan-
cial difficulties (Aaronson et al., 1993), see appendix A table A.1.
Brain tumour module QLQ-BN20 The brain tumour-specific quality of life questionnaire (QLQ-
BN20) only includes symptom scales that are specific for brain tumour patients: future uncer-
tainty, visual disorder, motor dysfunction, communication deficit, headaches, seizures, drowsi-
ness, itchy skin, hair loss, weakness of legs and bladder control (Taphoorn et al., 2010), see
appendix A table A.2.
Analysis of quality of life scales A QLQ comprises various questions, so-called items. For
evaluation, these questions are translated into symptom and functional scales. For some of
these scales, only one single question is used (single-item measures), while for others several
questions are combined to form a single score (multi-item measures). All questions are only used
once on different scales. The scoring of the scales is described by Fayers et al. (2001). First, the
raw score RS is calculated as the average of all n items Ii that together form one scale
RS =
∑︁n
i=1 Ii
n
. (2.6)
The raw score is then standardised to the final score S using a linear transformation to the interval
[0, 100]. On symptom scales, high scores represent a high level of symptomatology. High scores
for functional scales, however, represent a healthy level of functionality. This is taken into account
when calculating the score S
Functional scales S = 100 ·
(︄
1 − RS − 1
range
)︄
, (2.7)
Symptom scales S = 100 ·
(︄
RS − 1
range
)︄
, (2.8)
in which range is defined as the difference between the minimum and maximum possible value
of RS. For most items, range = 3 as they are scored from 1 to 4 with the following meaning: 1
not at all, 2 a little, 3 quite a bit and 4 very much. Global health status includes 7-point questions
with range = 6.
Some patients may avoid answering questions. To handle such missing items, the EORTC
QLQ-C30 Scoring Manual suggests the following: If at least half of the items have been answered
a score is calculated from all available items, otherwise it is set to missing (Fayers et al., 2001).
Interpretation of quality of life scores To interpret the scores of the above-mentioned EORTC
QLQ they can be compared to published data from healthy populations or other cancer patients.
Examples are the EORTC QLQ-C30 Reference Values Manual (Scott et al., 2008) or data from
a large Swedish population (Michelson et al., 2000). The clinical relevance of score differences
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between patient groups or changes over time can be classified into no change, a little, moderate
and very much for absolute differences in QoL scores of 0.0 – 4.9, 5.0 – 9.9, 10.0 – 19.9 and
≥ 20.0, respectively (Osoba et al., 1998).
2.3.3 Measures of neurocognitive function
Neurocognitive dysfunction is a frequent treatment or tumour sequela among long-term brain
tumour survivors, such as patients with benign tumours or LGG with prolonged survival (Buckner
et al., 2016) and young median age at diagnosis (Béhin and Delattre, 2003). Also for HGG
patients, who have a short life expectancy, an important goal of treatment is the preservation of
high QoL (Macdonald et al., 2005). Thus, several clinical trials in brain tumour patients include
the assessment of neurocognitive function as a relevant outcome measure (Taphoorn and Klein,
2004; Correa, 2010; Schagen et al., 2014).
Neurocognitive sequelae may be caused by a variety of tumour-, patient- or treatment-related
factors. These may also act synergistically although the exact mechanisms of neurocognitive
dysfunction are not yet fully understood (Klein et al., 2002; Klein et al., 2003; Taphoorn and
Klein, 2004). According to the interval between RT and the onset of CNS injury, neurocognitive
dysfunction can be classified into acute, early delayed (subacute) and late delayed (Correa, 2010;
Makale et al., 2017), see figure 2.7.
Several studies could not demonstrate an association between neurocognitive deficits and XRT
(Armstrong et al., 2002; Klein et al., 2002). Other comparative studies on irradiated and non-
irradiated LGG patients observed neurocognitive deficits (Surma-aho et al., 2001) as well as a
decline in memory (Correa et al., 2007; Armstrong et al., 2012) or in attentional and executive
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days to weeks
fatigue, nausea and vomiting, inflammation
Early delayed
one to four months
neuroinflammation, transient demyelination
somnolence, cognitive deficits
extensive and persistent cases are responsive to steroids
Late delayed
four-six months to one year
demyelination, white matter damage (necrosis)
loss of oligodendrocytes, neuronal precursors
gliosis, neuroinflammation
other poorly defined damage
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Figure 2.7: Time course of radiation-induced neurocognitive dysfunction. Adapted from Makale et al.
(2017).
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functioning (Douw et al., 2009). Both, radiation dose and volume of healthy brain tissue exposed
to radiation, appear to be determining factors of neurocognitive function (Brown et al., 2003;
Laack and Brown, 2004). In particular, the irradiation of certain structures of the brain such as
the cerebellum (Merchant et al., 2014; Eekers et al., 2017) or the hippocampus (Gondi et al.,
2012) may cause neurocognitive dysfunction. Thus, new RT techniques have been developed
to spare these structures (Gondi et al., 2014; Kazda et al., 2014; Tsai et al., 2015; Zhao et al.,
2017).
So far, most studies on neurocognitive function following PBT have been conducted in paedi-
atric populations that generally showed neurocognitive preservation (Greenberger et al., 2014;
Kahalley et al., 2016; Yang et al., 2019) or low decline in certain patient subgroups, for example,
young children (Greenberger et al., 2014), patients receiving high doses to the left hippocampus
(Greenberger et al., 2014; Zureick et al., 2018) and patients treated with craniospinal irradiation
(Pulsifer et al., 2018). Studies describing the neurocognitive outcome of adult brain tumour pa-
tients treated with protons are rare. In a small cohort of 20 adult LGG patients treated with PBT
no evidence for an overall decline in neurocognitive function or QoL could be observed (Shih
et al., 2015; Sherman et al., 2016).
Although neurocognitive dysfunction is an important side effect, it is difficult to measure. Along
with extensive neuropsychological assessment, a variety of rather objective and standardised
test batteries for neurocognitive outcome have been developed (van Loon et al., 2015). A com-
monly used test is the Mini-Mental State Examination (MMSE), as it requires only a short time
to complete (Folstein et al., 1975). Among brief screening instruments, the Montreal Cognitive
Assessment (MoCA) test (Nasreddine et al., 2005) showed superior sensitivity in detecting neu-
rocognitive impairment compared to the MMSE, 61.9 % vs 19.0 % at pre-defined cut-off scores
(Olson et al., 2011a). Since the MoCA test was analysed in this thesis, it is briefly described
below.
The Montreal Cognitive Assessment test The MoCA test was developed as a brief screening
tool to detect mild cognitive impairment (Nasreddine et al., 2005). Nevertheless, the MoCA test
has already been used in patients with brain tumours (Olson et al., 2008; Olson et al., 2011b).
It is available in both paper-and-pencil and electronic format and in several languages. Thus,
it is applicable regardless of nationality and allows for comparable results over diverse studies.
The MoCA test includes different tasks assessing several neurocognitive domains (visuospatial,
executive, naming, attention, concentration, calculation, language, abstraction, short-term mem-
ory, orientation in time and space). A more detailed explanation of the individual tasks for each
domain is given in appendix A. The single scores of each test sum up to a total score of 30
points. In trials with repeated measurement, learning effects may occur that may compromise
the assessment of neurocognitive function. To minimise these learning effects, three different
test versions have been developed (Cooley et al., 2015).
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The authors of the MoCA test initially suggested that below a test score of 26 mild cognitive
impairment is possible. This cut-off value has been discussed and may vary by age, education
level and ethnicity (Gagnon et al., 2013; Milani et al., 2018; Thomann et al., 2018).
2.4 Normal tissue complication probability models
An essential part of treatment plan assessment is to check whether the present dose distribution
exceeds tolerance doses of affected OARs to avoid severe side effects, see section 2.2.5. These
tolerance doses are results of clinical experience and information about the dose to different
organs, first summarised by Emami et al. (1991). This seminal work has been further developed
by numerous studies investigating the relationship between dose distribution and side effects.
These dose-response relationships can be expressed using various NTCP models. Some of the
different types of NTCP models are presented below.
2.4.1 Types of NTCP models
NTCP models aim to predict the probability of complications based on the dose distribution in
associated irradiated organs. For this, the real three-dimensional dose distribution is reduced
to a few simple metrics. Different methods for modelling clinical outcome data of retrospective
patient cohorts and their dose distributions are described in the following (Gulliford, 2015).
DVH-reduction models Based on the data published by Emami et al. (1991), the empirical
Lyman-Kutcher-Burman model (LKB model) was developed that describes the dose-response as
a function of irradiated volume, reduces DVH to a single metric and estimates model parameters
for specific OARs (Lyman, 1985; Kutcher and Burman, 1989; Burman et al., 1991; Kutcher et
al., 1991). The model parameters are TD50, m and n. The parameter TD50(V ) is the tolerance
dose for uniform irradiation of a partial volume V of an OAR at which 50 % of patients are likely
to experience toxicity. The parameter m represents the slope at the steepest part of the dose-
response curve, see figure 2.6. n indicates the volume effect of the investigated OAR (Gulliford
et al., 2012b). Serially structured organs such as the spinal cord are described by n ≈ 0, while
parallel organs are characterised by n ≈ 1. Taking fractional irradiation into account, the normal
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tissue complication probability for an LKB model NTCPLKB for a uniform dose D to a volume V of
an OAR is given by
NTCPLKB =
1√
2π
ˆ t
−∞
exp
(︄
−u2
2
)︄
du, (2.9)
where t =
D − TD50(V )
m · TD50(V )
, (2.10)
TD50(V ) =
TD50(VOAR)
V n
, (2.11)
where VOAR represents the entire volume of the considered OAR.
However, dose distributions to OARs are actually non-uniform. The inhomogeneous dose dis-
tribution can be reduced to a single metric that produces the same probability of a given side
effect as a corresponding uniform dose distribution. Such a metric is the widely used generalised
equivalent uniform dose (gEUD) given by
gEUD =
⎛⎝∑︂
i
ViDai
⎞⎠1/a , (2.12)
where Di is the dose defined for each bin i in a differential DVH, see figure 2.5B. Vi is the volume
in a dose bin i and a is a volume parameter that is equivalent to 1/n. This calculated uniform dose
can then be applied as D = gEUD in the LKB model in equation (2.10).
Tissue-architecture models Models have been developed that consider the functional archi-
tecture of the tissue by introducing functional subunits of an OAR. These can be anatomical
substructures, such as nephrons of the kidney, or the largest cell group that still functions as
long as it comprises a surviving clonogen (Gulliford, 2015). These functional subunits can be
arranged in serial or parallel order, or a combination of both. In parallel organs, functional sub-
units are performing rather independently so that side effects occur after the irradiated volume
exceeds a critical value. Side effects that arise from irradiation of parallel organs rather depend
on the mean dose deposited in these organs (e.g. liver, lung or kidney). This effect is described
in an LKB model with a parameter n ≈ 1. Serially structured organs, such as the spinal cord,
lose their entire organ function when a small area is irradiated with high doses. An LKB model
characterises such an OAR with the parameter n ≈ 0.
Källman et al. (1992) suggested the relative seriality model and Niemierko and Goitein (1993)
presented a critical volume model based on the assumption that NTCP is fully determined by the
number of surviving functional subunits of an OAR.
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Multiple-metric models The above-mentioned models predict the complication probability for
one specific side effect based on the dose to a corresponding OAR. However, some complica-
tions are affected by the irradiation of different OARs, e.g. swallowing dysfunction following the
irradiation of superior pharyngeal constrictor muscle and the supraglottic larynx (Christianen et
al., 2012) or heart valvular dysfunction by the irradiation of heart and lung (Cella et al., 2014).
To correct for this in LKB models, an interaction gEUD variable for both OARs can be introduced
(Cella et al., 2014). Nevertheless, side effects may also be modified by dose-independent clinical
parameters, such as age or radiation technique (Christianen et al., 2012). Multivariable logis-
tic regression models are appropriate to include clinical and dosimetric parameters. They are
defined by
NTCPLogistic =
(︂
1 + e−g(x)
)︂−1
, (2.13)
where g(x) = β0 +
p∑︂
i=1
βi xi , (2.14)
where βi denote model coefficients and xi are p individual explanatory variables.
A probability of 50 % for the occurrence of the considered side effect occurs if the condition
g(x) = β0 +
p∑︂
i=1
βi xi , = 0 (2.15)
is met. For univariable models including a single dosimetric parameter as a predictor, TD50 is
calculated by
TD50 = −
β0
β1
. (2.16)
Models considering the development over time For the analysis of longitudinal toxicity data
with repeated measures, as usual in patient follow-up, a generalised estimating equation (GEE)
approach can be applied (Liang and Zeger, 1986). For a cohort consisting of N patients, each
patient is seen for T follow-up visits. This number of visits T may differ between patients (Agresti,
2002). An observation for patient i ∈ [1, N] at follow-up visit t can be expressed by yit . Thus, all
observations of this patient over time form the vector Yi =
(︁
yi1, ..., yit , ..., yiT
)︁⊺, t ∈ [1, T ]. The
K corresponding explanatory variables for patient i at time t are combined in the vector x it . The
value of variable k is noted with xitk , k ∈ [0, K ]. For k = 0, xit = 1 for all patients. As the side
effects are measured repeatedly for each patient at different follow-up visits, these observations
are assumed to be correlated, but independent across different patients (Agresti, 2002; Wang,
2014). An appropriate link function g(.) relates the explanatory variables to the expected value
E(yit ) = µit via
g(µit ) = x
⊺
itβ, (2.17)
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where β is an unknown vector containing all K regression coefficients (Samur et al., 2014). For
the evaluation of side effects, the severity grades are commonly dichotomised, e.g. grade < 2 vs
grade ≥ 2. For such binary outcome data, yit is either 0 or 1. In this case, the logit function may
be an appropriate link function (Samur et al., 2014).
The regression coefficients βk can be estimated by the solution (e.g. using a maximum likeli-
hood approach) of the GEE
N∑︂
i=1
∂µi
∂βk
V −1i (Yi − µi ) = 0, k ∈ [0, K ] , (2.18)
where Vi indicates the variance-covariance matrix for Yi of patient i . It is expressed by
Vi = ϕA
1
2
i Ri (α)A
1
2
i , (2.19)
where Ai is a T × T diagonal matrix with the variance of Yi as the t-th diagonal element (Liang
and Zeger, 1986), ϕ is a scale parameter depending on the distributions of outcomes and Ri (α)
indexed by a vector of association parameters α represents the working correlation matrix of size
T × T . The working correlation matrix models the dependence of each observation with other
observations for the same patient. The elements of this matrix are the correlations between
the longitudinal observations within a patient. Commonly used working correlation structures for
GEE models are for example independent, autoregressive or unstructured (Wang, 2014). The
advantage of GEE models is that consistent estimates of the parameters can be obtained even if
the working correlation matrix is incorrectly specified (Samur et al., 2014).
2.4.2 Endpoint definition and parameter fitting
Data on side effects should be prospectively collected in clinical trials according to standardised
tests or grading systems for a defined follow-up duration, see section 2.3. For modelling, these
grades or scores may then be dichotomised according to severity (e.g. grade < 2 vs grade ≥ 2).
During univariable modelling, the eligible parameters are preselected. A method for fitting the
model parameters is maximum likelihood estimation (Cella et al., 2014; Gulliford, 2015). To find
the optimal coefficients, the agreement of the predicted outcome with the observed outcome is
maximised. For multivariable logistic regression models, the individual variables should not be
strongly correlated. This should be considered when selecting the appropriate model predictors.
DVH parameters are often correlated within a given cohort that may lead to problems with multi-
collinearity (Bentzen et al., 2010). Principle component analysis may be a method to overcome
this problem (Dawson et al., 2005). However, the principal components consist of various dosi-
metric parameters, which make them appear abstract and are therefore less practical in clinical
routine (e.g. in treatment planning). Cross-validation and bootstrapping ensure generalisability
(Gulliford, 2015).
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2.4.3 Assessment of model performance
Model performance can be assessed in terms of discrimination and calibration. Discrimination
refers to the ability to separate patients who do or do not develop a given side effect. Calibration
compares the predicted and observed outcome (Bentzen et al., 2010).
The discriminating ability of NTCP models can be assessed using receiver-operating charac-
teristic (ROC) analysis by calculating sensitivity and specificity (Gulliford, 2015). Sensitivity and
specificity are calculated from the contingency table of the predicted and observed outcome for
each possible cut-off of the continuous model variable. The ROC curve is a plot of sensitivity
against 1-specificity. The area under the receiver operating characteristic curve (AUC) is a met-
ric that ranges from 0 to 1. A value of 0.5 represents a random prediction, a value of 1 a perfect
prediction. In the medical field, AUC values do rarely exceed a value of 0.8 (Gulliford, 2015).
In a calibration plot, the observed outcome is plotted against the predicted NTCP values. For
perfectly calibrated models, the data points are aligned on the quadrant bisector. Calibration is
important if the models shall predict exact complication probabilities, e.g. for comparison between
different treatment plans.
2.4.4 Model validation
In this thesis, NTCP models are developed on a training cohort and internally validated using
cross-validation. Model performance has to be checked by applying the final NTCP model with
unchanged model coefficients on an external patient cohort and calculating AUC and the calibra-
tion plot. The Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis
(TRIPOD) Initiative published recommendations for the reporting of development and validation
of prediction models (Moons et al., 2015). The classification of different analysis types is pre-
sented in appendix A table A.3. Testing on an independent dataset from another institution (ex-
ternal validation) may reduce model performance due to different scoring of side effects, patient
demographics and comorbidities or treatment strategies (Bentzen et al., 2010).
2.5 Model-based approach for patient selection for proton beam
therapy
The number of operating proton facilities is increasing. The high technical and time expenditure
leads to high costs of this treatment modality. These high costs and their uncertain reimburse-
ment by health insurance companies limit the capacity for PBT. Therefore, it is important to offer
this treatment to those patients who may benefit most from PBT compared to XRT. However,
there are only a few RCTs that directly compare XRT and PBT, as such studies are complex to
conduct for several reasons (Liao et al., 2018). A feasible approach to meet these challenges
and to identify patients suitable for PBT is the so-called model-based approach (Langendijk et al.,
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2013). In the Netherlands and Denmark, it has already been implemented in clinical practice for
patients with head and neck cancer. This section discusses the need for alternatives to RCTs and
the principles of the two-phase model-based approach as proposed by Langendijk et al. (2013).
2.5.1 Limits of randomised controlled trials
Decisions in healthcare policy and practice are mainly evidence-based. Systematic reviews of
RCTs are considered the highest level of scientific evidence to explain a cause-effect relationship
between treatment and outcome (Burns et al., 2011). In an RCT, patients are randomly assigned
to either a treatment or control group. Ideally, neither patients nor clinicians should know the char-
acter of intervention (double-blind study) (Sibbald and Roland, 1998). These properties make
RCTs the gold standard, e.g. in pharmaceutical research, but they also have disadvantages, es-
pecially in practical and ethical aspects. RCTs are usually expensive and time-consuming. Blind-
ing conditions are not always feasible and reimbursement of costs of experimental treatments
cannot be guaranteed. Ethical concerns may arise, for example, if patients shall be treated only
with a placebo or a presumably less effective therapy.
In contrast to RCTs when comparing systemic therapies, there are challenges in performing
RCTs in RT to compare different techniques and draw general conclusions. When comparing a
new with a conventional irradiation technique, there are many degrees of freedom which may vary
between different institutions. There exists no standard application of RT, neither XRT (Fairchild
et al., 2014; Das et al., 2017) nor PBT (Taylor et al., 2016). Both terms are very general as
they cover a wide variety of techniques (Widder et al., 2016). The heterogeneity between cen-
tres in terms of treatment planning systems, quality assurance, training skills, image guidance,
treatment adaptation, immobilisation strategies etc. may be so pronounced that it may be difficult
to transfer results from RCTs into clinical routine (Widder et al., 2016; Langendijk et al., 2018).
Hence, alternative approaches need to be applied to generate evidence.
The dose distribution characteristics of PBT compared to XRT allow for two different treatment
strategies. On the one hand, dose-escalation in the target region can be achieved without addi-
tional exposure to adjacent normal tissues. Dose escalations to increase tumour control should
be investigated in the context of RCTs, as it is not known whether tumour control actually im-
proves and to what extent side effects are induced (Langendijk et al., 2018). On the other hand,
healthy tissue can be spared to a higher extent than in XRT while achieving equivalent target cov-
erage. Comparing PBT and XRT in terms of reduced side effects, some obstacles make RCTs
difficult to perform. Late radiation-induced side effects as relevant endpoints of such trials may
manifest many years following RT. Thus, results from large long-term RCTs may be obsolete as
RT (and PBT in particular) is still a rapidly evolving technology (Langendijk et al., 2013). Usually,
all eligible patients are enrolled in an RCT, regardless of their presumed extent of side effect re-
duction under PBT. However, the expected benefits from PBT may vary largely between patients.
An RCT may answer the question whether PBT is generally superior to XRT in terms of reduced
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side effects for certain tumour entities and patient groups, but cannot provide an answer about
the clinical benefits at a patient-individual level. Thus, RCT designs could address the hetero-
geneous extents of treatment effects by the inclusion of NTCP models (Scherman et al., 2019).
Furthermore, to observe a significant difference between both treatment modalities in a small
number of patients and thus a short study duration, a proper preselection of eligible patients is
necessary. Due to this preselection process, the estimated difference in complication probability
between both treatment groups is enhanced, leading to a supposed lack of equipoise. As a result,
RCTs can be considered unethical (Bentzen, 2008; Goitein and Cox, 2008; Suit et al., 2008).
2.5.2 Principles of the model-based approach
The model-based approach consists of two phases: model-based selection and model-based
validation. The first phase, in turn, comprises three steps: development and validation of NTCP
models, patient-specific plan comparison and estimation of the clinical benefit of PBT. The indi-
vidual steps are explained in more detail below.
Phase α: Model-based selection
Patients shall be selected regarding their reduction of side-effect probabilities under PBT com-
pared to XRT. If this reduction exceeds a given threshold, those patients will be suitable for PBT
treatment. The side-effect probabilities for each patient are estimated using NTCP models.
1. Development and validation of NTCP models The relation between dose to OARs and
associated side effects is mathematically described by NTCP models. For different entities and
relevant side effects that may occur following RT, multivariable NTCP models have to be devel-
oped and externally validated. The values of dosimetric parameters that are supposed to be
important in these models should be reduced, if possible, during treatment planning. Develop-
ment and external validation of NTCP models are described in section 2.4.
Up to now, most NTCP models have been derived from data of patients treated with XRT. It
has been demonstrated that NTCP models can differ between various XRT techniques (Beetz
et al., 2012b; Christianen et al., 2012; Troeller et al., 2015). Since dose distributions of XRT and
PBT differ substantially, the same side effect may be related to different dosimetric parameters.
If photon and proton models differ too much for certain side effects, technique-specific NTCP
models may become necessary.
To use existing photon-derived NTCP models to predict the NTCP for PBT, these models need
to be validated on prospectively collected PBT patient data. Blanchard et al. (2016) succeeded to
validate established NTCP models on head and neck cancer patients treated with PBT. However,
Pedersen et al. (2020) observed large differences in the prediction of rectal complications in
prostate cancer patients between both treatment modalities. Continuous model validation and
28
2.5 Model-based approach for patient selection for proton beam therapy
updating may be implemented, for example, in the framework of a rapid learning health care
system (Lambin et al., 2013a; Lambin et al., 2015).
2. Individual in silico planning comparative studies For each patient, two treatment plans
are created, one with protons and the other with a state-of-the-art photon RT technique. The
dose distributions of both treatment plans are compared, especially the dosimetric parameters of
OARs that are predictors in the NTCP models.
3. Estimation of the clinical benefit The treatment plans and NTCP models are used to
estimate the difference between side-effect probabilities of PBT and XRT. Figure 2.8A shows
impressively that an equal dose difference between a photon and a proton treatment plan may
lead to different NTCP reductions. This effect depends on the slope of the NTCP curve in which
both dose values are located. In a multivariable model including dosimetric predictors of two
different OARs, the difference in NTCP between the proton and photon plan may be even higher
if PBT is able to spare both OARs simultaneously (Christianen et al., 2012), see figure 2.8B.
In some cases, the occurrence of certain side effects is mainly determined by clinical cofactors
(e.g. comorbidities, administration of CTx). Hence, the dose difference may play a minor part in
the occurrence of the side effect (Lambin et al., 2013b).
A patient is finally selected for PBT if the extent of NTCP reduction in the PBT plan compared
to XRT exceeds a given threshold. This predefined threshold depends on the severity of the
considered side effects, with lower thresholds for more severe toxicities. For toxicities of CTCAE
grade 2, 3 and 4 – 5, the Dutch Society of Radiation Oncology suggests thresholds of 10, 5 and
2 percentage points, respectively (Langendijk et al., 2018). In some cases, multiple side effects
are considered in the selection procedure (NTCP profiles). Here, both the NTCP difference of
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Figure 2.8: Model-based approach according to Langendijk et al. (2013). (A) Two equal dose differences
in an OAR between a photon and proton plan (∆D1 = ∆D2) translate into different reductions in NTCP
(∆NTCP1 > ∆NTCP2). (B) In a multivariable model including dosimetric predictors of two different OARs,
the NTCP difference between proton and photon plan may be even higher if PBT is able to reduce dose to
both OARs simultaneously.
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every single endpoint as well as the summarised NTCP difference for all considered endpoints
must exceed different thresholds (Langendijk et al., 2018). If the NTCP difference remains below
the recommended threshold, the patient is treated with state-of-the-art XRT.
Phase β: Model-based validation
The initial hypothesis of reduced side effects after PBT compared to XRT is evaluated during
model-based validation, see figure 2.9. Patients who were selected for PBT during phase α
are enrolled in such prospective validation studies and treated with the proton treatment plan
created during step 2. The calculated NTCP values for both treatment modalities are averaged
over all patients enrolled in the study to estimate the expected toxicity rates. The finally observed
toxicity rates of patients treated with PBT are then compared to the initially predicted proton
NTCP values to detect possible shortcomings of the applied NTCP model (Langendijk et al.,
2018). Furthermore, it can be tested whether the observed toxicity rate following PBT is indeed
lower than the estimated NTCP values for XRT (calibration-in-the-large (Steyerberg et al., 2010)).
However, the true toxicity rates after PBT are only compared with a supposed toxicity probability
for XRT.
Another way to compare the real outcome of PBT and XRT directly is the use of prospectively
collected patient data as control groups, e.g. historical cohorts or patients treated in radiotherapy
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Figure 2.9: Schematic overview of the model-based validation according to Langendijk et al. (2013).
Where PBT is available, patient selection according to phase α of the model-based approach is applied
(left side). The outcome of these patients treated with PBT can be compared to prospectively collected
data from patients routinely treated with photons (right side). To ensure a fair comparison between both
groups, only those patients whose estimated NTCP reduction would have exceeded the threshold for PBT
are included in the control group.
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centres without access to PBT (Langendijk et al., 2013). Patients selected for and treated with
PBT according to phase α are enrolled in such clinical trials as the treatment group, see figure 2.9.
It is not reasonable to compare the outcome of this treatment group with the outcome of patients
who were rejected in phase α and treated with XRT instead. Therefore, an independent control
group has to be designed. It should consist of patients who would have been candidates for PBT
according to the same selection procedure but were still treated with XRT (the control group in
figure 2.9).
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3 Investigated patient cohorts
In this thesis, the outcome of patients with intracranial tumours treated with PBT is investigated.
Similar to what is proposed by the model-based approach (Langendijk et al., 2013), NTCP models
for early and late side effects are developed and validated in chapter 4. Chapter 5 investigates
dose-effect relations for neurocognitive function and QoL. Finally, a treatment plan comparison
study is conducted in chapter 6. Based on these treatment plans and NTCP models, the potential
benefit of PBT is estimated. In this chapter, all patients analysed in any of the following studies
are presented and characterised.
Patient cohorts Patient cohorts from three different PBT centres were available. These three
institutes are the University Proton Therapy Dresden (UPTD) at the Department of Radiotherapy
and Radiation Oncology of the University Hospital Carl Gustav Carus Dresden, the West Ger-
man Proton Therapy Centre Essen (WPE) and the Massachusetts General Hospital (MGH) in
Boston. Patients treated at UPTD were enrolled in different clinical trials (DRKS00007670, 2015;
DRKS00008569, 2015; NCT02824731, 2016) and treated using a DS technique. Patients from
WPE were enrolled in the clinical trial (DRKS00004384, 2012) and treated using a PBS tech-
nique. At MGH, patients were irradiated with a DS technique. All patients were consecutively
treated between 2013 and 2017.
General inclusion criteria were age ≥ 18 years, diagnosis of a tumour in the brain or skull
base, normo-fractionated PBT, Eastern Co-operative of Oncology Group (ECOG) performance
status ≤ 2 as well as written informed consent. Exclusion criteria were inability to MRI scans,
lack of patient compliance and limited possibilities for reproducible positioning. All studies were
approved by the local Ethics Committee and the respective institutional review boards.
Not all patients could be included in every study described in this thesis, see figure 3.1. For ex-
ample, neurocognitive testing was available only for patients who were enrolled in the clinical trial
Proto-R-Hirn (DRKS00007670, 2015). Moreover, for patients, that were enrolled in the ongoing
clinical trial Proto-Choice-Hirn (NCT02824731, 2016), late toxicity data could not be evaluated as
this is the primary endpoint of this study. Consequently, the patient composition will change for
the analyses presented in the following chapters.
Patient characteristics Table 3.1 gives an overview of several patient characteristics. Gener-
ally, the patient cohorts differed in most characteristics, especially in tumour histologies. While
the majority of patients treated at UPTD had glioblastomas (29 %), only 11 % of patients treated
at WPE were diagnosed with glioblastoma. In the cohort treated at MGH, there was no patient
with glioblastoma at all. In both WPE and MGH cohort, patients with meningioma were most fre-
quently present (37 % and 40 %, respectively). The different composition of the cohorts in terms
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Figure 3.1: Investigated patient cohorts.
of tumour histologies results in differences concerning surgery and CTx. In the UPTD cohort,
more patients underwent surgery or additional CTx compared to the WPE and MGH cohorts.
Tumour volumes were considerably larger for patients irradiated at UPTD than for patients of
the other two centres. Furthermore, the prescribed dose with a median value of 60 Gy(RBE) was
also higher in this cohort compared to the WPE and MGH cohort, which had a median prescribed
dose of 54 Gy(RBE). The median age was slightly higher in the UPTD cohort (49.9 years) than
in the other two groups (45.1 years and 46.1 years). Slightly more men than women were treated
in the UPTD cohort, while the ratio was almost reversed in the other two groups. Most patients in
the WPE and UPTD cohort had the tumour in the right hemisphere (39 % and 49 %, respectively),
while in most MGH patients the tumour was located on the left side (39 %). In the WPE and UPTD
cohorts, tumours affected the temporal lobe in most patients (59 % and 30 %, respectively), while
this was observed in only 25 % of patients in the MGH cohort. No significant difference between
the cohorts with regard to tumour location in the brain or skull base could be observed.
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Table 3.1: Characteristics of the investigated patient cohorts. To compare continuous variables, a Kruskal-
Wallis test was applied, for categorical variables, a χ2 test was used.
UPTD WPE MGH
Number of patients 138 71 96
PBT technique DS PBS DS
Characteristic Median (Range) Median (Range) Median (Range) p-value
Age at PBT in years 49.9 (18.8 – 84.7) 45.1 (18.1 – 79.6) 46.1 (18.5 – 89.3) 0.022
Tumour volume (CTV) in cm3 136.7 (1.2 – 499.1) 54.6 (2.1 – 368.1) 28.1 (1.2 – 267.2) < 0.001
Prescribed dose in Gy(RBE) 60.0 (30.0 – 74.0) 54.0 (42.5 – 60.0) 54.0 (36.0 – 70.2) < 0.001
N % N % N %
Gender 0.018
Male/female 80/58 (58/42) 33/38 (46/54) 38/58 (40/60)
Surgery 0.026
No/yes/missing 18/119/1 (13/86/1) 20/51/0 (28/72/0) 21/75/0 (22/78/0)
Chemotherapy 0.011
No/yes/missing 84/53/1 (61/38/1) 55/16/0 (77/23/0) 74/22/0 (77/23/0)
Re-irradiation 0.032
No/yes/missing 117/20/1 (85/14/1) 66/3/2 (93/4/3) 84/6/6 (88/6/6)
Tumour location 0.19
Brain/skull base/other 76/61/1 (55/44/1) 37/32/2 (52/45/3) 39/55/2 (41/57/2)
Tumour location 0.009
Left hemisphere 49 (36) 20 (28) 37 (39)
Right hemisphere 68 (49) 28 (39) 27 (28)
Central 18 (13) 20 (28) 28 (29)
Bilateral 3 (2) 3 (4) 4 (4)
Tumour location < 0.001
Temporal lobe 42 (30) 42 (59) 24 (25)
Frontal lobe 34 (25) 34 (48) 22 (23)
Parietal lobe 6 (4) 6 (8) 7 (7)
Occipital lobe 4 (3) 4 (6) 3 (3)
Multiple lobes 30 (22) 30 (42) 4 (4)
Other 22 (16) 22 (31) 36 (38)
Histology∗ < 0.001
Glioblastoma 40 (29) 8 (11) 0 (0)
Astrocytoma III 8 (6) 12 (17) 10 (10)
Oligoastrocytoma III 2 (1) 2 (3) 5 (5)
Oligodendroglioma III 1 (1) 1 (1) 0 (0)
Astrocytoma I-II 13 (9) 5 (7) 8 (8)
Oligoastrocytoma I-II 6 (4) 2 (3) 2 (2)
Oligodendroglioma I-II 5 (4) 1 (1) 1 (1)
Ependymoma 1 (1) 1 (1) 2 (2)
Craniopharyngioma 1 (1) 3 (4) 2 (2)
Meningioma 16 (12) 26 (37) 38 (40)
Medulloblastoma 0 (0) 2 (3) 0 (0)
Pituitary adenoma 10 (7) 1 (1) 11 (11)
Vestibullar schwannoma 0 (0) 0 (0) 9 (9)
Other 35 (25) 7 (10) 8 (8)
Abbreviations: N, number of patients; DS, double scattering; PBS, pencil beam scanning; CTV, clinical target volume; UPTD,
University Proton Therapy Dresden; WPE, West German Proton Therapy Centre Essen; MGH, Massachusetts General Hos-
pital. ∗Tumour classification according to WHO Classification of Tumours of the Central Nervous System, Fourth Edition.
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4 Modelling of side effects following cranial proton
beam therapy
Cranial RT may be associated with mild to severe side effects that can adversely affect patients’
QoL. Patients with HGGs have a short life expectancy (Stupp et al., 2009) and thus, an important
goal of treatment is the preservation of QoL as long as possible due to reduction of early side
effects. Patients with benign tumours or LGGs often have prolonged survival and young age at
diagnosis (Buckner et al., 2016). These long-term survivors may be more affected by late side
effects.
Based on dosimetric and clinical outcome data, NTCP models for different endpoints have
been developed for XRT (Burman et al., 1991; Bender, 2012; Gondi et al., 2012). However,
studies based on data from PBT or combined PBT and XRT are rare (De Marzi et al., 2015;
Palma et al., 2020). In this chapter, common physician-rated early and late side effects following
cranial PBT were investigated in patient cohorts from three PBT centres. These data were used
for developing NTCP models and for their external validation. Furthermore, an additional study
was carried out that investigated the interobserver variability for the side effects erythema and
alopecia.
Parts of the work presented in this chapter have been published (Dutz et al., 2019) and were
presented at several conferences (Dutz et al., 2017a; Dutz et al., 2017b; Dutz et al., 2018).
4.1 Experimental design for modelling early and late side effects
The patient cohorts have been characterised comprehensively in chapter 3. The cohorts inves-
tigated in each analysis for early and late side effects are described separately in the respective
section. They differed slightly since long-term follow-up was not available for all patients.
Radiotherapy planning and treatment delivery
For the patient cohorts treated at the UPTD and the MGH (except for two cases that were treated
with PBS due to scheduling reasons), treatment plans were calculated using a DS technique and
the treatment planning system XiO® (Elekta AB, Stockholm, Sweden). For the patient cohort
treated at the WPE, a PBS technique using XiO® was applied for patients treated between 2013
and 2014 and RayStation® (RaySearch AB, Stockholm, Sweden) was used for patients treated
between 2015 and 2016. For delineation and treatment planning, a CT scan with a slice thick-
ness of 3 mm (UPTD), 1 mm (WPE) or 1.25 mm (MGH) was acquired for each patient and rigidly
registered with (post-operative) MRI scans. The GTV included the tumour or the resection cavity
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with residual tumour volume, if present. The CTV included microscopic disease and oedema in
T2-weighted MRI scans taking into account anatomical boundaries.
In the cohort treated at UPTD, the target volume for the DS treatment plans was the CTV with
an in-beam margin of 3.5 % of the distal or proximal CTV depth and an additional absolute mar-
gin of 2 mm. In the cohort treated at MGH, the distal range expansion to the CTV was 3.5 %
and 1 mm with an additional modulation expansion of twice the distal expansion. For the cohort
treated at WPE using a PBS technique, a PTV was constructed by adding a 5 mm margin to the
CTV. For treatment planning, one to four beams in a patient individual beam setting were applied
according to clinical practice in the respective centres. The RBE was considered to be constant
at 1.1. Thus, the unit Gy(RBE) is used in the following. The dose-volume constraints differed
slightly between the cohorts treated at UPTD and WPE, see appendix B tables B.4 and B.5. Pa-
tient individual planning objectives were used at MGH. During PBT, patient positioning was daily
verified by manual registration of orthogonally paired X-ray images with digitally reconstructed
radiographs of the planning CT. In the cohort treated at MGH, most patients were immobilised
using a stereotactic bite block system.
Definition of endpoints and extraction of dose-volume parameters
Treatment-related side effects were prospectively scored at baseline, weekly during PBT, at the
end of PBT, 3 months after PBT and thereafter in regular intervals depending on the institution.
The CTCAE version 4 grading system was used. For early side effects, the maximum severity
grade was assessed during treatment and up to 3 months after PBT. The long-term follow-up
schemes differed between the institutions: every 3 months at UPTD, every 6 months at MGH
and every 12 months at WPE. Thus, late side effects were evaluated at 12 and 24 months after
PBT. For patients with non-zero baseline value and an increase in severity during treatment or
follow-up, the maximum score was used regardless of the pre-treatment value otherwise grade
0 was used. All endpoints were dichotomised at grade ≥ 1 (grade 0 vs remaining) and grade
≥ 2 (grade 0 and 1 vs remaining). Especially for young patients even relatively mild forms of side
effects (grade 1) may have an impact on their QoL, while side effects grade ≥ 2 are more severe
and therefore clinically more relevant for the general patient population.
All OARs that were contoured during the RT treatment planning process were retrospectively
checked and re-delineated. OARs that were not included in the original structure set were retro-
spectively contoured according to delineation guidelines (Schmahmann et al., 1999; Chera et al.,
2009; Sun et al., 2014; Scoccianti et al., 2015; Eekers et al., 2018). All dose distributions were
exported using RayStation® scripts. Volume parameters VxGy (RBE) ranging from 5 Gy(RBE) to
60 Gy(RBE) in increments of 5 Gy(RBE) were analysed. For the non-circumscribed organ skin,
absolute volume parameters (in cm3) were considered. For circumscribed OARs, relative volume
parameters (in per cent of the entire volume of the structure) were assessed. Dose parameters
Dx% ranging from 5 % to 55 % in increments of 10 % as well as D2% representing near-maximum
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doses were analysed. For OARs with volumes < 10 cm3, D2%, Dmean and Dmedian (D50%) were
considered. For very small structures with volumes < 2 cm3 (lacrimal gland and cochlea), only
D2% and Dmean were used. For brain stem and optic pathways, the near-maximum parameter
D2% was assessed. For paired OARs, ipsi- and contralateral structures were investigated. For
the hippocampus, dose-volume parameters of the bilateral hippocampi were considered. Struc-
tures located within the tumour volume were not delineated as related side effects were assumed
to be caused rather by the tumour itself than by radiation.
Development of NTCP models
The impact of both dose-volume parameters and clinical variables on the endpoints was evalu-
ated. The clinical parameters comprised age, prescribed total dose, tumour volume (CTV), CTx,
tumour location (brain or skull base), gender, and surgery. Uni- and multivariable logistic regres-
sion models were developed on the exploration cohort, see equation (2.13), using the AUC as a
performance metric. The following steps were performed: (I) A 3-fold internal cross-validation was
conducted 333 times on the exploration cohort to identify prognostic dose-volume parameters.
(II) Dose-volume parameters showing a significant association (p < 0.05) to the investigated end-
point in univariable logistic regression and the largest AUC value of the internal validation folds
were pre-selected. (III) Clinical parameters showing a significant association to the endpoint in
logistic regression were tested for correlation with the dose-volume parameters selected during
step (II) using the Spearman correlation coefficient ρ. Multivariable logistic regression models
containing the independent clinical parameters (in case |ρ| <0.5) and one dose-volume parame-
ter were built as described in step (I). Uni- or multivariable models with the largest AUC value in
internal cross-validation were selected as final NTCP models. (IV) The models derived from the
exploration cohort were applied without changes to the validation cohort, i.e. the models were
evaluated using the dose-volume parameters of the validation cohort and the model coefficients
derived from the exploration cohort. The resulting probabilities were compared to the observed
outcome by calculating the AUC value. The 2.5th and 97.5th percentiles of 1000 bootstrap sam-
ples were used to estimate the 95 % confidence interval (CI) of the AUC values for the validation
cohort. The prognostic performance was assessed by AUC values and calibration plots. Binary
variables were compared between the exploration and the validation cohort using exact Fisher
tests. Differences in categorical variables were evaluated by χ2 tests and in continuous vari-
ables by Mann-Whitney-U tests. Correlations between dose-volume parameters were assessed
using the Spearman correlation coefficient ρ. For all statistical analyses, two-sided tests were
performed using IBM SPSS Statistics 25 (IBM Corporation, Armonk, NY) and in-house written
Python (version 2.7.10) programmes using the module scipy (statsmodels). P-values < 0.05
were considered statistically significant without adjusting for multiple testing.
For the final models, the regression curves, calibration plots and ROC curves were graphically
displayed. The patients were sorted according to the value of the model predictor and subse-
39
4 Modelling of side effects following cranial proton beam therapy
quently divided into nearly equally sized sets. The mean value of each set was represented by
one data point. The error bar of each data point indicated the standard deviation of each set.
4.2 Modelling of early side effects
Patient data
The exploration cohort consisted of 113 patients treated within clinical studies (DRKS00007670,
2015; DRKS00008569, 2015; NCT02824731, 2016) at UPTD at the time of analysis (2017). Val-
idation cohort 1 comprised 71 patients treated within a clinical registry study (DRKS00004384,
2012) at the WPE and validation cohort 2 consisted of 96 patients treated at MGH. This retro-
spective trial was approved by the local Ethics Committee (EK219062016) and the institutional
review board at the external institutions. The study design is presented in figure 4.1 and the
patient cohorts are characterised in table 4.1.
Early endpoints and associated organs at risk
The treatment-related side effects alopecia, skin erythema, headache, fatigue and nausea were
investigated. For alopecia and erythema, the skin including the hair follicle was considered an
associated OAR. It was created by cropping the body contour by 3 mm. For the remaining side
effects, the brain excluding the target volume (brain-CTV) as well as the brain stem were investi-
gated. The brain included infra- and supratentorial parts of the brain excluding the brain stem.
4.2.1 Results
Glioblastoma was the most common diagnosis in the exploration cohort, whereas meningioma
was most frequent in the validation cohorts, leading to significant differences between the cohorts
Exploration cohort
UPTD
(n=113)
Validation cohort 1
WPE
(n=71)
Validation cohort 2
MGH
(n=96)
Extraction of DVH parameters and collection of outcome data
Uni- and multivariable
logistic regression Final validation
Figure 4.1: Study design to develop and validate models predicting early side effects. UPTD, Univer-
sity Proton Therapy Dresden; WPE, West German Proton Therapy Centre Essen; MGH, Massachusetts
General Hospital. Adapted from Dutz et al. (2019).
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Table 4.1: Patient characteristics of the exploration cohort and the two validation cohorts for the analysis
of early side effects. P-values refer to differences between the exploration and the respective validation
cohort.
Exploration cohort Validation cohort 1 Validation cohort 2
Characteristics Median (Range) Median (Range) p-value Median (Range) p-value
Age at PBT in years 49.3 (21.2 – 79.9) 45.1 (18.1 – 79.6) 0.085 45.9 (18.5 – 89.3) 0.094
Tumour volume (CTV) in cm3 153.9 (1.2 – 499.1) 50.9 (2.1 – 368.1) < 0.001 28.1 (1.2 – 267.2) < 0.001
Prescribed dose in Gy(RBE) 60.0 (30.0 – 74.0) 54.0 (42.5 – 60.0) < 0.001 54.0 (36.0 – 70.2) < 0.001
N (%) N (%) p-value N (%) p-value
Gender 0.094 0.003
Male/female 68/45 (60/40) 33/38 (46/54) 38/58 (40/60)
Surgery 0.011 0.067
Yes/no 99/14 (88/12) 51/20 (72/28) 75/22 (78/22)
Chemotherapy 0.49 0.45
Yes/no 31/82 (27/73) 16/55 (23/77) 22/74 (23/77)
Tumour location 0.11 < 0.001
Brain/skull base/other 77/35/1 (68/31/1) 39/30/2 (55/42/3) 37/57/2 (39/59/2)
Tumour histology∗ 0.002 < 0.001
High grade glioma 43 (38) 23 (32) 15 (16)
Low grade glioma 21 (19) 8 (11) 11 (11)
Meningioma 15 (13) 26 (37) 38 (40)
Other 34 (30) 14 (20) 32 (33)
Abbreviations: N, number of patients; CTV, clinical target volume; ∗Tumour classification according to WHO Classification of Tumours
of the Central Nervous System, Fourth Edition.
regarding CTV (p < 0.001), prescribed total dose (p < 0.001), and surgery (p = 0.011 for
validation cohort 1). Moreover, there were differences between exploration cohort and validation
cohort 2 in terms of gender and tumour location (p < 0.003). For all cohorts, the incidence of the
investigated acute side effects after PBT is given in table 4.2. Overall, less alopecia and erythema
grade 1 – 2 occurred in the validation cohorts compared to the exploration cohort (p < 0.001). No
statistically significant differences in the frequencies of fatigue and nausea were found between
the exploration and validation cohorts. Headaches were less common in validation cohort 2
compared to the exploration cohort (p < 0.001). The low incidence rates of nausea grade ≥ 2 in
all cohorts did not allow for NTCP modelling.
Side effects were tested for correlation with clinical cofactors in the exploration cohort, see
appendix B table B.6. Erythema as well as alopecia occurred significantly more often for larger
CTV (p < 0.024), prescribed total dose (p < 0.037), and performed surgery (erythema grade≥ 1:
p < 0.001, alopecia grade ≥ 2: p = 0.030). Fatigue grade ≥ 1 showed a higher prevalence in
women compared to men (p = 0.005).
Dose-volume parameters of the skin in the high dose region were significantly correlated to
erythema and alopecia on the exploration cohort. For erythema, the parameter revealing the
largest AUC values in cross-validation was V35Gy (RBE) (grade ≥ 1: AUC = 0.75, grade ≥ 2:
AUC = 0.77). For alopecia grade ≥ 1, D2% (AUC = 0.88) and for alopecia grade ≥ 2, D5%
(AUC = 0.82) were selected. As the clinical cofactors associated to erythema and alopecia were
significantly correlated with each other and with the selected dose-volume parameters of the skin,
see appendix B table B.8, univariable NTCP models including the above-mentioned dose-volume
parameters were finally developed, see table 4.3.
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Table 4.2: Comparison of the baseline-corrected early side effects (CTCAE v4.0) between the exploration
and validation cohorts. The number N of available datasets is given. P-values represent the results of the
χ2 test comparing the exploration cohort with the respective validation cohort.
Side effect Grade 0 Grade 1 Grade 2 Grade 3
Cohort N n (%) n (%) n (%) n (%) p-value
Alopecia
Exploration 111 15 (14) 26 (23) 70 (63)
Validation 1 71 22 (31) 35 (49) 14 (20) < 0.001
Validation 2 96 59 (61) 16 (17) 21 (22) < 0.001
Erythema
Exploration 113 15 (13) 57 (51) 40 (35) 1 (1)
Validation 1 71 32 (45) 39 (55) 0 (0) 0 (0) < 0.001
Validation 2 96 63 (66) 32 (33) 1 (1) 0 (0) < 0.001
Fatigue
Exploration 112 35 (31) 53 (47) 21 (19) 3 (3)
Validation 1 71 18 (25) 45 (63) 6 (9) 2 (3) 0.12
Validation 2 96 40 (42) 47 (49) 9 (9) 0 (0) 0.063
Headache
Exploration 113 57 (51) 33 (29) 18 (16) 5 (4)
Validation 1 71 49 (69) 15 (21) 6 (8) 1 (2) 0.079
Validation 2 96 75 (78) 19 (20) 2 (2) 0 (0) < 0.001
Nausea
Exploration 98 82 (84) 13 (13) 3 (3) 0 (0)
Validation 1 71 62 (87) 9 (13) 0 (0) 0 (0) 0.32
Validation 2 96 87 (91) 5 (5) 4 (4) 0 (0) 0.15
Abbreviation: n, number of patients.
Table 4.3: Logistic modelling results: Dose-volume parameters of different organs at risk and clinical
cofactors for early erythema, alopecia, and fatigue. Mean AUC values for 3-fold cross-validation (333
repetitions) and external validation are given. P-values were calculated on the exploration cohort. Fitting
parameters βi as defined in equation (2.13).
Model βi (95 % CI) p-value AUC (95 % CI)
Erythema grade ≥ 1 Cross validation 0.75 (0.54 – 0.90)
Skin V35Gy (RBE) 0.085 (0.02 – 0.15) 0.008 Validation 1 0.87 (0.77 – 0.95)
Constant 1.00 (0.32 – 1.69) Validation 2 0.80 (0.71 – 0.89)
Erythema grade ≥ 2 Cross validation 0.77 (0.64 – 0.89)
Skin V35Gy (RBE) 0.056 (0.03 – 0.08) < 0.001 Validation 1 *
Constant -1.54 (-2.20 – -0.88) Validation 2 0.84† (0.77 – 0.91)
Alopecia grade ≥ 1 Cross validation 0.88 (0.73 – 0.99)
Skin D2% 0.10 (0.05 – 0.15) < 0.001 Validation 1 0.82 (0.70 – 0.92)
Constant -0.94 (-2.14 – 0.27) Validation 2 0.84 (0.75 – 0.92)
Alopecia grade ≥ 2 Cross validation 0.82 (0.69 – 0.95)
Skin D5% 0.081 (0.05 – 0.11) < 0.001 Validation 1 0.77 (0.63 – 0.89)
Constant -1.33 (-2.91 – -0.47) Validation 2 0.85 (0.76 – 0.92)
Fatigue grade ≥ 1 Cross validation 0.68 (0.50 – 0.84)
Brain-CTV D2% 0.027 (0.00 – 0.06) 0.067 Validation 1 0.45 (0.31 – 0.61)
Gender 1.28 (0.33 – 2.23) 0.009 Validation 2 0.52 (0.40 – 0.64)
Constant -0.90 (-2.30 – 0.51)
Abbreviations: AUC, area under the receiver operating characteristic curve; CI, confidence interval; *Ex-
ternal validation not applicable due to zero incidence. † Only one event.
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The high-dose parameter D2% of brain-CTV was significantly associated with fatigue grade
≥ 1 and revealed an AUC value of 0.60 in exploration. As the cofactor gender was not correlated
to this dose-volume parameter (ρ = 0.15), a bivariable model was built that showed an improved
performance in cross-validation compared to the univariable model (AUC = 0.68), see table 4.3.
None of the dose-volume parameters of brain-CTV showed significant correlation to fatigue grade
≥ 2, headache, and nausea.
The final NTCP models developed on the exploration cohort were applied without changes
to the validation cohorts showing high AUC values for erythema and alopecia, see table 4.3.
Exemplarily, for erythema grade ≥ 1 and V35Gy (RBE) of the skin, the validation AUC was 0.87,
95 % CI: [0.77 – 0.95] in validation cohort 1 and 0.80 [0.71 – 0.89] in validation cohort 2. Similar
results were obtained for alopecia. Thus, both validation cohorts confirmed the results of the
exploration cohort. The regression curves and calibration plots for alopecia grade ≥ 2 and D5%
as well as erythema grade ≥ 1 and V35Gy(RBE) of the skin are shown in figure 4.2. The
calibration plots for both endpoints showed a right shift for both validation cohorts. Since only
one case of erythema grade ≥ 2 was reported in the validation cohorts, the NTCP models for
this endpoint could not be validated. External validation of the bivariable NTCP model for fatigue
grade ≥ 1 failed with low AUC values in both cohorts (validation cohort 1: 0.45 [0.31 – 0.61],
validation cohort 2: 0.52 [0.40 – 0.64]).
4.2.2 Discussion
This study on adult patients with intracranial tumours receiving PBT investigated the relation of
acute side effects and dose to associated OARs. Overall, PBT was well tolerated with very
low incidences of side effects grade 3. Dose-volume parameters in the high-dose region were
prognostic for erythema and alopecia. Fatigue was found to be associated with gender and high
doses to the brain-CTV. While the NTCP models for erythema as well as alopecia showed similar
or even improved performance for the validation cohorts compared to the exploration cohort, the
model for fatigue could not be validated.
Several relatively small studies documented acute side effects in the brain tumour patients
receiving PBT according to CTCAE v3 or v4 (Hauswald et al., 2012; Weber et al., 2012; Brown
et al., 2013; Grosshans et al., 2014; Shih et al., 2015). The incidence rate of alopecia grade 2
in the exploration cohort (63 %) is comparable to the results of Hauswald et al. (2012) (68 %),
even though in this study, the 19 glioma grade I-II patients were treated with an active scanning
technique and a median dose of 54 Gy(RBE). Wilkinson et al. (2016) assessed 58 patients with
grade II glioma treated with PBT doses between 50.4 and 54 Gy(RBE). During treatment, only
grade 1 or 2 toxicities were observed with alopecia (81 %), dermatitis (78 %), fatigue (47 %),
and headache (40 %) being the most common. These incidence rates of side effects are of the
same range as those reported in this thesis. Weber et al. (2012) investigated 39 skull base
meningioma patients treated with spot-scanning PBT with a total dose of 56 Gy(RBE) and Shih
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(A) Alopecia grade ≥ 2.
(B) Erythema grade ≥ 1.
Figure 4.2: NTCP models for acute alopecia grade ≥ 2 and erythema grade ≥ 1. Regression curve (left),
calibration plot (centre) and ROC curves (right) are displayed. Each data point and error bar represents
the mean value and standard deviation of each patient set, see section 4.1. Adapted from Dutz et al.
(2019).
et al. (2015) conducted a study on 20 glioma patients treated with a passive scattering technique
with a total dose of 54 Gy(RBE). Both studies did not report any cases of alopecia grade 2, but an
incidence rate for alopecia grade 1 of 60 % and 85 %, respectively. In two studies by Grosshans
et al. (2014) and Brown et al. (2013) investigating 15 skull base chordoma and chondrosarcoma
patients treated with spot-scanning PBT with doses of 69.8 Gy(RBE) and 68.4 Gy(RBE), and 19
medulloblastoma patients receiving a total dose of 54 Gy(RBE), respectively, no erythema grade
2 was documented. This is comparable to validation cohort 1 in this thesis. The incidence rate
of fatigue grade ≥ 1 both for the exploration (69 %) and validation cohort (75 %) are in line with
the findings of Grosshans et al. (2014) (66 %). For nausea grade ≥ 1, Shih et al. (2015) reported
similar results with 20 %, compared to the exploration cohort with 16 %.
The findings of this thesis regarding the association of skin dose-volume parameters with
alopecia and erythema are in line with other publications, in which photon doses to the skin
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were associated with these side effects. Reduction of the irradiated volume V24Gy and V30Gy
of follicle hair-bearing scalp prevented alopecia in a study using 11-field IMRT (Mahadevan et al.,
2015). In this thesis, the skin dose-volume parameter V25Gy (RBE) showed also a significant
association with alopecia. Nevertheless, the prognostic performance was slightly superior for
D2% (alopecia grade ≥ 1) as well as for D5% (alopecia grade ≥ 2) in internal cross-validation.
Another study investigated side effects after XRT in 61 cranially irradiated patients (Lawenda et
al., 2004). More than 50 % of the patients receiving a follicle dose > 43 Gy developed permanent
moderate to severe alopecia. The higher dose value of this prognostic parameter compared to the
findings in this thesis may be due to the endpoint of permanent manifestation of alopecia which
was investigated in this study. Sung et al. (2016) found the dose-volume parameter V35Gy
as the most significant predictor for radiation dermatitis grade ≥ 2 after hybrid IMRT for 101
breast cancer patients. As the same dose-volume parameter was found as the most predictive
parameter for erythema in this thesis, skin reaction in thoracic regions may be similar to those
after cranial irradiation. Mendelsohn et al. (2002) reported early dry desquamation (erythema
grade ≥ 1) if the total skin dose during conventional radiotherapy does not exceed 30 Gy and
acute moist desquamation (erythema grade ≥ 2 and 3) as an effect of total skin dose > 40 Gy.
These findings are in line with the results of this thesis as the reduction of V35Gy (RBE) is
predicted to lower the risk of erythema. However, in this study, it was observed that patients
who had only a low absolute skin volume exposed to 35 Gy(RBE) already had a high probability
of erythema grade ≥ 1, see figure 4.2B. This indicates that many patients who had developed
erythema were exposed to lower skin doses than 35 Gy(RBE). Thus, a high dose parameter
(e.g. D2% or D5%) that covers a wide range of doses continuously may be more appropriate to
describe this dose-effect relationship than a volume parameter which may introduce a threshold
effect.
The dose-volume parameters of the skin were highly correlated so that other parameters may
be relevant on other cohorts. A principal component analysis was conducted to create inde-
pendent parameters (principal components) representing different dose regions, see appendix B
tables B.9 and B.10. NTCP models based on these components showed similar AUC values in
internal and external validation, but they are more difficult to interpret. Therefore, they are less
suitable for use in clinical routine.
A shift in the calibration curves for alopecia and erythema was observed in both validation co-
horts for the presented model as well as for the models based on principal components. Different
rates of erythema and alopecia could be caused by differences in several patient and tumour
characteristics, such as tumour type and volume, see table 4.1. Nevertheless, other consider-
able factors such as malnutrition, age, and tobacco abuse history may also be important (Ginot
et al., 2010). Different treatment techniques in exploration (DS) and validation cohort 1 (PBS)
may also lead to differences in acute side effects. A study investigating skin dose differences
between PBS and DS PBT in prostate cancer patients found a lower skin dose in patients re-
ceiving actively formed PBT compared to patients treated with passive PBT (Arjomandy et al.,
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2009). With cranial irradiation, however, the target is located less deep in the body than with
pelvic irradiation. Moreover, in many brain tumour patients, the target volume is located directly
under the scalp, so that skin doses differ less between both techniques. A comparison of dose-
volume parameters of the skin between the exploration and validation cohort 1 showed significant
differences only in the low dose range, see appendix B table B.7. These findings and the shift
in calibration for validation cohort 2 (PBS) support the hypothesis, that the treatment techniques
are probably not the reason for different toxicity incidences in this thesis. Hence, the differences
are most likely due to different toxicity scoring by the physicians, even though the same grading
system was used. Therefore, a study investigating the interobserver variability of toxicity assess-
ment was conducted that is described in section 4.4. Di Maio et al. (2015) detected frequent
under-reporting of subjective side effects, such as alopecia and fatigue, by physicians at three
different centres to a variable extent compared to patients’ self-assessment. The incorporation
of patient-reported outcome versions of the CTCAE scale (PRO-CTCAE™) in clinical trials may
reduce such centre-specific differences in toxicity assessment (Basch et al., 2014).
For alopecia and erythema, univariable NTCP models have been developed. The clinical co-
factors surgery, prescribed dose, and CTV were highly correlated to both acute side effects and
dose-volume parameters of the skin. As diagnosis determines the dose prescription, tumour
volume, and margin size, patients with large CTV had significantly higher prescribed total doses
(p < 0.001), leading to larger dose-volume parameter values. Due to these high correlations,
the clinical cofactors were not included in potential multivariable NTCP models, since including
redundant information would not improve their prognostic ability.
For acute fatigue, a bivariable model including the dose-volume parameter D2% of brain-CTV
and the clinical cofactor gender was developed in this thesis. This model could not be validated.
Gulliford et al. (2012a) investigated the association of dose to cranial structures and acute fatigue
in 67 patients treated with 3D-CRT or IMRT and found significantly higher mean and maximum
dose values for posterior fossa, brain stem, and cerebellum for patients suffering from acute
fatigue grade ≥ 2 (p < 0.01). Ferris et al. (2018) found a significant correlation between patient-
reported fatigue based on Multidimensional Fatigue Inventory scores and maximum dose to the
brain stem as well as medulla in 124 patients treated with IMRT or VMAT (p < 0.05). In this
thesis, no statistically significant dose relationship between dose to the brain stem and acute
fatigue for patients treated with passively scattered proton beams could be observed; instead, a
significant correlation between fatigue grade ≥ 1 and female gender was found. One of the few
studies investigating cancer-related fatigue according to the EORTC QLQ-C30 scale also found
female gender associated with greater fatigue severity (Pater et al., 1997). However, as there are
only a few studies on gender differences in cancer-related fatigue, there is still concern about the
prevalence and severity of this side effect (Miaskowski, 2004).
Finally, no association between dose to the brain and acute nausea or headache was found in
this study. These endpoints are difficult to measure and may also be alternating. Radiation dose
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to brain structures or concomitant medication such as analgesics may play a role. No NTCP
models based on XRT or PBT data regarding these endpoints are available in the literature.
4.3 Modelling of late side effects
Patient data
Patient data from the three cohorts presented in chapter 3 were partly used to model late side
effects. Patients treated at UPTD were enrolled in two clinical registry trials (DRKS00007670,
2015; DRKS00008569, 2015). Long-term follow-up data were not available for all patients. Some
patients did not attend continuous visits, e.g. because they lived at great distances from the proton
therapy centres. Others developed a tumour recurrence or died. Thus, the patient cohorts from
UPTD and WPE were combined to a single exploration cohort to increase the number of patients.
The validation cohort consisted of patients treated at MGH. In contrast to the analysis of acute
side effects, the follow-up intervals differed markedly between the three cohorts. While follow-up
data were available every three months for patients treated at UPTD, data were only available
every six months for patients treated at MGH and only every 12 months for patients treated WPE.
It was decided not to evaluate the maximum value of severity grades (e.g. during one year), as
this may have introduced bias due to the different follow-up periods. In patients who are seen four
times a year, the probability of diagnosing a more severe side effect may be increased compared
to patients who are seen once a year, especially for side effects that may alternate or due to
interobserver variability. Hence, to ensure a comparable evaluation between the centres, the
models were developed for side effects occurring at 12 months and at 24 months following PBT,
see figure 4.3. Thus, at 12 months following PBT, 104 and 67 patients were included in the
exploration and validation cohort, respectively. Similarly, at 24 months following PBT, 74 and 65
patients were included in the exploration and validation cohort, respectively. The patient cohorts
are characterised in table 4.4 for the exploration and validation cohorts at 12 months and at 24
months after PBT. Due to the low incidence rates, additional models were developed using the
pooled cohorts at 12 months and at 24 months after PBT, see figure 4.3.
To consider all available patient data from all follow-up visits between 6 and 24 months following
PBT, GEEs on the pooled cohort including 216 patients were set up as described below (see
also section 2.4). The characteristics of the pooled cohort used in GEE analysis is presented in
appendix B table B.11.
This retrospective trial was approved by the local Ethics Committee (EK566122019) and the
institutional review board at the external institutions.
Late endpoints and associated organs at risk
Different physician-rated late side effects were recorded at the three centres. In all institutions,
the following side effects were scored according to CTCAE: alopecia, cataract, dry eye syndrome,
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Exploration cohort 1
UPTD
(n=80)
Exploration cohort 2
WPE
(n=53)
Exploration
Validation cohort
MGH
(n=83)
Validation
104 patients 67 patients12 months after PBT
Pooled cohort: 171 patients
74 patients 65 patients24 months after PBT
Pooled cohort: 139 patients
Generalised estimating equation analysis
Pooled cohort: 216 patients
Figure 4.3: Study design to develop and validate late side effects. UPTD, University Proton Therapy
Dresden; WPE, West German Proton Therapy Centre Essen; MGH, Massachusetts General Hospital.
Table 4.4: Patient characteristics of the exploration cohort and the validation cohort for the analysis of late
side effects at 12 months and at 24 months after PBT.
12 months following PBT 24 months following PBT
Exploration cohort Validation cohort Exploration cohort Validation cohort
Total number of patients 104 67 74 65
Characteristics Median (Range) Median (Range) p-value Median (Range) Median (Range) p-value
Age1 at PBT in years 48.2 (18.1 – 84.7) 45.9 (21.6 – 89.3) 0.22 45.3 (18.1 – 78.0) 47.0 (21.9 – 78.2) 0.93
Tumour volume (CTV)1 in cm3 71.3 (1.2 – 498.0) 29.6 (1.2 – 267.2) 0.003 61.2 (1.2 – 370.7) 29.4 (2.7 – 267.2) 0.015
Total dose1 in Gy(RBE) 54.0 (30.0 – 74.0) 54.0 (45.0 – 70.2) < 0.001 54.0 (30.0 – 74.0) 54.0 (45.0 – 70.2) < 0.001
N (%) N (%) p-value N (%) N (%) p-value
Gender2
Male/female 55/49 (53/47) 26/41 (39/61) 0.085 38/36 (51/49) 27/38 (42/58) 0.31
Surgery2
No/yes/missing 22/81/1 (21/78/1) 12/55/0 (18/82/0) 0.70 14/60 (19/81) 12/53 (18/82) 1.00
Chemotherapy2
No/yes/missing 76/27/1 (73/26/1) 48/19 (72/28) 0.86 57/17 (77/23) 49/16 (75/25) 0.84
Re-irradiation2
No/yes/missing 95/7/2 (91/7/2) 64/3 (96/4) 0.74 69/4/1 (93/5/1) 64/1/0 (98/2/0) 0.37
Tumour location2
Brain/skull base/other 49/53/2 (47/51/2) 32/34/1 (48/51/1) 0.98 36/37/1 (49/50/1) 29/35/1 (39/47/1) 0.89
Tumour location2
Left hemisphere 32 (31) 24 (36) 0.42 21 (28) 24 (37) 0.57
Right hemisphere 44 (42) 20 (30) 31 (42) 20 (31)
Central 25 (24) 20 (30) 19 (26) 18 (28)
Bilateral 3 (3) 3 (4) 3 (4) 3 (5)
Tumour location2
Temporal lobe 33 (32) 20 (30) 0.003 24 (32) 21 (32) 0.002
Frontal lobe 25 (24) 15 (22) 20 (27) 15 (23)
Parietal lobe 2 (2) 7 (10) 1 (1) 6 (9)
Occipital lobe 3 (3) 1 (1) 3 (4) 0 (0)
Multiple lobes 23 (22) 3 (4) 16 (22) 3 (5)
Other 18 (17) 21 (31) 10 (14) 20 (31)
Tumour histology2
High-grade glioma 25 (24) 13 (19) 0.68 16 (22) 11 (17) 0.63
Low-grade glioma 16 (15) 11 (16) 11 (15) 11 (17)
Meningioma 29 (28) 24 (36) 23 (31) 26 (40)
Other 34 (33) 19 (28) 24 (32) 17 (26)
Abbreviations: N, number of patients; CTV, clinical target volume; 1Mann-Whitney U test, 2 χ2 test.
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fatigue, headache, hearing and memory impairment, optic nerve failure, and seizure. While some
of these side effects were too unspecific to correlate them to dose-volume parameters of specific
OARs (e.g. seizure), the incidence rates for other side effects have been too low for developing
NTCP models (e.g. cataract). The side effects that were finally considered for NTCP modelling
and the potentially associated OARs are given in table 4.5. They were dichotomised and analysed
separately for grade ≥ 1 and ≥ 2, if at least 8 incidences occurred, see table 4.6.
Experimental design
The analyses of late side effects followed the same methodology as described in section 4.1.
A 3-fold internal cross-validation was conducted 333 times on the exploration cohort to identify
prognostic dose-volume parameters. Dose-volume parameters showing a significant association
(p < 0.05) to the investigated endpoint in univariable logistic regression and the largest AUC
value of the internal validation folds were pre-selected. Clinical parameters showing a significant
association to the endpoint in logistic regression were tested for correlation with the selected
dose-volume parameters. Multivariable logistic regression models containing the independent
clinical parameters and one dose-volume parameter were built. Uni- or multivariable models with
the largest AUC value in internal cross-validation were selected as final NTCP models. However,
only one instead of two validation cohorts was used.
Since the incidence rates of various side effects were low, an additional exploratory analysis
on the pooled data of all cohorts was conducted without external validation at 12 months and
at 24 months after PBT. For this pooled cohort, univariable logistic regression using dosimetric
parameters (see table 4.5) and clinical cofactors was applied. The clinical parameters comprised
age at PBT, prescribed total dose, tumour volume (CTV), CTx, tumour location (brain or skull
base), gender, and surgery. The dosimetric parameter of the model with the highest AUC value
among all models including dosimetric parameters was determined. Subsequently, this dosimet-
ric parameter as well as all clinical cofactors that were significantly associated with the endpoint
Table 4.5: Investigated late side effects, associated OARs and the investigated dosimetric parameters.
Side effect Associated organs at risk Dosimetric paremeters
Alopecia Skin D2%, D5%, D15%. . . , D55%, V5Gy (RBE), V10Gy (RBE), . . . , V60Gy (RBE) in cm3
Dry eye syndrome Lacrimal gland (ipsilateral) D2%, Dmean
Fatigue Brain-CTV, cerebellum D2%, D50%, Dmean, V5Gy (RBE), V10Gy (RBE), . . . , V60Gy (RBE) in % of entire volume
Brain stem D2%
Headache Brain-CTV, cerebellum D2%, D50%, Dmean, V5Gy (RBE), V10Gy (RBE), . . . , V60Gy (RBE) in % of entire volume
Brain stem D2%
Hearing impairment Cochlea (ipsilateral) D2%, Dmean
Memory impairment Brain-CTV, cerebellum D2%, D50%, Dmean, V5Gy (RBE), V10Gy (RBE), . . . , V60Gy (RBE) in % of entire volume
Hippocampi bilateral D2%, D50%, Dmean
Optic nerve failure Optic nerve (ipsilateral), chiasm D2%
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were included in multivariable models using stepwise forward variable selection based on likeli-
hood ratio using IBM SPSS Statistics 25. The inclusion testing was based on the significance
of the score statistic (p = 0.05), and exclusion testing (p = 0.10) based on the probability of a
likelihood-ratio statistic based on the maximum partial likelihood estimates. The 95 % confidence
intervals of the AUC values are asymptotic estimates.
To consider all recorded patient data from all follow-up visits, GEEs were set up to assess
which dose-volume parameters were significantly associated with the dichotomised side effects.
GEEs allow for the analysis of longitudinal data and account for the non-linear nature of the bi-
nary response as well as missing observations. A logit link function and an independent working
correlation matrix was used. For each endpoint and dosimetric or clinical parameter, two GEEs
were created. One included the dosimetric or clinical parameter and time as model predictors.
The other model additionally included the interaction between time and the dosimetric or clinical
parameter. The parameter time was defined as natural numbers in the interval [1, 7] representing
the follow-up visits, for equidistant (three months) intervals starting with 1 at 6 months after PBT
and ending with 7 at 24 months after PBT. For each side effect and grade, the model was se-
lected, which revealed the lowest quasi log-likelihood estimate and the corresponding dosimetric
or clinical predictor showed the lowest p-value. Additionally, the predictor was preferred, that
showed a significant association with the endpoint in both models including and excluding the
interaction term. These analyses were performed for the above-mentioned side effects on the
pooled cohort using IBM SPSS Statistics 25.
4.3.1 Results
Development of NTCP models and their external validation
Incidence rates of late side effects The exploration and validation cohort differed in a few
clinical characteristics at both time points of analysis (at 12 and at 24 months after PBT), see
table 4.4. The exploration cohort included patients with significantly larger tumours than the
validation cohort (median: 71.3 vs 29.6 cm3). The prescribed dose was higher in the exploration
cohort than in the validation cohort. Moreover, the cohorts differed significantly with respect to
the location of the tumours. In the exploration cohort, more patients had a tumour involving more
than one lobe compared to the validation cohort.
The incidence rates for late side effects at 12 and at 24 months following PBT are given in
table 4.6. Overall, the incidence rates of late radiation-induced side effects were low. At 12
months after PBT, fatigue was the most common side effect. Fatigue grade ≥ 1 was observed
in 36 % and 26 % of the patients in the exploration and validation cohort, respectively. Fatigue
grade ≥ 2 was observed in 15 % and 13 %, mild alopecia (grade ≥ 1) in 34 % and 22 % and
headache grade ≥ 1 in 25 % and 12 % of the patients in the exploration and validation cohort,
respectively. In three patients in the exploration cohort, optic nerve failure grade 4 was observed.
The incidence rates of the side effects did not differ between the exploration and validation cohort,
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Table 4.6: Comparison of the baseline-corrected late side effects (CTCAE v4.0) between exploration and
validation cohort at 12 and 24 months after PBT. The number N of available datasets is given. P-values
represent results of the χ2 test. Side effects considered for modelling are coloured.
12 months after PBT 24 months after PBT
Toxicity Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Cohort N n (%) n (%) n (%) n (%) n (%) p-value N n (%) n (%) n (%) n (%) n (%) p-value
Alopecia 0.26 0.057
Exploration 84 55 (65) 27 (32) 2 (2) 65 46 (71) 18 (28) 1 (2)
Validation 45 35 (78) 10 (22) 35 32 (91) 3 (9)
Dry eye syndrome 0.034 0.42
Exploration 102 92 (90) 6 (6) 4 (4) 70 68 (97) 1 (1) 1 (1)
Validation 65 65 (100) 59 59 (100)
Fatigue 0.56 0.004
Exploration 104 67 (64) 22 (21) 13 (13) 2 (2) 73 45 (62) 21 (29) 7 (10)
Validation 62 46 (74) 8 (13) 7 (11) 1 (2) 60 52 (87) 7 (12) 1 (2)
Headache 0.12 0.064
Exploration 104 78 (75) 16 (15) 7 (7) 3 (3) 73 57 (78) 9 (12) 7 (10)
Validation 62 55 (89) 6 (10) 1 (2) 61 52 (85) 8 (13) 0 (0) 1 (2)
Hearing impairment 0.72 0.21
Exploration 102 93 (91) 4 (4) 2 (2) 3 (3) 70 62 (89) 5 (7) 2 (3) 0 (0) 1 (1)
Validation 64 59 (92) 3 (5) 0 (0) 2 (3) 59 55 (93) 2 (3) 0 (0) 2 (3)
Memory impairment 0.061 0.011
Exploration 103 78 (76) 16 (16) 8 (8) 1 (1) 73 50 (68) 17 (23) 6 (8)
Validation 63 58 (92) 4 (6) 1 (2) 60 53 (88) 7 (12) 0 (0)
Optic nerve failure 0.10 0.17
Exploration 100 86 (86) 7 (7) 3 (3) 1 (1) 3 (3) 71 59 (83) 6 (8) 2 (3) 2 (3) 2 (3)
Validation 62 61 (98) 0 (0) 1 (2) 56 54 (96) 1 (2) 1 (2)
Cataract 0.94 0.36
Exploration 57 56 (98) 1 (2) 36 32 (89) 2 (6) 1 (3) 1 (3)
Validation 66 66 (100) 62 60 (97) 1 (2) 0 (0) 1 (2)
Seizure 0.53 0.18
Exploration 101 97 (96) 0 (0) 3 (3) 1 (1) 70 67 (96) 0 (0) 2 (3) 1 (1)
Validation 64 61 (95) 1 (2) 2 (3) 61 59 (97) 2 (3)
Abbreviation: n, number of patients.
except for dry eye syndrome (p = 0.034). Dry eye syndrome grade ≥ 1 was observed in 10 % of
the patients in the exploration cohort, but not in the validation cohort.
At 24 months following PBT, fatigue was still the most frequent side effect. Fatigue grade ≥ 1
was reported by 39 % and 16 %, memory impairment grade ≥ 1 in 31 % and 12 %, mild alopecia
(grade ≥ 1) occurred in 30 % and 9 % of the patients in the exploration and validation cohort,
respectively. In one and two patients of the exploration cohort, hearing impairment and optic
nerve failure grade 4 was observed, respectively. The incidence rates of the side effects differed
between the exploration and validation cohort for fatigue (p = 0.004) and memory impairment
(p = 0.011). Both side effects occurred with higher incidence rates and severity grades in the
exploration cohort.
The low incidence rates in the exploration cohort did not allow for NTCP modelling of several
side effects. At 12 months following PBT, the following side effects were considered: alopecia,
dry eye syndrome, headache, optic nerve failure, memory and hearing impairment grade ≥ 1 as
well as fatigue, headache and memory impairment grade ≥ 1 and ≥ 2. At 24 months after PBT,
alopecia, fatigue, headache, hearing and memory impairment and optic nerve failure grade ≥ 1
were investigated.
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NTCP models for side effects at 12 months after PBT Alopecia grade ≥ 1 was significantly
associated to a wide range of dosimetric parameters of the skin. In cross-validation, the highest
AUC value (0.93) was observed for two models, one including V45Gy (RBE) of the skin as model
predictor and the other model included the near-maximum dose D2% of the skin. Both param-
eters V45Gy (RBE) and D2% were also highly correlated (Spearman ρ = 0.95). Alopecia was
also associated to tumour volume (CTV), prescribed total dose, surgery, and location in the skull
base or brain (p < 0.02). In bivariable models, including one of the before-mentioned dosimetric
parameters and one of the significant clinical cofactors, the highest AUC value was observed
for a model including D2% of the skin and tumour volume (AUC = 0.93 [0.75 – 1.00]). As both
parameters were correlated (Spearman ρ = 0.75) and the AUC value did not further increase,
a univariable model was preferred. For the model including V45Gy (RBE) of the skin and the
tumour volume, the AUC value even decreased (0.91 [0.74 – 1.00]), while the model including
tumour volume as the only parameter had a smaller AUC value (AUC = 0.83 [0.69 – 0.95]). In
external validation, the model including D2% performed slightly better (AUC = 0.77 [0.64 – 0.89])
and showed better calibration than the model including V45Gy (RBE) (AUC = 0.65 [0.47 – 0.83]),
see figure 4.4. Characteristics of both models are summarised in table 4.7.
Mild physician-rated memory impairment grade ≥ 1 was significantly associated to the pre-
scribed total dose as the only predictive factor (p = 0.038, AUC = 0.64 [0.53 – 0.75]). However,
this model could not be validated externally (AUC = 0.45 [0.19 – 0.69]). An association with
dose-volume parameters of the considered brain structures could not be found.
Hearing impairment grade ≥ 1 was significantly associated with age at PBT (p = 0.002,
AUC = 0.83 [0.53 – 1.00]). In external validation, this model achieved AUC = 0.73 [0.40 – 0.96].
However, the 95 % CI included the value 0.5, which represents a random prediction. Moreover,
no dose-effect relationship could be observed.
For headache, fatigue, dry eye syndrome and optic nerve failure grade ≥ 1 as well as fatigue,
headache and memory impairment grade ≥ 2, no significant association with either dose-volume
parameters or clinical cofactors could be found in logistic regression.
NTCP models for side effects at 24 months after PBT Alopecia grade ≥ 1 was signifi-
cantly associated to a wide range of dose-volume parameters of the skin. The model including
V30Gy (RBE) of the skin showed the highest AUC value in cross-validation (0.80 [0.62 – 0.95],
p = 0.005). The model including D2% of the skin showed a similar AUC value and revealed the
lowest p-value (AUC = 0.78 [0.60 – 0.93], p < 0.001). Alopecia was also associated to tumour
volume (CTV), prescribed total dose, CTx, and location in the skull base or brain (p < 0.04). In
bivariable models, including one of the before-mentioned dosimetric parameters and one of the
significant clinical cofactors, the AUC value did not further increase. The dosimetric parameters
V30Gy (RBE) and D2% were highly correlated (Spearman ρ = 0.81). Both univariable models
including V30Gy (RBE) as well as D2% revealed high AUC values in external validation (0.90
[0.71 – 1.00] and 0.88 [0.69 – 1.00], respectively). However, external validation was challenging
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(A) Alopecia grade ≥ 1 and D2% of the skin.
(B) Alopecia grade ≥ 1 and V45Gy (RBE) of the skin.
Figure 4.4: NTCP models for alopecia grade ≥ 1 at 12 months following PBT with the model parameters
D2% (A) and V45Gy (RBE) of the skin (B). Regression curve (left), calibration plot (centre) and ROC
curves (right) are displayed. Each data point and error bar represents the mean value and standard
deviation of each patient set, see section 4.1.
due to the low number of incidences of this side effect in the validation cohort, see table 4.6.
This is also reflected in the non-ideal calibration, see figure 4.5. The model characteristics are
presented in table 4.7.
Hearing impairment grade ≥ 1 was significantly associated with mean and near-maximum
dose to the ipsilateral cochlea (p < 0.041). The model including the mean cochlea dose revealed
the highest AUC value in cross-validation (p = 0.035, AUC = 0.74 [0.42 – 1.00]). The high
validation AUC value of 0.87 [0.62 – 1.00] in the external cohort may be due to the low number of
events in this cohort. The low event rate of mild hearing impairment did not allow for multivariable
modelling. The model is presented in figure 4.6 and table 4.7. No significant association to age
at treatment could be observed (p = 0.20)
For memory impairment, headache and optic nerve failure grade ≥ 1, no significant association
with dose-volume parameters could be found in logistic regression.
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(A) Alopecia grade ≥ 1 and D2% of the skin.
(B) Alopecia grade ≥ 1 and V30Gy (RBE) of the skin.
Figure 4.5: NTCP models for alopecia grade ≥ 1 at 24 months following PBT with the model parameters
D2% (A) and V30Gy (RBE) of the skin (B). Regression curve (left), calibration plot (centre) and ROC
curves (right) are displayed. Each data point and error bar represents the mean value and standard
deviation of each patient set, see section 4.1.
Figure 4.6: NTCP model for hearing impairment grade ≥ 1 at 24 months following PBT. Regression
curves (left), calibration plot (centre) and ROC curve (right) are displayed. Each data point and error bar
represents the mean value and standard deviation of each patient set, see section 4.1.
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Table 4.7: NTCP models for late side effects at 12 months and at 24 months following PBT. Model coeffi-
cients βi as described in equation 2.13.
Model βi (95 % CI) p-value AUC (95 % CI)
12 months after PBT
Alopecia grade ≥ 1
Skin V45Gy (RBE) in cm−3 0.15 (0.08 – 0.22) < 0.001 Exploration 0.93 (0.85 – 1.00)
Constant -1.88 (-2.63 – -1.13) Validation 0.65 (0.47 – 0.83)
Skin D2% in Gy(RBE)−1 0.15 (0.09 – 0.21) < 0.001 Exploration 0.93 (0.84 – 0.99)
Constant -6.38 (-9.15 – -3.60) Validation 0.77 (0.64 – 0.89)
24 months after PBT
Alopecia grade ≥ 1
Skin V30Gy (RBE) in cm−3 0.048 (0.02 – 0.08) 0.003 Exploration 0.80 (0.62 – 0.95)
Constant -1.70 (-2.52 – -0.88) Validation 0.90 (0.71 – 1.00)
Skin D2% in Gy(RBE)−1 0.068 (0.03 – 0.11) 0.001 Exploration 0.77 (0.60 – 0.93)
Constant -3.18 (-4.74 – -1.62) Validation 0.88 (0.69 – 1.00)
Hearing impairment grade ≥ 1
Cochlea ipsilateral Dmean in Gy(RBE)−1 0.038 (0.00 – 0.07) 0.035 Exploration 0.74 (0.42 – 1.00)
Constant -3.03 (-4.47 – -1.58) Validation 0.87 (0.62 – 1.00)
Abbreviations: AUC, area under the receiver operating characteristic curve; CI, confidence interval.
Development of NTCP models based on pooled data
Due to the low incidence rates of several side effects, an exploratory analysis on the pooled
cohort, combining the exploration and validation cohort, was conducted. Side effects with at
least 10 incidences were considered. At 12 months after PBT, these comprised alopecia, dry
eye syndrome, fatigue, headache, hearing and memory impairment as well as optic nerve failure
grade ≥ 1 as well as fatigue, headache and memory impairment grade ≥ 2. At 24 months, the
side effects alopecia, fatigue, headache, hearing and memory impairment as well as optic nerve
failure grade ≥ 1 were investigated.
NTCP models for side effects at 12 months after PBT Alopecia grade ≥ 1 was signif-
icantly associated to several dosimetric parameters of the skin (D2%, D5%, D15%, D25%,
V10Gy (RBE), ..., V50Gy (RBE), p < 0.02). The near-maximum dose parameter D2% of the
skin revealed the highest AUC value (0.90 [0.85 – 0.95], p < 0.001) similar to the exploration-
validation study described before. This side effect was also associated to the clinical cofactors
surgery, tumour volume (CTV) and prescribed dose (p < 0.010). In multivariable modelling in-
cluding D2% and these clinical cofactors, the model predictors D2% of the skin and prescribed
dose remained after forward variable selection. Both parameters were correlated (Spearman
ρ = 0.69). Moreover, the AUC value of this bivariable model did not increase substantially com-
pared to the univariable model including only D2% of the skin (0.91 [0.81 – 0.99]). Thus, the
univariable model including D2% was preferred as the AUC value of the model including pre-
scribed dose only was lower (0.81 [0.73 – 0.89]). Model characteristics are given in table 4.8.
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Table 4.8: NTCP models for late side effects in the pooled analysis. The 95 % confidence intervals of the
AUC values are asymptotic estimates.
Model βi (95 % CI) p-value AUC (95 % CI)
12 months after PBT
Alopecia grade ≥ 1
Skin D2% in Gy(RBE)−1 0.12 (0.08 – 0.15) < 0.001 0.90 (0.85 – 0.95)
Constant -4.79 (-6.35 – -3.24)
Memory impairment grade ≥ 1
Hippocampi D2% in Gy(RBE)−1 0.023 (0.004 – 0.043) 0.017 0.66 (0.55 – 0.77)
Constant -2.32 (-3.12 – -1.51)
Memory impairment grade ≥ 2
Brain-CTV V25Gy (RBE)∗ 5.02 (0.03 – 10.01) 0.049 0.70 (0.52 – 0.88)
Constant -3.42 (-4.47 – -2.38)
Hearing impairment grade ≥ 1
Cochlea ipsi Dmean in Gy(RBE)−1 0.032 (0.00 – 0.06) 0.021 0.82 (0.70 – 0.93)
Age in years 0.072 (0.03 – 0.12) 0.001
Constant -7.02 (-9.86 – -4.18)
24 months after PBT
Alopecia grade ≥ 1
Skin D2% in Gy(RBE)−1 0.078 (0.04 – 0.11) < 0.001 0.82 (0.75 – 0.89)
Constant -3.80 (-5.26 – -2.34)
Memory impairment grade ≥ 1
Brain-CTV V35Gy (RBE)∗ 6.50 (1.30 – 11.70) 0.014 0.64 (0.52 – 0.75)
Constant -1.77 (-2.40 – -1.15)
Fatigue grade ≥ 1
Brain stem D2% in Gy(RBE)−1 0.021 (0.00 – 0.04) 0.035 0.68 (0.58 – 0.77)
Chemotherapy -1.16 (-2.30 – -0.02) 0.047
Constant -1.52 (-2.39 – -0.64)
Hearing impairment grade ≥ 1
Cochlea ipsi Dmean in Gy(RBE)−1 0.050 (0.019 – 0.081) 0.001 0.79 (0.68 – 0.90)
Constant -3.48 (-4.69 – -2.28)
Abbreviations: AUC, area under the receiver operating characteristic curve; CI, confidence interval; ∗as
fraction of the total volume.
Hearing impairment grade ≥ 1 was significantly associated with Dmean (p = 0.007) and D2%
of the ipsilateral cochlea (p = 0.010) in logistic regression. The model including Dmean revealed
the higher AUC value (0.70 [0.55 – 0.85]). Moreover, a significant relation between the clinical
cofactor age at treatment and hearing impairment was observed (p < 0.001, AUC = 0.79 [0.66
– 0.92]). The bivariable model including Dmean and age at PBT revealed the highest AUC value
(0.82 [0.70 – 0.93]). As both parameters were not correlated (ρ = 0.09), this model was preferred,
see figure 4.7A and table 4.8.
Memory impairment grade ≥ 1 was significantly associated to Dmean and D2% of the bilateral
hippocampi (p = 0.033 and p = 0.017), V20Gy (RBE) of the brain-CTV (p = 0.040), D2%,
V20Gy (RBE) and V20Gy (RBE) of the cerebellum (p < 0.043). The model with the highest
AUC value included the dosimetric parameter D2% of the hippocampi (0.66 [0.55 – 0.77]). The
clinical cofactor prescribed dose was also related to memory impairment grade ≥ 1 (p = 0.017).
However, during logistic regression including D2% of the hippocampi and prescribed dose using
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(A) Hearing impairment grade ≥ 1 at 12 months following PBT.
(B) Hearing impairment grade ≥ 1 at 24 months following PBT.
Figure 4.7: NTCP models for hearing impairment grade ≥ 1 at 12 months (A) and 24 months (B) following
PBT in the pooled analysis. Regression curve (left), calibration plot (centre) and ROC curve (right) are
displayed. The data points represent nearly equally sized patient groups, sorted according to the value of
the dosimetric parameter. Each data point and error bar represents the mean value and standard deviation
of each patient set, see section 4.1. For the model at 12 months after PBT, two regression curves for two
different age groups are shown as an illustration. The calibration plot and ROC curve refer to the model
including age as a continuous predictor.
forward selection, only the parameter D2% of the hippocampi was selected, see figure 4.8A and
table 4.8.
Memory impairment grade ≥ 2 was associated to D2% of the cerebellum (p = 0.024) and
V25Gy (RBE) of the brain-CTV (p = 0.049). The model including V25Gy (RBE) revealed the
highest AUC value (0.70 [0.52 – 0.88]), see figure 4.8B and table 4.8. No clinical cofactor was
significantly associated to this endpoint.
No relation between dosimetric parameters and fatigue (grade ≥ 1 and ≥ 2), headache, optic
nerve failure and dry eye syndrome at 12 months after PBT was observed.
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(A) Memory impairment grade ≥ 1 at 12 months following PBT.
(B) Memory impairment grade ≥ 2 at 12 months following PBT.
(C) Memory impairment grade ≥ 1 at 24 months following PBT.
Figure 4.8: NTCP models for memory impairment grade ≥ 1 and grade ≥ 2 at 12 months following PBT
(A, B) and grade ≥ 1 at 24 months following PBT (C) in the pooled analysis. Regression curve (left),
calibration plot (centre) and ROC curve (right) are displayed. Each data point and error bar represents the
mean value and standard deviation of each patient set, see section 4.1.
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NTCP models for side effects at 24 months after PBT Alopecia grade ≥ 1 was associated to
several dosimetric parameters of the skin (D2%, D5%, D15%, V10Gy (RBE), ..., V50Gy (RBE),
p < 0.02). The volume parameter V30Gy (RBE) of the skin revealed the highest AUC value
(0.83 [0.74 – 0.92], p < 0.001). This side effect was also associated to the clinical cofactors CTx,
tumour volume (CTV), prescribed dose, and tumour location in brain or skull base (p < 0.011).
In multivariable modelling including V30Gy (RBE) and these clinical cofactors using forward se-
lection, only the dosimetric parameter remained. Model characteristics are given in table 4.8.
Mild fatigue was associated to the near-maximum dose D2% of the brain stem (AUC = 0.62
[0.53 – 0.72], p = 0.018). The clinical cofactors CTx (p = 0.033) as well as tumour location in
brain or skull base (p = 0.027) were also associated to fatigue grade ≥ 1. A bivariable model
including CTx and D2% of the brain stem revealed the highest AUC value (0.68 [0.58 – 0.77]),
see figure 4.9 and table 4.8.
Mild hearing impairment was significantly associated to Dmean (p = 0.001) and D2% (p = 0.003)
of the ipsilateral cochlea in logistic regression. The model including the mean cochlear dose
revealed the highest AUC value (0.79 [0.68 – 0.90]). A weak association to the clinical cofactor
age at treatment was observed for hearing impairment at that time (p = 0.078). The model is
presented in figure 4.7B and table 4.8.
Physician-rated memory impairment grade ≥ 1 was significantly related to dosimetric param-
eters of the brain-CTV (V10Gy (RBE), ..., V50Gy (RBE) and Dmean, p < 0.035). The model
including V35Gy (RBE) revealed the highest AUC value (0.64 [0.52 – 0.75], p = 0.014), see
figure 4.8C and table 4.8. No significant association between mild memory impairment and any
clinical cofactors was observed at that time.
No relation between dosimetric parameters and headache as well as optic nerve failure grade
≥ 1 at 24 months after PBT was observed in logistic regression.
Figure 4.9: NTCP model for fatigue grade ≥ 1 at 24 months following PBT. Regression curve (left),
calibration plot (centre) and ROC curve (right) are displayed. Each data point and error bar represents the
mean value and standard deviation of each patient set, see section 4.1.
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Generalised estimating equations for late side effects
GEEs on the pooled cohort were created to analyse all recorded patient data for all follow-up
examinations between 6 and 24 months after PBT. Therefore, in addition to the dosimetric or
clinical parameters, the GEEs include time as an additional parameter. The equations were
created for all side effects shown in table 4.5 for grade ≥ 1 and grade ≥ 2, respectively.
Alopecia Significant associations between alopecia grade ≥ 1 and all considered dosimetric
parameters of the skin were observed (p < 0.04), except for V60Gy (RBE). The parameter D2%
revealed the lowest quasi-likelihood estimation and p-value (p < 0.001) among all dosimetric
parameters of the skin. This parameter D2% remained significant for the GEE that also includes
the interaction term between time and D2% (p < 0.001), see table 4.9. A significant association
with the endpoint was observed for the clinical cofactors prescribed dose and tumour volume
(CTV) in GEEs including and excluding the interaction term between time and the respective
cofactor (p < 0.02), see appendix B table B.12.
Several dosimetric parameters showed a significant association to alopecia grade ≥ 2 (D2%,
D5%, D15%, D25%, V10Gy (RBE), ..., V50Gy (RBE), p < 0.04). The lowest quasi-likelihood
estimation was observed for parameter D2% (p = 0.012) in both GEEs including and excluding
the interaction term between time and D2%, see table 4.9. A significant association with the
endpoint was observed for the clinical cofactors prescribed dose and tumour volume in GEEs
including and excluding the interaction term between time and the cofactor (p < 0.03), see
appendix B table B.12.
Dry eye syndrome A significant association between mild dry eye syndrome grade ≥ 1 and
Dmean of the ipsilateral lacrimal gland was observed in a GEE excluding the interaction term
with time and this dosimetric parameter, see table 4.9. Also for dry eye syndrome grade ≥ 2 a
significant association to Dmean of the ipsilateral lacrimal gland was observed in a GEE excluding
and including the corresponding interaction term with time, see table 4.9. Moreover, dry eye
syndrome grade ≥ 2 was significantly associated with the tumour location in brain or skull base
in GEEs (p < 0.001), see appendix B table B.12.
Fatigue A significant association between mild fatigue grade ≥ 1 and two dosimetric parame-
ters were observed in GEEs excluding the interaction term of the respective parameter and time:
D2% of the brain stem (p = 0.028) and D2% of the cerebellum (p = 0.034), see table 4.9. There
was no relation between fatigue grade ≥ 1 and clinical cofactors. Neither dosimetric nor clinical
parameters were found to be associated with fatigue grade ≥ 2.
Headache A relation between headache grade ≥ 1 and age at treatment was observed (p =
0.010). Younger age was associated with milder headaches, see appendix B table B.12. How-
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Table 4.9: GEE analysis for late side effects in the pooled analysis. The parameter time is defined as a
natural number representing the follow-up visit starting with 1 at 6 months following PBT.
Excluding interaction term between dosimetric parameter and time Including interaction term between dosimetric parameter and time
Model parameter βi (95 % CI) p-value Model parameter βi (95 % CI) p-value
Alopecia grade ≥ 1
Skin D2% in Gy(RBE)−1 0.088 (0.07 – 0.11) < 0.001 Skin D2% in Gy(RBE)−1 0.079 (0.04 – 0.12) < 0.001
Time -0.037 (-0.07 – 0.00) 0.048 Time -0.062 (-0.17 – 0.05) 0.27
Constant -3.33 (-4.24 – -2.42) Interaction 0.001 (0.00 – 0.00) 0.63
Constant -2.99 (-4.66 – -1.33)
Alopecia grade ≥ 2
Skin D2% in Gy(RBE)−1 0.10 (0.02 – 0.18) 0.012 Skin D2% in Gy(RBE)−1 0.25 (0.05 – 0.45) 0.012
Time -0.013 (-0.10 – 0.08) 0.79 Time 0.43 (-0.08 – 0.94) 0.10
Constant -7.62 (-10.89 – -4.36) Interaction -0.009 (-0.02 – 0.00) 0.086
Constant -15.28 (-25.51 – -5.05)
Dry eye syndrome grade ≥ 1
Lacrimal gland ipsi Dmean in Gy(RBE)−1 0.032 (0.00 – 0.06) 0.038 Lacrimal gland ipsi Dmean in Gy(RBE)−1 0.017 (-0.01 – 0.05) 0.27
Time -0.038 (-0.08 – 0.01) 0.11 Time -0.054 (-0.11 – 0.00) 0.041
Constant -2.41 (-3.28 – -1.54) Interaction 0.001 (0.00 – 0.00) 0.31
Constant -2.20 (-2.97 – -1.42)
Dry eye syndrome grade ≥ 2
Lacrimal gland ipsi Dmean in Gy(RBE)−1 0.053 (0.02 – 0.09) 0.003 Lacrimal gland ipsi Dmean in Gy(RBE)−1 0.045 (0.01 – 0.08) 0.006
Time -0.042 (-0.12 – 0.04) 0.31 Time -0.056 (-0.16 – 0.04) 0.27
Constant -3.93 (-5.47 – -2.38) Interaction 0.001 (0.00 – 0.00) 0.62
Constant -3.74 (-5.35 – -2.13)
Fatigue grade ≥ 1
Brain stem D2% in Gy(RBE)−1 0.015 (0.00 – 0.03) 0.028 Brain stem D2% in Gy(RBE)−1 0.016 (0.00 – 0.03) 0.094
Time -0.015 (-0.04 – 0.01) 0.24 Time -0.012 (-0.06 – 0.03) 0.62
Constant -1.23 (-1.86 – -0.60) Interaction 0.000 (0.00 – 0.00) 0.88
Constant -1.27 (-2.05 – -0.49)
Hearing impairment grade ≥ 1
Cochlea ipsi D2% in Gy(RBE)−1 0.027 (0.01 – 0.05) 0.007 Cochlea ipsi D2% in Gy(RBE)−1 0.022 (-0.01 – 0.05) 0.16
Time -0.006 (-0.05 – 0.04) 0.79 Time -0.018 (-0.09 – 0.06) 0.64
Constant -2.93 (-4.03 – -1.83) Interaction 0.000 (0.00 – 0.00) 0.67
Constant -2.76 (-4.14 – -1.39)
Memory impairment grade ≥ 1
Brain-CTV V25Gy (RBE)∗ 7.13 (3.88 – 10.38) < 0.001 Brain-CTV V25Gy (RBE)∗ 8.17 (1.85 – 14.49) 0.011
Time 0.017 (-0.01 – 0.05) 0.25 Time 0.026 (-0.02 – 0.08) 0.29
Constant -2.43 (-3.11 – -1.76) Interaction -0.069 (-0.40 – 0.27) 0.69
Constant -2.57 (-3.53 – -1.61)
Hippocampi D2% in Gy(RBE)−1 0.018 (0.00 – 0.03) 0.016 Hippocampi D2% in Gy(RBE)−1 0.019 (-0.01 – 0.04) 0.13
Time 0.017 (-0.01 – 0.05) 0.27 Time 0.019 (-0.02 – 0.06) 0.39
Constant -2.06 (-2.82 – -1.31) Interaction 0.000 (0.00 – 0.00) 0.92
Constant -2.09 (-3.02 – -1.16)
Cerebellum V20Gy (RBE)∗ 2.12 (0.50 – 3.73) 0.010 Cerebellum V20Gy (RBE)∗ 1.23 (-1.60 – 4.06) 0.39
Time 0.016 (-0.01 – 0.04) 0.28 Time 0.010 (-0.02 – 0.04) 0.54
Constant -1.71 (-2.28 – -1.15) Interaction 0.063 (-0.14 – 0.27) 0.55
Constant -1.63 (-2.21 – -1.06)
Memory impairment grade ≥ 2
Brain-CTV V25Gy (RBE)∗ 7.44 (2.96 – 11.92) 0.001 Brain-CTV V25Gy (RBE)∗ 6.43 (-2.29 – 15.15) 0.15
Time 0.004 (-0.05 – 0.06) 0.88 Time -0.007 (-0.10 – 0.09) 0.89
Constant -3.73 (-4.89 – -2.56) Interaction 0.066 (-0.38 – 0.51) 0.77
Constant -3.56 (-5.26 – -1.86)
Hippocampi Dmean in Gy(RBE)−1 0.037 (0.00 – 4.61) 0.032 Hippocampi Dmean in Gy(RBE)−1 0.005 (-0.05 – 0.07) 0.86
Time 0.000 (-0.05 – 0.00) 0.99 Time -0.027 (-0.09 – 0.03) 0.38
Constant -2.96 (-4.07 – 27.13) Interaction 0.002 (0.00 – 0.01) 0.18
Constant -2.57 (-3.63 – -1.50)
Abbreviations: CI, confidence interval; ipsi, ipsilateral; ∗as fraction of the total volume.
ever, an increased dose was not associated with headache in any dosimetric parameter. Neither
dosimetric nor clinical parameters were found to be associated with headache grade ≥ 2.
Hearing impairment The dosimetric parameters Dmean and D2% of the ipsilateral cochlea were
significantly associated to hearing impairment grade ≥ 1 (p < 0.012) in GEE without the inter-
action term with time, see table 4.9. In addition, a relation between hearing impairment grade
61
4 Modelling of side effects following cranial proton beam therapy
≥ 1 and age at treatment was seen in GEEs including and excluding the interaction term be-
tween time and the cofactor (p < 0.034), see appendix B table B.12. Older age was associated
with increased hearing impairment. No association between hearing impairment grade ≥ 2 and
dosimetric parameters of the ipsilateral cochlea was observed.
Memory impairment Several dosimetric parameters of different brain structures were signif-
icantly associated with memory impairment grade ≥ 1 in GEEs excluding the interaction term
with time: brain-CTV (D2%, Dmean, V10Gy (RBE), ..., V50Gy (RBE), p < 0.004), bilateral hip-
pocampi (D2%, Dmean, p < 0.016) and cerebellum (D2%, Dmean, V20Gy(RBE), V30Gy (RBE),
V40Gy (RBE), p < 0.05). For each of these OARs, the model with the lowest quasi-likelihood es-
timate is presented in table 4.9. However, only dosimetric parameters of the brain-CTV remained
significantly associated with memory impairment grade ≥ 1 in GEEs including the interaction
term with time. Among these, the parameter V25Gy (RBE) revealed the lowest quasi-likelihood
estimation, see table 4.9. A significant association with memory impairment grade ≥ 1 was ob-
served for the clinical cofactors prescribed dose and tumour volume (CTV) in GEEs including
and excluding the interaction term between time and the cofactor (p < 0.042), see appendix B
table B.12.
Significant associations between memory impairment grade ≥ 2 and Dmean of the bilateral
hippocampi (p = 0.032) as well as certain dosimetric parameters of the brain-CTV (D2%, Dmean,
V10Gy (RBE), ..., V50Gy (RBE), p < 0.014) were observed in GEEs excluding the interaction
term with time. Among these, the parameter V25Gy (RBE) revealed the lowest quasi-likelihood
estimation, see table 4.9.
Optic nerve failure No significant association between optic nerve failure and any parameter
could be observed.
4.3.2 Discussion
This study on adult patients with intracranial tumours receiving PBT investigated the relation of
late side effects within two years after PBT and dose to associated OAR. Overall, PBT was well
tolerated with very low incidences of side effects grade ≥ 3 (< 5 %). Due to these low incidence
rates, NTCP models for mostly mild forms of the side effects could be created (grade ≥ 1). Mild
alopecia was associated to doses of the skin at both 12 and 24 months after PBT. Mild hearing
impairment at 24 months after PBT was associated to the mean dose of the ipsilateral cochlea.
These three models could be validated on an external cohort and were also observed in the
analysis of the pooled cohort. Additionally, dose-response relations were found for physician-
rated memory impairment and intermediate to high doses to the remaining brain as well as high
doses to the hippocampi. Moreover, mild fatigue at 24 months after PBT was associated to high
doses to the brain stem as well as CTx when analysing the pooled cohort. In GEE analysis
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including patient data from all available follow-up visits, the findings regarding alopecia as well
as memory impairment could be confirmed. Additionally, dry eye syndrome grade ≥ 2 was
associated to the mean dose of the ipsilateral lacrimal gland.
Incidence rates of late side effects
Although many patients have already been treated with PBT, overall published data on incidence
rates of physician-rated side effects with a follow-up period of more than one year are rare. Shih et
al. (2015) investigated various late side effects in 20 LGG patients treated with 54 Gy(RBE) and a
DS PBT technique. During follow-up (median: 5.1 years), the most common physician-rated side
effects (CTCAE) after more than three months following treatment were persistent headaches,
fatigue, alopecia and new neurologic deficits. These findings are generally comparable to those in
this thesis. However, mild headache was less frequent in the present study (10 – 15 %) compared
to the study by Shih et al. (2015) (60 %). Similarly, less fatigue grade 3 was reported in the present
thesis (2 %) compared to the discussed study (15 %). However, the follow-up in this thesis was
somewhat shorter, so that more severe toxicities may develop later on.
Weber et al. (2012) assessed the long-term outcome of 39 patients with intracranial menin-
giomas treated with normo-fractionated PBS PBT and a median dose of 56 Gy(RBE). The mean
follow-up time was 5.2 years. Late side effects according to CTCAE were observed in 41 % of
the patients. Pituitary dysfunction was most common (10 %), followed by transient brain oedema
(8 %), optic nerve neuropathy (8 %), brain necrosis (5 %), and retinitis (5 %). 31.3 % of the pa-
tients presented with late side effects grade ≥ 3, although these patients were not pre-irradiated.
In comparison, in the present thesis, the incidence rate for side effects grade ≥ 3 was well below
30 %, see table 4.6. Optic nerve failure occurred with a comparable frequency. In the present
study, it ranged between 2 and 8 % (grade ≥ 2). However, it should also be noted that the present
study only had a follow-up period of 2 compared to 5 years in the study by Weber et al. (2012).
Moreover, several of the before-mentioned side effects observed by Weber et al. (2012) were not
investigated in all patients in this thesis, such as pituitary dysfunction or retinitis.
Noël et al. (2005) assessed the outcome of 51 patients with intracranial benign meningiomas
located in the skull base that were treated with a combination therapy of normo-fractionated XRT
and PBT and a median dose of 60.6 Gy(RBE). During follow-up (mean: 2.1 years), one patient
(2 %) reported grade 3 hearing loss and another a complete loss of pituitary function (grade 3
according to LENT-SOMA). However, they did not report mild or moderately severe clinical side
effects. The follow-up time was comparable between this study and the presented study, as was
the incidence rate of grade 3 hearing loss (3 %).
A study on 77 skull-base chondrosarcoma patients treated with PBS PBT and doses between
64.0 – 76.0 Gy(RBE) observed high-grade (grade ≥ 3) radiation-induced side effects in 8 % of
the patients including hearing loss, radiation necrosis and optic nerve neuropathy during a mean
follow-up of 5.8 years (Weber et al., 2016). They reported incidence rates of any side effects
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according to CTCAE but did not further specify the type of toxicity (grade 1: 21 %, grade 2: 30 %,
grade 3: 4 %, grade 4: 4 %).
In general, the incidence rates of late effects in this thesis did not differ markedly from those
reported in the other studies mentioned above.
Dose-response relationships for late side effects
In this thesis, dose-response relationships for several late side effects following PBT were ob-
served. In the following, the findings are compared with those of other dose-response studies.
Alopecia Mild alopecia was related to high dose parameters of the skin (D2%, V30Gy (RBE)
and V45Gy (RBE)) at 12 and 24 months after PBT. High AUC values were observed in explo-
ration and validation. Palma et al. (2020) investigated 116 adult brain tumour patients treated
with PBS PBT with a median dose of 54 Gy(RBE). Using the CTCAE grading system, late (> 90
days after PBT) and permanent (> 12 months after PBT) radiation-induced alopecia grade ≥ 2
was observed in 35 % and 19 % of the patients, respectively. These incidence rates are consider-
ably higher than those observed in this thesis as only 2 % of the patients in the exploration cohort
presented with alopecia grade ≥ 2 at 12 and 24 months after PBT. Palma et al. (2020) developed
NTCP models based on dose-surface histogram parameters. An LKB model showed increasing
tolerance values from 24 Gy(RBE) for late alopecia to 44 Gy(RBE) for permanent alopecia. The
effect of increasing tolerance doses over time was also observed in this thesis, as described
below in more detail. The most predictive dosimetric parameter for late alopecia grade ≥ 2 char-
acterised the skin surface receiving 25 Gy(RBE). Surgery was a risk factor for late alopecia grade
≥ 2 as it was in this thesis for late alopecia grade ≥ 1. Palma et al. (2020) found D2% of the scalp
as the only predictor for permanent alopecia. This parameter was also found to be predictive for
alopecia grade ≥ 1 in the presented thesis. Moreover, this factor seems to be predictive for both
PBT techniques, PBS and DS.
Lawenda et al. (2004) investigated permanent alopecia (> 12 months) after cranial XRT with
prescribed doses between 30.6 and 63 Gy in 26 patients. Permanent alopecia was correlated
to dose to the hair follicles. In logistic regression, the tolerance dose TD50 for alopecia grade
≥ 3 was found to be 43 Gy. Severity grading was not based on standardised scoring systems,
such as CTCAE, but on a 4-point scale with grade 1 none, grade 2 minimal, grade 3 moderate
and grade 4 severe. However, the CTCAE grading for alopecia ranges from 0 to 2 as the most
severe grade, see appendix B table B.13. Thus, alopecia grade 3 in the study by Lawenda et al.
(2004) may approximately correspond to alopecia grade 1 according to CTCAE. In the logistic
models developed in this thesis for alopecia grade ≥ 1 at 12 months after PBT including D2% of
the skin, the tolerance dose TD50 was estimated to 41.2 Gy(RBE) in the exploration cohort (see
4.4A and table 4.7) and 42.7 Gy(RBE) in the pooled cohort (see table 4.8). Although different
RT techniques were applied, these findings are in good agreement with those by Lawenda et al.
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(2004). The authors did not find an association between alopecia and age at treatment or gender.
This is in accordance with the findings of this thesis.
Hair loss is often considered a minor unavoidable side effect of cranial RT (Shih et al., 2009).
However, it may have a great impact on patients’ QoL, even years after the initial event. This is
reflected in reduced self-confidence and low self-esteem. These concerns could be addressed
by creating RT treatment plans that could reduce the probability of developing late alopecia.
Hearing impairment In this thesis, mild hearing impairment was found to be associated to
the mean dose to the ipsilateral cochlea as well as age at PBT. Other studies reported similar
causative factors in patients treated with XRT. Bhandare et al. (2010) published a comprehensive
review of literature about hearing loss following XRT or stereotactic RT for patients with head-
and-neck cancer or vestibular schwannoma. Several treatment- and patient-related factors to
hearing loss were revealed. Among treatment-related factors, the mean dose to the cochlea
during fractionated XRT was found to be important as in this thesis.
Hearing impairment 2 to 17 years after treatment was assessed by van der Putten et al. (2006)
in 21 patients with unilateral tumours of the parotid gland who underwent parotidectomy and
postoperative XRT. The contralateral ear was used as a reference in pure-tone and speech au-
diometry. A hearing loss of more than 15 dB in 3 frequencies was found in patients with mean
doses to the cochlea and Eustachian tube of more than 50 Gy. They also fitted an NTCP model
with a 10 % probability for asymmetric hearing loss of 15 dB for a mean dose to the inner ear of
42 Gy. However, they did not report the model coefficients. In 31 head-and-neck patients treated
with normo-fractionated 3D-CRT, Pan et al. (2005) investigated the differences in threshold level
between the ipsilateral and contralateral ears on pure-tone audiograms up to 3 years after XRT.
Hearing loss was related to the mean cochlear dose: a loss of ≥ 10 dB was observed in patients
with a mean cochlear dose of more than 45 Gy. The authors developed a linear model and pre-
sented a nomogram that included the test frequency, age at treatment, baseline hearing, and the
dose differences between the ipsi- and contralateral inner ear.
The model developed in this thesis predicts a 10 % probability for physician-rated hearing im-
pairment grade ≥ 1 for a mean cochlear dose of 21.8 Gy(RBE), see table 4.7. Grade 1 hearing
impairment is defined in the CTCAE for adults that were enrolled on a monitoring program as a
threshold shift of 15 – 25 dB averaged at 2 contiguous test frequencies in at least one ear. As
the patients enrolled in this thesis did not undergo such assessments using audiograms, CTCAE
grade 1 refers to a subjective change in hearing. The different methods of assessment may
explain the differences in model predictions and tolerance doses.
More recently, De Marzi et al. (2015) investigated 114 adult patients with chordoma and chon-
drosarcoma of the skull base treated with postoperative 3D-CRT and PBT with a median dose of
70 Gy(RBE) and a minimum follow-up of 26 months. Hearing impairment was defined as hearing
loss > 15 dB at two contiguous test frequencies, tinnitus or otitis media and recorded for each
ear separately. Patients with hearing impairment had a cochlear mean dose of 54.6 Gy(RBE)
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while this value was only 36.8 Gy(RBE) in patients without any effect. They developed a logistic
model including cochlear mean dose as model predictor with TD50 = 56.0 Gy(RBE). The NTCP
model predicting hearing impairment grade ≥ 1 at 24 months after PBT developed on the explo-
ration cohort in this thesis (see table 4.7) had a TD50 = 79.4 Gy(RBE). The logistic model for the
same endpoint on the pooled cohort (see table 4.8) had a TD50 = 69.4 Gy(RBE). These higher
values of TD50 compared to the study by De Marzi et al. (2015) may be explained by the differ-
ent assessment of toxicity. They analysed a combined endpoint (hearing loss > 15 dB at two
contiguous test frequencies, tinnitus or otitis media), while in this thesis, hearing impairment was
assessed by physicians according to the symptom hearing impairment as defined in the CTCAE
scoring system. Moreover, the follow-up period was shorter in this thesis compared to the study
by De Marzi et al. (2015). The authors may have detected hearing defects that may occur more
than 2 years after treatment but at lower cochlear doses.
Hearing loss was found to be associated to dose to the vestibulocochlear nerve in stereotactic
RT (Bhandare et al., 2010). However, this relation could not be analysed in this thesis, as the
eighth cranial nerve was not delineated. A possible synergistic effect of RT and CTx with cisplatin
to hearing loss was described for patients with head-and-neck cancer (Chen et al., 2006; Bhan-
dare et al., 2010). However, in brain tumour patients, this type of CTx drug is of minor importance
compared to other agents such as TMZ or PCV (Roth and Weller, 2015). Moreover, the incidence
rate of hearing loss after XRT increases with age (> 50 years) (Ho et al., 1999; Honoré et al.,
2002; Pan et al., 2005; Bhandare et al., 2007; Bhandare et al., 2010). This was also observed
in the present study on patients treated with PBT. One study observed higher incidence rates
of hearing loss after RT in men compared to women (Kwong et al., 1996). However, this effect
could not be confirmed in this thesis, nor in other studies (Bhandare et al., 2007).
As mentioned before, in this thesis, hearing loss was assessed by physicians, who had to base
their assessment on the patients’ explanations. As a result, the assessment strongly depended
on the type of questioning and interpretation, which gives the grading a more subjective character.
No audiograms were recorded that would allow an accurate assessment of the hearing condition
(Ho et al., 1999; Pan et al., 2005; Chen et al., 2006). The CTCAE scoring system provides
a grading based on audiogram data (referred to as Adults enrolled on a Monitoring Program).
Bhandare et al. (2010) have summarised comprehensive recommendations for scoring ototoxicity
including pre- and post-treatment evaluations of the same ear using audiograms, whereby the
evaluation should be performed first 6 months after RT and thereafter at least every 6 months.
Several important test frequencies are also presented there. For future studies, a standardised
measurement using pre-and post-treatment audiograms is recommended.
Memory impairment Memory impairment was related to intermediate and high doses to the
remaining brain as well as to high doses to the hippocampi in the pooled cohort. Fairly low AUC
values (< 0.7) were observed and these models need to be independently validated. Gondi
et al. (2012) investigated patients with benign or low-grade brain tumours and found a signifi-
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cant relationship between delayed recall on the Wechsler Memory Scale-III Word List (WMS-WL)
at 18 months after XRT and the dosimetric parameter D40% of the bilateral hippocampi with
TD50 = 14.88 Gy. In this thesis, the model for physician-rated memory impairment grade ≥ 1 at
12 months after PBT including D2% of the hippocampi as model predictor (see table 4.8) had a
much higher TD50 = 100.9 Gy(RBE). Physician-rated memory impairment according to CTCAE
was assessed in this thesis. The specifications of the individual severity grades are very impre-
cisely formulated, e.g. CTCAE grade 1 is defined as mild memory impairment, grade 2 moderate
memory impairment with limiting instrumental activities of daily living and grade 3 severe memory
impairment with limiting self-care activities of daily living. This clearly shows that the assessment
depends very much on the interpretation of the patient’s answers by the physicians. Due to the
rather unspecific nature of this endpoint, it is challenging to find dose-response relationships
for physician-rated memory impairment. Hence, a more detailed investigation of neurocognitive
deficits using specific tests is required. In chapter 5, a comprehensive analysis and discussion of
neurocognitive function after cranial PBT is presented.
Fatigue At 24 months after PBT, mild fatigue was associated to the near-maximum dose of the
brain stem as well as CTx when analysing the pooled cohort. This model revealed an AUC value
of 0.68 and requires independent validation. As discussed in section 4.2, in the PARSPORT
Phase III trial including patients with pharyngeal squamous-cell carcinoma, patients presenting
with acute fatigue grade ≥ 2 had higher maximum and mean doses in the posterior fossa, brain
stem and cerebellum compared to patients with acute fatigue grade ≤ 1 (Gulliford et al., 2012a).
However, data on late fatigue were not acquired in this trial, as it was not expected to be a late side
effect of RT (Nutting et al., 2011). Nevertheless, radiation-induced fatigue is a common chronic
side effect described by 30 % of the patients during follow-up (Jereczek-Fossa et al., 2002).
Similarly, in this thesis, fatigue was one of the most common late side effects, as in the study by
Shih et al. (2015). Self-reported fatigue was even found to be a predictor of survival of patients
with recurrent HGG (Peters et al., 2014). Due to the fact that chronic fatigue after cranial RT
is often underestimated by physicians, there are almost no studies on dose-effect relationships
for this side effect. Therefore, the prevalence and predictive factors of chronic fatigue are not
really understood (Jereczek-Fossa et al., 2002). Fatigue is potentially a synergistic effect of
many influencing factors. These could include biochemical factors, psychological disturbances
such as depression or anxiety, further therapies such as CTx, hormone therapy or surgery or
comorbidities such as pain or electrolytic disturbances (Jereczek-Fossa et al., 2002). In a study
on breast cancer patients, women treated with CTx presented with higher fatigue than those who
were not treated with CTx (Bower et al., 2011). In this thesis, however, patients treated with
CTx were found to present with lower fatigue than others. This was also observed in a study on
lung cancer patients, in which a lower frequency of fatigue was observed in patients with previous
surgery or CTx (Hickok et al., 1996). In a study of acute fatigue in head-and-neck cancer patients,
fatigue did not appear to be caused by CTx (Ferris et al., 2018). Because of these controversies,
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the relationships between fatigue and potential predictive factors should be investigated in larger
cohorts including QoL questionnaires.
Dry eye syndrome Dry eye syndrome grade ≥ 2 was associated to the mean dose of the
ipsilateral lacrimal gland in GEE analysis of the pooled cohort, which requires independent val-
idation. The finding is in accordance with other studies. Bhandare et al. (2012) retrospectively
assessed severe dry eye syndrome leading to vision compromise in 78 patients with extracranial
head-and-neck tumours treated with XRT between 1965 and 2000. The endpoint was assessed
using one or more specific tests that measure the amount, instability and changes in the tear film.
The incidence of dry eye syndrome increased with increasing dose to the lacrimal gland. The
authors developed an NTCP model with TD50 = 48.0 Gy. No association was seen to CTx, age
at treatment, and gender. This is in accordance with the findings of this thesis.
Batth et al. (2013) retrospectively investigated dose-response relations between dose to the
lacrimal gland and ocular toxicity in patients with sinonasal tumours treated with a median dose
of 66 Gy using IMRT. Ocular toxicity was defined as conjunctivitis, corneal ulceration and keratitis
according to the RTOG scoring system. During a median follow-up of 28.5 months, the incidence
rates of late ocular toxicity of grades 1, 2, and 3 were 10 %, 8 % and 13 %, respectively. In the
presented thesis, the incidence rates in the exploration cohort were lower with no grade 3 and
6 % and 4 % for grade 1 and grade 2, respectively, see table 4.6. No events of dry eye syndromes
were observed in the validation cohort. The differences in the incidence rates may be explained
by the different tumour histologies and locations as well as the higher prescribed doses in the
study by Batth et al. (2013). The authors developed a logistic NTCP model for late ocular toxicity
grade ≥ 1 including the maximum dose to the lacrimal gland as predictor but did not report all
model coefficients. With an increase of the maximum dose by 1 Gy, the odds of developing late
ocular toxicity grade ≥ 1 increased by 7 %.
As dry eye syndrome has a negative impact on patients’ QoL (Grubbs et al., 2014), a com-
prehensive assessment of dry eye syndrome following PBT could be included in future studies.
Additionally, specific QLQs could be used as the brain-tumour specific module of the EORTC
(QLQ-BN20) does not address this side effect.
Optic nerve failure In this thesis, no association between optic nerve failure and dose to the
optic nerve or chiasm was observed. This may be due to the low incidence rates in the observed
follow-up period. The latency period between RT and visual loss due to radiation-induced optic
neuropathy may range from three months to 8 years (Danesh-Meyer, 2010). Generally, it is often
reported that doses of more than 50 Gy or 60 Gy are necessary to induce radiation-induced optic
neuropathy (Danesh-Meyer, 2010; Mayo et al., 2010b).
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Dose-response over time
Mild alopecia was associated to high dose parameters of the skin, both at 12 months and at
24 months after PBT. All analyses showed that especially the near-maximum parameter D2%
was significantly related to this side effect at both time points. For this parameter, figure 4.10A
shows the logistic models for alopecia grade ≥ 1 at both time points for the pooled cohort. The
curve is slightly steeper at 12 months compared to 24 months after PBT, which is also appar-
ent in the different model coefficients (0.12 vs 0.08 Gy(RBE)−1, respectively) and the increasing
tolerance doses TD50 (41.2 vs 48.7 Gy(RBE), respectively). In GEE analysis including all follow-
up examinations up to 24 months after treatment, the parameter time had a negative coefficient
(p = 0.048), which indicates a slight decrease in the incidence of the side effect over time. A
similar effect for alopecia grade ≥ 2 was observed by Palma et al. (2020) when comparing late
and permanent alopecia.
Mild hearing impairment was associated to the mean dose of the ipsilateral cochlea, both at 12
months and at 24 months after PBT in the analysis of the pooled cohort. Figure 4.10B shows the
logistic models for hearing impairment grade ≥ 1 at both time points. In contrast to mild alopecia,
the curve is slightly shallower at 12 months than at 24 months after treatment, which is also
reflected in the model coefficients (0.035 vs 0.050 Gy(RBE)−1, respectively) and the decreasing
tolerance doses TD50 (89.5 vs 69.8 Gy(RBE), respectively). This indicates that the probability
of developing mild hearing deficits at the same mean cochlear dose increases over time. This
finding is consistent with other studies analysing patients treated for nasopharyngeal carcinoma
with 3D-CRT, IMRT and electrons (Ho et al., 1999; Chen et al., 2006). In both studies, pre- and
(A) Alopecia grade ≥ 1. (B) Hearing impairment grade ≥ 1.
Figure 4.10: NTCP models for alopecia grade ≥ 1 (A) and hearing impairment grade ≥ 1 (B) at 12 and
at 24 months following PBT on the pooled cohort for the same model predictors, respectively. Each data
point and error bar represents the mean value and standard deviation of each patient set, see section 4.1.
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post-RT pure-tone audiograms were performed to assess the extent of hearing loss and they
concluded that permanent hearing loss increases with time after treatment.
For the model-based selection of patients for PBT, comprehensive NTCP profiles could be
used that predict complication risks at multiple time points after treatment ideally including the
same model predictors (Van den Bosch et al., 2019).
Side effects not investigated in this thesis
Endocrine dysfunction due to irradiation of the hypothalamic–pituitary axis is a side effect that
occurs after cranial RT in children and adults (Darzy and Shalet, 2009). In adults, endocrine
dysfunction may develop over months to years and is often not diagnosed. Most hormone de-
ficiencies can usually be corrected by pharmacotherapy (Shih et al., 2009). In a study by Shih
et al. (2015), 20 LGG patients treated with PBT at a dose of 54 Gy(RBE) underwent endocrine
assessment during follow-up (median 5.1 years). In 6 patients a new endocrine dysfunction was
detected. De Marzi et al. (2015) investigated patients with chordoma or chondrosarcoma treated
with a combination of 3D-CRT and PBT. Of 103 adults, 45 patients developed endocrine dysfunc-
tion. They fitted an NTCP model for endocrine dysfunction with a TD50 value of 60.5 Gy(RBE)
for the pituitary gland. To establish accurate dose-response relationships between endocrine
dysfunction after PBT and pituitary dose, endocrine monitoring of all study patients would be
necessary and is recommended for future studies.
In this thesis, optic nerve failure has been assessed. However, other cranial nerves may also
be affected by irradiation, which may lead to cranial neuropathies. However, these radiation-
induced cranial neuropathies are rare and their occurrence may have a long latent period of
several years (Kong et al., 2011). Studies on patients with nasopharyngeal carcinoma revealed
several causative factors such as muscle fibrosis of the neck, total dose to the nasopharynx, CTx,
and cranial nerve failure at diagnosis (Lin et al., 2002; Kong et al., 2011). Although an accurate
diagnosis requires comprehensive physical examinations for each cranial nerve, future studies
on long-term effects of PBT may also record cranial neuropathies.
In this thesis, physician-rated side effects have been considered. These reflect the clinical
symptoms and therefore the relevance for the patients. However, assessments by third persons
are always affected by interobserver variability, as the physicians need to interpret the patients’
statements. In addition to physician-rated side-effects, a more objective evaluation of some RT
effects can be obtained using MR images during follow-up. In glioma patients treated with XRT
or PBT, white matter changes in terms of reduced diffusivity were observed in areas receiving 10
– 20 Gy(RBE) (Raschke et al., 2019) or even in areas receiving less than 10 Gy (Connor et al.,
2016). These changes were dose-dependent and deteriorated with time after treatment. These
image changes do not necessarily reflect the clinical condition of the patient. Nevertheless, fo-
cal image changes observed on MRI scans may develop into radiation-induced brain necrosis, a
severe side effect. The development of NTCP models for radiation-induced necrosis is demand-
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ing as a distinct differentiation of necrotic tissue from tumour progress is challenging. Various
MRI techniques such as diffusion tensor imaging, perfusion imaging and spectroscopy are com-
monly used for the diagnosis of necrotic brain tissue (Viselner et al., 2019). Moreover, patients
with brain necrosis may be asymptomatic or present with similar clinical symptoms as tumour
progress (Verma et al., 2013). Therefore, the definition of the modelling endpoint is complex.
Furthermore, necrosis presents as single or multifocal lesions involving one or more lobes in one
or both hemispheres (Verma et al., 2013). Due to this very local occurrence, it is difficult to define
a dedicated OAR for modelling. Radiation-induced enhancing foci are typically observed in the
periventricular region (Shah et al., 2012; Eulitz et al., 2019a). However, this area has not yet been
routinely contoured in clinical practice, so there are no validated models based on this structure
available.
Although radiation-induced necrosis is a rare side effect, reports of brain stem necrosis after
PBT indicate possible biological differences between XRT and PBT (Haas-Kogan et al., 2018).
For proton beams, both LET and RBE are variable and increase in the distal edge of the spread-
out Bragg-Peak (Paganetti, 2014; Lühr et al., 2018). For treatment plans with several beam
directions, LET/RBE may superimpose and further increase in the overlap area leading to en-
hanced biological effects. For single fields, the effect at field edges may also be substantial,
since the LET/RBE of several fields cannot be averaged.
These effects could be even more pronounced when moving from DS techniques to intensity-
modulated PBT, as these may further alter LET and RBE (Haas-Kogan et al., 2018). There is a
growing interest in understanding the development of contrast-enhancing lesions that may evolve
into necrotic brain regions by exploring the capabilities of treatment plan evaluation based on LET
and RBE. Models predicting the local occurrence probability of contrast-enhancing lesions is part
of ongoing research (Eulitz et al., 2019a; Eulitz et al., 2019b).
Scoring of side effects of paired organs
In paired organs, such as the lacrimal gland, optic nerve or cochlea, one organ is usually exposed
to higher doses compared to the other. As a result, the associated side effects may occur only on
one side, e.g. dry eye syndrome, optic nerve failure or hearing impairment. However, the affected
side of the respective toxicity was not recorded in all cohorts included in this thesis. Therefore,
it was assumed that the severity grade of the side effect referred to the side that was exposed
to a higher dose. Thus, only the respective ipsilateral organ was examined. For a more detailed
analysis, it would be advisable to precisely record the side of the toxicity in future studies.
Limitations of the studies on early and late side effects
The cohorts included in this study were rather heterogeneous with regard to different tumour his-
tologies. The exploration cohort included patients with glioblastoma who have a comparably short
life expectancy. However, a separate analysis for different tumour histologies was not feasible as
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the number of patients and events in each subgroup would have been even lower. An increas-
ing number of patients is being treated within ongoing clinical trials, e.g. (NCT02824731, 2016).
Once these studies will have been completed and the primary endpoint is evaluated, these pa-
tient data can be used to validate the NTCP models presented in this thesis or to develop further
NTCP models.
All dosimetric parameters were based on the planned dose distribution. The differences be-
tween the planned dose and the delivered dose were not considered in this study. The planning
CT is only a single snapshot that is not representative of the anatomical situation during every
treatment fraction. For OARs with small volumes, such as cochlea or lacrimal gland, slight posi-
tioning errors may lead to deviations of the delivered dose from the planned dose. To evaluate
the administered dose, regular CT scans must be acquired during the course of treatment to
calculate the actual dose distribution. In brain tumour patients, however, this is usually not done
because they can be fixed very well using tight masks. Moreover, there is practically no organ
movement that would justify such frequent CT scans. It can, therefore, be assumed that the re-
sults of this study would not differ substantially if the estimated delivered dose would have been
assessed.
The dosimetric parameters extracted from DVHs may not consider the spatial information of
the three-dimensional dose-distribution. Thus, different parts of an OAR are treated as having
equal functions but this does not necessarily have to be correct (Marks et al., 2010; Gulliford,
2015). However, this may be of little relevance for small organs such as the cochlea or lacrimal
gland, but it may be more important for large organs such as the remaining brain that consists
of various substructures. Therefore, in this thesis, some subregions of the brain were analysed,
e.g. hippocampi or cerebellum. Due to the specific dose prescriptions for different tumour histolo-
gies, only data for certain dose ranges have been available (30 – 74 Gy(RBE)). Thus, only a part
of the NTCP curve could be estimated based on these data, leading to an increased uncertainty
beyond this dose range.
Another important uncertainty arises from variations in the delineation of OARs. Associated
dosimetric parameters are affected, which in turn would modify the NTCP models. Although
standardised delineation guidelines were used in this study, physician-individual variations may
still occur, as contouring can be largely inconsistent between clinicians (Foppiano et al., 2003;
Rosewall et al., 2011; Nelms et al., 2012a). However, this variability, which inevitably also occurs
in clinical practice, is therefore already incorporated into the models. To reduce contouring vari-
ability, consistent use of delineation guidelines and atlases is essential (Wright et al., 2019). In
clinical practice, often only essential OARs are delineated that are expected to receive consid-
erable doses and for which published dose constraints exist. For modelling purposes, however,
other structures that are not routinely contoured are relevant to generate dose-response rela-
tionships that may lead to new OARs and associated dose constraints in clinical practice. The
retrospective contouring of large cohorts is a challenge. To reduce the delineation time, the im-
plementation of auto-contouring tools could be considered (Vinod et al., 2016). These tools are
72
4.4 Interobserver variability of alopecia and erythema assessment
currently being further improved, e.g. by deep-learning-based segmentation approaches (van der
Heyden et al., 2019; van Dijk et al., 2020).
The patients included in this thesis have been enrolled in different clinical trials. The study
protocols of these trials included a physician-rated assessment of several side effects according
to CTCAE. NTCP modelling was mainly limited due to the low incidence rates and severity grades
of several physician-rated side effects. However, in order to further reduce the observed side
effects, NTCP models and dose limits are still required. Therefore, future studies should enrol a
larger number of patients, which can only be achieved in a multicentre approach.
A general issue in daily practice and clinical trials is underreporting of toxicities (Trotti and
Bentzen, 2004; Bentzen et al., 2010). Furthermore, the toxicity assessment by different physi-
cians during follow-up is subject to interobserver variability even if the same scoring system is
used, see section 4.4. Especially in case of rather unspecific side effects, the grading depends on
the physician’s experience (e.g. communication skills and interpretation of patient’s answers). It
is therefore essential to hold regular training courses, achieving an equal side effect assessment
in at least one institute.
A major limitation of modelling late side effects in this study were different follow-up schemes
applied in the participating institutions. Thus, only patient data from two different time points
(12 and 24 months after PBT) could be used for modelling and validation. In this thesis, side
effects up to 2 years after therapy could be investigated. However, some side effects manifest
later on, e.g. optic neuropathy (Danesh-Meyer, 2010). The longer the follow-up, the more patient
data will be missing because some patients have a short life expectancy, develop a recurrence
or may just not attend follow-up visits. Instead of a complete case analysis, multiple imputation
methods could be used to impute both predictor variables and outcome values (Sterne et al.,
2009). However, these techniques may also introduce bias, especially when imputing outcome
data and thus, cannot replace high-quality data collection.
In the course of this thesis, many clinical variables were investigated that may affect the oc-
currence of several side effects, for example, age at treatment for hearing impairment. However,
other cofactors that have not been recorded may also cause clinical effects. Especially in the
case of rather unspecific side effects such as fatigue, further factors may influence the occur-
rence, e.g. biochemical factors, psychological disturbances or comorbidities (Jereczek-Fossa et
al., 2002). If studies investigate such rather unspecific endpoints, more detailed data on the living
conditions of the patients should be collected.
4.4 Interobserver variability of alopecia and erythema assessment
The quality of an NTCP model is essentially determined by the accuracy of the input parameters.
For NTCP models, dosimetric parameters as well as toxicity scores serve as input values, which
both may be subject to inaccuracies. The dosimetric parameters may not reflect the applied dose
derived from planning CT scans. Due to varying patient positioning or changes in the anatomy,
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the delivered dose may deviate in vivo from the planned dose. However, for brain tumour patients
treated with PBT, these effects may be mostly negligible compared to other tumour entities.
Patients are immobilised with rigid facial masks and anatomic changes (e.g. weight loss or gain
or tumour shrinkage) are rarely present in the cranial region.
A further uncertainty may be the assessment of side effect severity. Some side effects following
cranial RT are difficult to quantify, e.g. headache, concentration or fatigue. The clinician’s sever-
ity estimation depends greatly on the patients’ symptom description and thus on the clinician’s
investigative questions. Furthermore, follow-up visits are just snapshots in time, while side effect
severity may vary. Additionally, the same patient may be assessed by different clinicians during
the course of follow-up visits. Thus, efforts have been taken to standardise the assessment. A
variety of grading systems has been developed in the last decades, see section 2.3.1. These
grading systems such as the CTCAE are widely used in both clinical routine and trials. Although
they offer guidelines for assessing a variety of side effects, grading scores may still vary between
both individual observers and institutions. In the study on modelling early side effects of PBT, a
shift in the calibration of the alopecia model was observed, most likely caused by different toxicity
assessments, see section 4.2.2. As consistent toxicity assessment is crucial for modelling of side
effects, this study aims to investigate the interobserver variability of erythema and alopecia using
cranial photographs of brain tumour patients treated with PBT.
4.4.1 Patient cohort and experimental design
Patient data
A patient cohort of 15 patients with brain tumours treated with PBT at UPTD, who were enrolled
in the clinical trial (NCT02824731, 2016), were included in this study. All patients gave informed
consent. Two anonymised photographs of the external cranial irradiation area were taken for each
patient in the first week and later during treatment. Every appointment was regarded as a single
study case. For one patient, only one photograph could be taken in the first week of treatment,
resulting in a total of 29 cases that could be analysed. All photos for all cases were merged into
one single document. An example case is given in appendix B figure B.1. Twenty-three radiation
oncologists from five different institutions were asked to assess all cases with regard to erythema
and alopecia according to CTCAE version 4.0. The definitions of each grade for both side effects
are given in appendix B table B.13. The number of physicians varied between the institutions: 9
physicians from UPTD, 3 physicians from WPE, 4 physicians from MGH, 3 physicians from the
Department of Radiation Oncology of the University Hospital Tuebingen (TUEB) and 3 physicians
from the Department of Radiation Oncology and Radiotherapy of the Charité Berlin (BER).
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Evaluation
To evaluate the variability of the toxicity assessment between the different scorers and differ-
ent institutes, percent agreement as well as other metrics were analysed (described below). In
some cases, where physicians recorded two grades at a time (as may occur in clinical routine),
the maximum value was used. As there is no single true severity grade, the modal value was
calculated for each case across all clinicians. This overall modal value was considered as true
severity grade. Additionally, the modal value of all ratings within each institute was evaluated.
The incidence rates of each side effect were compared between all institutions based on these
modal values. Moreover, the percent agreement with the true severity grade (modal value) of all
physicians was assessed for each case and side effect. For each institute, the number of cases
deviating from the true severity grade was obtained.
To measure the reliability between observers for toxicity grading as a categorical metric, Co-
hen’s kappa κC was used. In contrast to percent agreement, κC considers that agreements can
also occur randomly (Cohen, 1960). As this metric only assesses the agreement between two
scorers, pairwise κC were calculated for all combinations of scorers and the arithmetic mean
κC was evaluated as suggested by Light (1971). Additionally, the agreement of the scorers was
assessed using the intraclass correlation coefficient ICC based on a two-way random model, sin-
gle measures and absolute agreement (also called ICC(2, 1)) as both patients and scorers were
randomly chosen from a larger pool of potential subjects (Shrout and Fleiss, 1979). Moreover,
the coefficient Krippendorff’s alpha αK was used (Krippendorff, 2004). This metric is applica-
ble to any number of scorers and is able to handle missing data. All these metrics can reach
a maximum value of 1, indicating an almost perfect agreement. Values of 0 (or less) represent
an agreement that would be expected by chance. More detailed interpretation of the values has
been described in different publications. While Landis and Koch (1977) suggested values in the
range of 0.81 – 1.00 as almost perfect, 0.61 – 0.80 as substantial, 0.41 – 0.60 as moderate and
0.21 – 0.40 as fair, Koo and Li (2016) indicated > 0.90 as excellent, 0.75 – 0.90 as good, 0.50 –
0.75 as moderate and < 0.50 as poor.
In clinical practice, the severity grade is usually recorded by only one physician rather than
the modal value of several physicians of an institute. Hence, the interobserver variability was
additionally investigated by randomly selecting only one physician from each of the institutes.
The mean value for 1000 samples was examined. The analysis was conducted in R (R Core
Team, 2017) with the package irr (Gamer et al., 2010).
4.4.2 Results
Interobserver variability between all clinicians
The distribution of the scored severity grades for alopecia and erythema in terms of modal values
for each of the 29 cases over all physicians is given in the first row of table 4.10. For alopecia,
75
4 Modelling of side effects following cranial proton beam therapy
Table 4.10: Distribution of severity grades for the scoring of alopecia and erythema in terms of modal
values for each case over all physicians (first row) and each institute, given in per cent.
Alopecia Erythema
Institute Grade 0 Grade 1 Grade 2 Grade 0 Grade 1 Grade 2 Grade 3
All 27.6 37.9 34.5 27.6 72.4 0.0 0.0
WPE 34.5 55.2 10.3 27.6 62.1 10.3 0.0
MGH 24.1 34.5 41.4 20.7 69.0 10.3 0.0
UPTD 44.8 27.6 27.6 34.5 62.1 3.4 0.0
BER 24.1 48.3 27.6 24.1 72.4 3.4 0.0
TUEB 31.0 37.9 31.0 34.5 58.6 6.9 0.0
Abbreviations: WPE, West German Proton Therapy Centre Essen; MGH, Massachusetts
General Hospital in Boston; UPTD, University Proton Therapy Dresden; BER, Department
of Radiation Oncology and Radiotherapy of the Charité Berlin; TUEB, Department of Radi-
ation Oncology of the University Hospital Tuebingen.
37.9 % and 34.5 % of the cases were rated with grade 1 and grade 2, respectively. No patient
was rated with erythema grade 2 or grade 3 during treatment based on the modal values of all
physicians. Mild erythema grade 1 was most common (72.4 % of the cases).
Figure 4.11 shows the distribution of the gradings of all physicians and for all cases sorted
by severity grade (overall modal value) and percent agreement. The percent agreement for all
cases was above 43.5 % with an average percent agreement of 69.3 % and 73.2 % for alopecia
and erythema, respectively. The distribution of the percent agreement values is displayed in
appendix B figure B.2. For some cases, the assessment differed between grade 0 and grade 2
(alopecia) or grade 1 and grade 3 (erythema).
The metrics quantifying the interobserver variability are presented in table 4.11. All three met-
rics αK , κC , and ICC showed similar values. For alopecia, they ranged between 0.50 (αK ) and
0.58 (ICC) indicating a moderate agreement according to Landis and Koch (1977) and Koo and
Li (2016). For erythema, the metrics ranged between 0.42 (ICC) and 0.49 (αK ) which is referred
to as moderate (Landis and Koch, 1977) or even poor agreement (Koo and Li, 2016).
Interobserver variability with regard to different institutions
For each institute, the distribution of the severity grades for alopecia and erythema in terms of
modal values for each of the 29 cases is given in table 4.10. For alopecia, the rate of grade 2
assessments was lowest for physicians from WPE (10.3 %) and highest at MGH (41.4 %). The
highest rate of alopecia grade 0 was observed at UPTD (44.8 %). For erythema, no case was
assessed with grade 3. In comparison to the overall modal value without any grade 2 occurrence,
at least 3.4 % of the cases were rated with grade 2 in each institution, but not consistently the
same patients. The highest rate of erythema grade 2 was reported by physicians from WPE and
MGH (10.3 %).
Deviations of each institution’s modal value from the overall modal value is shown in figure 4.12
for all cases. Exemplarily, for alopecia, physicians of WPE scored in 34 % of the cases lower and
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Figure 4.11: Distribution of the gradings for alopecia and erythema for all cases and all physicians sorted
by severity grade (overall modal value) and percent agreement.
Table 4.11: Metrics assessing interobserver variability for the scoring of alopecia and erythema for all
clincicians and at each institute separately.
Alopecia Erythema
All WPE MGH UPTD BER TUEB All WPE MGH UPTD BER TUEB
ICC 0.58 0.37 0.69 0.48 0.61 0.65 0.42 0.36 0.49 0.45 0.45 0.61
αK 0.50 0.39 0.68 0.41 0.61 0.62 0.49 0.43 0.56 0.50 0.51 0.63
κC 0.51 0.38 0.69 0.45 0.60 0.64 0.45 0.39 0.51 0.47 0.50 0.61
Abbreviations: αK , Krippendorff’s alpha; ICC, intraclass correlation coefficient; κC , average over pairwise Co-
hen’s kappa; WPE, West German Proton Therapy Centre Essen; MGH, Massachusetts General Hospital in
Boston; UPTD, University Proton Therapy Dresden; BER, Department of Radiation Oncology and Radiother-
apy of the Charité Berlin; TUEB, Department of Radiation Oncology of the University Hospital Tuebingen.
in 3 % of the cases higher than the value determined by all physicians. At UPTD, the grading was
lower than the overall grading in 21 % of the cases. At MGH, 10 % of the cases were rated higher
than the overall grading by all physicians. The best agreement between institutional and overall
modal values was observed among physicians from TUEB (93 %). For erythema, physicians at
MGH rated 17 % of the cases higher than the modal value. At WPE, 14 % of the cases were rated
higher and 3 % of the cases were rated lower than the overall modal values.
The metrics assessing the interobserver variability between physicians at each institute are
given in table 4.11. In general, the values of the three individual metrics were similar for each
institution. The agreement between physicians was generally slightly better for the assessment
of alopecia than for erythema. The highest agreement was observed between physicians at
MGH for assessing alopecia and between physicians from TUEB for assessing erythema (sub-
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Figure 4.12: Deviations of the institutional modal values from overall modal values for the scoring of alope-
cia and erythema. WPE, West German Proton Therapy Centre Essen; MGH, Massachusetts General Hos-
pital in Boston; UPTD, University Proton Therapy Dresden; BER, Department of Radiation Oncology and
Radiotherapy of the Charité Berlin; TUEB, Department of Radiation Oncology of the University Hospital
Tuebingen.
stantial/moderate agreement according to Landis and Koch (1977) and Koo and Li (2016), re-
spectively). The lowest agreement was shown between physicians at WPE both for assess-
ing alopecia and erythema (fair/poor according to Landis and Koch (1977) and Koo and Li
(2016), respectively). Comparing the agreement between the institutes based on their individ-
ual modal values, a substantial/moderate agreement was observed for the assessment of alope-
cia (ICC = 0.72, αK = 0.71, κC = 0.70). The agreement between institutes was moderate for
erythema (ICC = 0.59, αK = 0.62, κC = 0.58).
In order to reflect the real-life clinical situation, in which each case is assessed by only one
physician from each institution, one physician’s assessment was randomly drawn and the agree-
ments between the five resulting assessments were investigated. The mean values for 1000
samples are presented in table 4.12 and were similar to those when comparing the agreement of
all physicians, see table 4.11. The agreement for assessing alopecia and erythema was moder-
ate and moderate/poor, respectively.
Table 4.12: Metrics of interobserver variability for assessing alopecia and erythema based on a random
selection of one physician for each institute. The mean value of 1000 samples as well as the 95 % confi-
dence interval is given as 2.5th and 97.5th percentile.
ICC αK κC
Mean (95 % CI) Mean (95 % CI) Mean (95 % CI)
Alopecia 0.55 (0.43 – 0.70) 0.53 (0.40 – 0.64) 0.54 (0.43 – 0.65)
Erythema 0.41 (0.26 – 0.58) 0.48 (0.35 – 0.61) 0.44 (0.31 – 0.57)
Abbreviations: αK , Krippendorff’s alpha; ICC, intraclass correlation coefficient; κC , average
over pairwise Cohen’s kappa; CI, confidence interval.
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4.4.3 Discussion
This study investigated to what extent physicians’ assessments of erythema and alopecia differ
when using the same grading system based on 23 radiation oncologists from five institutions. Fur-
thermore, potential differences in grading between individual institutions were examined. Gener-
ally, the agreement between all physicians for assessing alopecia and erythema was moderate.
For the development of NTCP models, both the precise determination of dosimetric parame-
ters and side effects are important. When discussing uncertainties of these input parameters, the
focus laid mostly on the uncertainties of dose determination, for example, differences between
planned and delivered dose (Shelley et al., 2017; McCulloch et al., 2018) and interobserver vari-
abilities in contouring of OARs (Foppiano et al., 2003; Rosewall et al., 2011; Nelms et al., 2012b).
Although the accuracy of the assessment of side effects may also impact the shape of the NTCP
curves, uncertainties due to interobserver variability in scoring according to CTCAE have rarely
been examined. Kapur et al. (2013) investigated the interobserver variability between 12 care-
givers (6 radiation oncologists and 6 nurses) when assessing skin reactions of irradiated breast
cancer patients based on images. When scoring according to CTCAE, a Fleiss-kappa value of
0.43 was revealed (moderate and poor agreement according to Landis and Koch (1977) and
Koo and Li (2016), respectively). This value is comparable to the agreement for the grading of
erythema in this thesis. The authors also examined the agreement when using an internally de-
veloped scoring system based on RTOG guidelines and literature reviews instead of the CTCAE
scale. With this internal grading system, the agreement was much lower compared to CTCAE
(Fleiss-kappa: 0.29). This clearly underlines that the use of standardised grading systems is es-
sential, even if there is still potential for improvement. Based on the results by Kapur et al. (2013),
Goyal et al. (2015) investigated whether variations between the severity grades for radiation der-
matitis were related to free text toxicity assessment based on clinical records of 8 caregivers for
30 patient cases. As the agreement for terms that are explicitly included in the CTCAE scale
showed comparatively low kappa values, the authors concluded that the assessment criteria
were interpreted differently by the caregivers. In some cases, caregivers paraphrased the side
effect with terms that indicate a certain severity grade, but they did not assign the corresponding
but a lower grade. This implied that the examiners did not assign grades according to the exact
definitions of the CTCAE, but according to other factors that do not necessarily correspond to the
CTCAE terminology. Regular training sessions could help to improve the agreement between
physicians in the assessment of side effects. It should be reviewed later on if there has been any
real improvement.
The differences between the individual centres were not as distinct as it could be expected
from the shift in the calibration for the model of acute alopecia, see section 4.2.2. There, lower
incidence rates were observed in patients treated at WPE and MGH than predicted by the NTCP
model. In this interobserver variability study, in 34 % of the cases evaluated by physicians at the
WPE, lower values were assigned than the modal value of all physicians. At MGH, however,
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slightly higher grades were scored than the modal value of all physicians. This effect could arise
because the physicians participating in this interobserver variability study may not necessarily
have been the same who examined the patients included in NTCP modelling. Since the agree-
ment within the respective centres was also only moderate or fair, such variations may explain
the differences in acute toxicity assessment.
The agreement between physicians was slightly better for scoring alopecia than erythema. This
may be either because alopecia is easier to distinguish on an image or because the definitions
of the CTCAE are more explicit. Moreover, alopecia is defined for only three different severity
grades (0 – 2). Erythema, on the other hand, can be assessed with 6 different grades (0 – 5). For
the cases included in this thesis, severity grades ranging from 0 to 3 were assigned. With a higher
number of available grades, it is more difficult to achieve an exact agreement. Furthermore, not
all severity grades were observed with similar frequency, e.g. erythema grade 3 was assigned
in very few cases by few physicians, see figure 4.11. Krippendorff (2004) advised planning the
reliability test such that all possible characteristics (severity grades) occur in sufficient variation,
which is questionable for the assessment of erythema in this study.
The evaluation of the agreement between physicians is challenging, as there is no single true
severity grade. Therefore, the modal value was chosen for each case in this study. Additionally,
an agreement between physicians in the evaluation of side effects may also occur by chance
alone. Therefore, a respective random distribution is shown in appendix B figure B.2. This dis-
tribution of percent agreement between 23 raters was generated assuming the same distribution
of severity grades as in this study, but random drawing of grades from a normal distribution. The
percent agreements of the physicians were above the 95th percentile of the random distribution
in 23/29 cases for alopecia and in 13/29 cases for erythema, which indicates a rather moderate
agreement.
This study was limited by the small sample size of images and the restricted variation in the
expression of different severity grades for erythema. Furthermore, the images are only surrogates
and cannot reflect a real evaluation of the side effect during personal interaction with the patient,
as it is performed in clinical practice. The physicians could not palpate, get a three-dimensional
impression, examine in different lighting conditions or communicate with the patients. As a result,
the agreement between the physicians in assessing these side effects may be higher in real-life.
In paper-based patient records, physicians may tick simultaneously two adjacent severity grades,
which makes the evaluation considerably more complicated. Therefore, it is essential to imple-
ment a digital recording of side effects, which only allows for a clear assignment of one severity
level. A further alternative could be the use of subjective QoL questionnaires, which do not re-
quire further interpretation by third persons and reflect the patient’s condition from his point of
view.
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4.5 Summary
In this thesis, NTCP models for early and late side effects following cranial PBT have been
developed and externally validated. Dose-volume parameters of the skin were associated to
early alopecia and erythema. Validation confirmed that the presented dose-volume parameters
are strongly associated with these endpoints for all investigated cohorts, but the calibration dif-
fered. Thus, centre-specific differences in toxicity assessment should be considered carefully.
Late alopecia was also associated to dose-volume parameters of the skin while late hearing
impairment was related to cochlear doses. Additionally, in analyses of the pooled cohort, dose-
response relations between late physician-rated memory impairment and the dose to the remain-
ing brain as well as the hippocampi. Late fatigue was related to dose to the brain stem and CTx.
Due to the relatively low incidence rates and low severity of late side effects, NTCP models could
only be developed for mild forms. In a model-based approach for patient selection for PBT, how-
ever, only models that predict side effects grade ≥ 2 would be considered (Langendijk et al.,
2018). Although dose-response relationships for alopecia and dry eye syndrome grade ≥ 2 were
found in GEE analyses, they still have to be validated.
To establish accurate dose-response relationships for side effects following modern RT tech-
niques, multicentre studies are essential. Reliable NTCP models require high-quality toxicity
data including extensive pre- and post-treatment examinations such as neurocognitive tests, au-
diograms or tests of endocrine function. Such tests are not subject to interobserver variability as
with physician-rated side effects and are therefore more precise. But since they are considerably
more time-consuming than a physician’s evaluation, the most important side effects should be
selected in new study designs. Prospective electronic recording of side effects (and their ab-
sence), comorbidities, medication and other possible cofactors is important to easily access and
combine these data with imaging data and RT treatment parameters (Kessel et al., 2014).
In order to reduce the required time and manpower, a more comprehensive follow-up could
possibly be achieved with larger follow-up intervals, e.g. biannually. Moreover, it should be en-
sured that all participating centres have the same follow-up interval. As there exist only a few
PBT facilities in Germany, these have fairly large catchment areas, so that a lower frequency
of follow-up may accommodate patients living in further distance. Other alternatives are study
endpoints on QoL, as the patient can fill in questionnaires at home. Although these are highly
subjective, they reflect the actual condition of the patient without interpretation by a physician and
could be used for NTCP model endpoints.
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5 Assessing the neurocognitive function following
cranial proton beam therapy
Neurocognitive dysfunction is an important radiation-induced side effect as it is the most frequent
complication among long-term survivors (Béhin and Delattre, 2003). Thus, several clinical trials
on brain tumour patients include the assessment of neurocognitive function and QoL as relevant
outcome measures (Taphoorn and Klein, 2004; Correa, 2010; Schagen et al., 2014). Both ra-
diation dose and volume of healthy brain tissue exposed to radiation appear to be determining
factors of neurocognitive function (Brown et al., 2003; Laack and Brown, 2004). Therefore, OARs
and dosimetric parameters associated with changes in neurocognition have to be identified and
considered for contouring and treatment planning in clinical routine. In particular, the irradiation
of certain substructures of the brain such as the cerebellum (Merchant et al., 2014; Eekers et al.,
2017) or the hippocampus (Gondi et al., 2012) may cause neurocognitive dysfunction. Besides
several approaches in the development of advanced treatment planning techniques aiming to
spare such brain structures (Gondi et al., 2014; Kazda et al., 2014; Tsai et al., 2015; Zhao et al.,
2017), a potential dosimetric benefit of PBT has been discussed (Harrabi et al., 2016). However, it
is still uncertain whether this dosimetric benefit leads to a potential reduction of radiation-induced
neurocognitive dysfunction (Grosshans et al., 2017).
This exploratory study aims to investigate neurocognitive function assessed by the objective
MoCA test and self-reported QoL in adults affected by brain tumours during a maximum follow-
up of two years after primary or post-operative cranial PBT delivered with standard fractionation.
Dose-volume parameters of several brain structures were investigated to find any relation to
objective and subjective changes in neurocognition. Parts of the work presented in this chapter
have been published (Dutz et al., 2020).
5.1 Patient cohort and experimental design
Patient data
The patient cohort analysed in this study is a subgroup of the cohort treated at UPTD described
in chapter 3. It included patients diagnosed with LGG, HGG, meningioma, pituitary adenoma
or craniopharyngioma that were consecutively treated with PBT between 07/2015 and 07/2017
within the prospective clinical trial (DRKS00007670, 2015). The trial comprised 90 patients at the
time of data analysis (02/2019). For this study, 62 patients were selected who met further criteria:
normo-fractionated PBT and available baseline data on neurocognitive function, see figure 5.1.
The patient cohort is characterised in table 5.1. This retrospective study was approved by the
local Ethics Committee (EK48012019).
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Clinical trial DRKS00007670
PBT: 07/2015 – 07/2017
(n=90)
a) No proton beam therapy (n=8)
b) Not normo-fractionated (n=2)
c) No MoCA baseline data available (n=18)
Analysed
(n=62)
Figure 5.1: Design of the study on neurocognition. Adapted from Dutz et al. (2020).
Radiotherapy planning and treatment delivery
The planning CT scans were rigidly registered with (post-operative) T2- and T1-weighted MRI
scans with contrast agent applied. GTVs encompassed the macroscopic tumour or the resection
cavity including the residual tumour, if present. CTVs included microscopic disease and oedema
and were created considering tumour histology as well as anatomical boundaries. Treatment
plans were calculated using a DS PBT technique (XiO®). For treatment planning, a constant
RBE of 1.1 was anticipated. Dose prescription ranged from 30 to 60 Gy(RBE) with 2 Gy(RBE)
per fraction. Patient positioning was verified daily by manual registration of orthogonally paired
X-ray images with digitally reconstructed radiographs of the planning CT. Treatment planning is
described in detail in section 4.1.
Endpoint definition
Neurocognitive function and QoL were assessed at baseline prior to PBT on the day of the plan-
ning CT scan. Regular clinical follow-up visits were performed three months after treatment and
at intervals of three months thereafter until disease progression occurred. The MoCA test was
conducted by trained study nurses. No significant differences in MoCA total scores between
different interviewers were observed. Neurocognitive function was assessed by the German ver-
sion of the paper-and-pencil MoCA test (Nasreddine et al., 2005), see section 2.3.3. To minimise
learning effects, three alternative test versions were iterated between each assessment (Cooley
et al., 2015). At baseline, all patients started with the same test version. QoL was assessed
by the validated EORTC QLQ-C30 version 3.0 (Aaronson et al., 1993) and the brain-tumour
specific module EORTC QLQ-BN20 (Osoba et al., 1996) in German. The evaluation of QoL
was restricted to relevant scales in the context of PBT of brain tumour patients including global
health status, cognitive, physical, emotional, social and role function, fatigue, pain and insomnia
(EORTC QLQ-C30). The items future uncertainty, headache, seizures, hair loss, visual disor-
der and communication deficit were selected from EORTC QLQ-BN20. QLQs were evaluated
according to the EORTC scoring guidelines (Fayers et al., 2001), see section 2.3.2. To inves-
tigate the association between the objective MoCA test and self-reported QoL, subitems from
both measures were correlated: QLQ cognitive function (EORTC QLQ-C30) with MoCA total
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Table 5.1: Detailed patient characteristics of the study on neurocognition.
Characteristic Median Range
Age at PBT in years 47.0 18.8 – 84.7
Tumour volume (CTV) in cm3 119.9 1.2 – 472.8
Prescribed dose in Gy(RBE) 57.0 30.0 – 60.0
Recurrence-free follow-up in months 22.5 0.0 – 37.2
N (%)
Gender [female/male] 23/39 (37.1/62.9)
Chemotherapy [yes/no] 24/38 (38.7/61.3)
Surgery [yes/no] 53/9 (85.5/14.5)
Corticosteroids at baseline [yes/no] 25/33 (40.3/53.2)
Impairment at baseline [MoCA<26/MoCA≥26] 30/32 (48.4/51.6)
Re-irradaition [yes/no] 15/47 (24.2/75.8)
Tumour histology
Glioma II 4 (6.5)
Glioma III 16 (25.8)
Glioma IV 20 (32.2)
Meningioma 8 (12.9)
Other 14 (22.6)
IDH1 [mutant/wild-type/missing]
Glioma II 3/1/0 (75.0/25.0/0.0)
Glioma III 11/4/1 (15.0/75.0/10.0)
Glioma IV 3/15/2 (68.7/25.0/6.3)
MGMT [unmethylated/methylated/missing]
Glioma II 0/1/3 (0.0/25.0/75.0)
Glioma III 4/8/4 (25.0/50.0/25.0)
Glioma IV 11/9/0 (55.0/45.0/0.0)
Tumour location∗ [left/right/central] 21/29/11 (33.9/46.8/17.7)
Frontal lobe 1/8/1 (1.6/12.9/1.6)
Temporal lobe 12/12/1 (19.4/19.4/1.6)
Parietal lobe 5/1/0 (8.1/1.6/0.0)
>1 lobe 2/4/0 (3.2/6.5/0.0)
Other lobe 0/2/9 (0.0/3.2/14.5)
ECOG Performance Status [0/1/2] 34/24/4 (54.8/38.7/6.5)
Local recurrence after PBT 21 (27.4)
Abbreviations: IDH, isocitrate dehydrogenase; MGMT, methylguanine-DNA methyl-
transferase; ECOG, Eastern Co-operative of Oncology Group; ∗One patient had a
lesion in the left temporal lobe and another lesion in the right frontal lobe.
score, QLQ communication deficit (EORTC QLQ-BN20) with MoCA language score, QLQ visual
disorder (EORTC QLQ-BN20) with MoCA visuospatial examination score and single item QLQ
memory (EORTC QLQ-C30, 4-point scale) with MoCA memory score.
The impact of the following clinical cofactors on test results was investigated: age at PBT,
gender, ECOG status, tumour histology, location of the tumour (side and lobe), tumour volume
(CTV), surgery, re-irradiation, CTx (TMZ), administration of corticosteroids (dexamethasone) and
impaired MoCA total score at baseline (< 26).
Extraction of dose-volume parameters
Different brain structures were retrospectively contoured on registered MRI scans by experi-
enced radiation oncologists. These included hippocampi, amygdalae, thalami, cerebellum (pos-
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terior, anterior and entire organ), frontal and temporal lobes using specific contouring guidelines
(Schmahmann et al., 1999; Chera et al., 2009; Sun et al., 2014; Scoccianti et al., 2015; Eek-
ers et al., 2018). All dose distributions were retrospectively exported using RayStation® scripts.
Dose-volume parameters were extracted for the above-mentioned structures as well as the entire
brain and brain excluding the CTV (brain-CTV). Relative volume parameters VxGy (RBE) ranging
from 10 Gy(RBE) to 60 Gy(RBE) in increments of 10 Gy(RBE), mean and median doses and the
near-maximum dose D2% were analysed.
Statistical analyses
Differences in MoCA scores between two patient groups classified according to binary clinical
cofactors were evaluated by Mann-Whitney U tests. If a binary cofactor-based classification
was not applicable, the Kruskal-Wallis test has been applied. Correlations between continuous
variables were assessed using the Spearman correlation coefficient ρ. Analyses were restricted
to a maximum follow-up period of 24 months as only a few patients (n < 20) remained for
evaluation after this time point (response rates are given in appendix C table C.1). Test scores
between follow-up and baseline were compared using the Wilcoxon signed-rank test. Changes
in QoL were scaled to no change, a little, moderate and very much (Osoba et al., 1998), see
section 2.3.2. For the MoCA test, differences of 4 or more points were defined as large, since
the threshold for impairment is defined as 26 out of 30 points by the authors of the MoCA test
(Nasreddine et al., 2005).
To investigate differences from baseline over time, repeated-measure analysis (mixed-model
analysis) with first-order autoregressive covariance structure and restricted maximum likelihood
was conducted. This included clinical cofactors, time after PBT and the corresponding interaction
term between time and the cofactor as fixed-effects covariates. For MoCA and QLQ cognitive
function, dose-volume parameters were also included as predictors in univariable models. All
dose-volume parameters showing a significant association with differences of the MoCA score
or QLQ cognitive function compared to baseline were included in multivariable models with clin-
ical cofactors that also showed a significant association in univariable analysis. Mixed-model
analyses were also performed on all subscales of the MoCA test.
For visualisation, patients were classified into two groups according to the dosimetric pa-
rameters that were significant in mixed-model analyses. To define the classification threshold,
the dosimetric parameters were dichotomised at several cut-off values. Mixed-model analyses
were performed including time, dichotomised dosimetric parameter and their interaction. The
dichotomised dosimetric parameter with the lowest p-value was selected as the classification
threshold. For these two patient groups, changes in neurocognitive function compared to base-
line were visualised over time.
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For all mentioned statistical analyses, two-sided tests were performed using IBM SPSS Statis-
tics 25 and in-house written Python (version 2.7.10) programmes using the module scipy (stats-
models). P-values < 0.05 were considered statistically significant.
5.2 Results
5.2.1 Performance at baseline
At baseline, the mean MoCA total score was 24.8 with a standard deviation (SD) of 4.2, indicating
a minor cognitive impairment according to the threshold of 26 defined by Nasreddine et al. (2005),
see table 5.2. Significantly lower MoCA scores were observed for patients with worse (higher)
ECOG performance status (p = 0.036) and tumour location in the left hemisphere (p = 0.009).
Grade II glioma patients performed significantly better than patients with different histology (p =
0.043). Self-reported QLQ cognitive function was 68.9 (SD = 26.6) at baseline indicating a
slightly decreased performance compared to healthy populations (Michelson et al., 2000). High
self-reported cognitive function was associated with good ECOG performance status at baseline
(p = 0.006) or prescription of concomitant CTx (p = 0.021). For other QoL items from the QLQ-
BN20 and QLQ-C30 questionnaires, mean baseline values are given in appendix C table C.1.
Patients who were classified as impaired according to their MoCA test result (MoCA total score
< 26) reported lower cognitive function compared to normal performing patients (p = 0.028)
at baseline. These patients also described significantly lower global health status, physical and
role function as well as more fatigue, pain, headache and communication deficits compared to
normal performing patients (MoCA total score ≥ 26) at baseline. A tumour location in the left
hemisphere was significantly associated with lower global health status, worse emotional and
role function, a higher level of fatigue and communication deficits. A high ECOG performance
status was associated with a reduced condition of a variety of items: global health status, social,
emotional, physical and role function as well as higher levels of fatigue, pain and headache. CTx
was associated with higher role function and lower fatigue, headache and fewer communication
deficits at baseline. Women complained significantly more about pain, headache and hair loss
compared to men. Re-irradiated patients had significantly higher fatigue and lower role function
than others.
5.2.2 Correlation between subjective and objective measures
At most time points, MoCA total score and QLQ cognitive function, MoCA memory score and
QLQ memory as well as MoCA language score and QLQ communication deficit were significantly
correlated, see table 5.3. Especially at later follow-up visits (> 18 months), these items were
highly correlated (ρ > 0.70, p < 0.001). However, no or only a low correlation was observed for
MoCA visuospatial examination score and QLQ visual disorder.
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Table 5.2: Comparison of the MoCA total scores and self-reported cognitive function according to the
EORTC-QLQ-C30 questionnaire (QLQ cognitive function) at baseline between patient groups.
MoCA test QLQ cognitive function
Mean p-value Mean p-value
Entire cohort 24.8 68.9
Gender [female/male] 25.0/24.7 0.54 70.5/67.9 0.85
Surgery [yes/no] 24.7/25.3 0.32 67.6/75.9 0.31
Chemotherapy [yes/no] 23.8/25.4 0.075 77.1/63.5 0.021
Corticosteroids [yes/no] 23.9/25.9 0.079 61.8/71.7 0.29
Re-irradiation [yes/no] 25.2/24.7 0.68 65.5/69.9 0.43
Impairment at baseline
[MoCA< 26/MoCA≥ 26] 21.3/28.1 < 0.001 60.6/76.9 0.028
Tumour histology 0.043 79.2 0.47
Glioma II 29.5 79.2
Glioma III 23.9 67.8
Glioma IV 23.9 71.7
Meningioma 25.3 56.3
Other 25.6 70.2
Tumour location 0.15 0.86
Frontal 26.2 70.0
Temporal 23.8 69.3
Parietal 22.2 70.0
Occipital 24.0 44.4
>1 lobe 25.5 75.0
Other 26.8 69.4
Tumour location
[left/right/central] 22.3/25.8/26.6 0.009 59.5/75.6/69.7 0.084
ECOG performance status[0/1/2] 25.9/24.0/20.0 0.036 77.3/62.5/37.5 0.006
Spearman ρ p-value Spearman ρ p-value
Tumour volume (CTV) in cm3 -0.14 0.27 -0.05 0.71
Age at PBT in years -0.18 0.16 0.16 0.22
Prescribed dose in Gy(RBE) 0.04 0.74 0.14 0.27
Abbreviations: CTV, clinical target volume; ECOG, Eastern Co-operative of Oncology Group.
Table 5.3: Spearman correlation (correlation coefficient ρ) between MoCA items and self-reported quality
of life items at different time points after PBT.
Baseline 3 months 6 months 9 months 12 months 15 months 18 months 21 months 24 months
MoCA item QLQ item N 61 48 37 35 27 27 21 24 26
Total score+ Cognitive ρ 0.29 0.46 0.59 0.49 0.29 0.38 0.72 0.76 0.71
function+ p-value 0.023 0.001 < 0.001 0.003 0.14 0.053 0.001 < 0.001 < 0.001
Memory+ Memory− ρ -0.17 -0.43 -0.26 -0.45 -0.38 -0.37 -0.51 -0.79 -0.70
p-value 0.2 0.002 0.13 0.008 0.05 0.066 0.018 < 0.001 < 0.001
Language+ Communication ρ -0.52 -0.31 -0.55 -0.41 -0.24 -0.12 -0.69 -0.77 -0.48
deficit− p-value < 0.001 0.03 < 0.001 0.016 0.24 0.56 0.001 < 0.001 0.020
Visuospatial Visual disorder− ρ 0.02 -0.09 -0.36 -0.11 -0.06 -0.41 -0.43 -0.47 -0.21
examination+ p-value 0.88 0.53 0.027 0.52 0.78 0.036 0.051 0.021 0.35
Abbreviation: N, number of patients. + high score represents high function, − high score represents low function
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5.2.3 Time-dependent score analyses
The median recurrence-free follow-up time was 22.5 months, see table 5.1. The mean MoCA
total score and QLQ cognitive function remained stable over time, see figure 5.2. No statistically
significant difference was observed between baseline values and test results at any recurrence-
free time after PBT for both measures. The individual changes in both MoCA total score and
QLQ cognitive function are depicted in figure 5.3. The majority of patients (n = 29) experienced
no or only small changes in MoCA score averaged over 6 to 24 months after PBT. At the same
time, two patients improved their test result by ≥ 4 points and seven patients by 2 to 4 points.
Four patients deteriorated by 2 to 4 points and 4 patients by more than 4 points. The mean
self-reported cognitive function of the entire cohort showed no or small changes. Averaged over
6 to 24 months after PBT, twelve patients reported a moderate (n = 7) or even large (n = 5)
improvement in QLQ cognitive function. However, twelve patients deteriorated to a large extent.
Figure 5.2: MoCA total score and self-reported cognitive function (QLQ cognitive function) over time.
Absolute scores are shown in the top row, differences to baseline (B) below. Shaded areas mark the
extent of changes in QLQ and MoCA (red: worsening, green: improvement). Extent of QLQ changes from
light to dark: a little (5.0 – 9.9), moderate (10.0 – 19.9) and very much (≥ 20.0) (Osoba et al., 1998).
Extent of MoCA changes from light to dark: moderate (2 – 4 points), large (≥ 4 points). Adapted from
Dutz et al. (2020).
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Figure 5.3: Clinically relevant changes in MoCA scores (top) and self-reported (quality of life questionnaire,
QLQ) cognitive function (bottom). Last column: mean change between 6 to 24 months. The extent of
changes for QLQ cognitive function as defined by Osoba et al. (1998) and for the MoCA test as follows:
moderate (2 to 4 points), large (4 or more points). Adapted from Dutz et al. (2020).
In mixed-model analyses, MoCA differences compared to baseline were associated with tu-
mour location: patients with a tumour location in the left hemisphere improved significantly more
compared to patients with central tumours (p = 0.036), see table 5.4. No clinical cofactor was sig-
nificantly associated with changes in self-reported cognitive function compared to baseline. For
other selected QoL items, results of mixed-model analyses are given in appendix C table C.2.
The mixed-model analyses including dose-volume parameters of different brain structures re-
vealed a significantly reduced MoCA score with increasing V30Gy (RBE) and V40Gy (RBE) of
the anterior cerebellum, see table 5.4. Classification thresholds were V30Gy (RBE) ≥ 35 % and
V40Gy (RBE) ≥ 20 %. Figure 5.4 shows MoCA differences over time for patient groups classified
according to these thresholds.
In multivariable mixed-model analyses including V30Gy (RBE) or V40Gy (RBE) of the anterior
cerebellum and tumour location (left/right hemisphere or central), both dose-volume parameters
of the anterior cerebellum were still significantly associated with a reduced MoCA score com-
pared to baseline (p < 0.010), see table 5.4. Both dosimetric parameters V30Gy (RBE) and
V40Gy (RBE) of the anterior cerebellum were highly correlated (ρ = 0.96, p < 0.001). Both time
and the interaction between time and dose-volume parameters were not significantly associated
with the MoCA score differences compared to baseline. This indicates that the effect of the dosi-
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Table 5.4: Results of the mixed-model analyses on differences of the MoCA score to baseline including all
time points. Model coefficients and standard deviation of the clinical or dosimetric parameters, time after
proton beam therapy and their interaction term are given. Presented are univariable (top) and multivariable
(bottom) models with significant associations.
Model parameter Coefficient SD p-value
Univariable analysis
Location [reference: central]
Left 2.31 1.09 0.036
Right 1.24 1.03 0.24
Time after treatment 0.17 0.17 0.30
Interaction of time and location [reference: central]
Left -0.19 0.22 0.38
Right -0.21 0.21 0.31
Constant -1.75 0.86
Cerebellum anterior V30Gy (RBE) -4.28 2.08 0.042
Time after treatment -0.03 0.09 0.77
Interaction of time and cerebellum anterior V30Gy (RBE) 0.43 0.41 0.30
Constant 0.11 0.46
Cerebellum anterior V40Gy (RBE) -5.63 2.69 0.039
Time after treatment -0.03 0.09 0.73
Interaction of time and cerebellum anterior V40Gy (RBE) 0.61 0.54 0.27
Constant 0.11 0.45
Multivariable analysis
Location [reference: central]
Left 2.37 1.00 0.020
Right 1.34 0.95 0.16
Cerebellum anterior V30Gy (RBE) -5.14 1.93 0.009
Time after treatment 0.11 0.16 0.50
Interaction of time and location [reference: central]
Left -0.18 0.20 0.36
Right -0.18 0.19 0.34
Interaction of time and cerebellum anterior V30Gy (RBE) 0.58 0.38 0.13
Constant -1.16 0.79
Location [reference: central]
Left 2.42 0.99 0.018
Right 1.42 0.95 0.14
Cerebellum anterior V40Gy (RBE) -6.85 2.51 0.008
Time after treatment 0.10 0.15 0.50
Interaction of time and location [reference: central]
Left -0.19 0.20 0.35
Right -0.19 0.19 0.31
Interaction of time and cerebellum anterior V40Gy (RBE) 0.87 0.51 0.090
Constant -1.21 0.78
Abbreviation: SD, standard deviation.
metric parameters on the MoCA change compared to baseline did not change over time. In this
study, no association between changes in the MoCA total score and dose-volume parameters of
further brain structures such as hippocampus were observed, see appendix C table C.3.
Results of the mixed-model analyses for the MoCA subscales are given in appendix C ta-
ble C.4. Deterioration in the MoCA memory domain over time was significantly associated with
most dosimetric parameters of the anterior cerebellum as well as D2% of the entire cerebellum.
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Figure 5.4: Mean MoCA differences from baseline over time for patient subgroups classified according
to the volume of the anterior cerebellum receiving 30 Gy(RBE) and 40 Gy(RBE). Error bars represent
standard deviations. Adapted from Dutz et al. (2020).
The association of MoCA memory score with V40Gy (RBE) of the anterior cerebellum revealed
the lowest p-value (p = 0.005). No significant relations between deterioration in MoCA memory
and doses to the hippocampi or temporal lobes could be observed. No associations were found
between dose-volume parameters and self-reported cognitive function.
5.3 Discussion and conclusion
In this study on brain tumour patients treated with PBT, self-reported and objectively measured
neurocognition and many other considered QLQ domains remained largely stable over time dur-
ing recurrence-free follow-up. The objective and self-reported measures for neurocognition were
highly correlated. Patients with impaired neurocognition on the MoCA test at baseline performed
worse on many QLQ items compared to normal performing patients. An higher relative volume
of the anterior cerebellum exposed to doses of 30 to 40 Gy(RBE) was associated with a slight
deterioration of the MoCA score.
Prior to treatment, the mean MoCA total score was similar to that of other brain tumour pa-
tients (Robinson et al., 2015; Schiavolin et al., 2018) and healthy populations (Rossetti et al.,
2011; Thomann et al., 2018), see appendix C table C.5. Among the investigated QoL items
at baseline, patients in this study reported lower functional QoL and higher fatigue compared
to healthy individuals (Michelson et al., 2000; Schwarz and Hinz, 2001; Scott et al., 2008), but
similar values compared to other reported brain tumour patients (Scott et al., 2008; Renovanz
et al., 2018). Symptoms of the brain-tumour specific questionnaire QLQ-BN20 in this study were
similar compared to other brain tumour patients (Taphoorn et al., 2010; Renovanz et al., 2018).
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Neurocognitive dysfunction before any treatment in diffuse glioma patients has been described
previously (van Kessel et al., 2017). However, studies reporting the cognitive outcome of adult
patients treated with protons are rare. Two studies based on the same small cohort of 20 adult
LGG patients treated with PBT did not find any evidence for an overall decline in neurocognitive
function or QoL during 5-year follow-up (Shih et al., 2015; Sherman et al., 2016). Test perfor-
mance did not differ significantly between LGG patients and normative data (Sherman et al.,
2016).
In this study, most items from the objective MoCA test correlated to self-reported neurocognitive
function. Several studies investigating the association between objective and self-reported mea-
sures of neurocognition reported only moderate correlations (Klein et al., 2002; Li et al., 2008;
Olson et al., 2011a; Boele et al., 2014). Olson et al. (2011a) observed a moderate correlation of
the MoCA test with self-reported community integration (Spearman ρ = 0.35) that assesses dis-
ability and functioning in home, social interactions and productive activities. The function domain
of the self-reported brain-tumour specific QLQ FACT brain tumour module (FACT-Br) measuring
the ability to work, sleep, enjoy life and regular activities was associated with the visuospatial-
executive domain of the MoCA test (Spearman ρ = 0.37) (Olson et al., 2011a). For the same
cohort, Boele et al. (2014) observed weak to moderate correlations between the self-reported
physical function of the 36-item Short-Form Health Survey (SF-36) and QLQ-BN20 with many
neurocognitive domains measured with different neuropsychological tests. The correlation of
MoCA test results with QoL items at baseline is in line with a study conducted by Noll et al.
(2017) that analysed 103 glioma patients observing a relation between impaired cognition and
reductions in QoL even prior to treatment. The high correlation of both measures in the present
study showed that the MoCA test reflects the neurocognitive condition of the patients quite well.
Most QoL scales showed no or only minor changes during follow-up in this study in contrast
to other studies on patients treated with cranial XRT (Bosma et al., 2007; Aaronson et al., 2011;
Cole et al., 2013). Aaronson et al. (2011) described a decreased performance in many QoL
items after 5.6 years from diagnosis in 195 LGG patients treated with or without XRT. Self-
reported neurocognitive dysfunction among these patients was associated with reduced QoL. In
contrast to most studies describing the course of neurocognition in LGG patients, Bosma et al.
(2007) applied standardised tests in HGG patients at 8 months (n = 14) and 16 months (n = 18)
following XRT. During this time, neurocognitive function decreased considerably and patients with
tumour progression showed even worse results than patients without progression.
In the present study, MoCA differences compared to baseline were associated with the lateral
location of the tumour. Although patients with left-sided tumours performed significantly worse on
the MoCA test at baseline, they improved more after PBT compared to patients with a right-sided
or central tumour, see figure 5.5. This may be due to the location of brain areas responsible
for neurocognitive processes (lateralisation), e.g. language processing is mainly left lateralised
(Frost et al., 1999). Greater impairment in verbally mediated domains in patients with left-sided
compared to right-sided tumours has previously been described (Surma-aho et al., 2001; Klein
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Figure 5.5: MoCA difference from baseline over time, patient classification according to tumour location
in the left hemisphere vs other location (right hemisphere or central location) and prescribed dose. Error
bars represent standard deviations. Adapted from Dutz et al. (2020).
et al., 2002; Schagen et al., 2014). For patients with left-sided LGG, Sherman et al. (2016)
observed a significant impairment on verbal measures prior to PBT and an improvement after
PBT. Raysi Dehcordi et al. (2013) showed improvement after surgery, while Correa et al. (2007)
did not find any difference in neurocognitive function according to tumour location after XRT.
Deterioration of the MoCA score was associated with an increased relative volume of the ir-
radiated anterior cerebellum exposed to doses of 30 to 40 Gy(RBE) in this study. Deficits on
several neurocognitive domains as well as acute fatigue have previously been described as a
result of cerebellar damage (Schmahmann, 2010; Grimaldi and Manto, 2012; Gulliford et al.,
2012a; Merchant et al., 2014; Eekers et al., 2017). In a study on 76 children with infratentorial
ependymoma treated with adjuvant XRT up to 59.4 Gy, Merchant et al. (2014) observed cor-
relations of dose to the posterior cerebellum and deficits in intelligence quotient during 5-year
follow-up. Furthermore, they found significant associations of declined intelligence quotient and
mean dose to infratentorial as well as anterior and posterior cerebellar volumes. A decline in aca-
demic achievement, as another measure of cognition, was mainly related to dose to the posterior
cerebellum.
The present study comprised re-irradiated patients that may show a different neurocognitive
performance over time compared to primary brain tumour patients. However, in multivariable
mixed-model analyses including re-irradiation as a separate parameter, deterioration of the MoCA
score was still significantly associated with increased V30Gy (RBE) and V40Gy (RBE) of the an-
terior cerebellum. Even in analyses excluding re-irradiated patients, these dosimetric parameters
were significantly associated with neurocognitive decline. In order to spare the cerebellar regions
from radiation dose, the cerebellum may be considered as OAR and therefore routinely delin-
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eated. However, due to the relatively small sample size of our analysis, these findings should be
validated in larger studies.
Against the expectations, no relation between neurocognitive decline and the prescription dose
could be shown, see figure 5.5. Furthermore, no relation between neurocognitive dysfunction and
irradiation of the hippocampi could be observed as previously hypothesised (Gondi et al., 2012),
see appendix C table C.3. Apart from the issue that hippocampal dose-volume parameters could
not be determined in patients with a tumour or resection cavity in the hippocampi region, it is
furthermore possible that minor neurocognitive changes cannot be detected accurately with the
brief MoCA test. It may not be sensitive enough to detect impairment in every neurocognitive
domain (Chan et al., 2014; Robinson et al., 2015). Results of subscales of the MoCA test are
combined into a total score, whereby information about individual neurocognitive domains may be
lost. Hence, the subscales were analysed separately, showing associations between cerebellar
dose and deterioration in the MoCA memory subscale. Furthermore, differences to baseline of
the MoCA total score were correlated to differences of the MoCA memory subscale (Spearman
ρ = 0.68). Thus, it is consistent that similar dosimetric parameters of the cerebellum were related
to the deterioration of both the MoCA total score and the MoCA memory score in this analysis.
To standardise neurocognitive assessment, comprehensive series of tests have been rec-
ommended for individualised neuropsychological assessment of both LGG and HGG patients.
These testing batteries include ten different tests on memory, attention and executive function,
intellectual function and information processing (Taphoorn and Klein, 2004). However, these
extensive neuropsychological tests are time-consuming, require substantial manpower and may
cause fatigue and reduced compliance of brain tumour patients. For clinical studies with contin-
uous follow-up, brief (ten minutes) tests are more feasible (Taphoorn and Klein, 2004; Meyers
and Brown, 2006). Among these tests, the MoCA test showed superior sensitivity in detecting
neurocognitive impairment and correlation to QoL compared to the widely used MMSE (Olson
et al., 2011a; Olson et al., 2011b). In future studies, neurocognitive tests could be performed
less frequently, but with an extended test battery that could provide more detailed information
about different neurocognitive domains. A longer time interval between interviews could further
reduce possible learning effects, although three different test versions have already been used
in this study. In an even more detailed follow-up, more specific questionnaires could be used
that only address the subjective perception of neurocognitive function such as the FACT-Cog
questionnaire (Wagner et al., 2009). The comprehensive EORTC-QLQs include only a few items
concerning self-reported neurocognitive function.
The detection of correlations with dosimetric parameters is challenging as neurocognitive se-
quelae can be consequences of multiple causes: the tumour itself (Klein et al., 2002; Klein et
al., 2003), treatment with neurosurgery, RT, CTx, antiepileptics or corticosteroids or comorbidi-
ties. Additionally, patient-related factors such as tumour regrowth, leptomeningeal involvement,
metabolic disturbances or tumour-related epilepsy may have an impact (Taphoorn and Klein,
2004).
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Limitations A limitation of this study is the heterogeneity of the rather small cohort with regard
to different tumour histologies. While patients with benign tumours or LGGs often show a rather
long survival, patients with HGGs, especially glioblastomas and IDH wild-type gliomas, tend to
have poorer survival. Inclusion of HGG patients may lead to bias in the evaluation of the time
course of neurocognitive function. However, all four patients with IDH1 wild-type grade III glioma
had a survival of more than 29 months and 68 % of all glioblastoma patients were still alive 12
months after PBT. Patients who were excluded from follow-up due to death or local recurrence
did not perform significantly worse at their last valid follow-up visit than patients with local control,
see appendix C figure C.1. Despite a relatively long median follow-up period of 22.5 months,
an even longer follow-up would be desirable, since neurocognitive deterioration associated with
dose to the brain may manifest many years after treatment (Douw et al., 2009).
For treatment planning, RBE was considered to be constant at 1.1. If the distal edge of the
Bragg peak with potentially increased RBE (Lühr et al., 2018; Willers et al., 2018) is located
in structures responsible for neurocognition, PBT may even lead to an increase of such side
effects (Jhaveri et al., 2018). In the context of this study, premorbid intellectual abilities could
not be estimated as neurocognitive test results were not available for the period prior to tumour
diagnosis (as usual for clinical studies). Since information about the years of education was
missing, an education correction could not be applied (Nasreddine et al., 2005; Thomann et al.,
2018). Therefore, this study focused on changes in MoCA scores and only patients with available
baseline values were included. Since deterioration of the MoCA score was observed in only a
few patients, the development of NTCP models including dosimetric parameters as predictors
based on this data was not feasible.
5.4 Summary
In this study, self-reported and objectively measured neurocognition and most other QoL do-
mains remained largely stable over time during recurrence-free follow-up in brain tumour patients
treated with PBT. Slight deterioration of the MoCA score was associated with an increased rela-
tive volume of the irradiated anterior cerebellum exposed to doses of 30 to 40 Gy(RBE). Larger
studies, such as the ongoing comparative clinical trials (NCT03180502, 2017) and (NCT02824731,
2016) may allow for validation of these findings, development of NTCP models and a direct com-
parison to neurocognitive changes of patients treated with either cranial PBT or XRT.
Future studies on radiation-induced neurocognitive dysfunction may profit from more compre-
hensive standardised test batteries. The detailed follow-up may also comprise specific ques-
tionnaires to address the subjective perception of neurocognitive function, e.g. the FACT-Cog
questionnaire. This extended testing procedure could be performed less frequently, e.g. yearly,
for a follow-up of several years. Furthermore, additional patient-specific information, e.g. years of
education, should be obtained.
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6 Treatment plan and NTCP comparison for patients
with intracranial tumours
6.1 Motivation
The treatment decision for PBT is often justified by the superior dose distribution of PBT com-
pared to XRT. Patient-individual in silico comparison of treatment plans of both techniques may
provide the rationale for treatment decisions. The model-based approach for patient selection,
however, goes beyond a purely physical treatment plan comparison and converts the dosimetric
differences into side effect probabilities.
This chapter retrospectively investigates and quantifies the dosimetric benefit of PBT in terms
of dose distribution compared to XRT for several brain structures on a patient cohort treated with
PBT in the first section. The potential benefit in terms of reduced probabilities of radiation-induced
side effects is estimated based on a variety of NTCP models in the second section.
6.2 Treatment plan comparison of cranial proton and photon
radiotherapy
6.2.1 Patient cohort and experimental design
Patient data
The patient cohort included two subgroups of patients with intracranial tumours characterised in
detail in chapter 3. Subgroup 1 comprised 117 patients treated between 12/2014 and 11/2016
at UPTD. Subgroup 2 enclosed 67 patients treated at WPE between 08/2013 and 08/2016. Pa-
tient data from MGH were not considered for dose comparison as no general dose constraints
but patient-specific treatment constraints were applied for PBT planning. Inclusion criteria were
diagnosis of LGG, HGG, meningioma, pituitary adenoma or craniopharyngioma, age ≥ 18 years
and ECOG performance status ≤2, normo-fractionated PBT as well as written informed consent.
Exclusion criteria were inability to MRI planning, lack of patient compliance and lack of or limited
possibilities for reproducible positioning. A further exclusion criterion was a treatment scheme
with sequential boost (45 patients). As this dose-comparison study investigated the dose differ-
ences in normal tissues, equivalent target coverage for the PBT and the XRT treatment plan had
to be ensured. Therefore, further strict CTV coverage criteria were applied for both treatment
plans (described in more detail below). After this selection, 92 patients remained in the cohort
which is further characterised in table 6.1. This retrospective study was approved by the local
Ethics Committee (EK566122019).
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Table 6.1: Patient characteristics of the dose-comparison study.
Characteristic Median Range
Age at PBT in years 45.6 18.1 – 84.7
Tumour volume (CTV) in cm3 93.6 1.2 – 396.1
Prescribed dose in Gy(RBE) 54.0 30.0 – 60.0
N (%)
Gender [female/male] 45/47 (48.9/51.1)
Surgery [yes/no] 75/17 (81.5/18.5)
Chemotherapy [yes/no] 25/67 (27.2/72.8)
PBT technique [DS/PBS] 45/47 (48.9/51.1)
Re-irradiation [yes/no/missing] 7/82/3 (7.6/89.1/3.3)
Tumour location
Temporal 25 (27.2)
Frontal 16 (17.4)
Parietal 5 (5.4)
Occipital 4 (4.3)
>1 lobe 31 (33.7)
Other 11 (12.0)
Tumour histology
High grade glioma 31 (33.7)
Low grade glioma 14 (15.2)
Meningioma 22 (23.9)
Other 25 (27.2)
Abbreviations: CTV, clinical target volume; N, number of pa-
tients; DS double scattering; PBS, pencil beam scanning.
Delineation of target volumes and organs at risk
For delineation, a CT scan with a slice thickness of 2 mm (subgroup 1) or 1 mm (subgroup 2) was
acquired for each patient and rigidly coregistered with pre-therapeutic MRI scans (T1-weighted,
T2-weighted or fluid-attenuated inversion recovery (FLAIR) with and without contrast agent). Tar-
get delineation was performed in clinical routine as described in section 2.2.4. The GTV com-
prised the macroscopic tumour or the resection cavity with residual tumour volume, if present.
The CTV included microscopic disease and oedema and was created based on the GTV or re-
section cavity taking into account information from MRI and the original tumour histology as well
as anatomical boundaries.
Additional OARs that were not contoured and considered during treatment planning for clin-
ical application were retrospectively delineated on the original treatment planning CT and the
coregistered MRI scans. These additional structures included hippocampi, cerebellum (posterior,
anterior and entire organ), frontal and temporal lobes using organ-specific contouring guidelines
(Schmahmann et al., 1999; Chera et al., 2009; Sun et al., 2014; Scoccianti et al., 2015; Eekers et
al., 2018), see table 6.2. The brain stem consisted of the medulla oblongata, pons and midbrain.
The brain included infra- and supratentorial structures excluding the brain stem. The remaining
brain (brain-CTV), created by subtracting the CTV from the brain structure, was considered for
evaluation. In paired organs, the organ with a higher mean dose was defined as ipsilateral and
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Table 6.2: Considered organs at risk and dose-volume parameters for comparison of treatment modalities.
Structure Dose-volume parameter
Brain stem D2%
Brain-CTV D2%, D50%, Dmean, V10Gy (RBE), V20Gy (RBE), . . . , V60Gy (RBE) in % of entire volume
Cerebellum D2%, D50%, Dmean, V10Gy (RBE), V20Gy (RBE), . . . , V60Gy (RBE) in % of entire volume
Cerebellum anterior D2%, D50%, Dmean, V10Gy (RBE), V20Gy (RBE), . . . , V60Gy (RBE) in % of entire volume
Cerebellum posterior D2%, D50%, Dmean, V10Gy (RBE), V20Gy (RBE), . . . , V60Gy (RBE) in % of entire volume
Chiasm D2%
Cochlea∗ D2%, Dmean
Frontal lobe∗ D2%, D50%, Dmean, V10Gy (RBE), V20Gy (RBE), . . . , V60Gy (RBE) in % of entire volume
Hippocampus∗ D2%, D50%, Dmean
Lacrimal gland∗ D2%, Dmean
Lens∗ D2%, Dmean
Optic nerve∗ D2%
Pituitary D2%, Dmean
Skin D2%, D5%, D15%. . . , D55%, V10Gy (RBE), V20Gy (RBE), . . . , V60Gy (RBE) in cm3
Temporal lobe∗ D2%, D50%, Dmean, V10Gy (RBE), V20Gy (RBE), . . . , V60Gy (RBE) in % of entire volume
∗ipsi- and contralateral organs separately
the remaining organ as contralateral. The contra- and ipsilateral hippocampus as well as the
bilateral hippocampi were considered. Structures located directly within the macroscopic tumour
volume were not contoured. Delineation was performed using RayStation®.
Treatment planning
The clinically applied PBT treatment plan was evaluated. The XRT plan was retrospectively
created using a state-of-the-art VMAT technique.
Proton treatment planning Both centres were equipped with an IBA (Ion Beam Applications
S.A., Louvain-La-Neuve, Belgium) system utilised with an isochronous cyclotron and an isocen-
tric gantry. Some patients of subgroup 2 were treated at a fixed beamline.
For subgroup 1, treatment plans were calculated using a DS technique and the treatment
planning system XiO®. The target volume was the CTV with a relative in-beam margin of 3.5 %
of the distal or proximal CTV depth and an additional absolute margin of 3 mm. The treatment
planning was based on the beam data of an IBA universal nozzle. The highest available proton
energy was 230 MeV. A range shifter was inserted to enable the dose application close to the
patient surface. The air gap between range shifter and the patient surface was set to 5 cm. Field-
specific brass apertures and milled lucite range compensators were created to conform the dose
to the target. A 3 × 3 × 3 mm3 dose calculation grid and a pencil-beam dose algorithm was used.
For subgroup 2, a PBS technique was applied. Treatment plans were generated using the
treatment planning systems XiO® (2013 – 2014) and RayStation® (2015 – 2016). Treatment
was planned on a PTV constructed by adding a 5 mm margin to the CTV. For both treatment
planning systems XiO® and RayStation®, treatment planning was based on beam data of the
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IBA dedicated nozzle. For patients treated at a fixed beamline, an IBA universal nozzle was
used. The sigma of the Gaussian spot size varied between 2.7 and 3.1 mm in air at isocentre for
the highest proton energy depending on the treatment room. A regular spot grid with a variable
spot spacing between 0.8 and 1.0 cm was used. The energy layer distance was automatically
selected by the treatment planning system. The minimal required number of monitor units per
spot was set at 0.04. For the treatment of superficial tumours, a range shifter was inserted. The
fixed air gap between the range shifter and the isocentre was 43 cm for the dedicated nozzle. For
the universal nozzle, a fixed air gap of 5 cm between range shifter and the patient surface was
applied if there was no risk of collision. Dose calculation was performed based on a pencil beam
algorithm with a dose calculation grid of 1 × 1 × 1 mm3.
One to four beams in a patient individual beam setting (coplanar or non-coplanar) could be
applied according to clinical practice in the respective centres. The RBE was considered to be
constant at 1.1. To account for this dose weighting, the unit Gy(RBE) is used for both treatment
modalities throughout this dose-comparison study. The dose-volume constraints differed slightly
between both subgroups, see appendix B tables B.4 and B.5.
Photon treatment planning Treatment planning of VMAT was performed using the planning
system RayStation® with a collapsed-cone algorithm. Treatment plans were conformed to a PTV
created by adding a uniform margin of 5 mm to the CTV. Two gantry rotations were applied (clock-
wise and counter-clockwise). Start and stop angles were slightly adapted to avoid unnecessary
exposure of normal tissue for small unilateral located volumes. Coplanar arcs were used in the
majority of patients. Angles of the multi-leaf collimator were 45◦ and 315◦, respectively. A photon
energy of 6 MV was used. Treatment planning was based on beam data of a Varian linear ac-
celerator 2100 (Varian Medical Systems, Palo Alto, CA, USA) with a dynamic multileaf collimator
(dMLC) with 60 leaf pairs at a width of 5 mm and 10 mm for the central 40 pairs and the remain-
ing, respectively. The maximum field size was 40 × 40 cm2. The arc gantry spacing between the
control points of the sliding window segments was set to 4◦, the maximum gantry angle speed
was 5.54◦s−1. The dose calculation grid was set to 1×1×1 mm3. All evaluations were performed
for the calculated nominal dose distributions.
Treatment planning aimed for clinically acceptable treatment plans in terms of target coverage
and dose constraints for OARs. To assure comparability, the same OARs and dose constraints as
in PBT treatment planning were applied, see appendix B tables B.4 and B.5. At least 95 % of the
target (PTVs) should receive 95 % of the prescribed dose (V95% > 95 %). Volumes receiving
more than 107 % of the prescribed dose should be avoided or minimised (D2% < 107 %). The
brain stem was considered as an avoidance structure with higher priority than the target coverage.
Thus, the planning goals for the target volumes could be compromised for the sake of brain stem
sparing.
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Treatment plan evaluation
The retrospectively created XRT treatment plans were qualitatively evaluated by one experienced
radiation oncologist. This was done additionally to the above-mentioned quantitative parameters
(e.g. V95%, D2%), as these simple metrics cannot reflect the three-dimensional dose distribution
exactly. Hence, treatment plans that did not pass the evaluation for clinical acceptability were
re-planned or dismissed although they met the nominal criteria. All PBT plans had been applied
clinically and thus were approved by experienced radiation oncologists during clinical routine.
All data were derived from patients that had already been treated with PBT. To allow for a
comparison between related PBT and XRT treatment plans, similar target coverage had to be
ensured. For this sake, further strict selection criteria for the CTV were applied to each plan:
D98% ≥ 95 % and D95% ≥ 98 % of the prescribed dose. These target coverage criteria were
not met in 9, 24 and 14 patients for the XRT, PBT or both treatment plans, respectively. Finally,
92 patients were included in the dose-comparison study for which both treatment plans met these
strict requirements. One reason why the XRT plans did not meet the requirements could be that
the patients were all selected and treated with PBT for various reasons. For example, because
the target coverage may not be achieved with XRT. Patients with a tumour located very close to
the brain stem were especially selected for PBT because the steep dose gradient was expected
to provide better target volume coverage. For some PBT plans, the planning objectives were met,
but not the stricter selection criteria for this plan comparison study.
Evaluation parameters All dose distributions were exported using RayStation® scripts. For
comparison of the target coverage between XRT and PBT treatment plans, CTV coverage was
evaluated due to the fact that DS PBT planning was performed based on CTVs rather than
PTVs. The following metrics of the CTV were assessed: D98%, D2%, V95%, V105%, V107%,
the conformity index CI for 98 % of the prescribed dose, see equation 2.4 and the homogeneity
index HI, see (2.5).
For the comparison of dose to OARs, different DVH parameters were selected. An overview is
given in table 6.2. Absolute volume parameters (in cm3) were considered for the non-circumscribed
organ skin. For circumscribed OARs, relative volume parameters (in per cent of the entire vol-
ume of the structure) were assessed. For the brain stem and optic pathways, only the near-
maximum dose was considered (D2%). For OARs with volumes < 10 cm3, the near-maximum
dose D2%, Dmean and Dmedian (D50%) were considered. As the median and mean dose are very
similar for very small structures (lens, cochlea, lacrimal gland, pituitary gland), only D2% and
Dmean were assessed.
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Dosimetric analysis
Absolute differences in dosimetric parameters ∆Dabs, ∆Vabs between both treatment modalities
XRT and PBT were assessed by
∆Dabs = DXRT − DPBT (6.1)
∆Vabs = VXRT − VPBT, (6.2)
where DXRT and DPBT represent dose parameters and VXRT and VPBT represent volume pa-
rameters of the XRT and PBT treatment plan, respectively. Relative differences in dosimetric
parameters ∆Drel, ∆Vrel between both treatment modalities XRT and PBT were expressed by
∆Drel =
DXRT − DPBT
DXRT
= 1 − DPBT
DXRT
(6.3)
∆Vrel =
VXRT − VPBT
VXRT
= 1 − VPBT
VXRT
. (6.4)
The patient-individual differences between the XRT and PBT plan were assessed by a Wilcoxon
signed-rank test. Moreover, to evaluate the extent of the dose sparing that can be achieved
using PBT instead of XRT, a threshold of 10 % was applied to individual dosimetric parameters
that were suggested to be clinically relevant by Scoccianti et al. (2015). These comprise mean
doses of the hippocampi and cochlea as well as maximum doses of the brain stem, optical
pathways, lacrimal gland, lens and pituitary. Furthermore, a dosimetric comparison for patient
groups classified according to the tumour location (frontal, temporal, parietal and multiple affected
lobes) was conducted.
6.2.2 Results
Target coverage
The CTV coverage was similar for both treatment techniques, see table 6.3. The high-dose
parameter V107% was below 0.15 % for all treatment plans and thus, not further evaluated.
No statistically significant difference between XRT and PBT could be observed for D98%, D2%
and V105%. Even though the difference between both techniques for V95% was statistically
significant, the absolute difference was very small (< 1 percentage point). Conformity was better
for the PBT plans and homogeneity was marginally better for XRT plans.
Dose comparison for organs at risk
All investigated dose-volume parameters for all considered OARs are given in appendix D ta-
ble D.1 for both XRT and PBT treatment plans. For almost all investigated structures and dosimet-
ric parameters, PBT reduced the dose significantly compared to XRT. No significant difference
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Table 6.3: Comparison of parameters characterising the target coverage. Volume parameters Vx% are
given in per cent of the volume of the CTV, dose parameters Dx% are given in per cent of the prescribed
dose. Mean values and standard deviations are presented. P-values were derived from Wilcoxon signed-
rank tests.
Parameter PBT XRT XRT – PBT p-value
D98% in % 98.6 ± 0.8 98.7 ± 0.7 0.16 ± 0.87 0.12
D2% in % 102.4 ± 0.9 102.2 ± 0.9 -0.17 ± 1.29 0.13
V95% in % 99.9 ± 0.3 99.9 ± 0.3 0.04 ± 0.26 0.006
V105% in % 0.1 ± 0.3 0.1 ± 0.3 0.02 ± 0.48 0.89
V107% in % 0.0 ± 0.0 0.0 ± 0.0 0.00 ± 0.02 0.062
HI in % 3.8 ± 1.2 3.5 ± 1.2 -0.33 ± 1.58 0.028
CI98% in % 49.9 ± 14.7 43.3 ± 15.1 -6.63 ± 6.61 <0.001
Abbreviations: HI, homogeneity index; CI98%, conformity index for 98 % isodose.
could be observed for the parameter V60Gy (RBE) describing the very high dose region. For
both treatment techniques, the relative values of V60Gy (RBE) in the temporal and frontal lobes,
cerebellar structures and brain-CTV were very low (mean values below 3.5 %). Similarly, the ab-
solute values of V60Gy (RBE) of the skin were below 0.5 cm3. Dose reduction using PBT instead
of XRT was mainly observed in the low dose region described by V10Gy (RBE) or V20Gy (RBE).
Figure 6.1 exemplarily shows selected volume parameters of brain-CTV and skin for both treat-
ment modalities. For brain-CTV, almost all dosimetric parameters were significantly lower for PBT
compared to XRT. For the skin, however, only low to intermediate dose areas were significantly
reduced for PBT compared to XRT. The volume of the skin receiving high doses described by
V40Gy (RBE) to V50Gy (RBE) was smaller for XRT compared to PBT, however not significantly.
This effect can be illustrated by the build-up region for photon beams that is not present for proton
beams.
In paired organs, PBT allowed greater sparing of the contralateral than the ipsilateral organ
compared to XRT. This is shown exemplarily for the hippocampus in figure 6.2. While PBT
could reduce the near-maximum dose parameter D2% of the ipsilateral hippocampus in 80.8 %
of the patients, a reduction of this parameter could be achieved in 91.8 % of the patients for
the contralateral hippocampus. For even more patients, the mean hippocampal dose could be
reduced by using PBT compared to XRT. This was the case in 89.7 % of the patients for the
ipsilateral and in 96.5 % of the patients for the contralateral hippocampus. In a large number of
patients, PBT deposited almost no dose in the contralateral hippocampus, while XRT delivered
mean doses up to 35 Gy(RBE).
Patient-individual dosimetric differences between both treatment modalities were also calcu-
lated for selected DVH parameters for intracranial OARs suggested by Scoccianti et al. (2015).
These relative differences are presented in appendix D figure D.1 for each patient. Appendix D
figure D.2 shows the parameters exceeding a threshold of 10 %. It demonstrates that most pa-
rameters of all patients can be reduced by more than 10 % when using PBT instead of XRT.
However, the relative difference does not indicate the extent of the reduction and whether this
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(A) Brain-CTV. (B) Skin.
Figure 6.1: Volume parameters VxGy (RBE) abbreviated as Vx of brain-CTV (A) and skin (B) for XRT
and PBT treatment plans. The upper panel shows absolute values, the bottom panel shows the difference
between XRT and PBT values. P-values of the paired Wilcoxon test are given; ∗∗∗ represents p < 0.001.
Figure 6.2: Dosimetric parameters of the ipsilateral (left panel) and contralateral hippocampus (right
panel). The dashed line represents equal values for both treatment modalities. The percentage of pa-
tients above or below this line is indicated.
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reduction is also clinically relevant. This will be explained in the following using two example pa-
tients. For these two exemplary patients, the dose distributions for both treatment modalities are
displayed on CT images in figure 6.3. The characteristics of these patients are given in table 6.4.
Figure 6.4 shows absolute differences and classified relative differences between XRT and
PBT as well as the absolute dose values for the above-mentioned parameters for both example
patients. For patient 1, the relative reduction using PBT instead of XRT is larger than 10 % for all
selected parameters. PBT is able to reduce a number of dosimetric parameters to zero, while the
corresponding doses for XRT are between 2 and 20 Gy(RBE), i.e. also for XRT the general level
of dose exposure is comparatively low. For patient 2, only a few parameters could be reduced
Figure 6.3: Dose distributions for both treatment modalities (PBT and XRT) of two example patients.
Doses are given in per cent of the prescribed dose (60 Gy(RBE) for patient 1 and 54 Gy(RBE) for patient
2). The white lines in the sagittal view represent the sectional planes of the coronal and axial views.
Table 6.4: Characteristics of the example patients.
Characteristic Patient 1 Patient 2
Gender Female Female
Tumour histology Oligoastrocytoma grade III Astrocytoma grade II
Tumour location Left-sided Right-sided
Frontal lobe > 1 lobe involved
Surgery Yes Yes
CTx Yes No
PBT technique DS PBS
Age in years 48 61
Tumour volume (CTV) in cm3 117 240
Prescribed dose in Gy(RBE) 60 54
Abbreviations: CTV, clinical target volume; CTx, chemotherapy; DS, double scatter-
ing; PBS, pencil beam scanning.
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Figure 6.4: Relative and absolute difference of selected DVH parameters between PBT and XRT for two
example patients. The absolute PBT and XRT values of the respective dosimetric parameters represent
the left and right limits of the bars. The shading indicates whether the XRT plan revealed lower doses than
the PBT plan (relative difference ∆Drel below 0 %, blue), or the PBT plan revealed lower doses than the
XRT plan (relative difference ∆Drel above 0 %, grey). If the relative improvement using PBT was greater
than 10 %, the bar is shaded in orange. Parameter selection and dose constraints (given as red lines,
multiple constraints for some parameters) as suggested by Scoccianti et al. (2015). ipsi, ipsilateral; contra,
contralateral.
by more than 10 % using PBT instead of XRT. However, the dose to the ipsilateral lens could be
reduced substantially. Also, dosimetric parameters of the lacrimal glands as well as contralateral
lens and cochlea could be reduced by more than 10 % using PBT. For the mean dose of the
ipsilateral cochlea, the reduction remained below 10 % as the dose exposure was relatively high
for both treatment modalities (> 40 Gy(RBE)). Though being rather moderate, this reduction may
be relevant as cochlea dose is very close to its constraints. The maximum doses in the brain
stem, optic pathways and pituitary were minimally reduced with the XRT plan. The dose to the
bilateral hippocampi was not shown, as the ipsilateral hippocampus was completely covered by
the tumour.
An analysis of differences in dosimetric parameters (Dmean and D2%) between the two treat-
ment modalities for different tumour localisations (frontal, temporal, parietal and multiple affected
lobes) is presented in appendix D table D.2. The highest relative dose reduction could be ob-
served for tumours located in the parietal lobe. The median relative reduction for the majority
of OARs was above 50 %, except for ipsilateral hippocampus and temporal lobe. The great-
est median absolute reduction was observed for D2% of the contralateral frontal temporal lobe
(30.2 Gy(RBE)). However, only five patients had a tumour location restricted to the parietal lobe.
For patients with a tumour located in the frontal lobe, a median relative reduction of 100 % for
cerebellar doses could be observed using PBT. The greatest median absolute reduction was
seen for D2% of the brain stem (15.7 Gy(RBE)). The dose reduction using PBT was slightly less
pronounced in temporal tumours. The contralateral lacrimal gland, lens and cochlea could be
spared by 100 % in the median. The greatest median absolute reduction was observed for D2%
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of the contralateral hippocampus (15.8 Gy(RBE)) using PBT instead of XRT. For patients with a
tumour located in more than one lobe, a large relative sparing (> 90 %) could be observed es-
pecially in contralateral structures (cochlea, lacrimal gland, lens, temporal lobe, hippocampus).
The greatest median absolute reduction was observed for D2% of the contralateral hippocampus
(14.1 Gy(RBE)).
6.2.3 Discussion
PBT was able to reduce the dose in almost all investigated OARs and dosimetric parameters
substantially, especially in the low and intermediate dose range and for contralateral organs. The
only exception was the skin, where the dose in the intermediate to high range was even slightly
increased for PBT. In contrast to photon beams, proton beams show no build-up effect, leading
to higher skin doses.
The presented results are in line with other dose-comparison studies. However, most of the
publications comprised only a small number of patients and did not investigate the skin as an
OAR. Baumert et al. (2001) compared stereotactic XRT with a micro-multileaf collimator and
PBS PBT in seven patients with differently shaped targets (concave, ellipsoid isolated, superficial
and close to an OAR as well as irregular complex). They found no benefit for PBT compared
to stereotactic XRT in simple shaped or superficial tumours. For complex targets or targets
located near critical structures, PBT seemed to be a potentially better choice than XRT. Bolsi
et al. (2003) compared three different XRT techniques (3D-CRT, stereotactic arc therapy and
IMRT) and two different PBT techniques (PBS and DS) in a cohort of twelve patients with benign
brain tumours. Both PBT techniques had superior dosimetric properties compared to all XRT
techniques concerning target dose uniformity and conformity and in terms of sparing OARs. The
authors even proposed to consider PBT as the treatment of choice for patients with a long life
expectancy.
Dennis et al. (2013) conducted a dose-comparison study between IMRT and DS PBT in eleven
LGG patients. They estimated a halving of gEUD in healthy tissues surrounding the tumour
using PBT instead of IMRT. Moreover, they stated that the risk of secondary tumour induction
after IMRT would be twice as high as with PBT. As in this thesis, the authors concluded that
PBT was dosimetrically superior to XRT, especially for critical structures that were located on the
contralateral side compared to the tumour.
Adeberg et al. (2016) compared intensity-modulated PBT, VMAT and 3D-CRT in a small cohort
of twelve patients with HGG. They also found a considerable dose reduction for PBT, especially
in contralateral organs of neurocognitive function and in areas of neurogenesis. Harrabi et al.
(2016) investigated the dose distribution of intensity-modulated PBT and 3D-CRT plans in 74
HGG patients. They concluded similarly that PBT is dosimetrically superior to conventional XRT,
especially for OARs that are considered critical for neurological function and neurocognition or
that play an important role in the preservation of QoL.
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Adeberg et al. (2018) performed a treatment plan comparison between PBT, 3D-CRT and
VMAT to identify patient subgroups based on tumour localisation that may benefit most from
PBT. They investigated relative dose differences in 50 patients with five different tumour localisa-
tions (frontal, suprasellar, temporal, parietal and posterior fossa). Patients with parietal tumours
exhibited the greatest relative dose reductions in most OARs, especially in the optical pathways
and contralateral OARs. For tumours located in the temporal lobe, the reductions were prominent
in the mean dose of the infra- and supratentorial brain as well as the whole brain. For frontal lobe
tumours, mainly the mean dose of the infratentorial brain and contralateral hippocampus could
be reduced. These results described by Adeberg et al. (2018) are consistent with the results of
the dose-comparison study presented in this thesis. However, the dosimetric benefit refers to
the relative reduction and absolute dose differences were not analysed. In this context, some
relative dose reductions could be overrated. For example, a 100 per cent relative reduction can
easily be achieved if no dose at all is deposited in an OAR by PBT and only very low doses are
delivered by XRT. Adeberg et al. (2018) concluded that their results could improve the selection
of patients who should receive PBT, as patients with rather small tumours near critical structures
could benefit most from PBT with regard to dosimetric benefits. Nevertheless, the classification
into one of the five localisation groups does not necessarily allow for conclusions on the benefit
of an individual patient. As an example, the authors suggest that the dosimetric benefit of PBT for
contralateral OARs of a midline and a well-lateralised frontal lobe lesion may differ considerably,
although both tumours would be assigned to the same localisation group.
This dose-comparison study showed that the highest relative dose reduction can be achieved
in organs that are at a greater distance from the target (contralateral). Since PBT deposits almost
no dose in distant organs, the relative reductions compared to XRT may be substantial, although
the absolute XRT doses also may be relatively low (see example patient 1). Thus, a state-
of-the-art XRT technique may be a valuable option for these patients, too. In some patients
the tumour is very space-occupying, sometimes it covers large parts of one hemisphere (the
maximum tumour volume in this study was almost 400 cm3). In patients with large tumours,
even the contralateral organs may be located in the near to middle distance and can hardly be
spared with either technique (see example patient 2). This suggests, that patients with a very
large tumour may benefit less from PBT compared to patients with a rather small tumour and
may be treated with a state-of-the-art XRT technique. However, no correlation (with Spearman
|ρ| > 0.5) could be observed between increasing tumour volume (CTV) and decreasing relative
and absolute dosimetric differences for all investigated OARs. This indicates that, in general, the
extent of a dosimetric benefit cannot be determined solely on the basis of tumour location or size,
but that a patient-specific assessment is required.
In general, clinical decisions to treat certain brain tumour patients with PBT are based on a
comparison of dose distributions rather than a detailed comparison of NTCP values. So far, the
availability of validated NTCP models predicting side effects following cranial RT is limited. Thus,
figures like figure 6.4 could guide physicians in the treatment decision, as relevant dosimetric pa-
108
6.2 Treatment plan comparison of cranial proton and photon radiotherapy
rameters are displayed at a glance. For use in daily routine, however, the obstacle remains that
clinically relevant OARs and dosimetric parameters must be defined. Furthermore, appropriate
threshold values must be specified above which PBT is considered to be indicated. As shown
above, a large relative difference in dosimetric parameters between treatment options does not
necessarily have to be clinically relevant, so that both absolute differences and absolute values
should be considered. Due to this multitude of degrees of freedom and decisions, the estab-
lishment of consistent guidelines (at least within one clinic) requires a great effort by clinicians in
close cooperation with other professional groups. The most demanding challenge is the definition
of the term clinical relevance. It is not defined so far since no results of prospective clinical studies
comparing XRT and PBT for brain tumour patients are available yet (Adeberg et al., 2017). Fur-
thermore, for each individual patient, sparing of OARs may be prioritised differently depending
on patient-specific factors, e.g. comorbidities, age, life expectancy or patient preference. Hence,
it is even more difficult to specify consistent selection criteria in clinical practice.
To reduce the number of degrees of freedom and to assess the quality of treatment plans for
decision making, different single metrics have been developed including assessment of the target
coverage as well as sparing of OARs. Target coverage metrics are for example the homogeneity
or several conformity indices (Paddick, 2000; Feuvret et al., 2006; Yoon et al., 2007). To evaluate
OAR sparing, the healthy tissue overdosage factor HTOF (Feuvret et al., 2006), critical organ-
scoring index COSI (Menhel et al., 2006) or the healthy tissue conformity index HTCI (Feuvret
et al., 2006) have been suggested. Most metrics have in common that they usually evaluate
only one aspect and cannot assess the quality of the overall treatment plan. But there are also
metrics that attempt to evaluate target coverage and OAR sparing simultaneously to provide
overall quality scores (Miften et al., 2004; Akpati et al., 2008). A decision-support system to
choose between different tentative treatment plans has been proposed by Alfonso et al. (2015)
based on a dose distribution index DDI. It incorporates different metrics regarding the target as
well as sparing of OARs and the remaining volume at risk. However, these more complex metrics
are based only on physical parameters and are rarely implemented in clinical practice.
These difficulties, especially the clinical assessment of dose reduction, can be addressed if
the dose parameters are directly converted into NTCP estimates. Whether the shown dosimetric
superiority of PBT over XRT translates into a clinical benefit in terms of NTCP is assessed in the
following section.
Limitations of the dose-comparison study
This treatment plan comparison was retrospectively conducted. Several OARs were retrospec-
tively contoured and were therefore not included in the active planning process. As there are
(still) no dose limits for many of these structures, they are not yet considered in clinical routine.
The dose to OARs mainly depends on the applied treatment planning technique, beam arrange-
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ment, treatment goals and objectives during the treatment planning optimisation process, which
narrows the generalisability of all in silico dose-comparison studies.
The study cohort could be subject to a selection bias because the patients have already been
treated with PBT and were selected for this treatment for certain reasons, e.g. sufficient target
coverage may be not achieved using the available XRT techniques. However, this issue was re-
duced in the dose-comparison study by applying additional selection criteria to ensure compara-
ble target coverage with both modalities. Although the patient cohort was rather heterogeneous,
it reflects the wide range of possible clinical cases.
This dose-comparison study examined only the VMAT technique for XRT. Although 3D-CRT
is also still common in clinical practice, this technique was not considered here as the study
aimed at comparing PBT with a state-of-the-art XRT technique. Both PBT techniques, DS and
PBS, were investigated, as patients included in this study were treated with DS at that time at
the UPTD. Since the introduction of PBS at this centre, all patients with intracranial tumours
have been treated with PBS. To investigate the impact of the PBT technique, the dosimetric
differences between XRT and PBT were compared for the subgroups of patients treated with
either PBT technique. For the skin, no significant differences between both patient groups could
be observed for the absolute and relative dosimetric difference of a majority of parameters. For
other parameters, the absolute and relative difference between XRT and PBT was on average
higher in the group treated with DS compared to patients treated with PBS (e.g. V10Gy (RBE)).
However, a comprehensive comparison between both PBT techniques, PBS and DS, requires
an in silico treatment planning for each individual patient, as tumour-related parameters such
as location, tumour size, prescribed dose and target volume concepts differed between both
subgroups. This was out of the scope of this study comparing XRT and PBT in general.
Dose uncertainties in the dose calculation of RT treatment plans may have occurred due to
the used dose calculation algorithms. The extent of these uncertainties mainly depends on the
tissue heterogeneities in the beam path. They increase in areas with high tissue heterogeneity,
for example at interfaces of air-filled nasal cavities, bone (skull) and soft tissues. Therefore, these
dose calculation uncertainties are more likely in patients with a tumour in the skull base than in
patients who do not require irradiation of the heterogeneous area (cranial lesions). Moreover, the
dose uncertainties depend on the applied dose calculation algorithm. In this study, the clinically
applied PBT treatment plans were calculated using a pencil beam algorithm. XRT plans were
retrospectively calculated based on a collapsed cone algorithm. For XRT, this algorithm outper-
formed the pencil beam algorithm especially in the vicinity of interfaces and within low-density
regions (Krieger and Sauer, 2005; Knöös et al., 2006). More accurate Monte Carlo dose cal-
culation algorithms are becoming available in commercial treatment planning systems for both
XRT and PBT. For PBT, a substantial impact of Monte Carlo algorithms compared to analytical
algorithms is expected in complex anatomical regions (Paganetti, 2012). The evaluated dose
differences in this study may be subject to uncertainties that arise from the different applied dose
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calculation algorithms. However, the majority of patients in this study had a tumour located in the
brain with less tissue heterogeneity.
6.3 Application of NTCP models
The results of the dose-comparison study in section 6.2 vividly confirmed that PBT plans can
spare dose to healthy tissues compared to XRT, especially in the low to intermediate dose range
and in contralateral OARs. An estimation of whether this dosimetric superiority translates into
differences in treatment-related side effects can be quantified using NTCP models. For the fol-
lowing feasibility study, available NTCP models were selected that predict side effects associated
with cranial irradiation. However, multivariable, externally validated models for modern treatment
techniques are still rare for these side effects. It is essential to bear in mind that the following
models are subject to several uncertainties outlined in the discussion. Consequently, the NTCP
values for each patient and each side effect are rather rough estimates.
6.3.1 Patient cohort and experimental design
Selection of NTCP models
As explained in section 2.4, models used for patient selection need to be validated externally
in terms of calibration and discrimination. Ideally, NTCP models should be derived from sim-
ilar patient populations regarding tumour site, RT technique, and concomitant treatments, etc.
However, for brain tumour patients, validated NTCP models for modern techniques are rare.
This is due to the rather unspecific nature of common side effects (e.g. fatigue) and due to dif-
ficulties in their measurement such as for neurocognitive sequelae or radiation-induced brain
necrosis. Nevertheless, different NTCP models were selected, that describe several radiation-
induced side effects following treatments of tumours of the brain and skull base. The models
were derived from normo-fractionated treatment data or use a correction for other fractionation
schemes (e.g. EQD2). Eleven different side effects were investigated: acute alopecia, acute ery-
thema, blindness, brain and brain stem necrosis, cataract requiring intervention, delayed recall,
endocrine dysfunction, hearing loss, ocular toxicity, temporal lobe injury and tinnitus (Burman
et al., 1991; Bender, 2012; Gondi et al., 2012; Batth et al., 2013; De Marzi et al., 2015; Lee
et al., 2015; Kong et al., 2016; Dutz et al., 2019). They comprise severe toxicities such as brain
necrosis and rather less severe side effects such as alopecia, which can even though impact
patients’ quality of life. Both acute and late side effects were considered. Side effects that may
occur following irradiation of one of a paired organ (e.g. cataract, hearing loss or tinnitus) were
investigated for the contra- and ipsilateral OAR separately. The investigated NTCP models, pa-
rameters and coefficients are presented in table 6.5. They comprise different model types such
as logistic models and LKB models using gEUD as a model predictor (see equation 2.12). The
investigated side effects and selected models are presented in alphabetic order in the following.
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Alopecia Acute alopecia is a common side effect following cranial RT that may affect patients’
QoL. A logistic model for acute alopecia grade ≥ 2 following PBT including D5% of the skin as
model predictor was applied as comprehensively described in section 4.2 (Dutz et al., 2019).
Blindness Irradiation of the optic nerves and chiasm may lead to visual loss as a severe late
side effect of cranial RT. This side effect may occur in patients treated for tumours located in the
vicinity of optic pathways (e.g. orbit, paranasal sinuses, skull base or frontal lobes). Loss of vision
usually occurs 18 months after therapy with irradiation of more than 50 Gy (Danesh-Meyer, 2010;
Thakkar et al., 2017). If irradiation is unavoidable, the risk of visual loss may be accepted by
many patients to eliminate the tumour. However, since vision loss is difficult to treat, the risk of
Table 6.5: Considered NTCP models for potential side effects following cranial radiotherapy.
Endpoint NTCP model Model coefficients
Alopecia1 grade ≥ 2
Acute
Dutz et al. 2019
NTCP =
(︁
1 + e−β0−β1D5%
)︁−1
Skin D5%
β0 = −1.33, β1 = 0.08 Gy(RBE)−1
Blindness
5 years post-RT
Burmann et al. 1991
NTCP =
1√
2π
ˆ t
−∞
exp
(︃
−u2
2
)︃
du, t =
gEUD − TD50
m · TD50
Chiasm and optic nerves gEUD
TD50 = 65.0 Gy, m = 0.14, a = 4.0
Brain necrosis
5 years post-RT
Bender et al. 2012
NTCP =
(︄
1 +
(︃
D50
EQD2
)︃4γ)︄−1
Brain-CTV and brain stem Dmax (EQD2)
D50 = 109.0 Gy, γ = 2.8,
α/β = 0.96 Gy
Cataract requiring intervention
5 years post-RT
Burmann et al. 1991
NTCP =
1√
2π
ˆ t
−∞
exp
(︃
−u2
2
)︃
du, t =
gEUD − TD50
m · TD50
Lenses gEUD
TD50 = 18.0 Gy, m = 0.27, a = 3.33
Delayed recall2
1.5 years post-RT
Gondi et al. 2012
NTCP =
1√
2π
ˆ t
−∞
exp
(︃
−u2
2
)︃
du, t =
EQD2 − EQD502
m · EQD502
Bilateral hippocampi D40% (EQD2)
EQD502 = 14.88 Gy,
m = 0.540, α/β = 2 Gy
Endocrine dysfunction1
At least 0.5 – 2 years post-RT
De Marzi et al. 2015
NTCP =
(︄
1 +
(︃
TD50
gEUD
)︃4γ50)︄−1
Pituitary gEUD
TD50 = 60.5 Gy, γ50 = 5.2, a = 6.4
Erythema1 grade ≥ 2
Acute
Dutz et al. 2019
NTCP =
(︁
1 + e−β0−β1V35Gy (RBE)
)︁−1
Skin V35Gy (RBE), absolute volume
β0 = −1.54, β1 = 0.06 cm−3
Hearing loss1
At least 0.5 – 2 years post-RT
De Marzi et al. 2015
NTCP =
(︄
1 +
(︃
TD50
gEUD
)︃4γ50)︄−1
Cochlea gEUD
TD50 = 56.0 Gy, γ50 = 2.9 a = 1.2
Ocular toxicity3 grade ≥ 2
Acute
Batth et al. 2013
NTCP =
(︁
1 + e−β0−β1Dmax
)︁−1
Ipsilateral lacrimal gland D4max
β0 = −5.174, β1 = 0.205 Gy−1
Temporal lobe injury
5 years post-RT
Kong et al. 2016
NTCP =
(︁
1 + e−β0−β1Dmax
)︁−1
Temporal lobe D4max
β0 = −18.61, β1 = 0.227 Gy−1
Tinnitus5 grade ≥ 2
1–2 years post-RT
Lee et al. 2015
NTCP =
1√
2π
ˆ t
−∞
exp
(︃
−u2
2
)︃
du, t =
Dmean − TD50
m · TD50
Cochlea Dmean
TD50 = 46.52 Gy, m = 0.35
1CTCAE, Common Terminology Criteria for Adverse Events; 2on Wechsler Memory scale III Word Lists, 3RTOG, Radiation Therapy
Oncology Group; 4parameter fit from published data, 5LENT-SOMA, late effects of normal tissues – subjective, objective, management
and analytic.
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its potential occurrence should be considered during treatment planning (Danesh-Meyer, 2010).
Burman et al. (1991) developed an LKB model to estimate the probability of vision loss following
irradiation of the optic nerves and chiasm. Based on the gEUD of each of these structures, three
different predictions for blindness caused by the irradiation of the ipsi- or contralateral optic nerve
or the chiasm were determined.
Brain and brain stem necrosis Necrosis of the brain or brain stem is a devastating late side
effect that is essentially considered during treatment planning (Mayo et al., 2010b). To prevent
necrosis at all costs, conservative dose constraints for the brain stem are usually applied and
often given higher priority than target volume coverage. Moreover, it is difficult to differentiate
radiation-induced necrosis from tumour progression, since both outcomes often occur in a similar
pattern on MRI (Verma et al., 2013). Thus, confirmed incidences are rare so that hardly any
NTCP models for modern treatment techniques exist. Bender (2012) developed an NTCP model
for brain and brain stem necrosis five years after RT by combining outcome and dose data from
case reports of several institutions summarised by Lawrence et al. (2010). Thus, the model is
derived from different patient populations, fractionation schemes and treatment techniques. The
maximum doses of the brain stem and brain-CTV were converted to EQD2 to account for these
differences.
Cataract requiring intervention Radiation to the crystalline lens of the eye may cause a
cataract that commonly leads to vision impairment. As the lens is a radio-sensitive structure
(Ferrufino-Ponce and Henderson, 2006), the maximum dose should be below 5 or 10 Gy (Henk
et al., 1993; Lee et al., 2008; Piroth et al., 2009; Scoccianti et al., 2015). Although cataract
surgery and replacement with artificial lenses are performed routinely, sparing during treatment
planning is still the preferred solution, if possible. Burman et al. (1991) developed an LKB model
to predict the probability of cataract requiring intervention based on gEUD of the lenses.
Delayed recall Neurocognitive sequelae are late side effects following cranial irradiation that
may affect patients’ QoL as described in detail in chapter 5. Gondi et al. (2012) assessed several
neurocognitive functions in patients with LGG or benign brain tumours at 1.5 years following
IMRT. Delayed recall on the WMS-WL was associated with D40% of the bilateral hippocampus.
Endocrine dysfunction Irradiation of the pituitary gland and hypothalamus may cause hor-
monal deficits such as impairment of growth hormone production, hyperprolactinemia and defi-
ciency in gonadotrophin, thyroid-stimulating hormone and adrenocorticotropic hormone (Darzy
and Shalet, 2009; Scoccianti et al., 2015). Dose constraints for the pituitary gland range between
50 and 60 Gy for adults (Pai et al., 2001; Lee et al., 2008). Endocrine functions outside the normal
reference range (hyperprolactinemia, delayed thyroid-stimulating hormone response to thyroid-
releasing hormone and panhypopituitarism) were modelled by De Marzi et al. (2015) based on
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the dose to the pituitary gland for patients after combined treatment with PBT and 3D-CRT. They
developed a logistic and an LKB model. As the predictions did not differ between both models,
the NTCP values of the LKB model were considered in the present study.
Erythema Acute erythema as a radiation-induced reaction of the skin is comprehensively de-
scribed in section 4.2. As NTCP models for modern XRT techniques are rare, a logistic model
developed for PBT was applied (Dutz et al., 2019).
Ocular toxicity Irradiation of the lacrimal gland can affect tear production leading to reduced
lubrication of the cornea and conjunctiva or dry eyes (Scoccianti et al., 2015). Fibrosis of the
lacrimal gland with loss of tear production may be caused by doses of more than 57 Gy (Je-
ganathan et al., 2011). Batth et al. (2013) investigated ocular toxicity according to the RTOG
scoring system. The degree of conjunctivitis, keratitis, corneal ulceration retinopathy and visual
loss were the considered endpoint in patients with sinonasal tumours treated with IMRT. Acute
ocular toxicity grade ≥ 2 could be predicted by the maximum dose to the ipsilateral lacrimal gland.
As model coefficients were not given in this publication, the published dosimetric and outcome
data were fitted in a logistic model in this thesis.
Ototoxicity Ototoxicity, i.e. hearing loss, tinnitus and/or vertigo, is a toxicity that occurs after
irradiation of the ear and auditory nerve (Landier, 2016). Late sensorineural hearing loss has
been described as a consequence of cochlear mean doses above 45 to 50 Gy (Pan et al., 2005;
Lee et al., 2008; Bhandare et al., 2010). De Marzi et al. (2015) developed different logistic and
LKB models to predict hearing loss for patients with tumours in the skull base after combined
treatment with PBT and 3D-CRT based on the dose to the inner ear, cochlea and internal au-
ditory canal. Hearing loss > 15 dB at two contiguous test frequencies as well as tinnitus were
considered as endpoints. Lee et al. (2015) investigated tinnitus grade ≥ 2 according to LENT-
SOMA in head and neck cancer patients treated with IMRT. They developed a logistic and an
LKB model based on the cochlear mean dose. For both side effects (hearing loss and tinnitus),
the corresponding LKB model based on the dose to the cochlea was considered in the present
study as the predictions of the logistic and the LKB model did not differ.
Temporal lobe injury Late temporal lobe necrosis is a severe side effect for patients treated
with high doses for tumours of the skull base (Pehlivan et al., 2012). A study on patients with
tumours located in the skull base treated with PBT investigated a relation of the occurrence of this
side effect and dose to the temporal lobes. Although Pehlivan et al. (2012) observed a trend for
grade 1 and grade 3 when gEUD exceeded 60 Gy(RBE), no NTCP model for temporal lobe injury
could be developed. Another study investigated contrast-enhanced lesions on post-contrast T1-
weighted MR images in patients for nasopharyngeal carcinoma treated with IMRT (Kong et al.,
2016). They developed a logistic NTCP model for this endpoint at five years after IMRT based
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on the maximum dose to the temporal lobe as predictor. As model coefficients were not given in
the publication by Kong et al. (2016), the published dosimetric and outcome data were fitted in a
logistic model in this thesis.
Evaluation of NTCP values
For each patient, NTCP values for all side effects were estimated for both treatment modalities,
i.e. XRT and PBT. For some patients, the considered OAR was located within the tumour tissue,
e.g. the pituitary for patients with pituitary adenoma. Thus, the NTCP value for the associated
side effect could not be evaluated. Patient-individual differences ∆NTCP were assessed by
∆NTCP = NTCPXRT − NTCPPBT, (6.5)
where NTCPXRT and NTCPPBT represent the NTCP value based on the XRT and PBT treatment
plan, respectively. Dose parameters were derived for the considered OARs based on the dose
distribution on the planning CT scan.
For side effects with a given severity grade ≥ 2, a threshold of 10 percentage points was con-
sidered for ∆NTCP as suggested by Langendijk et al. (2018). However, not all side effects were
physician-rated using scoring systems based on severity grades. For example, delayed recall
was assessed using a neurocognitive test (Gondi et al., 2012). Due to the lack of further avail-
able recommendations for side effects not measured on a Likert scale and to ensure consistency,
a threshold of 10 percentage points was also applied to all other side effects. A patient would
finally be selected for PBT if ∆NTCP exceeds the threshold of 10 percentage points for at least
one of all investigated side effects. For those cases where NTCP could not be predicted due to
tumour invasion of the associated OAR, it was assumed that PBT is not more beneficial for the
patient than XRT. For example, if one prediction was missing and the threshold was exceeded for
at least one other side effect, the patients would be selected for PBT. If one prediction was miss-
ing and the threshold was not exceeded for any other side effect, the patients would be selected
for XRT.
6.3.2 Results
The NTCP predictions of all investigated side effects and both modalities are given in table 6.6.
For temporal lobe injury (Kong et al., 2016), contralateral hearing loss (De Marzi et al., 2015)
as well as brain and brain stem necrosis (Bender, 2012), the maximum NTCP value for both RT
modalities were below 5 %. Therefore, these side effects were not considered any further. For
the remaining side effects, all ∆NTCP values and a threshold of 10 percentage points are shown
in figure 6.5. The NTCP values for both techniques covered a wide range in some models, espe-
cially those predicting side effects after irradiation of ipsilateral organs such as cataract and ocular
toxicity as well as tinnitus and hearing loss. But also the NTCP values for delayed recall, acute
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Table 6.6: NTCP predictions for different side effects following cranial RT. Mean and standard deviations
are given in the first row, median and range are shown in the second row. P-values are derived from
Wilcoxon signed rank tests. Number of patients, for which ∆NTCP exceeds a threshold of 10 percentage
points (pp) is given in the right column.
NTCPPBT NTCPXRT ∆NTCP Patients with
Side effect in % in % in percentage point p-value ∆NTCP≥10 pp
Alopecia 60.2 ± 25.0 63.5 ± 20.8 3.3 ± 8.5 0.001 21/92
Dutz et al. (2019) 63.2 (20.9 – 96.8) 60.0 (31.4 – 96.9) 3.0 (-19.8 – 21.0)
Blindness (chiasm) 2.2 ± 3.9 2.8 ± 4.1 0.5 ± 2.0 < 0.001 1/91
Burman et al. (1991) 0.0 (0.0 – 13.3) 0.2 (0.0 – 17.5) 0.0 (-3.3 – 12.3)
Blindness (ON contra) 0.1 ± 0.8 0.2 ± 1.3 0.1 ± 1.1 < 0.001 1/92
Burman et al. (1991) 0.0 (0.0 – 7.7) 0.0 (0.0 – 10.3) 0.0 (-0.6 – 10.2)
Blindness (ON ipsi) 1.5 ± 3.2 1.8 ± 3.3 0.3 ± 1.1 < 0.001 0/91
Burman et al. (1991) 0.0 (0.0 – 15.1) 0.0 (0.0 – 12.9) 0.0 (-4.1 – 4.3)
Cataract (contra) 0.1 ± 0.4 4.1 ± 15.9 4.0 ± 15.6 < 0.001 6/92
Burman et al. (1991) 0.0 (0.0 – 3.4) 0.1 (0.0 – 99.7) 0.1 (0.0 – 99.4)
Cataract (ipsi) 5.7 ± 20.4 21.7 ± 35.4 16.0 ± 35.0 < 0.001 24/91
Burman et al. (1991) 0.0 (0.0 – 100.0) 0.3 (0.0 – 100.0) 0.2 (-85.8 – 99.8)
Delayed recall 31.6 ± 38.3 65.3 ± 34.7 33.7 ± 32.4 < 0.001 51/78
Gondi et al. (2012) 4.9 (3.2 – 100.0) 77.1 (3.7 – 100.0) 24.8 (-29.1 – 93.8)
Endocrine dysfunction 1.3 ± 3.1 1.8 ± 3.7 0.4 ± 1.4 < 0.001 0/87
De Marzi et al. (2015) 0.0 (0.0 – 13.8) 0.0 (0.0 – 18.1) 0.0 (-2.0 – 8.6)
Erythema 34.0 ± 21.3 34.5 ± 21.5 0.5 ± 8.1 0.63 8/92
Dutz et al. (2019) 23.0 (17.7 – 99.0) 23.6 (17.7 – 95.9) 0.0 (-32.9 – 24.6)
Hearing loss (contra)∗ 0.0 ± 0.0 0.0 ± 0.4 0.0 ± 0.4 < 0.001 0/92
De Marzi et al. (2015) 0.0 (0.0 – 0.1) 0.0 (0.0 – 3.6) 0.0 (-0.1 – 3.5)
Hearing loss (ipsi) 4.7 ± 12.1 6.4 ± 15.5 1.7 ± 11.6 < 0.001 7/92
De Marzi et al. (2015) 0.0 (0.0 – 61.8) 0.0 (0.0 – 67.0) 0.0 (-41.6 – 65.8)
Necrosis (brain stem)∗ 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.007 0/92
Bender (2012) 0.0 (0.0 – 0.2) 0.0 (0.0 – 0.1) 0.0 (-0.1 – 0.0)
Necrosis (brain)∗ 0.1 ± 0.1 0.1 ± 0.1 0.0 ± 0.0 0.095 0/92
Bender (2012) 0.1 (0.0 – 0.3) 0.1 (0.0 – 0.3) 0.0 (-0.1 – 0.1)
Ocular toxicity (ipsi) 30.4 ± 40.6 36.0 ± 40.3 5.6 ± 26.6 < 0.001 24/91
Batth et al. (2013) 1.1 (0.6 – 99.9) 9.6 (0.6 – 99.9) 1.6 (-69.6 – 88.8)
Temporal lobe injury (contra)∗ 0.1 ± 0.1 0.1 ± 0.2 0.0 ± 0.0 < 0.001 0/92
Kong et al. (2016) 0.0 (0.0 – 0.9) 0.0 (0.0 – 1.0) 0.0 (-0.1 – 0.3)
Temporal lobe injury (ipsi)∗ 0.3 ± 0.3 0.4 ± 0.4 0.0 ± 0.2 0.044 0/80
Kong et al. (2016) 0.2 (0.0 – 1.4) 0.2 (0.0 – 1.6) 0.0 (-0.2 – 0.7)
Tinnitus (contra) 0.7 ± 2.1 2.6 ± 5.3 1.9 ± 3.8 < 0.001 3/92
Lee et al. (2015) 0.2 (0.2 – 16.9) 0.5 (0.2 – 39.6) 0.3 (-1.1 – 22.7)
Tinnitus (ipsi) 14.5 ± 23.0 17.2 ± 24.2 2.6 ± 10.6 < 0.001 13/92
Lee et al. (2015) 0.3 (0.2 – 77.1) 3.8 (0.2 – 78.9) 0.4 (-49.8 – 49.6)
Abbreviations: ON, optic nerve; ipsi, ipsilateral; contra, contralateral. ∗excluded from further analysis as maximum NTCP for both
modalities <5 %
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Figure 6.5: NTCP differences between XRT and PBT plans for different side effects. A threshold of 10
percentage points is indicated as orange line. ON, optic nerve; ipsi, ipsilateral; contra, contralateral.
alopecia and erythema showed a large spread. In general, low probabilities of developing blind-
ness (highest mean value: 1.8 % with XRT) and endocrine dysfunction (mean value: 1.8 % with
XRT) were observed. For the majority of the investigated models, the differences between XRT
and PBT predictions were statistically significant, except for acute erythema and brain necrosis.
The significance only indicates that NTCP predictions differ systematically between both modal-
ities for most side effects. However, the extent of these differences is not evaluated and should
be therefore characterised by the use of threshold values.
Of all NTCP predictions, the highest median NTCP value was estimated for delayed recall
for XRT plans (77.1 %). For PBT plans, acute alopecia had the highest median NTCP (63.2 %)
among all investigated side effects. For almost all side effects, the median difference between
NTCPPBT and NTCPXRT remained below 5 percentage points except for delayed recall (Gondi et
al., 2012). For this side effect, the median ∆NTCP was estimated to 24.8 percentage points. Ap-
plying a threshold of 10 percentage points, 51 of 78 patients (65.4 %) would have been selected
for PBT based on this side effect. In 14 patients the tumour completely affected the ipsilateral
hippocampus. Hence, it could neither be delineated, nor could the bilateral hippocampi be eval-
uated. For both ipsilateral ocular toxicity and cataract, 24 of 91 patients (26.4 %) exceeded the
threshold of 10 percentage points. For ipsilateral hearing loss, contralateral cataract and acute
erythema, only 6 to 8 of 92 patients would have been selected (6.5 – 8.7 %). No patients would
have been selected for PBT based on the predictions for blindness (Burman et al., 1991) or
endocrine dysfunction (De Marzi et al., 2015) using a threshold of 10 percentage points.
All side effects for which ∆NTCP of more than 10 percentage points was predicted in at least
five patients are depicted in figure 6.6. Here, the absolute NTCP estimates and different pat-
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Figure 6.6: NTCP predictions for XRT and PBT plans for selected side effects. The solid line represents
equal NTCP values for both treatment modalities. A threshold of 10 percentage points is indicated as a
dashed line. The percentage of patients selected for each treatment based on this threshold is given.
terns can be observed. For some side effect, the NTCP estimates were generally low for both
treatment techniques (e.g. contralateral tinnitus: NTCP < 20 % for almost all patients). For other
side effects, the estimates for both techniques were higher for all patients and both techniques
(e.g. acute alopecia: NTCP > 20 %). For cataract, the NTCP predictions for PBT were nearly
zero for the majority of patients, while a greater spread was estimated for XRT. This fact leads
to larger NTCP differences so that 26.4 % and 6.5 % of the patients exceeded the 10 percentage
points threshold for ipsi- or contralateral cataract, respectively.
For the majority of patients, the probability of developing one (32 patients) or two of the in-
vestigated side effects (30 patients) was reduced by more than 10 percentage points using PBT
instead of XRT, see table 6.7. In twelve patients, ∆NTCP did not exceed the required threshold
for any of the investigated side effects.
Table 6.7: Number of patients and side effects with ∆NTCP exceeding a threshold of 10 percentage
points. For those cases where NTCP could not be predicted due to tumour invasion of the associated
OAR, it was assumed that PBT is not more beneficial than XRT.
Side effects with ∆NTCP ≥ 10 percentage points 0 1 2 3 ≥4
Patients (%) 12 (13.0) 32 (34.8) 30 (32.6) 9 (9.8) 9 (9.8)
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The NTCP differences between both treatment modalities for the considered side effects and
each patient are presented in appendix D figure D.3. Appendix D figure D.4 shows the side effects
for which ∆NTCP exceeds a threshold of 10 percentage points for all patients.
For the two example patients, already discussed in section 6.2 and presented in table 6.4 and
figure 6.3, ∆NTCP estimates for the investigated side effects and the corresponding dosimetric
parameters are displayed in figure 6.7 for each NTCP model.
For patient 1, for only one side effect, namely delayed recall, the NTCP reduction using PBT
instead of XRT exceeded the threshold of 10 percentage points. All other ∆NTCP estimates
remained below this threshold. The probability of developing acute alopecia and erythema were
(A) Patient 1.
(B) Patient 2.
Figure 6.7: Differences of DVH parameters between the XRT and PBT plan (left panel) and associated
NTCP values for selected side effects (right panel) for two patients. The dashed line indicates a threshold
of 10 percentage points. DVH parameters with a relative difference of more than 10 % and side effects
with ∆NTCP exceeding the threshold of 10 percentage points are shaded in orange. ON, optic nerve; ipsi,
ipsilateral; contra, contralateral.
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even slightly reduced using XRT. Although the relative differences in dosimetric parameters were
more than 10 % (except for the skin), they could not be translated into a potential clinical benefit
for the majority of side effects using PBT. The absolute doses for these parameters were rela-
tively low for both treatments and are thus located in the flat initial region of the NTCP curves. As
a result, the NTCP values of both therapies hardly differ. For patient 2, the substantially reduced
dose to the lenses resulted in a large reduction of the probability of ipsilateral cataract induction
when treated with PBT instead of XRT (∆NTCP > 80 %). Additionally, the potential NTCP differ-
ence for ipsilateral tinnitus exceeded the threshold of 10 percentage points. Remarkably, that the
relative and absolute dose difference for the mean dose to the ipsilateral cochlea was quite small
(4.3 Gy(RBE) and 9.2 %). However, the small dose difference could be converted into an NTCP
reduction of more than 10 percentage points using PBT instead of XRT. In comparison, the dose
reduction in the contralateral side was substantially greater for PBT (14.3Gy(RBE) and 83.6 %).
Nevertheless, the NTCP difference for contralateral tinnitus remained below the threshold of 10
percentage points. For this patient, the probability of developing acute erythema and alopecia
would be slightly increased using PBT instead of XRT.
Differences in NTCP reduction with regard to tumour location
Median NTCP predictions for both treatment modalities as well as ∆NTCP were analysed sepa-
rately for different tumour locations, see appendix D table D.3. For the majority of side effects, the
median ∆NTCP estimates remained below 3 percentage points for the investigated tumour loca-
tions. However, for delayed recall, a much higher median ∆NTCP compared to the entire cohort
(24.8 percentage point) could be observed for patients with tumours located in the parietal (43.9
percentage point) or temporal lobe (45.4 percentage point). For patients with a tumour located in
the frontal lobe, this estimated ∆NTCP was comparable with the entire cohort (25.0 percentage
point), while for patients with a tumour located in more than one lobe, lower ∆NTCP values were
observed (10.4 percentage point). For tumours in the parietal lobe, median ∆NTCP for alopecia
(11.2 percentage point) and erythema (18.4 percentage point) were increased compared to the
entire cohort (3.0 and 0.0 percentage point, respectively).
6.3.3 Discussion
For the majority of patients and a variety of side effects, NTCP predictions were higher for XRT
than for PBT as expected, but ∆NTCP did often not exceed a threshold of 10 percentage points
for an individual side effect. However, based on the model selection in this study, a majority of
patients (87.0 %) would still have been selected for PBT if this decision would be based on a
threshold of 10 percentage points for at least one side effect. One reason for this effect is that a
variety of different side effects have been considered in this study. Furthermore, individual side
effects had a high impact on the selection process, namely delayed recall (Gondi et al., 2012). 51
of 78 patients would have been selected for PBT only because of this side effect. Moreover, no
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ranking or weighting of the clinical severity between different side effects was done. For example,
permanent ocular toxicity, ranging from conjunctivitis, keratitis, corneal ulcer, retinopathy or de-
tachment to loss of vision, might be more severe than cataract because it is possible to replace
the crystalline lens. If such a ranking of side effects should be considered for a model-based
selection, it has to be established by experienced radiation oncologists.
Although a variety of NTCP models were analysed in this study covering a wide range of po-
tential side effects that may occur following cranial RT, there may be even more side effects, for
that no NTCP model exists so far or the underlying dose-effect relationship is not yet fully un-
derstood. Especially for neurocognitive dysfunction, more reliable NTCP models than the model
for delayed recall by Gondi et al. (2012) have to be developed as it turned out to overestimate
the actual incidence as explained in detail below (Jaspers et al., 2019). This important side ef-
fect may be one of the decisive side effects for the selection of patients for PBT as it adversely
affects patients’ QoL. In the present study, 16 patients (17.4 %) would have been selected for
PBT solely based on delayed recall. In the other patients with ∆NTCP for delayed recall above
10 percentage points, at least one more side effect would have been decisive for treatment with
PBT.
Influence of tumour- and treatment-specific parameters In general, NTCP differences for
specific tumour locations did not differ from those of the entire cohort. In patients with a tu-
mour in multiple lobes, ∆NTCP for delayed recall was at least strongly pronounced. Patients
with a tumour in the parietal or temporal lobe showed particularly strong reductions in delayed
recall compared to the entire cohort. These patients might particularly benefit from PBT since
neurocognitive dysfunction is a major side effect. However, as explained in the dose-comparison
study (see section 6.2), a dedicated localisation group may include many different specific tumour
sites and therefore cannot provide a general basis for selection for PBT. Thus, it is still important
to conduct a patient-specific analysis.
As described in the dose-comparison study, the relative dose reduction in OARs achieved by
PBT is particularly prominent in contralateral structures. However, as the absolute doses in the
contralateral structures are fairly low for both techniques, both NTCP estimates also remain low,
leading to small ∆NTCP values. For ipsilateral structures, the NTCP differences were often
higher compared to contralateral structures although the relative dose differences were smaller.
Thus, a greater portion of the patients would be selected for PBT due to the ipsilateral side effects
rather than the contralateral. This effect was observed for the bilateral side effects hearing loss,
tinnitus as well as cataract.
For delayed recall, a correlation between increasing ∆NTCP values and increasing tumour
volume (CTV) (Spearman ρ = 0.78, p < 0.001) as well as increasing prescribed dose was
observed (Spearman ρ = 0.56, p < 0.001). This suggests that patients with large tumours and a
high prescription dose may benefit from PBT to a larger extent with regard to this side effect than
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others. For all other investigated side effects, such correlations (with Spearman |ρ| > 0.5) could
be observed for neither tumour volume nor prescribed dose.
When comparing ∆NTCP predictions between the subgroups treated with PBS and DS, no
significant differences were observed for alopecia, blindness (chiasm, contralateral optic nerve)
and delayed recall. For the other side effects, the benefit from using PBT instead of XRT was
increased in the group treated with PBS compared to DS for cataract, ocular toxicity, endocrine
dysfunction, ipsilateral hearing loss and tinnitus. Significantly more patients would be selected
for PBT based on a threshold of 10 percentage points for cataract (ipsilateral p < 0.001 and
contralateral, p = 0.026) and ocular toxicity (p = 0.031) in the group treated with PBS compared
to a DS treatment. However, these side effects depend largely on tumour size and location as well
as the prescribed dose. Similarly to the dose-comparison study, a comprehensive comparison
between PBT techniques requires a PBS and DS plan for each patient. This investigation was
out of the scope of this study.
NTCP model for delayed recall Of all investigated NTCP models, the model for delayed recall
on the WMS-WL at 1.5 years following IMRT (Gondi et al., 2012) predicted the largest median
difference between NTCPPBT and NTCPXRT. Based on this side effect, 65.4 % of the patients
would have been selected for PBT using a ∆NTCP threshold of 10 percentage points. A recent
study investigated the performance of this model on an external cohort of LGG patients treated
with XRT (Jaspers et al., 2019). They observed that the model predictions overestimated the
actual neurocognitive outcome measured by the Rey Verbal Auditory Learning test delayed recall
(AVLT-DR). For 22 of 29 patients, a probability for neurocognitive dysfunction of more than 99 %
was predicted. However, only 7 patients were found to have a decline. They explained this by
the fact that the model was developed for a narrow dose range, but was extrapolated to a larger
dose range during validation. Figure 6.8 shows the NTCP model for delayed recall and the dose
range for that it was developed on. As the steep part of the NTCP curve is located in a narrow
dose range up to 30 Gy, dose differences between both treatment techniques in this dose range
lead to large NTCP differences. In contrast to this model, the NTCP model for tinnitus grade ≥ 2
is also depicted in figure 6.8 (Lee et al., 2015). This model was developed within a broad dose
range up to 60 Gy. The slope of the NTCP curve is much shallower than of the NTCP model for
delayed recall. Special care should be taken when using NTCP models outside the dose range
in which they were developed.
Selection of appropriate thresholds In the present study, a ∆NTCP threshold of 10 percent-
age points above which a patient would be selected for PBT was applied to all NTCP models.
Langendijk et al. (2018) proposed this threshold for side effects grade 2 that may occur after
head and neck RT. As some NTCP models included in this study predicted side effects of grade
≥ 2 and no further suggestions had been available for the NTCP model predicting delayed recall,
this specific threshold was chosen. Delayed recall was not measured on a Likert-scale as it is
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Figure 6.8: Applied NTCP models for delayed recall (Gondi et al., 2012) and tinnitus (Lee et al., 2015).
Dose ranges for which the respective NTCP models were developed are shaded in grey.
the case for other measures such as CTCAE. As the number of patients selected for PBT based
on delayed recall was 65.4 %, the applied threshold may be disputable. Figure 6.9 shows the
patient selection distribution for different ∆NTCP thresholds for delayed recall. An increase of
the threshold to 20 or 30 percentage points would reduce the number of patients selected for
PBT to about 57.7 % and 43.6 %, respectively. This demonstrates that a comprehensive analysis
of the potential NTCP reduction should be conducted before the implementation of the model-
based approach in clinical practice. Similar plots are depicted for the remaining investigated
NTCP models in appendix D figure D.5. As NTCP models were derived from physician-rated
side effects recorded on different scoring systems (CTCAE, RTOG or LENT-SOMA) it should be
investigated whether the threshold suggestions based on the CTCAE scale are also reasonable
for other scoring systems.
Figure 6.9: Patient selection for PBT based on the NTCP model for delayed recall for different thresholds
(Gondi et al., 2012). The applied threshold of 10 percentage points is shaded in orange.
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Time-dependence of the onset of side effects The present study included NTCP models of
both acute and late side effects. Figure 6.10 shows the time spans for the occurrence of these
side effects that were endpoints of the considered NTCP models. For patients with a short life
expectancy (e.g. HGG), acute side effects may be more important to maintain QoL as long as
possible than side effects that have an onset after several years. In contrast, patients with a
long life expectancy (e.g. benign tumours) may experience late side effects as more burdensome
than potential transient early side effects. The curves in figure 6.10 symbolise exemplarily the
de- and increasing importance of different side effects for both patient groups. Consequently, the
different NTCP predictions could be weighted with a time-dependent weighting factor with regard
to the life expectancy. This could alter patient selection according to the model-based approach.
The development of such weight functions for different patient groups should be done in close
collaboration with physicians.
Re-irradiated patients The study included six patients that received re-irradiation with PBT.
For these patients, PBT may have been chosen because the normal tissue has already been
affected by the previous irradiation assuming that the steep dose gradient in PBT could better
spare this exposed tissue. However, since the model-based approach is intended to be used
for all patients without standard indications for PBT, re-irradiated patients were also considered
in this study. Results of the analysis for all patients without re-irradiation are presented in ap-
pendix D figures D.6 and D.7. The proportion of patients selected and the other conclusions
barely change. In these six patients, the first irradiation was at least two years, but in most pa-
tients even five years prior to PBT, so that early reactions had completely subsided. It has been
shown, that the skin regains the primary tolerance threshold for acute skin reactions. In studies
on re-irradiated patients with head and neck cancer, breast cancer and others, acute skin re-
actions were within the same range as those at first irradiation (Nieder and Langendijk, 2016).
Figure 6.10: Importance of side effects for patients with different life expectancies. Observation time
spans of various side effects underlying the investigated NTCP models are displayed as bars. The curves
symbolise exemplary weight functions representing the de- and increasing importance of certain side
effects for both patient groups.
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Thus, it seems appropriate to use models for early alopecia and erythema even for re-irradiated
patients. Late side effects associated with re-irradiation of the brain are difficult to assess, as
not even data from animal experiments are available. Moreover, depending on the blood supply
of different brain areas, the toxicity risk may also differ. It is generally assumed that late side
effects will persist for many years after the treatment. However, there is limited knowledge about
re-irradiation tolerance for several important late effects, including neurocognitive or endocrine
dysfunction (Nieder and Langendijk, 2016). To predict the complication risk of an individual pa-
tient for choosing an optimal treatment strategy, validated NTCP models for re-irradiation would
be required. However, developing such models will be even more difficult than those for initial
RT treatment. First, fewer patients may be eligible compared to first-course treatment, which
limits the cohort size. Furthermore, additional parameters are needed to characterise the pre-
irradiation, such as the dose of the initial irradiation, the time interval between both RT courses
and concomitant systemic therapies (Eekers et al., 2016).
Radiation-induced brain necrosis In this study, the probability of the induction of brain or brain
stem necrosis was estimated to be comparatively low with a maximum NTCP value of 0.3 % for
both techniques based on the model by Bender (2012), which was derived from XRT data. Devel-
opment of NTCP models for radiation-induced necrosis is demanding as a distinct differentiation
of necrotic tissue from tumour progress is challenging as discussed in section 4.3.2.
Whether the models developed based on XRT data can also be utilised in PBT, is questionable.
Although radiation-induced necrosis is a rare side effect, reports of brain stem necrosis after PBT
indicate possible biological differences between XRT and PBT (Haas-Kogan et al., 2018). For
proton beams, both LET and RBE are variable and increase in the distal edge of the spread-out
Bragg-Peak leading to enhanced biological effects (Paganetti, 2014; Lühr et al., 2018). There
is a growing interest in investigating the influence of LET and RBE on the treatment to estimate
the development of contrast-enhancing lesions that may evolve into necrotic brain regions (Eulitz
et al., 2019a; Eulitz et al., 2019b). Since brain necrosis is such a severe side effect, it should
definitively be considered when applying the model-based approach, as soon as these models
exist and are validated. Due to the severity of this side effect, a rather low threshold value should
be applied.
The effect of increased biological effectiveness could of course also affect other side effects
besides brain necrosis. This would require the validation of existing XRT models on PBT patients.
However, this was not feasible in the context of the study. The published photon-derived models
predicted side effects that on the one hand were not recorded in the PBT trials used in this thesis
(DRKS00004384, 2012; DRKS00007670, 2015; DRKS00008569, 2015; NCT02824731, 2016)
or on the other hand the follow-up time within these PBT trials was still too short. And vice-versa,
for the applied proton-derived models, there was no outcome data of patients treated with XRT
available for validation.
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Competing side effects So far, the model-based approach assumes that the use of PBT in-
stead of XRT will reduce the occurrence of side effects. This assumption is based on dosimetric
plan comparisons and only the extent of the expected reduction is regarded for a patient to be
treated with PBT. However, it should be discussed whether PBT might not also intensify some
side effects. This effect may even be enhanced when considering LET and RBE variations of
PBT. Negative threshold values in favour of XRT could be defined. Consequently, competing
side effects have to be considered, e.g. PBT may reduce the probability of one side effect while
potentially increasing that of another side effect.
Treatment planning approaches For both, PBT and XRT plans, a patient individual beam
arrangement was used according to clinical practice. Besides the selection of the beam ar-
rangements, the objectives, as well as their weightings during treatment plan optimisation, have
an important impact on the final dose distribution. The different prioritisation of several OARs
depending on the severity of the associated side effects may lead to bias. In both treatment
modalities, a high priority – even higher than target coverage – was given to the avoidance of
high-dose areas in the brain stem to prevent necrosis. Hence, almost no difference between PBT
and XRT was seen in the NTCP values for brain stem necrosis with the applied NTCP models.
Differences in the prediction of side effects are most likely to be achieved for those side effects for
which the severity of their occurrence is of minor importance compared to the target coverage,
e.g. cataract. This also applies to OARs for which clinical dose constraints have not yet been
specified and which are therefore not yet considered in treatment planning. So far, treatment
plan optimisation mainly includes physical dose parameters focusing on OARs for which well-
established dose constraints exist. Furthermore, most often only these structures are delineated
in clinical routine.
With the availability of intensity-modulated RT techniques, highly conformal dose distributions
can be achieved that can be much more adapted compared to 3D-CRT techniques. One ap-
proach to account for this development is biological treatment planning. In addition to physical
optimisation parameters, biological optimisation parameters are included in the objective func-
tion. The most common biological optimisation parameters are based on gEUD depending on
the tissue-specific parameter a (Niemierko, 2006). It has been shown that intensity-modulated
treatment plans, generated by biological optimisation parameters, lead to an improved sparing of
normal tissue compared to objective functions with conventional physical dose-volume parame-
ters (Qi et al., 2009). This seems to be a promising approach to reduce side effects. Neverthe-
less, caution is required when selecting adequate models and tissue-specific model parameters,
as valid models are not yet available for all tumour types and side effects. Moreover, model un-
certainties are not considered during biological optimisation (Qi et al., 2009). Another approach,
which goes one step further than just using gEUD, directly incorporates multivariable NTCP
models in the objective function (Kierkels et al., 2014). Provided that reliable NTCP models are
available, the identification of optimal planning objectives could be simplified. Such personalised
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and automated optimisation could make the creation of comparison plans more efficient (Wu
et al., 2003). This, in turn, could lower the inhibition threshold for introducing the model-based
approach in clinical practice, as in silico plan comparison is very time-consuming.
Limitations Since the comparison of the NTCP values is based on the underlying treatment
plans, all limitations of the treatment plan comparison also apply here, see section 6.2. Addi-
tionally, there are further limitations regarding the NTCP models and their selection described
below.
All dosimetric parameters and NTCP predictions were calculated based on the planned dose
distribution and nominal model coefficients. The uncertainties of each model coefficient as well as
differences of nominal dose to delivered dose were not considered in this study. However, model
and dose uncertainties may influence the accuracy of the selection process. Since treatment
decision is taken before treatment, model-based patient selection is based on the planned dose
rather than the accumulated delivered dose. The planning CT is only a single snapshot that is not
representative of the anatomical situation during every treatment fraction. For OARs with small
volumes, such as lens, cochlea or lacrimal gland, slight positioning errors can lead to deviations
of the delivered dose from the planned dose, which in turn, may alter the probability of associated
side effects as estimated from the planned dose distribution. To evaluate dose uncertainties prior
to PBT, robust treatment plan optimisation or analyses can be performed. Both methods consider
positioning as well as calculation uncertainties caused by the conversion of CT numbers to mass
stopping power.
Bijman et al. (2017) evaluated the model-based patient selection for three different NTCP mod-
els on a cohort of 78 patients with oropharyngeal cancer. They calculated nominal NTCP differ-
ences for an IMRT and a PBT plan based on the initial planning dose distributions and nominal
model coefficients. Additionally, the effects of uncertainties in the model coefficients and differ-
ences from delivered to planned dose were investigated by a sampling of model coefficients and
doses from their probability distribution. Selection accuracy defined as the fraction of consistent
selections in both the nominal and sample scenarios were about 70 % for NTCP model uncer-
tainties only. It further decreased by excessive dose uncertainties. For patients with head and
neck cancer, both tumour and OARs may change remarkably during treatment due to tissue re-
sponses such as tumour shrinkage or tissue swelling (Barker et al., 2004). Therefore, differences
between planned and delivered doses are common in head and neck patients, which adaptive RT
is intended to compensate. Brain tumour patients may be less prone to these variations. How-
ever, tissue changes close to the resection cavity might be considered for post-operative patients
(Kim and Lim, 2013).
Besides dose and model coefficient uncertainties, the NTCP models developed at other institu-
tions are subject to further uncertainties such as differences in treatment techniques, delineation
guidelines, scoring of side effects or patient population. The patient population may differ with
regard to tumour histology and location. In this treatment planning study, a VMAT technique was
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applied as a state-of-the-art XRT technique. However, the investigated NTCP models are de-
rived from different techniques including 3D-CRT or IMRT, as the available treatment techniques
changed rapidly during the last decades. Different XRT techniques may alter the predictions of
the NTCP models (Christianen et al., 2012).
Differences in the treatment fractionation schemes were corrected using EQD2 values, for ex-
ample in the model predicting brain necrosis by Bender (2012). Different scoring systems are
used at different centres to assess radiation-induced side effects (e.g. CTCAE, RTOG or LENT-
SOMA). Severity grades may vary depending on the systems used (Höller et al., 2003). Moreover,
the interobserver variability among clinicians can be rather high, especially when monitoring sub-
jective symptoms such as pain, nausea or fatigue (Brundage et al., 1993; Neben-Wittich et al.,
2011).
Another important uncertainty arises from variations in the delineation of OARs. Associated
dosimetric parameters are affected, which in turn modifies the predictions of the NTCP models
(Brouwer et al., 2014). Although standardised delineation guidelines were used in this study, it
remains unclear which guidelines have been used to contour the OARs included in the applied
published models. The issue of potentially different structures is likely to arise if the models are
not generated from one cohort but from several data sets, such as the model for brain necrosis
(Bender, 2012). However, such studies cover a large variability, which nevertheless occurs in
everyday clinical practice. To reduce contouring variability, consistent use of delineation guide-
lines and atlases is essential. Additionally, the implementation of auto-contouring tools could be
considered (Vinod et al., 2016). These tools are currently being further improved, e.g. by deep-
learning-based segmentation approaches (van der Heyden et al., 2019; van Dijk et al., 2020).
Besides reducing the delineation time, auto-contouring can also facilitate the segmentation of
additional OARs. These could be used in NTCP modelling to investigate unknown relationships
between dose to these structures and side effects such as neurocognition.
In everyday clinical practice, existing NTCP models have to be used, since it is not feasi-
ble for an institute to generate its own models for all possible side effects, patient subgroups
and histologies, treatment techniques, concomitant therapies, uniform contouring, fractionation
schemes and available long-term follow-up, etc. However, the existing models should be vali-
dated on centre-specific data, if possible. This requires a continuous long-term scoring of side
effects, with the same tests and scoring systems that were used for model creating. Prior to the
implementation of a model-based patient selection for PBT, a comprehensive analysis of side
effects and existing models is necessary.
In this thesis, available NTCP models were evaluated for a variety of side effects, although
they did not reach the highest level of the TRIPOD classification, see appendix A table A.3.
This is because validated models for adverse effects after cranial RT with modern techniques
are scarce. It was not possible to validate either the XRT or the PBT models investigated. For
example, the clinical outcome data of the patients enrolled studies used for this thesis were
recorded by different scoring systems than in the investigated published models. Moreover, the
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follow-up time was too short to detect late side effects. No clinical outcome data were available
for similar cohorts treated with modern XRT techniques. Although NTCP differences rather than
absolute values were evaluated in this study, the presented results provide only an estimate of
the potential probability of side effects and should therefore be interpreted with caution.
Induction of secondary malignancies is a rare complication of RT with long latency between
treatment and onset. The probability of developing a radiation-induced secondary tumour de-
pends on the type of tissue, the dose and irradiated volume as well as the age of the patient
(Prasad and Haas-Kogan, 2009; Schneider, 2011). As children are considered more radiosen-
sitive than adults while having a longer life expectancy, retrospective analyses were mainly con-
ducted in paediatric populations treated with outdated RT techniques due to the long time be-
tween irradiation and onset of the secondary tumour. One of these studies investigated sec-
ondary malignancies in patients treated for childhood cancer. Interestingly, one-third of the sec-
ondary tumours were located in areas receiving very low doses < 2.5 Gy (Diallo et al., 2009).
This is of particular concern for modern intensity-modulated XRT techniques, as they deliver rel-
atively high distant peripheral doses compared to 3D-CRT or PBT (Klein et al., 2006). For adults,
the data situation is even more limited. Available data are derived from atomic bomb survivors,
nuclear industry workers, clean-up workers after the Chernobyl nuclear accident or adults after
repeated CT imaging (Prasad and Haas-Kogan, 2009). Models based on these data were devel-
oped mainly for radiation protection and are based on lower doses than those applied during RT
treatment and should therefore not be applied for risk estimates in RT. Since fractionation affects
carcinogenesis, better models include cell repopulation between dose fractions. However, the
uncertainties are still very large for most tissues as the underlying processes are not well under-
stood (Schneider, 2011). As RT is part of the standard treatment of patients with brain tumours,
it is very challenging to find cohorts that compare irradiated and non-irradiated adults (Prasad
and Haas-Kogan, 2009). Since there are practically no models appropriate for secondary tu-
mours after cranial irradiation, they were not evaluated in this study. Moreover, for HGG patients,
secondary malignancies may play a minor role due to the limited life expectancy.
The patients included in this study cover a wide range of tumour histologies and locations. How-
ever, some tumour histologies (e.g. high-grade meningioma) and tumour locations (e.g. occipital)
were underrepresented. For patients with a tumour in the skull base, additional OARs may be
relevant, for example, salivary glands. These OARs were considered during treatment planning
for both modalities according to the dose constraints at each centre, see appendix B tables B.4
and B.5. However, they were not contoured for all patients enrolled in this study, as for the ma-
jority of brain tumour patients, the salivary glands would be exposed to zero or very low doses. If
the model-based approach would be applied to this patient subgroup further NTCP models could
be considered, for example, xerostomia after irradiation of the parotid gland (Beetz et al., 2012c).
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6.4 Summary
The present study showed, that cranial PBT can achieve a substantial relative dose reduction
compared to XRT in a variety of OARs, especially in contralateral organs. However, if the dose in
contralateral structures is quite low for both modalities, the large relative dose reduction may be
less clinically relevant. Thus, treatment decisions based on dosimetric plan comparisons have
to consider relative and absolute dose differences as well as the absolute dose value. A model-
based selection of patients for PBT is based on NTCP predictions for both modalities. For the
majority of patients and a variety of side effects, NTCP predictions were higher for XRT than for
PBT, but the NTCP differences did often not exceed a threshold of 10 percentage points for an
individual side effect. However, based on the model selection in the presented study, a majority of
patients would still have been selected for PBT if the treatment decision would be based on this
threshold value for at least one side effect. The available NTCP models for side effects following
cranial RT should be used with caution in clinical practice as they are subject to a variety of
uncertainties and limitations. One of the most decisive side effects for the treatment modality
decision may be neurocognitive dysfunction. Thus, future studies on XRT and PBT should focus
on comprehensive testing of neurocognition to develop valid NTCP models for this side effect.
For extensive data collection, electronic medical charts and structured databases are essential.
Prior to the application of NTCP models for treatment decision, the applied thresholds should be
examined intensively by conducting dose and NTCP comparing studies.
The presented feasibility study underlines that physical dose-volume parameters or metrics
alone may not be sufficient to describe the clinical relevance between different treatment plans
and techniques. However, physical parameters have the advantage of being determined with
relatively high accuracy. To estimate the clinical impact of the dosimetric differences, NTCP
models may be more appropriate. The major limitations of this approach, however, are the model
uncertainties which add to the dosimetric uncertainties. In order to reduce these uncertainties,
further NTCP models for different modern treatment techniques or even re-irradiated patients are
needed, allowing the radiobiological approach to demonstrate its validity in clinical practice.
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Radiotherapy is an essential component in the treatment of patients with intracranial tumours.
Compared to XRT techniques, PBT offers the possibility to reduce the integral dose and the
volume of healthy tissue irradiated with low and intermediate doses due to the physical properties
of protons. Although the number of PBT centres is still increasing, their capacity remains limited
due to the high personnel, technical and therefore financial expenditure. Thus, patients need to
be identified that may benefit most from treatment with PBT. Dosimetric comparisons suggest that
PBT may be beneficial in two different aspects. First, dose could be escalated in radioresistant
tumours, increasing tumour control while keeping potential side effects at a level comparable to
non-escalated XRT regimes, e.g. in some lesions in the skull base. Second, a reduction in long-
term side effects could be expected at the same tumour coverage compared to XRT, since the
healthy tissue surrounding the tumour is less affected. However, up to now, there are no data
from RCTs available that demonstrate the superiority of PBT over modern XRT in brain tumour
patients.
In Germany, the reimbursement of costs varies between health insurance companies. Some
conduct individual case examination, while others have agreements with single PBT facilities for
specific tumour entities. In other European countries, the allocation of limited PBT capacities
among patients that are likely to benefit from PBT is organised differently. In the Netherlands, the
nationwide model-based approach has been implemented by the National Health Care Institute.
For patients that are considered to benefit most from PBT according to the model-based selection
procedure, the costs of PBT will be reimbursed irrespective of the health care insurance company
(Langendijk et al., 2018).
In this thesis, it was investigated whether the model-based approach, which has so far mainly
been used for head and neck cancer patients, can be extended to patients with intracranial tu-
mours. For this purpose, data from a total of 305 patients diagnosed with LGG, HGG, menin-
gioma and other benign tumours, were evaluated. All patients were treated with PBT at one of
three different PBT facilities. NTCP models for acute and late physician-rated side effects fol-
lowing cranial PBT have been developed and externally validated. Dose-volume parameters of
the skin characterising high doses were associated with early alopecia grade ≥ 2 and erythema
grade ≥ 1. Validation confirmed that the presented dose-volume parameters were strongly as-
sociated with these endpoints for all investigated cohorts, but the calibration differed. Thus,
centre-specific differences in toxicity assessment should be considered carefully. Late alopecia
grade ≥ 1 was also associated with high dose-volume parameters of the skin while late hearing
impairment grade ≥ 1 was related to cochlear mean doses. Additionally, in analyses of pooled
data from the three PBT centres, dose-response relations between late physician-rated memory
impairment and the dose to the remaining brain and the hippocampi as well as late fatigue and
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dose to the brain stem were observed. Due to the relatively low incidence rates and low severity
grades of late side effects, NTCP models could only be developed for mild forms. In a model-
based approach for PBT patient selection, however, only models that predict side effects of grade
≥ 2 would be considered (Langendijk et al., 2018). Dose-response relationships for alopecia and
dry eye syndrome of grade ≥ 2 were found in GEE analyses, but they still need to be validated
externally.
The preservation of neurocognitive function after RT is an important aim of treatment, as this
side effect may considerably reduce patients’ quality of life. Hence, the neurocognitive function
up to two years after cranial PBT was investigated in this thesis. Self-reported and objectively
measured neurocognitive function (MoCA test) and most QoL domains remained largely sta-
ble over time during recurrence-free follow-up after PBT. Slight deterioration of the MoCA score
was associated with an increased relative volume of the irradiated anterior cerebellum exposed
to doses of 30 to 40 Gy(RBE). Larger studies, such as the ongoing comparative clinical trials
(NCT02824731, 2016; NCT03180502, 2017), may allow for validation of these findings, devel-
opment of NTCP models and a direct comparison of neurocognitive changes between patients
treated with either cranial PBT or XRT.
An integral part of the model-based patient selection for PBT is an in silico treatment plan
comparison between a photon and proton treatment plan to estimate the potential benefit of
PBT over XRT for an individual patient. In this thesis, a comparison of PBT and VMAT plans
was conducted for 92 patients. Additionally, the created treatment plans and eleven published
NTCP models predicting different side effects were used to investigate the feasibility of the model-
based approach for patients with intracranial tumours. It was observed that PBT can achieve a
substantial relative dose reduction compared to XRT in many OARs, especially in contralateral
organs. However, if the absolute dose in contralateral structures is quite low for both modalities,
the large relative dose reduction may be of less clinical relevance. Thus, treatment decisions
based on dosimetric plan comparisons have to consider relative and absolute dose differences
as well as the absolute dose value. Corresponding to these dosimetric results, NTCP predictions
for the majority of patients and a variety of side effects were higher for XRT than for PBT, but
often their difference did not exceed a threshold of 10 percentage points. However, since several
models have been investigated, the majority of patients would finally have been selected for
PBT if treatment decision was based upon a 10 percentage point threshold for at least one side
effect. It is obvious that the number of selected patients for PBT largely depends on the applied
thresholds for NTCP reduction. To avoid heterogeneity in clinical trials selecting patients for PBT
according to the model-based approach, the thresholds have to be consistent inter-institutional
(Grau, 2013).
Furthermore, patient selection highly depends on the created treatment plans for both RT
techniques. Often, treatment plan quality greatly varies between institutions or planners (Das
et al., 2008; Nelms et al., 2012a; Tol et al., 2014; Das et al., 2017). In the future, automated
planning systems enabling standardised planning may be used for this purpose, such as Rapid-
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Plan™(Varian Medical Systems, Palo Alto, CA). These knowledge-planning solutions could also
improve the clinical implementation of the model-based patient selection, as two treatment plans
for each patient are required (Delaney et al., 2017). Comparisons of PBT patients with a histor-
ical cohort of photon therapy patients should be treated carefully, as photon RT techniques are
still evolving.
The presented feasibility study underlines that physical dose-volume parameters alone may not
be sufficient to describe the clinical relevance between different treatment plans and techniques.
To estimate the clinical impact of dosimetric differences, NTCP models may be more appropriate.
However, physical parameters have the advantage of being determined with relatively high accu-
racy (depending on dose algorithm, positioning and contouring accuracy, etc.), while for NTCP
predictions, comparatively large model uncertainties add to dosimetric uncertainties. Even with
validated models, these uncertainties may strongly influence the accuracy of patient selection
(Bijman et al., 2017). To reduce these effects, further NTCP models for different modern treat-
ment techniques are needed, allowing the radiobiological approach to demonstrate its validity in
clinical practice.
Further perspectives
The introduction of the model-based approach for the selection of patients with intracranial tu-
mours for PBT into clinical practice requires further detailed investigations. To calibrate or de-
velop new NTCP models, large prospective clinical trials comprising patients of different treatment
modalities need to be conducted. Reliable NTCP models require additional high-quality toxicity
data including extensive pre- and post-treatment testing, such as endocrine function tests or au-
diograms to measure hearing ability. Comprehensive standardised test batteries should be used
to assess neurocognitive dysfunction. In contrast to physician-rated side effect assessment, such
tests are not subject to interobserver variability and may therefore be more precise. But since
they are considerably more time-consuming than a physician’s evaluation, it should be focused
on the most decisive side effects. To reduce the required time and manpower, larger follow-up
intervals could be performed for a follow-up of several years, e.g. biannually or even yearly for
extended testing procedures for neurocognitive function. In multi-centre studies, it should be
ensured that all participating centres have the same follow-up intervals.
Other alternatives to physician-rated study endpoints or objective measures are QoL measures.
Although these are highly subjective, they reflect the actual condition of the patient without inter-
pretation by a physician. Detailed follow-up may also comprise specific questionnaires to address
the subjective perception of neurocognitive function, e.g. the FACT-Cog questionnaire.
Prospective electronic recording of side effects (and their absence) as well as patient and
treatment-specific information such as comorbidities, medication, clinical cofactors and years of
education, is important to access and combine these data with imaging data and RT treatment
parameters easily.
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In addition to the collection of extensive outcome data, a precise determination of the dose-
volume parameters is important for NTCP modelling. This also includes consistent contouring
of the OARs to be examined. To reduce contouring variability between physicians, consistent
use of delineation guidelines and atlases is essential. Additionally, the implementation of auto-
contouring tools could be considered (Vinod et al., 2016). These tools are currently being further
improved, e.g. by deep-learning-based segmentation approaches (van der Heyden et al., 2019;
van Dijk et al., 2020). Besides reducing the delineation time, auto-contouring can also facilitate
the segmentation of additional OARs. These could be used in NTCP modelling to investigate
unknown relationships between dose to these structures and side effects such as neurocognitive
function.
Machine learning approaches have been widely used for survival data analysis based on imag-
ing data in the field of radiation oncology (Parmar et al., 2015; Leger et al., 2017). It has been
proposed to extend these methods to normal tissue response by combining features describing
the dose distributions (dosiomics), image features of the OARs (radiomics), genetic variations
leading to alterations in radiosensitivity (genomics) and biomarkers characterising inflammatory
reactions as well as clinical characteristics (Alsner et al., 2008; El Naqa et al., 2009; Lambin et
al., 2013b; Gulliford, 2015; Dean et al., 2017; El Naqa et al., 2017; El Naqa et al., 2018; Gabryś
et al., 2018). Several models using machine learning techniques have been developed to predict
different side effects such as genitourinary and gastrointestinal toxicity (Pella et al., 2011; Ospina
et al., 2014), radiation-induced pneumonitis (Chen et al., 2007; Valdes et al., 2016) or xerostomia
(Buettner et al., 2012; Gabryś et al., 2018). With these approaches, different challenges of NTCP
modelling, such as a large number of possible predictors, varying follow-up times, group imbal-
ance due to low incidence rates, and heterogeneous and noisy data, could be handled (Gabryś
et al., 2018). However, new challenges are arising, such as the choice of classifier and feature
selection algorithms, as they may impact the predictive performance of the models. As these ad-
vanced modelling techniques are less transparent, it may be more difficult to implement them in
clinical planning routines. In the future, machine learning could offer new perspectives for NTCP
modelling but still requires high-quality input data as with classical NTCP modelling. However,
to benefit from machine learning algorithms compared to normal logistic regression approaches,
much larger patient cohorts are needed, since no advantage has been demonstrated for small
patient cohorts so far (Gabryś et al., 2018).
In addition to physician-rated side-effects, further objective radiation-induced effects on MR im-
ages could be assessed during follow-up. Although MR image changes do not necessarily reflect
the clinical condition of the patient, focal image changes may develop into radiation-induced brain
necrosis, a severe side effect. The development of NTCP models for radiation-induced necrosis
is challenging because a clear distinction between necrotic tissue and tumour progression is dif-
ficult and makes the definition of the modelling endpoint complex. As necrosis occurs as very
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local single or multifocal lesions, it is difficult to define a dedicated OAR for modelling. Radiation-
induced enhancing foci were observed in the periventricular region (Shah et al., 2012; Eulitz et
al., 2019a), and this area may be delineated routinely in the future to develop and validate models
based on this structure. Although radiation-induced necrosis is a rare side effect, reports of brain
necrosis after PBT indicate possible biological differences between XRT and PBT (Haas-Kogan
et al., 2018). As this endpoint can be so severe for the patient, it should be considered in a
model-based approach in the future.
In clinical practice, RBE is so far considered constant, although it is known that in proton beams
both LET and RBE are variable and increase at the distal edge of the spread-out Bragg peak
(Paganetti, 2014; Lühr et al., 2018). For treatment plans with several beam directions, LET/RBE
may superimpose and further increase in the overlap area leading to enhanced biological effects.
These effects may be pronounced in intensity-modulated PBT due to highly altered LET and RBE
values (Haas-Kogan et al., 2018). In future, the development of NTCP models for PBT could not
only consider the physical dose distribution (weighted with the constant RBE factor of 1.1.) but
also LET or RBE distributions.
It can be concluded from this thesis that the introduction of the model-based approach for the
selection of patients with intracranial tumours for PBT is feasible. However, some effort is still
required for its implementation. In a nutshell, the following steps should be realised in the future:
• Careful selection of clinically most relevant side effects to be considered in a model-based
approach; in particular: choice of rather objectively measurable side effects, such as neu-
rocognitive function with extensive test batteries and relevant changes on MRI (severe brain
necrosis) as well as the selection of subjective QoL endpoints
• Long-term studies including these side effects as well as distinctive endpoints (and thus
also tests and grading systems) of published NTCP models for calibration or validation
• Extension of the follow-up intervals (e.g. biannually) to ensure practical implementation
• Electronic recording of all patient- and treatment-relevant parameters and endpoints
• Determination of appropriate ∆NTCP threshold values for the selected NTCP models, de-
pending on available PBT capacities
This thesis has highlighted that the extent of clinical benefits may vary greatly on a patient-
individual level. By developing different NTCP models and investigating neurocognitive function
following PBT, this thesis provided a basis for future studies on treatment selection enabling the
best possible patient care.
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8 Zusammenfassung
Hintergrund
Die Strahlentherapie ist ein wesentlicher Bestandteil der Behandlung von Patienten mit intrakra-
niellen Tumoren. Im Vergleich zur konventionellen Photonentherapie bietet die Protonentherapie
aufgrund der physikalischen Eigenschaften von Protonen die Möglichkeit, das Volumen des ge-
sunden Gewebes, das mit niedrigen und mittleren Dosen bestrahlt wird, zu reduzieren. Anhand
dosimetrischer Vergleiche lassen sich potentielle Vorteile der Protonentherapie im Vergleich zur
Photonentherapie ableiten. Beispielsweise könnte bei gleicher Tumorerfassung eine Reduktion
der Langzeitnebenwirkungen erwartet werden, da das gesunde Gewebe im Vergleich zur Pho-
tonentherapie weniger stark belastet wird. Bislang liegen jedoch keine Daten aus randomisierten
Studien vor, die eine Überlegenheit der Protonentherapie gegenüber modernen Photonenthera-
pietechniken bei Hirntumorpatienten nahelegen würden. Obwohl die Zahl der Protonentherapie-
zentren weiter steigt, bleiben ihre Kapazitäten aufgrund des hohen technischen, personellen und
damit finanziellen Aufwands begrenzt. In Deutschland hängt die Kostenerstattung für eine Pro-
tonentherapie primär von den Krankenkassen ab, während in anderen europäischen Ländern die
limitierten Protonentherapieplätze landesweit zentral verteilt werden. In den Niederlanden wurde
der modellbasierte Ansatz zur Auswahl der Patienten, die am meisten von einer Protonentherapie
profitieren können, vorgeschlagen und umgesetzt. Dabei werden anhand von Modellen die Wahr-
scheinlichkeiten für Normalgewebskomplikationen (NTCP) eines Protonen- und eines Photonen-
therapieplans für jeden Patienten individuell abgeschätzt. Liegt die potentielle NTCP-Reduktion
des Protonentherapieplans über einem definierten Schwellwert, z.B. 10 Prozentpunkte, wird der
Patient anhand dieses Bestrahlungsplans mit Protonen behandelt. Allerdings existieren bisher
nur wenige dieser obligatorischen NTCP-Modelle für verschiedene Nebenwirkungen nach kra-
nialer Strahlentherapie, insbesondere für die Protonentherapie.
Fragestellung
Im Rahmen dieser Arbeit wurde untersucht, inwieweit der modellbasierte Ansatz, der bisher vor
allem für Patienten mit Kopf-Hals-Tumoren verwendet wurde, auf Patienten mit intrakraniellen
Tumoren ausgedehnt werden kann. Zu diesem Zweck wurden verschiedene NTCP-Modelle für
Früh- und Spätnebenwirkungen entwickelt und extern validiert. Bei Hirntumorpatienten stellt au-
ßerdem der Erhalt der neurokognitiven Funktion nach einer Strahlentherapie ein wichtiges The-
rapieziel dar, da diese Nebenwirkung die Lebensqualität der Patienten erheblich beeinträchtigen
kann. Daher wurde die neurokognitive Funktion von Patienten, die mit kranialer PBT behandelt
wurden, untersucht, um mögliche Dosis-Wirkungs-Beziehungen zu erkennen. Als integraler Be-
standteil des modellbasierten Ansatzes wurde ein patientenindividueller Planvergleich durchge-
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führt, um den potenziellen Nutzen der Protonentherapie gegenüber der Photonentherapie abzu-
schätzen.
Material und Methoden
Es wurden Daten von insgesamt 305 Patienten ausgewertet, bei denen niedrig- oder hochgradi-
ge Gliome, Meningiome oder andere gutartige, intrakranielle Tumoren diagnostiziert wurden. Alle
Patienten wurden in einem von drei verschiedenen Protonentherapiezentren behandelt. Diver-
se NTCP-Modelle für akute und späte Nebenwirkungen wurden mittels logistischer Regression
anhand klinischer Nachsorgedaten sowie dosimetrischer Parameter assoziierter Risikoorgane
erstellt. Diese Modelle wurden extern validiert. Die neurokognitive Funktion bis zu zwei Jahre
nach kranialer Protonentherapie wurde mit Hilfe von Fragebögen zur subjektiven Lebensquali-
tät und dem objektiven Montreal Cognitive Assessment (MoCA) Test untersucht. Veränderungen
der neurokognitiven Funktion wurden mit dosimetrischen Parametern verschiedener Hirnstruktu-
ren in gemischten Modellen analysiert. Ein Vergleich von Protonen- mit Photonentherapieplänen,
die mit einer volumenmodulierten Technik erstellt wurden, wurde bei 92 Patienten durchgeführt.
Zusätzlich wurde anhand dieser Behandlungspläne sowie elf veröffentlichter NTCP-Modelle für
verschiedene Nebenwirkungen die Realisierbarkeit des modellbasierten Ansatzes für Patienten
mit intrakraniellen Tumoren untersucht.
Ergebnisse
Frühe Alopezie Grad ≥ 2 und Erytheme Grad ≥ 1 waren mit Dosis-Volumen-Parametern der
Haut assoziiert, die den Hochdosisbereich charakterisieren. Die Validierung der Modelle bestä-
tigte, dass diese Dosis-Volumen-Parameter bei allen untersuchten Patientenkohorten stark mit
diesen Endpunkten assoziiert waren. Da sich jedoch Abweichungen in der Kalibrierung zeigten,
sollten zentrumsspezifische Unterschiede in der Bewertung und Vorhersage von Nebenwirkungs-
wahrscheinlichkeiten sorgfältig berücksichtigt werden. Späte Alopezie Grad ≥ 1 war ebenfalls
mit Hochdosisparametern der Haut assoziiert, während späte Hörminderungen Grad ≥ 1 mit
der mittleren Dosis der ipsilateralen Cochlea in Verbindung standen. Darüber hinaus wurden bei
Analyse der gepoolten Daten aller drei Protonentherapiezentren Zusammenhänge zwischen spät
auftretenden Gedächtnisstörungen und der Dosis im nichtbetroffenen Gehirn sowie der Hippo-
campi beobachtet. Ebenso wurde ein Zusammenhang zwischen spät auftretender Fatigue und
dem Hochdosisbereich im Hirnstamm gefunden, jedoch müssen diese Zusammenhänge noch
anhand externer Kohorten validiert werden.
Sowohl die subjektiven Einschätzungen als auch die objektiv gemessene neurokognitive Funk-
tion blieben innerhalb der rezidivfreien Nachbeobachtungszeit weitgehend stabil. Eine leichte
Verschlechterung des MoCA-Wertes war mit einem erhöhten relativen Volumen des bestrahlten
anterioren Cerebellums assoziiert, das einer Dosis von 30 bis 40 Gy(RBW) ausgesetzt war.
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Der Vergleich der Bestrahlungspläne ergab, dass mit der Protonentherapie im Vergleich zur
Photonentherapie in vielen, insbesondere in kontralateralen, Risikoorganen eine erhebliche rela-
tive Dosisreduktion erreichen werden konnte. Fällt die absolute Dosis in kontralateralen Struktu-
ren jedoch bei beiden Modalitäten recht niedrig aus, ist die große relative Dosisreduktion mögli-
cherweise von geringerer klinischer Relevanz. Behandlungsentscheidungen auf Grundlage von
dosimetrischen Planvergleichen sollten deshalb sowohl relative und absolute Dosisunterschiede
als auch die Beträge der absoluten Dosiswerte berücksichtigen. Die Vorhersagen der NTCP-
Werte waren für die Mehrheit der Patienten und eine Reihe von Nebenwirkungen für die Pho-
tonentherapie höher als für die Protonentherapie. Für die meisten untersuchten Nebenwirkun-
gen und Patienten lagen die NTCP-Differenzen jedoch nicht über einem Schwellwert von 10
Prozentpunkten. Trotzdem wäre anhand der Untersuchungen in dieser Arbeit eine Mehrheit der
Patienten für die Protonentherapie ausgewählt worden, da viele verschiedene NTCP-Modelle
untersucht wurden und bereits durch Schwellwertüberschreitung bei einem einzigen Modell eine
Protonentherapie indiziert wäre.
Schlussfolgerung
Die vorgestellte Analyse unterstreicht, dass der modellbasierte Ansatz als Therapieentschei-
dungsstrategie zwischen Photonen- oder Protonentherapie auch für Patienten mit intrakraniellen
Tumoren anwendbar sein kann, da NTCP-Vorhersagen besser geeignet sind als physikalische
Dosis-Volumen-Parameter, um die klinische Relevanz zwischen verschiedenen Behandlungs-
techniken abzuschätzen. NTCP-Vorhersagen unterliegen jedoch im Vergleich zu physikalischen
Parametern sowohl dosimetrischen als auch Modellunsicherheiten, die die Genauigkeit der Pa-
tientenauswahl stark beeinflussen können. Neurokognitive Funktionsstörungen könnten in Kom-
bination mit anderen akuten und späten Nebenwirkungen eine der entscheidenden Nebenwir-
kungen sein, die bei der modellbasierten Patientenauswahl berücksichtigt werden sollten. Vor
der Implementierung des Ansatzes für Patienten mit intrakraniellen Tumoren sind jedoch weitere
Langzeitstudien mit objektiven und subjektiven Charakteristika notwendig, um die essentiellen
NTCP-Modelle zu validieren und geeignete Schwellwerte zu definieren. Darüber hinaus sollten
auch Variationen der radiobiologischen Wirksamkeit beachtet werden, z.B. um strahleninduzierte
Hirnnekrosen adäquat zu berücksichtigen.
Diese Arbeit hat gezeigt, dass das Ausmaß des klinischen Nutzens der Protonentherapie pa-
tientenindividuell sehr unterschiedlich sein kann. Durch die Entwicklung verschiedener NTCP-
Modelle und die Untersuchung der neurokognitiven Funktion nach Protonentherapie wurde eine
Grundlage für zukünftige Entwicklungen einer personalisierten Behandlungsentscheidung ge-
schaffen.
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9 Summary
Background
Radiotherapy is an essential component in the treatment of patients with intracranial tumours.
Compared to conventional photon therapy (XRT) techniques, proton beam therapy (PBT) offers
the possibility to reduce the volume of healthy tissue irradiated with low and intermediate doses
due to the physical properties of protons. Dosimetric comparisons suggest that PBT may be
beneficial in different aspects, e.g. by reducing side effects at the same tumour coverage com-
pared to XRT. However, up to now, there are no data from randomised controlled trials available
that demonstrate the superiority of PBT over modern XRT in brain tumour patients. Although the
number of PBT centres is still increasing, their capacity remains limited due to the high technical,
personnel and therefore financial expenditure. In Germany, the reimbursement of costs varies
between health insurance companies, while in other European countries, the allocation of lim-
ited PBT capacities is organised in a nationwide standard procedure. In the Netherlands, the
model-based approach has been suggested and implemented to select patients that may benefit
most from treatment with PBT. Using normal tissue complication probability (NTCP) models, the
complication risks of a proton and photon therapy plan are estimated for each patient. If the
potential NTCP reduction of the PBT plan exceeds a predefined threshold, e.g. 10 percentage
points, the patient is treated with protons. However, mandatory NTCP models for different side
effects following cranial radiotherapy are rare, especially for PBT.
Objectives
This thesis investigated whether the model-based approach, which has so far mainly been used
for head and neck cancer patients, can be extended to patients with intracranial tumours. For this
purpose, different NTCP models for early and late physician-rated side effects were developed
and externally validated. Moreover, for brain tumour patients, the preservation of neurocognitive
function after radiotherapy is an especially important aim of treatment, as this side effect may
considerably reduce patients’ quality of life. Hence, the neurocognitive function of patients treated
with cranial PBT was investigated to reveal potential dose-effect relationships. As an integral part
of the model-based patient approach, an in silico treatment plan comparison was conducted to
estimate the presumed benefit of PBT over XRT for individual patients.
Material and methods
Data from a total of 305 patients diagnosed with low-grade and high-grade glioma, meningioma
and other benign intracranial tumours were evaluated. All patients were treated with PBT at one
of three different PBT institutes. NTCP models for early and late physician-rated side effects have
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been created using logistic regression based on clinical outcome data and dosimetric parameters
of associated organs at risk. These models were externally validated.
Neurocognitive function up to two years after cranial PBT was investigated using subjective
quality of life questionnaires and the objective Montreal Cognitive Assessment (MoCA) test.
Changes in the neurocognitive function were related to dosimetric parameters of different brain
structures using mixed model analyses.
The treatment plan comparison was conducted in 92 patients. Dosimetric parameters of differ-
ent organs at risk were compared between retrospectively created XRT plans (volumetric mod-
ulated arc therapy) and the clinically applied PBT plan. Additionally, these treatment plans and
eleven published NTCP models were used to estimate potential complication risks and to inves-
tigate the feasibility of the model-based approach for patients with intracranial tumours.
Results
Dose-volume parameters of the skin characterising high doses were associated with early alope-
cia grade ≥ 2 and erythema grade ≥ 1. Validation confirmed that the presented dose-volume
parameters were strongly associated with these endpoints for all investigated cohorts, but the
calibration differed. Thus, centre-specific differences in toxicity assessment should be consid-
ered carefully. Late alopecia grade ≥ 1 was also associated with high dose-volume parameters
of the skin, while late hearing impairment grade ≥ 1 was related to cochlear mean doses. Addi-
tionally, in analyses of pooled data from the three PBT centres, dose-response relations between
late physician-rated memory impairment and the dose to the remaining brain and the hippocampi
as well as late fatigue and dose to the brain stem were observed, but still need to be validated
externally.
Self-reported and objectively measured neurocognitive function (MoCA test) and most quality
of life domains remained largely stable over time during recurrence-free follow-up after PBT.
Slight deterioration of the MoCA score was associated with an increased relative volume of the
irradiated anterior cerebellum exposed to doses of 30 to 40 Gy(RBE).
Treatment plan comparison revealed that PBT is able to achieve a substantial relative dose
reduction compared to XRT in many organs at risk, especially in contralateral organs. However,
if the absolute dose in contralateral structures is quite low for both modalities, the large relative
dose reduction may be of less clinical relevance. Thus, treatment decisions based on dosimetric
plan comparisons have to consider relative and absolute dose differences as well as the absolute
dose value. Corresponding to these dosimetric results, NTCP predictions for the majority of
patients and a variety of side effects were higher for XRT than for PBT, but often their difference
did not exceed a threshold of 10 percentage points. However, since several models have been
investigated, the majority of patients would finally have been selected for proton beam therapy if
treatment decision was based upon a 10 percentage point threshold for at least one side effect.
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Conclusion
The present feasibility study underlines that the model-based approach could be a suitable treat-
ment decision strategy between proton or photon therapy for patients with intracranial tumours, as
NTCP predictions may be more appropriate than physical dose-volume parameters to estimate
the clinical relevance between different treatment techniques. However, NTCP predictions are
subject to both dosimetric and model uncertainties which may strongly influence the accuracy of
patient selection. Neurocognitive dysfunction could be one of the decisive side effects included
in the model-based patient selection, in combination with other acute and late side effects. Be-
fore implementing the approach for patients with intracranial tumours, further long-term studies
using objective and subjective measures to define patient outcome are necessary to validate the
mandatory NTCP models and to define appropriate thresholds for treatment decision. Further-
more, variations in radiobiological effectiveness should also be considered, e.g. to adequately
address radiation-induced brain necrosis.
This thesis highlighted that the extent of the clinical benefit of PBT may vary greatly on a
patient-individual level. By developing different NTCP models and investigating neurocognitive
function following PBT, this thesis provided a basis for future studies on treatment selection en-
abling the best possible patient care.
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A Theoretical background
Table A.1: Scales and number of questions of the quality of life core questionnaire EORTC QLQ-C30.
Scale Name Number of questions
Global health status
Global health status QL 2
Functional scales
Physical function PF 6
Role function RF 2
Emotional function EF 4
Cognitive function CF 3
Social function SF 2
Symptom scales
Fatigue FA 3
Nausea and vomiting NV 2
Pain PA 2
Dyspnoea DY 1
Insomnia SL 1
Appetite loss AP 1
Constipation CO 1
Diarrhoea DI 1
Financial difficulties FI 1
Table A.2: Scales and number of questions of the brain-tumour specific quality of life questionnaire EORTC
QLQ-BN20.
Scale Name Number of question
Future uncertainty BNFU 4
Visual disorder BNVD 3
Motor dysfunction BNMD 3
Communication deficit BNCD 3
Headaches BNHA 1
Seizures BNSE 1
Drowsiness BNDR 1
Itchy skin BNIS 1
Hair loss BNHL 1
Weakness of legs BNWL 1
Bladder control BNBC 1
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The Montreal Cognitive Assessment test
The MoCA test includes different tasks assessing several neurocognitive domains. The visu-
ospatial and executive domain is tested by the Trial Making test, Cube Copy test and Clock
Drawing test. To test the domain naming, the patient has to recognise three animals that are
rarely seen in Western countries. In the Digit Span test the patient has to repeat five numbers in
forward and three in backward order. Here, the ability of attention is assessed. Focused atten-
tion, i.e. concentration is tested by Letter tapping: the interviewer reads a list of letters and the
patient has to tap his hand every time a certain letter is named. For calculation, the patient has
to subtract 7 from 100. Two tests assess the language domain: Sentence Repetition and Letter
fluency, for that the patient has to name as many words as possible beginning with a certain
letter in one minute. For abstraction, similarity between objects has to be found. Delayed recall
assesses the short-term memory. For that, the patient has to remember 5 words that were read
by the interviewer during the MoCA test. To assess the ability of orientation in time and space
the patient has to name the current date, month, year, day as well as place and city (Julayanont
et al., 2013).
Table A.3: Analysis types of prediction models according to the TRIPOD classification (Moons et al.,
2015).
Type Description
1a Development of a predictive model and direct evaluation of model performance on the same data set
1b Development of a predictive model using the entire data set including resampling strategies
2a Random split of the cohort in two groups, a training and a validation cohort
2b Nonrandom split of the cohort in two groups, a training and a validation cohort
3 Development of a predictive model on a training cohort and evaluation on a separate cohort
4 Evaluation of the performance of an existing predictive model on a separate cohort
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Table B.4: Clinical goals for treatment planning in the cohort treated at UPTD. Given are dose-volume
parameters of different organs at risk and the values, which should not be exceeded.
Organ at risk Parameter Value
Brain stem Dmax 54 Gy(RBE) (Mayo et al., 2010b)
Spinal cord Dmax 45 – 60 Gy(RBE)
Inner ear Dmean 45 – 60 Gy(RBE) (Jereczek-Fossa et al., 2003)
Chiasma Dmax 54 Gy(RBE) (Mayo et al., 2010a)
Optic nerves Dmax 54 Gy(RBE) (Mayo et al., 2010a)
Lenses Dmax 5 – 6 Gy(RBE)
Lacrimal glands Dmax 40 – 45 Gy(RBE) (Gordon et al., 1995)
Salivary glands Dmedian 26 Gy(RBE)
Brain Dmean 40 Gy(RBE) (Lawrence et al., 2010)
Table B.5: Clinical goals for treatment planning in the cohort treated at WPE. Given are dose-volume
parameters of different organs at risk and the values, which should not be exceeded.
Chordoma,
Organ at risk chondrosarcoma Meningeoma I Meningeoma II–III Glioma II Glioma III–IV
Brain stem Dmax 66 Gy(RBE) Dmax 55 Gy(RBE) Dmax 60 Gy(RBE) Dmax 55 Gy(RBE) Dmax 60 Gy(RBE)
D1% 64 Gy(RBE)
D2% 62 Gy(RBE)
Brain stem, centre D2% 54 Gy(RBE) Dmax 54 Gy(RBE)
Spinal cord Dmax 54 Gy(RBE)
Dmean 50 Gy(RBE)
Spinal cord, centre D2% 50 Gy(RBE)
Inner ear, ipsilateral Dmax < 105 %
Inner ear, at least one side Dmax 60 Gy(RBE)
Cochlea Dmean 45 Gy(RBE) Dmean 45 Gy(RBE) Dmean 45 Gy(RBE) Dmean 45 Gy(RBE) Dmean 45 Gy(RBE)
Chiasma D2% 60 Gy(RBE) Dmax 56 Gy(RBE) Dmax 60 Gy(RBE) Dmax 55 Gy(RBE) Dmax 60 Gy(RBE)
Optic nerves D2% 60 Gy(RBE) Dmax 56 Gy(RBE) Dmax 56–60 Gy(RBE) Dmax 55 Gy(RBE) Dmax 60 Gy(RBE)
Temporal lobes D2% 70 Gy(RBE)
V60Gy (RBE) < 10 %
Lenses Dmean 10 Gy(RBE)
Lacrimal glands Dmean 36 Gy(RBE) Dmean 36 Gy(RBE) Dmean 36 Gy(RBE) Dmean 36 Gy(RBE) Dmean 36 Gy(RBE)
Salivary gland, unilateral D2% 36 Gy(RBE)
Salivary gland, contralateral Dmean 26 Gy(RBE)
Brain, contralateral Dmax 36 Gy(RBE) Dmax 36 Gy(RBE) Dmax 36 Gy(RBE) Dmax 36 Gy(RBE)
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Table B.6: Results of univariable logistic regression for clinical cofactors and early side effects.
Erythema Alopecia Fatigue
Clinical cofactor grade ≥1 grade ≥2 grade ≥1 grade ≥2 grade ≥1
Surgery p-value < 0.001 0.085 0.36 0.030 0.40
No/yes OR 17.52 3.90 1.93 3.66 0.56
(95 % CI) (4.74 – 64.82) (0.83 – 18.38) (0.47 – 7.93) (1.13 – 11.81) (0.15 – 2.16)
Gender p-value 0.094 0.90 0.96 0.15 0.005
Male/female OR 0.39 0.95 1.03 1.81 3.90
(95 % CI) (0.13 – 1.18) (0.43 – 2.08) (0.34 – 3.12) (0.81 – 4.07) (1.52 – 9.99)
Tumour location p-value 0.68 0.83 0.83 0.77 0.90
Brain/skull base OR 1.29 1.09 0.88 1.13 0.95
(95 % CI) (0.38 – 4.38) (0.48 – 2.51) (0.28 – 2.80) (0.49 – 2.63) (0.40 – 2.25)
Chemotherapy p-value 0.49 0.44 0.47 0.29 0.75
No/yes OR 1.60 1.39 1.65 1.63 1.16
(95 % CI) (0.42 – 6.10) (0.60 – 3.25) (0.43 – 6.29) (0.67 – 3.99) (0.47 – 2.86)
Age at PBT p-value 0.85 0.43 0.29 0.14 0.12
in years OR 1.00 0.99 0.98 0.98 1.02
(95 % CI) (0.96 – 1.03) (0.96 – 1.02) (0.94 – 1.02) (0.95 – 1.01) (0.99 – 1.05)
Tumour volume (CTV) p-value 0.004 0.024 < 0.001 < 0.001 0.82
in cm3 OR 1.01 1.00 1.03 1.01 1.00
(95 % CI) (1.00 – 1.02) (1.00 – 1.01) (1.01 – 1.04) (1.01 – 1.02) (1.00 – 1.00)
Prescribed total dose p-value 0.037 0.001 0.028 0.033 0.84
in Gy(RBE) OR 1.07 1.14 1.07 1.06 1.01
(95 % CI) (1.00- 1.14) (1.05 – 1.23) (1.01 – 1.14) (1.00 – 1.12) (0.95 – 1.06)
Abbreviations: OR, Odds Ratio; CI, confidence interval; CTV, clinical target volume.
Table B.7: Comparison of selected dose-volume parameters of the skin between the exploration and
validation cohort 1 for different total dose prescriptions (54 Gy(RBE) and 60 Gy(RBE)). P-values represent
results from the Mann-Whitney U test.
Prescribed total dose 54 Gy(RBE) Prescribed total dose 60 Gy(RBE)
Exploration Validation 1 Exploration Validation 1
Parameter N = 26 N = 43 N = 56 N = 19
in cm3 or Gy(RBE) p-value Mean SD Mean SD p-value Mean SD Mean SD
V5Gy (RBE) 0.001 34 19 57 36 0.044 57 18 74 30
V10Gy (RBE) 0.11 30 17 43 33 0.10 53 17 64 27
V20Gy (RBE) 0.061 21 16 19 29 0.81 46 16 47 27
V30Gy (RBE) 0.15 6 11 13 23 0.29 28 16 33 23
V40Gy (RBE) 0.34 4 8.1 8 17 0.29 17 12 23 19
V50Gy (RBE) 0.84 2.1 4.5 2.7 6.6 0.78 8.5 8.6 8.9 9.9
V60Gy (RBE) 0.01 0.7 2.2 0.00 0.01
D2% 0.20 25 15 23 15 0.14 44 11 39 14
D5% 0.86 16 15 14 12 0.079 34 12 26 15
D15% 0.012 0.8 1.9 2.0 5.6 0.24 5.3 8.7 1.7 3.2
D25% < 0.001 0.02 0.04 0.29 0.87 0.31 0.5 2.9 0.11 0.22
D35% < 0.001 0 0.02 0.06 0.19 < 0.001 0.02 0.09 0.04 0.04
D45% < 0.001 0 0 0.02 0.03 < 0.001 0.00 0.01 0.02 0.01
Abbreviations: N, number of patients; SD, standard deviation.
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Table B.8: Spearman correlation coefficients ρ for clinical cofactors and dose-volume parameters selected
as predictors for different acute side-effects. Tumour location determines whether the tumour is located in
the brain or the skull base.
Surgery Gender Location CTx Age CTV Prescribed dose
[no/yes] [male/female] [brain/skull base] [no/yes] in years in cm3 in Gy(RBE)
Skin V25Gy(RBE) ρ 0.38 -0.05 -0.08 0.09 0.03 0.83 0.70
in cm3 p-value < 0.001 0.59 0.41 0.32 0.73 < 0.001 < 0.001
Skin V35Gy(RBE) ρ 0.41 -0.05 -0.03 0.05 0.01 0.75 0.69
in cm3 p-value < 0.001 0.57 0.76 0.58 0.94 < 0.001 < 0.001
Skin D2% ρ 0.38 0.03 -0.10 0.07 0.00 0.74 0.65
in Gy(RBE) p-value < 0.001 0.77 0.28 0.45 0.99 < 0.001 < 0.001
Skin D5% ρ 0.34 0.06 -0.04 0.21 0.04 0.81 0.50
in Gy(RBE) p-value < 0.001 0.52 0.69 0.03 0.67 < 0.001 < 0.001
Brain-CTV D2% ρ 0.15 0.15 0.02 0.02 -0.06 0.59 0.31
in Gy(RBE) p-value 0.11 0.11 0.84 0.83 0.53 < 0.001 0.001
Surgery ρ 1.00 -0.19 -0.09 0.05 0.02 0.31 0.24
[no/yes] p-value 0.046 0.32 0.59 0.80 0.001 0.010
Gender ρ -0.19 1.00 0.01 -0.10 -0.04 -0.14 -0.03
[male/female] p-value 0.046 0.92 0.32 0.70 0.14 0.79
Location ρ -0.09 0.01 1.00 -0.15 -0.17 -0.06 -0.06
[brain/skull base] p-value 0.32 0.92 0.12 0.08 0.51 0.50
CTx ρ 0.05 -0.10 -0.15 1.00 0.02 0.37 0.09
[no/yes] p-value 0.59 0.32 0.12 0.85 < 0.001 0.32
Age at PBT ρ 0.02 -0.04 -0.17 0.02 1.00 -0.04 0.00
[years] p-value 0.80 0.70 0.08 0.85 0.71 0.99
CTV ρ 0.31 -0.14 -0.06 0.37 -0.04 1.00 0.55
in cm3 p-value 0.001 0.14 0.51 < 0.001 0.71 < 0.001
Prescribed dose ρ 0.24 -0.03 -0.06 0.09 0.00 0.55 1.00
in Gy(RBE) p-value 0.010 0.79 0.50 0.32 0.99 < 0.001
Abbreviations: CTx, chemotherapy; CTV, clinical target volume.
Table B.9: Results of the principal component analysis. The first three unrotated and rotated components
with eigenvalues greater than one are given and their corresponding explained total variance.
Dose-volume parameters
Percentage of total variance represented by
Component Eigenvalue Without rotation Varimax rotation rotated components
Component 1 11.3 70.8% 49.3% V10Gy (RBE) − V20Gy (RBE), D2%, D5%
Component 2 1.9 12.0% 30.7% V50Gy (RBE) − V60Gy (RBE)
Component 3 1.1 7.0% 9.9% D15%, D25%
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Table B.10: Univariable logistic modelling results: Rotated (Varimax) principal components of the skin for
acute erythema and alopecia. Mean AUC values for 3-fold cross-validation (333 repetitions) and external
validation are given. P-values were calculated on the exploration cohort, confidence intervals (CI) were
obtained using 1000 bootstrap samples. Fitting parameters βi as defined in equation (2.13).
External validation External validation
Cross validation cohort 1 cohort 2
Model AUC (95% CI) AUC (95 % CI) AUC (95 % CI) β0 (95 % CI) β1 (95 % CI) p-value
Erythema grade ≥ 1
Component 1 0.75 (0.58 – 0.89) 0.81 (0.69 – 0.91) 0.76 (0.65 – 0.86) 2.12 (1.46 - 2.78) 0.83 (0.23 – 1.42) 0.006
Erythema grade ≥ 2
Component 1 0.69 (0.55 – 0.82) * 0.00 (0.00 – 0.00) -0.63 (-1.04 – 0.22) 0.70 (0.25 - 1.15) 0.002
Alopecia grade ≥ 1
Component 1 0.85 (0.64 – 0.99) 0.83 (0.71 – 0.92) 0.83 (0.73 – 0.92) 2.80 (1.77 – 3.83) 1.71 (0.89 – 2.53) < 0.001
Alopecia grade ≥ 2
Component 1 0.83 (0.71 – 0.94) 0.75 (0.60 – 0.87) 0.88 (0.81 – 0.94) 0.74 (0.25 – 1.22) 1.51 (0.94 – 2.09) < 0.001
Abbreviations: AUC, area under the receiver operating characteristic curve; CI, confidence interval. *not applicable, as
the incidence rate was zero
Table B.11: Patient characteristics for the generalised estimating equation analysis of late side effects for
the pooled cohort.
Total number of patients 216
Characteristics Median (Range)
Age1 in years 47.8 (18.1 – 89.3)
Tumour volume (CTV)1 in cm3 51.4 (1.2 – 498.0)
Prescribed dose1 in Gy(RBE) 54.0 (30.0 – 74.0)
N (%)
Gender2 (male/female) 103/113 (48/52)
Surgery2 (no/yes/missing) 44/171/1 (20/79/0.5)
Chemotherapy2 (no/yes/missing) 157/58/1 (73/27/0.5)
Re-irradiation2 (no/yes/missing) 201/13/2 (93/6/1)
Tumour location2 (brain/skull base/other) 99/113/4 (46/52/2)
Tumour location2 (hemisphere)
Left 74 (34)
Right 81 (38)
Central 54 (25)
Bilateral 7 (3)
Tumour location2 (lobe)
Temporal lobe 66 (31)
Frontal lobe 51 (24)
Parietal lobe 11 (5)
Occipital lobe 5 (2)
Multiple lobes 30 (14)
Other 53 (25)
Tumour histology∗,2
High-grade glioma 51 (24)
Low-grade glioma 30 (14)
Meningioma 67 (31)
Other 68 (31)
Abbreviations: N, number of patients; CTV, clinical target volume. ∗Tumour
classification according to WHO Classification of Tumours of the Central
Nervous System. Fourth Edition. 1Mann-Whitney U test, 2 χ2 test.
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Table B.12: Generalised estimating equation analyses for late side effects and cofactors in the pooled
analysis. The parameter time is defined as a natural number representing the follow-up visit starting with
1 at 6 months following PBT.
Excluding interaction term between dosimetric parameter and time Including interaction term between dosimetric parameter and time
Model parameter βi (95 % CI) p-value Model parameter βi (95 % CI) p-value
Alopecia grade ≥ 1
Prescribed dose in Gy(RBE)−1 0.29 (0.16 – 0.42) < 0.001 Prescribed dose in Gy(RBE)−1 0.27 (0.09 – 0.44) 0.003
Time -0.031 (-0.06 – 0.00) 0.046 Time -0.13 (-0.74 – 0.48) 0.67
Constant -16.97 (-24.50 – -9.44) Interaction 0.002 (-0.01 – 0.01) 0.74
Constant -15.54 (-25.61 – -5.47)
Tumour volume (CTV) in cm−3 0.009 (0.01 – 0.01) < 0.001 Tumour volume (CTV) in cm−3 0.008 (0.00 – 0.01) 0.017
Time -0.030 (-0.06 – 0.00) 0.058 Time -0.044 (-0.10 – 0.01) 0.094
Constant -1.56 (-2.17 – -0.95) Interaction 0.000 (0.00 – 0.00) 0.53
Constant -1.36 (-2.22 – -0.50)
Alopecia grade ≥ 2
Prescribed dose in Gy(RBE)−1 0.25 (0.09 – 0.41) 0.002 Prescribed dose in Gy(RBE)−1 0.39 (0.05 – 0.73) 0.025
Time -0.013 (-0.10 – 0.08) 0.78 Time 0.52 (-0.38 – 1.41) 0.26
Constant -17.93 (-27.01 – -8.85) Interaction -0.009 (-0.02 – 0.01) 0.24
Constant -26.08 (-45.95 – -6.21)
Tumour volume (CTV) in cm−3 0.007 (0.00 – 0.01) < 0.001 Tumour volume (CTV) in cm−3 0.011 (0.00 – 0.02) < 0.001
Time -0.012 (-0.10 – 0.08) 0.78 Time 0.038 (-0.10 – 0.17) 0.58
Constant -4.42 (-5.88 – -2.96) Interaction 0.000 (0.00 – 0.00) 0.22
Constant -5.17 (-7.26 – -3.08)
Dry eye syndrome grade ≥ 2
Tumour located in brain [ref: skull base] -2.78 (-4.93 – -0.63) 0.011 Tumour located in brain [ref: skull base] -7.11 (-9.37 – -4.84) < 0.001
Time -0.040 (-0.12 – 0.04) 0.32 Time -0.056 (-0.14 – 0.03) 0.19
Constant -2.49 (-3.81 – -1.17) Interaction 0.25 (0.17 – 0.34) < 0.001
Constant -2.29 (-3.51 – -1.06)
Headache grade ≥ 1
Age at PBT in 1/years -0.021 (-0.04 – -0.01) 0.010 Age at PBT in 1/years 0.008 (-0.02 – 0.03) 0.55
Time -0.019 (-0.04 – 0.01) 0.13 Time 0.077 (0.00 – 0.15) 0.040
Constant 0.083 (-0.75 – 0.92) Interaction -0.002 (0.00 – 0.00) 0.012
Constant -1.21 (-2.41 – -0.02)
Hearing impairment grade ≥ 1
Age at PBT in 1/years 0.057 (0.02 – 0.09) 0.001 Age at PBT in 1/years 0.057 (0.00 – 0.11) 0.034
Time 0.006 (-0.04 – 0.05) 0.79 Time 0.006 (-0.16 – 0.17) 0.94
Constant -5.40 (-7.55 – -3.26) Interaction 0.000 (0.00 – 0.00) 0.99
Constant -5.41 (-8.56 – -2.26)
Memory impairment grade ≥ 1
Prescribed dose in Gy(RBE)−1 0.064 (0.01 – 0.11) 0.011 Prescribed dose in Gy(RBE)−1 0.091 (0.02 – 0.16) 0.012
Time 0.020 (-0.01 – 0.05) 0.16 Time 0.130 (-0.08 – 0.34) 0.23
Constant -5.20 (-7.96 – -2.44) Interaction -0.002 (-0.01 – 0.00) 0.31
Constant -6.78 (-10.79 – -2.77)
Tumour volume (CTV) in cm−3 0.004 0.00 0.01 0.004 Tumour volume (CTV) in cm−3 0.005 (0.00 0.01 0.042
Time 0.021 (-0.01 – 0.05) 0.15 Time 0.029 (-0.01 – 0.07) 0.16
Constant -2.14 (-2.75 – -1.53) Interaction 0.000 (0.00 – 0.00) 0.63
Constant -2.27 (-3.05 – -1.48)
Abbreviations: CI, confidence interval; CTV, clinical target volume.
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Table B.13: Definitions of alopecia and dermatitis according to CTCAE v4.0 (National Cancer Institute,
2009).
Alopecia
A disorder characterized by a decrease in density of hair compared to normal for a given individual at a given
age and body location.
Grade 0 Absence of alopecia or within normal limits.
Grade 1 Hair loss of < 50 % of normal for that individual that is not obvious from a distance but only on close
inspection; a different hairstyle may be required to cover the hair loss but it does not require a wig
or hair piece to camouflage.
Grade 2 Hair loss of ≥ 50 % normal for that individual that is readily apparent to others; a wig or hair piece is
necessary if the patient desires to completely camouflage the hair loss; associated with psychosocial
impact.
Radiation dermatitis
A finding of cutaneous inflammatory reaction occurring as a result of exposure to biologically effective levels of
ionizing radiation.
Grade 0 Absence of dermatitis or within normal limits.
Grade 1 Faint erythema or dry desquamation.
Grade 2 Moderate to brisk erythema; patchy moist desquamation, mostly confined to skin folds and creases;
moderate oedema.
Grade 3 Moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or
abrasion.
Grade 4 Life-threatening consequences; skin necrosis or ulceration of full-thickness dermis; spontaneous
bleeding from the involved site; skin graft indicated.
Grade 5 Death
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Alopecia
Radiation 
dermatitis Grade 0 Grade 1 Grade 4Grade 3Grade 2 Grade 5
Grade 0 Grade 1 Grade 2
Figure B.1: Example case of the interobserver variability study.
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Figure B.2: Percent agreement for scoring of alopecia and erythema compared to random agreement
based on the distribution of the modal value. The 95 % percentile is given as dashed line. The number of
cases above this threshold out of the number of total cases (29) is indicated.
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Table C.1: Response rates and scores of the MoCA test and quality of life questionnaires EORTC QLQ-
C30 and EORTC QLQ-BN20 over time (months after treatment are given). Data are given in mean (stan-
dard deviation). MoCA score ranges from 0 to 30, QoL items from 0 to 100.
Baseline 3 months 6 months 9 months 12 months 15 months 18 months 21 months 24 months
MoCA test
Number of patients 62 48 38 35 27 27 21 24 26
MoCA total score 24.8 (4.2) 24.7 (4.2) 25.1 (4.1) 25.9 (3.6) 25.7 (3.3) 26.7 (3.5) 24.8 (4.9) 26.4 (2.9) 25.2 (4.2)
EORTC-QLQ-C30
Number of patients 61 48 37 37 30 30 25 26 26
Cognitive function 68.9 (26.6) 64.2 (30.0) 63.5 (29.1) 65.3 (29.2) 66.1 (30.8) 71.1 (23.5) 62.7 (29.8) 64.1 (27.4) 66.0 (25.2)
Physical function 75.4 (23.8) 73.5 (25.1) 75.4 (24.3) 76.0 (25.4) 76.0 (23.7) 82.0 (15.6) 77.3 (24.6) 79.5 (17.9) 75.1 (22.0)
Social function 61.7 (32.5) 57.6 (35.7) 58.6 (38.2) 66.2 (31.5) 57.5 (33.5) 70.0 (26.8) 57.3 (33.5) 59.6 (34.3) 60.3 (32.0)
Emotional function 61.2 (25.4) 62.7 (25.4) 65.5 (25.7) 65.3 (25.6) 61.3 (2.38) 69.2 (19.6) 58.6 (25.5) 64.1 (24.2) 66.0 (23.4)
Role function 64.7 (34.3) 60.4 (36.2) 64.5 (32.5) 69.4 (33.9) 60.6 (36.0) 64.4 (29.9) 58.0 (35.7) 60.3 (31.3) 60.3 (34.0)
Global health status 58.9 (22.2) 58.0 (26.3) 58.3 (23.9) 64.6 (23.7) 56.9 (26.0) 65.6 (21.1) 54.0 (26.1) 56.4 (26.6) 56.1 (23.9)
Fatigue 43.0 (29.6) 46.1 (30.4) 48.2 (30.5) 39.3 (26.7) 48.9 (33.3) 38.5 (28.8) 48.9 (33.3) 38.5 (28.8) 48.5 (28.1)
Pain 27.0 (29.2) 32.3 (35.1) 28.9 (29.7) 27.5 (31.7) 31.7 (35.4) 26.1 (31.2) 32.7 (31.0) 23.1 (29.5) 37.2 (32.8)
Insomnia 27.9 (33.4) 26.4 (32.2) 31.6 (30.9) 34.2 (32.9) 34.4 (39.6) 27.8 (34.0) 37.3 (35.1) 30.8 (31.2) 28.2 (29.4)
EORTC-QLQ-BN20
Number of patients 61 48 39 38 30 29 26 26 25
Communication deficit 20.4 (26.3) 20.4 (26.1) 26.3 (30.2) 23.4 (27.2) 21.5 (25.3) 15.7 (20.9) 24.0 (27.2) 18.8 (22.6) 20.4 (21.7)
Visual disorder 21.1 (23.3) 16.4 (22.1) 15.5 (21.1) 19.5 (25.8) 17.4 (24.0) 19.9 (30.0) 20.9 (24.3) 20.9 (28.7) 27.6 (32.6)
Future uncertainty 44.7 (26.3) 38.5 (27.4) 35.9 (28.1) 32.4 (26.5) 36.9 (27.4) 28.4 (24.9) 44.7 (30.7) 34.9 (25.7) 33.7 (24.6)
Headache 36.6 (32.6) 33.3 (35.1) 28.9 (30.2) 32.4 (34.7) 38.9 (35.1) 31.0 (34.4) 34.7 (32.6) 26.9 (31.3) 34.7 (34.7)
Seizures 2.7 (14.0) 5.6 (15.9) 7.6 (23.0) 1.9 (11.1) 1.1 (6.2) 6.0 (22.3) 6.7 (13.6) 2.6 (13.1) 5.3 (18.5)
Hair loss 8.8 (19.4) 26.2 (34.0) 23.7 (33.7) 24.3 (34.8) 25.6 (36.8) 13.8 (30.2) 16.0 (27.4) 16.7 (33.0) 18.1 (35.4)
+high score: high functionality, −high score: high symptomatology.
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Figure C.1: MoCA total score and self-reported cognitive function (QLQ cognitive function) over time.
Patients are classified whether they were lost to follow-up from the next visit on due to death or local
recurrence or not. Absolute scores in the top row, differences to baseline (B) below. Shaded areas mark
the extent of changes in QLQ and MoCA (red: worsening, green: improvement). Extent of QLQ changes
from light to dark: a little (5.0 – 9.9), moderate (10.0 – 19.9) and very much (≥ 20.0) (Osoba et al., 1998).
Extent of MoCA changes from light to dark: moderate (2 – 4 points), large (≥ 4 points). No significant
differences between both groups could be observed at any time. Adapted from Dutz et al. (2020).
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Table C.2: Results of the mixed model analyses on differences from baseline for selected quality of life
items and clinical parameters including all times. Model coefficients and standard deviation (standard
deviation) of the parameters, time after proton beam therapy and their interaction term are given.
Model parameter Coefficient (SD) p-value
QLQ-C30 Physical function
Corticosteroids [reference: yes] 13.4 (6.00) 0.028
Time after radiotherapy 0.72 (0.93) 0.44
Interaction of time and corticosteroids -1.17 (1.14) 0.31
QLQ-C30 Emotional function
Age at PBT in years -0.63 (0.27) 0.022
Time after radiotherapy -2.81 (2.42) 0.25
Interaction of time and age 0.06 (0.05) 0.23
QLQ-C30 Social function
Age at PBT in years -0.83 (0.35) 0.019
Time after radiotherapy -1.42 (3.10) 0.65
Interaction of time and age 0.03 (0.06) 0.64
QLQ-C30 Role function
Gender [reference: female] 38.4 (11.1) 0.001
Time after radiotherapy 1.45 (1.57) 0.36
Interaction of time and gender -2.66 (2.04) 0.19
Corticosteroids [reference: yes] 24.3 (11.8) 0.042
Time after radiotherapy 1.62 (1.86) 0.38
Interaction of time and corticosteroids -2.83 (2.28) 0.22
QLQ-C30 Pain
Age at PBT in years 0.63 (0.26) 0.019
Time after radiotherapy 1.86 (2.59) 0.47
Interaction of time and age -0.03 (0.05) 0.53
QLQ-BN20 Visual disorder
Surgery [reference: yes] -13.1 (8.55) 0.13
Time after radiotherapy -0.02 (0.65) 0.97
Interaction of time and surgery 4.70 (1.63) 0.005
QLQ-BN20 Seizures
Corticosteroids [reference: yes] -11.0 (4.47) 0.015
Time after radiotherapy -1.17 (0.77) 0.14
Interaction of time and corticosteroids 1.47 (0.95) 0.13
Abbreviations: QLQ-BN20, brain tumour-specific quality of life questionnaire;
QLQ-C30, quality of life core questionnaire; SD, standard deviation.
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Table C.3: Results of the mixed model analyses on differences from baseline of the MoCA total score and
self-reported cognitive function and dose-volume parameters of the hippocampus including all time points.
Model coefficients and standard deviation (standard deviation) of dosimetric parameters, time after proton
beam therapy and their interaction term are given.
MoCA test QLQ cognitive function
Model parameter Coefficient (SD) p-value Coefficient (SD) p-value
Hippocampi V10Gy (RBE) 1.45 (1.73) 0.40 0.66 (16.6) 0.97
Time 0.04 (0.13) 0.75 0.55 (1.26) 0.67
Interaction of time and hippocampi V10Gy (RBE) -0.15 (0.33) 0.66 -1.85 (3.17) 0.56
Constant -0.85 (0.66) 0.20 -5.4 (6.34) 0.40
Hippocampi V20Gy (RBE) 1.52 (1.73) 0.38 -0.78 (16.5) 0.96
Time 0.04 (0.12) 0.76 0.56 (1.18) 0.64
Interaction of time and hippocampi V20Gy (RBE) -0.14 (0.33) 0.66 -2.08 (3.14) 0.51
Constant -0.83 (0.62) 0.19 -5.02 (5.94) 0.40
Hippocampi V30Gy (RBE) 1.59 (1.76) 0.37 -1.14 (16.8) 0.95
Time 0.04 (0.12) 0.75 0.51 (1.14) 0.65
Interaction of time and hippocampi V30Gy (RBE) -0.17 (0.34) 0.63 -2.10 (3.19) 0.51
Constant -0.81 (0.60) 0.18 -4.96 (5.70) 0.39
Hippocampi V40Gy (RBE) 1.74 (1.83) 0.35 2.23 (17.6) 0.90
Time 0.03 (0.12) 0.79 0.52 (1.11) 0.64
Interaction of time and hippocampi V40Gy (RBE) -0.16 (0.36) 0.67 -2.45 (3.41) 0.47
Constant -0.79 (0.58) 0.17 -5.64 (5.48) 0.31
Hippocampi V50Gy(RBE) 2.92 (2.17) 0.18 3.86 (21.2) 0.86
Time 0.01 (0.11) 0.90 0.44 (1.09) 0.69
Interaction of time and hippocampi V50Gy (RBE) -0.08 (0.45) 0.85 -2.86 (4.27) 0.50
Constant -0.91 (0.56) 0.11 -5.76 (5.43) 0.29
Hippocampi V60Gy (RBE) -4.59 (10.2) 0.65 -65.3 (103.2) 0.53
Time -0.01 (0.10) 0.92 -0.04 (0.91) 0.96
Interaction of time and hippocampi V60Gy (RBE) 0.94 (2.03) 0.64 3.64 (18.9) 0.85
Constant -0.38 (0.48) 0.43 -4.45 (4.55) 0.33
Hippocampi D2% 0.02 (0.02) 0.34 0.01 (0.18) 0.96
Time -0.08 (0.16) 0.62 1.00 (1.54) 0.52
Interaction of time and hippocampi D2% 0.00 (0.00) 0.54 -0.03 (0.04) 0.44
Constant -1.06 (0.77) 0.17 -5.56 (7.53) 0.46
Hippocampi Dmean 0.03 (0.03) 0.35 0.02 (0.33) 0.95
Time 0.04 (0.13) 0.77 0.56 (1.20) 0.64
Interaction of time and hippocampi Dmean 0.00 (0.01) 0.68 -0.04 (0.06) 0.51
Constant -0.86 (0.63) 0.17 -5.44 (6.01) 0.37
Hippocampi D50% 0.05 (0.03) 0.16 0.00 (0.32) 1.00
Time 0.05 (0.10) 0.62 0.13 (0.96) 0.89
Interaction of time and hippocampi D50% -0.01 (0.01) 0.23 -0.02 (0.06) 0.73
Constant -0.71 (0.49) 0.15 -5.21 (4.76) 0.28
Abbreviation: SD, standard deviation.
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Table C.4: Results of the mixed model analyses on score differences of the MoCA subscales compared
to baseline including all times. Model coefficients (standard deviation) of the clinical or dosimetric parame-
ters, time after proton beam therapy and their interaction term are given. Only parameters with statistically
significant association are shown. If more than one dosimetric parameter of a structure was significantly
associated to changes in the MoCA subscales score, the parameter with the lowest p-value is given.
Model parameter Coefficient (SD) p-value
MoCA test: memory
Cerebellum D2% -0.02 (0.01) 0.041
Time -0.06 (0.07) 0.41
Interaction of time and cerebellum D2% 0.00 (0.00) 0.050
Constant 0.57 (0.33)
Cerebellum anterior V40Gy (RBE) -4.80 (1.67) 0.005
Time -0.04 (0.06) 0.52
Interaction of time and cerebellum anterior V40Gy (RBE) 0.76 (0.33) 0.023
Constant 0.55 (0.28)
Chemotherapy [reference: yes] -1.48 (0.50) 0.004
Time -0.05 (0.09) 0.56
Interaction of time and chemotherapy [reference: yes] 0.14 (0.11) 0.21
Constant 1.10 (0.41)
MoCA test: orientation
Right frontal lobe V10Gy (RBE) -1.44 (0.60) 0.019
Time 0.02 (0.04) 0.51
Interaction of time and right frontal lobe V10Gy (RBE) 0.04 (0.11) 0.74
Constant 0.12 (0.19)
Cerebellum D50% -0.06 (0.02) 0.018
Time 0.01 (0.02) 0.54
Interaction of time and cerebellum D50% 0.01 (0.00) 0.27
Constant -0.10 (0.13)
Cerebellum posterior D50% -0.05 (0.02) 0.044
Time 0.02 (0.02) 0.52
Interaction of time and cerebellum posterior D50% 0.00 (0.00) 0.33
Constant -0.12 (0.13)
MoCA test: attention
ECOG performance status [reference: ECOG 2]
ECOG 0 1.52 (0.84) 0.070
ECOG 1 2.09 (0.86) 0.016
Time 0.30 (0.23) 0.20
Interaction of time and ECOG 0 -0.26 (0.23) 0.26
Interaction of time and ECOG 1 -0.35 (0.23) 0.13
Constant -1.83 (0.82)
MoCA test: abstraction
Cerebellum posterior D50% -0.02 (0.01) 0.035
Time -0.02 (0.01) 0.22
Interaction of time and cerebellum posterior D50% 0.00 (0.00) 0.10
Constant 0.09 (0.06)
Age at therapy 0.01 (0.00) 0.010
Time 0.02 (0.04) 0.57
Interaction of time and age at therapy 0.00 (0.00) 0.40
Constant -0.40 (0.18)
Abbreviations: SD, standard deviation; ECOG, Eastern Co-operative of Oncology Group.
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Table C.5: Mean baseline values for MoCA and quality of life values compared to reference populations. Data are given in mean (standard deviation).
MoCA score ranges from 0 to 30, QoL items from 0 to 100.
Present Reference population
study Healthy populations Brain tumour patients
MoCA test Rossetti et al. (2011)I Rossetti et al. (2011)II Thomann et al. (2018)III Robinson et al. (2015) Schiavolin et al. (2018)IV
MoCA total score+ 24.8 (4.2) 23.7 (3.8) 25.6 (2.9) 26.1 (2.5) 26.5 (2.1) 23.2 (3.7)
EORTC-QLQ-C30 Scott et al. (2008) Schwarz and Hinz (2001)III Michelson et al. (2000)VI Michelson et al. (2000)VII Renovanz et al. (2018) Scott et al. (2008)V
Cognitive function+ 68.9 (26.6) 86.1 (20.0) 91.2 (17.0) 88.5 (17.7) 88.0 (17.0) 58.1 (29.8) 72.8 (26.1)
Global health status+ 58.3 (22.2) 71.2 (22.4) 70.8 (22.1) 74.7 (22.2) 78.1 (21.3) 43.6 (22.4) 61.6 (22.2)
Social function+ 61.7 (32.5) 87.5 (22.9) 91.0 (19.4) 90.4 (19.6) 91.3 (19.3) 50.4 (31.0) 66.8 (31.0)
Physical function+ 75.4 (23.8) 89.8 (16.2) 90.1 (16.7) 88.0 (17.7) 91.5 (16.4) 64.7 (32.6)
Emotional function+ 61.2 (25.4) 76.3 (22.8) 78.7 (21.0) 78.3 (21.9) 84.0 (19.8) 46.1 (27.8) 70.9 (23.4)
Role function+ 64.7 (34.3) 84.7 (25.4) 88.0 (22.9) 86.0 (24.4) 87.2 (24.4) 58.1 (32.9)
Fatigue− 43.0 (29.6) 24.1 (24.0) 17.1 (22.0) 23.4 (22.4) 18.7 (20.7) 49.7 (32.2) 37.5 (26.2)
Insomnia− 27.9 (33.4) 21.8 (29.7) 16.4 (27.2) 20.3 (27.5) 14.0 (24.5) 21.7 (29.2)
Pain− 27.0 (29.2) 20.9 (27.6) 15.4 (24.4) 20.6 (26.9) 16.0 (23.3) 33.7 (34.2) 16.5 (23.9)
EORTC-QLQ-BN20 Taphoorn et al. (2010)VIII
Communication deficit− 20.4 (26.3) 17.5 (24.5)
Visual disorder− 21.1 (23.3) 12.8 (18.8)
Future uncertainty− 44.7 (26.2) 56.2 (32.4) 37.0 (27.1)
Headache− 36.6 (32.6) 40.0 (35.8) 21.2 (26.2)
Seizures− 2.7 (14.0) 6.1 (18.5)
Hair loss− 8.8 (19.4) 9.4 (22.6)
+high score: high functionality, −high score: high symptomatology; I general population; II white population; III German healthy population; IV after surgery; V brain tumour patients; VI female
population; VII male population; VIII baseline values
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Table D.1: Dose comparison for organs at risk for the photon (XRT) and proton treatment plans (PBT)
as well as the difference of both. Median, mean and standard deviation are given for each modality
and patient-individual differences. P-values are derived from Wilcoxon test. Median relative changes
∆Vrel = (VXRT − VPBT)/VXRT and ∆Drel = (DXRT − DPBT)/DXRT in per cent are given.
PBT XRT XRT-PBT
Organ at risk Parameter Median (Mean ± SD) Median (Mean ± SD) Median (Mean ± SD) p-value ∆V rel, ∆Drel
Brain-CTV V10Gy (RBE) [%] 21.6 (23.4 ± 13.5) 51.3 (48.9 ± 24.1) 23.8 (25.6 ± 18.7) < 0.001 54 %
V20Gy (RBE) [%] 13.5 (15.9 ± 11.0) 30.1 (30.9 ± 19.5) 11.1 (15.0 ± 12.4) < 0.001 47 %
V30Gy (RBE) [%] 9.8 (11.9 ± 9.1) 17.4 (18.7 ± 12.9) 4.6 (6.9 ± 6.7) < 0.001 37 %
V40Gy (RBE) [%] 7.5 (8.8 ± 7.6) 10.0 (11.5 ± 8.9) 1.4 (2.7 ± 3.6) < 0.001 26 %
V50Gy (RBE) [%] 4.5 (5.9 ± 5.4) 5.8 (7.3 ± 6.1) 0.9 (1.3 ± 2.0) < 0.001 22 %
V60Gy (RBE) [%] 0.0 (0.9 ± 1.4) 0.0 (1.0 ± 1.7) 0.0 (0.1 ± 0.9) 0.28 3 %
Dmean [Gy(RBE)] 7.3 (8.2 ± 5.2) 16.1 (15.7 ± 8.0) 7.2 (7.5 ± 4.8) < 0.001 52 %
D2% [Gy(RBE)] 53.8 (50.6 ± 11.2) 53.9 (51.9 ± 9.6) 0.4 (1.2 ± 3.4) < 0.001 1 %
D50% [Gy(RBE)] 0.0 (1.4 ± 4.5) 10.7 (10.8 ± 8.7) 9.1 (9.5 ± 7.9) < 0.001 99 %
Brain stem D2% [Gy(RBE)] 31.5 (30.7 ± 22.8) 44.6 (39.2 ± 15.9) 3.8 (8.4 ± 11.2) < 0.001 15 %
Cerebellum V10Gy (RBE) [%] 1.4 (11.4 ± 19.0) 36.7 (43.6 ± 36.8) 24.7 (32.2 ± 28.1) < 0.001 93 %
V20Gy (RBE) [%] 0.5 (8.0 ± 14.9) 10.3 (22.7 ± 27.0) 8.0 (14.7 ± 17.7) < 0.001 87 %
V30Gy (RBE) [%] 0.0 (5.5 ± 11.3) 2.1 (10.8 ± 17.6) 0.8 (5.3 ± 8.5) < 0.001 66 %
V40Gy (RBE) [%] 0.0 (3.8 ± 8.0) 0.0 (5.9 ± 11.8) 0.0 (2.1 ± 4.7) < 0.001 52 %
V50Gy (RBE) [%] 0.0 (2.3 ± 5.2) 0.0 (3.3 ± 7.5) 0.0 (1.1 ± 2.8) < 0.001 49 %
V60Gy (RBE) [%] 0.0 (0.1 ± 0.7) 0.0 (0.1 ± 0.7) 0.0 (0.0 ± 0.3) 0.89 −18 %
Dmean [Gy(RBE)] 0.4 (4.0 ± 6.8) 9.5 (12.6 ± 10.2) 7.0 (8.6 ± 5.9) < 0.001 95 %
D2% [Gy(RBE)] 5.6 (20.0 ± 23.0) 30.2 (31.1 ± 18.5) 9.3 (11.1 ± 10.3) < 0.001 82 %
D50% [Gy(RBE)] 0.0 (1.5 ± 5.3) 7.8 (10.7 ± 10.1) 6.9 (9.2 ± 8.0) < 0.001 100 %
Cerebellum V10Gy (RBE) [%] 2.5 (19.5 ± 30.1) 90.2 (63.7 ± 39.6) 35.7 (44.2 ± 36.4) < 0.001 93 %
anterior V20Gy (RBE) [%] 0.4 (14.5 ± 25.3) 30.9 (40.0 ± 38.7) 19.9 (25.6 ± 28.2) < 0.001 89 %
V30Gy (RBE) [%] 0.0 (11.0 ± 21.4) 2.5 (21.7 ± 31.6) 2.0 (10.7 ± 15.8) < 0.001 82 %
V40Gy (RBE) [%] 0.0 (8.3 ± 17.6) 0.0 (12.8 ± 23.8) 0.0 (4.5 ± 8.8) < 0.001 50 %
V50Gy (RBE) [%] 0.0 (5.2 ± 12.0) 0.0 (7.6 ± 16.3) 0.0 (2.4 ± 6.0) < 0.001 48 %
V60Gy (RBE) [%] 0.0 (0.3 ± 1.5) 0.0 (0.3 ± 1.3) 0.0 (0.0 ± 1.2) 0.50 −25 %
Dmean [Gy(RBE)] 0.9 (7.2 ± 12.0) 17.8 (19.2 ± 13.6) 10.2 (11.9 ± 7.6) < 0.001 93 %
D2% [Gy(RBE)] 12.0 (21.8 ± 23.4) 30.4 (32.8 ± 18.5) 10.3 (11.0 ± 10.7) < 0.001 55 %
D50% [Gy(RBE)] 0.0 (6.0 ± 13.1) 16.7 (18.4 ± 14.8) 9.9 (12.3 ± 8.9) < 0.001 100 %
Cerebellum V10Gy (RBE) [%] 0.1 (10.2 ± 18.3) 29.0 (40.8 ± 38.7) 21.2 (30.7 ± 30.2) < 0.001 93 %
posterior V20Gy (RBE) [%] 0.0 (7.0 ± 14.3) 5.9 (20.2 ± 26.9) 2.8 (13.1 ± 18.0) < 0.001 89 %
V30Gy (RBE) [%] 0.0 (4.6 ± 10.6) 0.0 (9.1 ± 16.4) 0.0 (4.5 ± 7.9) < 0.001 66 %
V40Gy (RBE) [%] 0.0 (3.0 ± 7.1) 0.0 (4.7 ± 10.5) 0.0 (1.7 ± 4.2) < 0.001 51 %
V50Gy (RBE) [%] 0.0 (1.7 ± 4.5) 0.0 (2.6 ± 6.6) 0.0 (0.9 ± 2.4) < 0.001 44 %
V60Gy (RBE) [%] 0.0 (0.1 ± 0.7) 0.0 (0.1 ± 0.7) 0.0 (0.0 ± 0.2) 0.61 30 %
Dmean [Gy(RBE)] 0.1 (3.4 ± 6.4) 8.6 (11.5 ± 10.1) 6.3 (8.1 ± 6.0) < 0.001 98 %
D2% [Gy(RBE)] 0.7 (17.4 ± 22.2) 23.3 (26.6 ± 19.8) 7.6 (9.2 ± 9.2) < 0.001 94 %
D50% [Gy(RBE)] 0.0 (1.3 ± 5.0) 7.4 (10.1 ± 9.6) 7.4 (8.8 ± 7.7) < 0.001 100 %
Chiasm D2% [Gy(RBE)] 45.1 (32.3 ± 23.9) 50.4 (37.5 ± 20.1) 2.2 (5.3 ± 8.5) < 0.001 9 %
Cochlea Dmean [Gy(RBE)] 0.0 (1.9 ± 5.4) 5.1 (8.9 ± 9.0) 4.4 (7.1 ± 7.0) < 0.001 100 %
contralateral D2% [Gy(RBE)] 0.0 (2.8 ± 7.0) 7.3 (10.6 ± 10.7) 4.9 (7.8 ± 7.8) < 0.001 100 %
Cochlea Dmean [Gy(RBE)] 2.4 (16.0 ± 20.3) 17.6 (21.5 ± 18.8) 3.4 (5.5 ± 8.3) < 0.001 78 %
ipsilateral D2% [Gy(RBE)] 4.9 (19.8 ± 22.9) 21.7 (24.4 ± 20.1) 2.8 (4.6 ± 8.8) < 0.001 67 %
Frontal lobe V10Gy (RBE) [%] 4.8 (21.4 ± 28.1) 27.2 (39.6 ± 37.8) 8.4 (18.2 ± 32.4) < 0.001 74 %
contralateral V20Gy (RBE) [%] 0.8 (12.8 ± 21.2) 9.3 (24.3 ± 31.6) 2.1 (11.4 ± 19.1) < 0.001 56 %
V30Gy (RBE) [%] 0.2 (9.8 ± 18.1) 3.3 (14.6 ± 24.2) 0.3 (4.8 ± 10.1) < 0.001 55 %
V40Gy (RBE) [%] 0.0 (7.3 ± 14.9) 0.4 (9.1 ± 18.3) 0.0 (1.8 ± 5.4) < 0.001 31 %
V50Gy (RBE) [%] 0.0 (5.1 ± 12.0) 0.0 (6.0 ± 13.8) 0.0 (0.9 ± 3.3) < 0.001 16 %
V60Gy (RBE) [%] 0.0 (1.3 ± 4.2) 0.0 (1.7 ± 5.7) 0.0 (0.4 ± 2.9) 0.16 25 %
Dmean [Gy(RBE)] 1.6 (7.2 ± 10.7) 8.4 (13.0 ± 13.2) 3.6 (5.8 ± 7.3) < 0.001 78 %
D2% [Gy(RBE)] 14.1 (24.6 ± 24.7) 33.0 (32.2 ± 20.5) 4.1 (7.6 ± 10.5) < 0.001 37 %
D50% [Gy(RBE)] 0.0 (4.8 ± 10.8) 6.9 (11.3 ± 13.7) 3.4 (6.5 ± 10.5) < 0.001 100 %
Abbreviation: SD, standard deviation.
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Table D.1 [continued]: Dose comparison for organs at risk for the photon (XRT) and proton treatment
plans (PBT) as well as the difference of both. Median, mean and standard deviation are given for each
modality and patient-individual differences. P-values are derived from Wilcoxon test. Median relative
changes ∆Vrel = (VXRT − VPBT)/VXRT and ∆Drel = (DXRT − DPBT)/DXRT in per cent are given.
PBT XRT XRT-PBT
Organ at risk Parameter Median (Mean ± SD) Median (Mean ± SD) Median (Mean ± SD) p-value ∆V rel, ∆Drel
Frontal lobe V10Gy (RBE) [%] 29.3 (34.7 ± 31.7) 33.9 (43.7 ± 35.7) 6.5 (9.0 ± 32.1) 0.017 30 %
ipsilateral V20Gy (RBE) [%] 12.5 (21.7 ± 24.7) 15.6 (31.1 ± 32.2) 2.5 (9.4 ± 19.0) < 0.001 35 %
V30Gy (RBE) [%] 7.6 (16.0 ± 20.9) 9.1 (21.0 ± 24.6) 1.2 (5.0 ± 9.1) < 0.001 23 %
V40Gy (RBE) [%] 3.5 (11.9 ± 18.1) 4.3 (13.3 ± 18.6) 0.0 (1.4 ± 4.5) 0.007 19 %
V50Gy (RBE) [%] 1.0 (8.6 ± 15.6) 2.0 (9.4 ± 15.5) 0.0 (0.8 ± 2.2) 0.011 13 %
V60Gy (RBE) [%] 0.0 (2.4 ± 6.2) 0.0 (3.3 ± 9.2) 0.0 (0.9 ± 4.0) 0.53 9 %
Dmean [Gy(RBE)] 7.6 (11.6 ± 12.3) 10.1 (15.5 ± 13.6) 2.3 (3.8 ± 7.3) < 0.001 40 %
D2% [Gy(RBE)] 45.8 (35.8 ± 23.5) 49.8 (40.4 ± 20.0) 0.8 (4.7 ± 7.8) < 0.001 2 %
D50% [Gy(RBE)] 0.6 (9.4 ± 15.1) 4.9 (13.6 ± 15.9) 1.3 (4.2 ± 10.8) < 0.001 93 %
Hippocampus Dmean [Gy(RBE)] 0.1 (5.3 ± 10.7) 12.8 (16.0 ± 12.0) 9.5 (10.7 ± 8.3) < 0.001 99 %
contralateral D2% [Gy(RBE)] 0.6 (13.0 ± 19.1) 22.6 (26.2 ± 16.1) 11.4 (13.2 ± 11.4) < 0.001 95 %
D50% [Gy(RBE)] 0.0 (4.3 ± 10.3) 13.1 (15.5 ± 12.1) 9.5 (11.1 ± 8.8) < 0.001 100 %
Hippocampus Dmean [Gy(RBE)] 12.2 (18.5 ± 19.1) 28.8 (28.2 ± 16.8) 8.3 (9.7 ± 8.6) < 0.001 48 %
ipsilateral D2% [Gy(RBE)] 39.6 (33.1 ± 23.2) 44.4 (40.1 ± 18.0) 2.9 (7.0 ± 11.1) < 0.001 6 %
D50% [Gy(RBE)] 6.5 (17.3 ± 20.9) 26.6 (28.0 ± 17.8) 9.1 (10.7 ± 10.0) < 0.001 67 %
Hippocampi Dmean [Gy(RBE)] 5.9 (11.0 ± 12.2) 19.8 (21.2 ± 12.7) 8.7 (10.2 ± 7.1) < 0.001 54 %
bilateral D2% [Gy(RBE)] 36.3 (31.9 ± 23.2) 42.0 (39.3 ± 18.0) 2.9 (7.4 ± 11.0) < 0.001 6 %
Lacrimal gland Dmean [Gy(RBE)] 0.0 (0.6 ± 2.5) 4.4 (5.6 ± 5.6) 4.1 (5.1 ± 5.1) < 0.001 100 %
contralateral D2% [Gy(RBE)] 0.0 (1.4 ± 5.5) 5.6 (7.7 ± 7.4) 5.1 (6.3 ± 6.4) < 0.001 100 %
Lacrimal gland Dmean [Gy(RBE)] 0.4 (7.9 ± 12.6) 9.4 (13.6 ± 12.5) 4.2 (5.7 ± 8.9) < 0.001 94 %
ipsilateral D2% [Gy(RBE)] 2.4 (13.6 ± 18.3) 12.8 (18.8 ± 16.0) 5.4 (5.2 ± 10.9) < 0.001 84 %
Lens Dmean [Gy(RBE)] 0.0 (0.3 ± 1.1) 3.4 (4.7 ± 5.2) 3.3 (4.4 ± 4.7) < 0.001 100 %
contralateral D2% [Gy(RBE)] 0.0 (0.6 ± 1.6) 4.2 (5.5 ± 6.1) 3.9 (5.0 ± 5.4) < 0.001 100 %
Lens Dmean [Gy(RBE)] 0.0 (2.2 ± 6.0) 4.4 (9.6 ± 10.0) 4.1 (7.4 ± 8.7) < 0.001 100 %
ipsilateral D2% [Gy(RBE)] 0.0 (3.2 ± 7.8) 4.8 (10.8 ± 11.2) 4.3 (7.6 ± 9.8) < 0.001 100 %
Optic nerve ipsilateral D2% [Gy(RBE)] 4.1 (17.1 ± 20.4) 24.2 (24.9 ± 18.5) 4.7 (7.9 ± 10.3) < 0.001 82 %
Optic nerve contralateral D2% [Gy(RBE)] 40.6 (30.1 ± 24.4) 47.2 (34.4 ± 21.7) 1.9 (4.3 ± 8.9) < 0.001 13 %
Pituitary Dmean [Gy(RBE)] 4.7 (18.7 ± 22.0) 28.7 (27.7 ± 20.2) 5.1 (9.0 ± 10.4) < 0.001 81 %
D2% [Gy(RBE)] 12.3 (23.4 ± 23.7) 36.1 (31.9 ± 21.1) 4.9 (8.5 ± 10.5) < 0.001 48 %
Skin V10Gy (RBE) [cm3] 40.5 (42.1 ± 29.0) 82.4 (83.4 ± 49.6) 32.3 (41.4 ± 30.9) < 0.001 51 %
V20Gy (RBE) [cm3] 29.7 (27.5 ± 27.7) 24.5 (36.4 ± 34.8) 4.0 (8.9 ± 14.9) < 0.001 36 %
V30Gy (RBE) [cm3] 8.4 (17.4 ± 22.0) 9.0 (18.6 ± 22.0) 0.0 (1.2 ± 8.1) 0.12 10 %
V40Gy (RBE) [cm3] 2.8 (10.9 ± 15.9) 1.9 (10.2 ± 14.1) 0.0 (-0.7 ± 6.3) 0.46 −2 %
V50Gy (RBE) [cm3] 0.0 (4.8 ± 8.1) 0.0 (3.9 ± 7.3) 0.0 (-0.9 ± 4.5) 0.088 −12 %
V60Gy (RBE) [cm3] 0.0 (0.2 ± 1.3) 0.0 (0.2 ± 1.9) 0.0 (0.0 ± 0.7) 0.051 −46 %
D2% [Gy(RBE)] 30.1 (32.0 ± 17.0) 30.8 (32.3 ± 15.3) 0.6 (0.3 ± 5.3) 0.36 2 %
D5% [Gy(RBE)] 23.4 (24.0 ± 16.2) 21.7 (25.8 ± 13.8) 2.1 (1.8 ± 5.6) 0.002 9 %
D15% [Gy(RBE)] 0.5 (4.8 ± 9.2) 13.0 (14.1 ± 8.6) 8.4 (9.3 ± 6.7) < 0.001 95 %
D25% [Gy(RBE)] 0.0 (1.1 ± 4.3) 6.5 (8.3 ± 5.8) 5.8 (7.2 ± 5.4) < 0.001 99 %
D35% [Gy(RBE)] 0.0 (0.4 ± 1.7) 4.1 (4.9 ± 4.0) 4.1 (4.5 ± 3.6) < 0.001 99 %
D45% [Gy(RBE)] 0.0 (0.1 ± 0.4) 2.4 (2.8 ± 2.4) 2.2 (2.7 ± 2.2) < 0.001 99 %
D55% [Gy(RBE)] 0.0 (0.0 ± 0.1) 1.2 (1.7 ± 1.6) 1.2 (1.6 ± 1.5) < 0.001 100 %
Temporal lobe V10Gy (RBE) [%] 0.2 (12.5 ± 21.8) 37.4 (43.4 ± 34.8) 23.5 (31.0 ± 32.7) < 0.001 99 %
contralateral V20Gy (RBE) [%] 0.0 (5.0 ± 12.4) 5.3 (20.7 ± 27.7) 3.8 (15.7 ± 22.8) < 0.001 96 %
V30Gy (RBE) [%] 0.0 (2.7 ± 7.1) 0.1 (7.1 ± 14.4) 0.1 (4.4 ± 8.6) < 0.001 78 %
V40Gy (RBE) [%] 0.0 (1.8 ± 5.4) 0.0 (2.8 ± 7.8) 0.0 (1.0 ± 2.9) < 0.001 47 %
V50Gy (RBE) [%] 0.0 (1.0 ± 3.4) 0.0 (1.4 ± 4.6) 0.0 (0.4 ± 1.6) < 0.001 37 %
V60Gy (RBE) [%] 0.0 (0.0 ± 0.0) 0.0 (0.0 ± 0.1) 0.0 (0.0 ± 0.1) 0.18 86 %
Dmean [Gy(RBE)] 0.2 (3.1 ± 5.7) 9.4 (11.8 ± 8.5) 7.6 (8.7 ± 6.4) < 0.001 97 %
D2% [Gy(RBE)] 1.7 (14.6 ± 19.5) 23.1 (27.0 ± 15.8) 10.5 (12.4 ± 10.7) < 0.001 86 %
D50% [Gy(RBE)] 0.0 (2.1 ± 5.3) 8.3 (10.7 ± 8.5) 7.5 (8.6 ± 7.3) < 0.001 100 %
Temporal lobe V10Gy (RBE) [%] 42.4 (45.3 ± 29.1) 74.6 (69.9 ± 29.8) 21.6 (24.6 ± 22.5) < 0.001 38 %
ipsilateral V20Gy (RBE) [%] 26.5 (33.7 ± 28.8) 51.5 (51.3 ± 31.4) 14.2 (17.6 ± 16.6) < 0.001 38 %
V30Gy (RBE) [%] 18.5 (26.6 ± 27.2) 29.7 (36.4 ± 30.1) 8.2 (9.8 ± 10.4) < 0.001 38 %
V40Gy (RBE) [%] 12.0 (21.2 ± 25.7) 15.3 (25.6 ± 27.5) 2.9 (4.4 ± 6.3) < 0.001 24 %
V50Gy (RBE) [%] 7.1 (15.8 ± 22.7) 7.8 (18.1 ± 23.8) 1.0 (2.3 ± 3.9) < 0.001 18 %
V60Gy (RBE) [%] 0.0 (3.0 ± 9.4) 0.0 (3.3 ± 9.7) 0.0 (0.3 ± 2.2) 0.37 14 %
Dmean [Gy(RBE)] 12.6 (17.2 ± 14.4) 23.3 (24.9 ± 14.0) 7.5 (7.7 ± 5.4) < 0.001 34 %
D2% [Gy(RBE)] 53.7 (44.6 ± 17.9) 54.1 (48.6 ± 13.0) 0.6 (4.0 ± 7.5) < 0.001 1 %
D50% [Gy(RBE)] 3.5 (13.8 ± 18.4) 20.8 (23.5 ± 16.4) 8.3 (9.6 ± 8.2) < 0.001 75 %
Abbreviation: SD, standard deviation.
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Figure D.1: Relative difference of selected DVH parameters between photon and proton treatment plans
for each patient. The difference between the XRT and PBT value is normalised to the XRT value.
Figure D.2: Relative difference of selected DVH parameters between photon and proton treatment plans
exceeding a threshold of 10 % for each patient. The difference between the XRT and PBT value is nor-
malised to the XRT value.
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Table D.2: Differences in the near-maximum parameter D2% and the mean dose Dmean for organs at risk
with patient classification according to tumour location. Absolute differences ∆Dabs = DXRT − DPBT are
given in Gy(RBE) and relative differences are given ∆Drel = (DXRT − DPBT)/DXRT in per cent. The median
values of each dosimetric parameter for each localisation group are given. P-values are derived from
Wilcoxon test.
Frontal lobe Parietal lobe Temporal lobe Multiple lobes
∆Dabs ∆Drel ∆Dabs ∆Drel ∆Dabs ∆Drel ∆Dabs ∆Drel
N in Gy(RBE) in % p-value N in Gy(RBE) in % p-value N in Gy(RBE) in % p-value N in Gy(RBE) in % p-value
D2%
Brain-CTV 16 0.1 0 0.38 5 0.6 1 0.043 25 0.8 2 0.035 31 0.3 0 0.017
Brain stem 16 15.7 90 0.002 5 9.1 70 0.080 25 0.8 2 0.045 31 2.0 6 0.006
Cerebellum 16 10.2 100 < 0.001 5 17.2 83 0.043 25 9.0 29 0.001 31 9.6 51 < 0.001
Cerebellum anterior 16 12.2 100 < 0.001 5 16.8 53 0.043 25 6.8 34 0.002 31 9.7 43 < 0.001
Cerebellum posterior 16 6.6 100 < 0.001 5 3.9 98 0.043 25 5.6 48 0.001 31 9.4 87 < 0.001
Chiasm 15 3.9 16 0.036 5 7.3 100 0.042 25 0.3 1 0.093 31 3.0 5 0.003
Cochlea contra 16 1.8 100 0.001 5 1.6 100 0.025 25 7.2 100 < 0.001 31 7.8 100 < 0.001
Cochlea ipsi 16 3.5 100 0.001 5 2.4 100 0.034 25 0.4 1 0.19 31 3.7 64 < 0.001
Frontal lobe contra 15 0.2 0 0.19 5 8.7 100 0.039 25 5.7 76 0.002 31 2.7 6 < 0.001
Frontal lobe ipsi 5 0.1 0 0.69 4 5.9 55 0.068 23 0.8 2 0.021 25 0.4 1 0.013
Hippocampus contra 16 9.9 100 0.001 4 22.1 100 0.066 23 15.8 83 < 0.001 27 14.1 97 < 0.001
Hippocampus ipsi 15 14.0 93 0.001 4 1.2 2 0.14 19 1.5 3 0.036 26 0.8 1 0.007
Hippocampi 15 15.6 94 0.001 4 1.7 3 0.068 19 1.2 2 0.044 26 0.9 2 0.014
Lacrimal gland contra 16 5.7 99 < 0.001 5 7.6 100 0.025 25 3.6 100 < 0.001 31 5.5 100 < 0.001
Lacrimal gland ipsi 15 1.0 26 0.91 5 5.6 100 0.034 25 6.5 64 0.034 31 5.8 70 < 0.001
Lens contra 16 3.2 97 < 0.001 5 1.5 100 0.025 25 4.3 100 < 0.001 31 4.1 100 < 0.001
Lens ipsi 15 3.9 94 0.001 5 1.8 100 0.025 25 5.7 100 < 0.001 31 4.7 99 < 0.001
Optic nerve contra 16 4.6 80 0.017 5 2.8 100 0.025 25 3.6 30 0.001 31 8.3 67 < 0.001
Optic nerve ipsi 15 1.0 5 0.22 5 3.0 100 0.034 25 -0.1 0 0.21 31 3.2 13 0.002
Pituitary 16 6.7 53 0.004 5 5.3 100 0.039 23 1.1 2 0.003 30 7.7 46 < 0.001
Skin 16 -2.8 -5 0.35 5 5.4 15 0.080 25 0.8 4 0.76 31 0.1 0 0.98
Temporal lobe contra 16 12.9 98 0.001 5 30.2 100 0.039 25 9.9 51 < 0.001 31 11.6 98 < 0.001
Temporal lobe ipsi 16 6.9 15 0.007 3 0.6 1 0.11 19 0.3 1 0.077 27 0.5 1 0.031
Dmean
Brain-CTV 16 9.6 58 < 0.001 5 10.5 57 0.043 25 3.2 51 < 0.001 31 8.8 47 < 0.001
Cerebellum 16 3.5 100 < 0.001 5 2.9 89 0.043 25 9.0 88 < 0.001 31 10.4 94 < 0.001
Cerebellum anterior 16 7.2 100 < 0.001 5 8.5 91 0.043 25 11.8 91 < 0.001 31 12.9 94 < 0.001
Cerebellum posterior 16 3.0 100 < 0.001 5 2.0 99 0.042 25 7.9 92 < 0.001 31 10.1 98 < 0.001
Cochlea contra 16 1.5 100 < 0.001 5 1.2 100 0.025 25 6.7 100 < 0.001 31 5.9 100 < 0.001
Cochlea ipsi 16 3.2 100 < 0.001 5 1.8 100 0.034 25 1.3 5 0.016 31 4.3 84 < 0.001
Frontal lobe contra 15 12.9 37 0.047 5 15.0 100 0.039 25 1.6 88 0.073 31 8.6 69 < 0.001
Frontal lobe ipsi 5 2.4 25 0.50 4 12.4 89 0.068 23 0.5 34 0.58 25 7.7 23 0.004
Hippocampus contra 16 7.3 100 < 0.001 4 16.8 100 0.066 23 9.8 97 < 0.001 27 8.9 99 < 0.001
Hippocampus ipsi 15 9.9 98 0.001 4 6.2 27 0.068 19 5.8 18 0.001 26 3.8 12 < 0.001
Hippocampi 15 8.7 99 0.001 4 11.3 51 0.068 19 7.9 46 < 0.001 26 7.5 41 < 0.001
Lacrimal gland contra 16 4.1 99 < 0.001 5 3.1 100 0.025 25 2.9 100 < 0.001 31 4.7 100 < 0.001
Lacrimal gland ipsi 15 2.4 51 0.14 5 3.5 100 0.025 25 6.0 87 0.006 31 5.0 89 < 0.001
Pituitary 16 5.5 73 0.001 5 3.9 100 0.039 23 2.1 6 0.001 30 8.2 81 < 0.001
Temporal lobe contra 16 5.7 99 0.001 5 11.6 100 0.039 25 7.4 92 < 0.001 31 9.3 100 < 0.001
Temporal lobe ipsi 16 8.8 68 < 0.001 3 7.3 36 0.11 19 5.3 26 0.001 27 6.3 23 < 0.001
Abbreviations: N, number of patients; CTV, clinical target volume; ipsi, ipsilateral; contra, contralateral.
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Figure D.3: Difference in NTCP between XRT and PBT for selected side effects for each patient.
Figure D.4: Difference in NTCP between XRT and PBT for selected side effects exceeding a threshold of
10 percentage points for each patient.
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Figure D.5: Patient selection for different side effects and different thresholds. The applied threshold of 10
percentage points in this study is shaded in orange.
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Table D.3: NTCP differences with patient classification according to tumour location. Tumour localisations other than those indicated are not considered.
Median estimates for photon plans (NTCPXRT) and proton plans (NTCPPBT) in per cent as well as median difference (∆NTCP = NTCPXRT − NTCPPBT) in
percentage points are given for each localisation group. P-values are derived from Wilcoxon test.
Frontal lobe Parietal lobe Temporal lobe Multiple lobes
Side effect N NTCPXRT NTCPPBT ∆NTCP p-value N NTCPXRT NTCPPBT ∆NTCP p-value N NTCPXRT ∆NTCP ∆NTCP p-value N NTCPXRT NTCPPBT ∆NTCP p-value
Alopecia 16 78 79 -1.5 0.76 5 80 69 11.2 0.043 25 50 47 1.7 0.11 31 79 77 0.2 0.33
Blindness (chiasm) 15 0 0 0.0 0.017 5 0 0 0.0 0.043 25 1 0 0.0 0.17 31 0 0 0.0 0.004
Blindness (ON contra) 16 0 0 0.0 0.030 5 0 0 0.0 0.043 25 0 0 0.0 0.069 31 0 0 0.0 0.002
Blindness (ON ipsi) 15 0 0 0.0 0.027 5 0 0 0.0 0.043 25 0 0 0.0 0.074 31 0 0 0.0 0.002
Cataract contra 16 0 0 0.1 < 0.001 5 0 0 0.0 0.043 25 0 0 0.1 < 0.001 31 0 0 0.2 < 0.001
Cataract ipsi 15 0 0 0.2 0.005 5 0 0 0.0 0.043 25 0 0 0.4 < 0.001 31 0 0 0.3 < 0.001
Delayed recall 15 61 3 25.0 0.001 4 88 21 43.9 0.068 19 81 21 45.4 < 0.001 26 91 9 10.4 < 0.001
Endocrine dysfunction 16 0 0 0.0 0.015 5 0 0 0.0 0.043 23 0 0 0.0 0.013 30 0 0 0.0 0.004
Erythema 16 36 39 -0.8 0.78 5 39 21 18.4 0.068 25 18 18 0.0 0.33 31 36 39 0.0 0.89
Hearing loss ipsi 16 0 0 0.0 0.007 5 0 0 0.0 0.043 25 0 0 0.0 0.17 31 0 0 0.0 0.004
Necrosis (brain stem) 16 0 0 0.0 0.005 5 0 0 0.0 0.043 25 0 0 0.0 < 0.001 31 0 0 0.0 < 0.001
Ocular toxicity 15 49 52 0.1 0.91 5 2 1 1.3 0.043 25 6 2 3.0 0.093 31 52 15 2.4 0.001
Tinnitus contra 16 0 0 0.1 0.007 5 0 0 0.1 0.043 25 1 0 0.6 < 0.001 31 1 0 0.4 < 0.001
Tinnitus ipsi 16 0 0 0.2 0.002 5 0 0 0.1 0.043 25 19 16 0.4 0.17 31 6 0 0.3 0.007
Abbreviations: N, number of patients; ON, optic nerve; ipsi, ipsilateral; contra, contralateral.
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Figure D.6: NTCP differences between XRT and PBT plans for different side effects excluding patients
with re-irradiation. A threshold of 10 percentage points is indicated.
Figure D.7: NTCP values for XRT and PBT plans for selected side effects excluding patients with re-
irradiation. The solid line represents equal NTCP values for both treatment modalities. A threshold of 10
percentage points is indicated as dashed line. The percentage of patients selected for each treatment is
given.
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